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Greetings
It is a pleasure of the Hungarian Society for Pharmaceutical Sciences 
that the 7th BBBB Conference is held in Hungary, where this conference 
series started in 2005. The goal of the founders by organizing regional 
conferences named “The Balaton-Baltic-Bled-Bosphorus Conference 
on Pharmaceutical Sciences” was to establish a close cooperation 
among the Pharmaceutical Societies of Hungary, Finland, Estonia, Slo-
venia and the Turkish Pharmaceutical Technology Scientists’ Associa-
tion, member organizations of EUFEPS. 
This scientifi c forum traditionally gathers the members of these Societ-
ies and colleagues from neighboring and other countries, and serves as 
a strong and stable background for permanent dialogue between phar-
macists and professionals working in the fi elds of pharmaceutical sci-
ences, drug research and development. 
The conference provides the possibility for the participants to present 
new results, discuss recent developments and future directions of the 
pharmaceutical sciences in a broad sense. It oﬀ ers a good opportunity to promote scientifi c achieve-
ments for talented young pharmacists in Pharmaceutical Companies, Departments of Pharmaceutical 
Faculties and Academic Institutes. Other goals of this regional conference series include the initiation of 
common research projects, and fostering the application of the results of new approaches for the accel-
erated development and introduction of safer and more eﬀ ective medicines.
I am pleased that more than 400 colleagues will participate at the conference. We have received 280 ab-
stract submissions, and the program includes 11 plenary lectures, 67 oral and 188 poster presentations. 
I am looking forward to having a successful conference at Balatonfüred with vivid and fruitful discus-
sions.
Prof. Éva Szökő
Chair of the 7th BBBB International Conference on Pharmaceutical Science
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Conference Chair
Prof. Éva Szökő, Semmelweis University, Budapest
President of the Hungarian Society for Pharmaceutical Sciences
Secretary General
Tamás Tábi, Semmelweis University, Budapest
International Scientifi c Advisory Board
Estonian Society for Pharmaceutical Science
Karin Kogermann, University of Tartu, Tartu
Urve Paaver, University of Tartu, Tartu
Ivo Laidmäe, University of Tartu, Tartu
Finnish Pharmaceutical Society
Prof. Niklas Sandler, Åbo Akademi University, Åbo
Leena Peltonen, University of Helsinki, Helsinki
Hungarian Society for Pharmaceutical Sciences
Prof. György Bagdy, Semmelweis University, Budapest
Prof. Imre Klebovich, Semmelweis University, Budapest
Prof.  Éva Szökő, Semmelweis University, Budapest
Slovenian Society for Pharmaceutical Sciences
Prof. Julijana Kristl, University of Ljubljana, Ljubljana
Prof. Mirjana Gašperlin, University of Ljubljana, Ljubljana
Prof. Albin Kristl, University of Ljubljana, Ljubljana
Turkish Pharmaceutical Technology Scientists’ Association
Prof. Nevin Çelebi, Gazi University, Ankara
Prof. Nilüfer Tarımcı, Ankara University, Ankara
Prof. Yıldız Özsoy, Istanbul University, Istanbul
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Local Scientifi c Committ ee
Prof. Piroska Szabó-Révész, University of Szeged
Committ ee chair
István Antal, Semmelweis University, Budapest
Ildikó Csóka, University of Szeged
Ádám Dávid, EGIS Pharmaceuticals Plc.
Prof. Ferenc Fülöp, University of Szeged
Prof. István Greiner, Chemical Works of Gedeon Richter Plc.
Prof. Judit Hohmann, University of Szeged
Prof. Krisztina Takács-Novák, Semmelweis University, Budapest
Prof. Pál Perjési, University of Pécs
Prof. Gyöngyvér Soós, University of Szeged
Miklós Vecsernyés, University of Debrecen
Prof. Romána Zelkó, Semmelweis University, Budapest
Local Organizing Committ ee
Gézáné Takács, Réthy Pál Hospital, Békéscsaba
Committ ee Chair
Att ila Bódis, Chemical Works of Gedeon Richter Plc.,
Dezső Csupor, University of Szeged
Mária Hajdú, Semmelweis University, Budapest
Ilona Higyisán, Bajcsy-Zsilinszky Hospital, Budapest
László Horváth, University of Debrecen
Hedvig Juhász, Sanofi -Aventis Hungary
Kristóf Kovács, EGIS Pharmaceuticals Plc.
Ildikó Kovácsné Bácskay, University of Debrecen
Sarolta Márkus, EGIS Pharmaceuticals Plc.
Att ila Marosi, Chemical Works of Gedeon Richter Plc.
Géza Regdon Jr., University of Szeged
Gergely Völgyi, Semmelweis University, Budapest
István Zupkó, University of Szeged
Conference Secretariat: 
Club Service Ltd., 7thbbbb@7thbbb.com
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Curriculum Vitae of Invited Speakers
Erem Bilensoy
Department of Pharmaceutical Technology, Hacett epe University, Faculty of Pharmacy, Ankara, Turkey
Erem Bilensoy is full professor of pharmaceutical technology. She graduated 
from Hacett epe University Faculty of Pharmacy in 1992. She obtained her double 
Ph.D. degree with a co-tutelle thesis between Université Paris-Sud and Hacett epe 
University in 2002 under the supervisions of Dominique Duchene and Atilla 
Hıncal on the evaluation of amphiphilic ß-cyclodextrins modifi ed on the primary face 
as novel excipients in the preparation of nanospheres and nanocapsules. She has been 
appointed as associate professor in 2007 and received full professor position in 
2013. She is the author of more than 60 scientifi c articles, 11 international book 
chapters receiving more than 1100 citations with a current H-index of 21. She also 
worked as Editor of the book entitled “Cyclodextrins in the Field of Pharmaceu-
tics, Cosmetics and Biomedicine: Current and Future Industrial Applications” published by John 
Wiley&Sons in 2012. Dr. Bilensoy served as Bioavailability/Bioequivalence Evaluation Commission 
member within Turkish Medicines and Medical Devices Agency between 2007-2012 and from December 
2015 onwards. She was Vice Dean of Faculty of Pharmacy between 2010-2013. She is founder member 
and Head for EUFEPS Network on Nanomedicine and Board Member for European Cyclodextrin Soci-
ety. Erem Bilensoy joined European Federation for Pharmaceutical Sciences EUFEPS Executive Commit-
tee in 2012 and was elected as President of EUFEPS starting from June 2015. She is also on the Consul-
tancy Board for Projects on Nanobiotechnology at TUBİTAK Turkish Scientifi c and Technological Re-
search Council. She was recently elected as Vice Chairman for Hacett epe Technology Transfer Center 
Executive Committ ee on January 2016. Her current research interests include targeted nanoparticles in 
cancer therapy, cationic nanoparticles, cyclodextrin-based drug delivery, inkjet and 3D printed drug de-
livery systems, biomedical applications of nanoparticles and regulatory approaches on bioavailability/
bioequivalence. 
Erik Bogsch Jr.
Head of the Biotechnology R&D Division at Gedeon Richter Plc.
Dr. Erik Bogsch is Head of the Biotechnology R&D Division at Gedeon Richter 
Plc. He is responsible for leading the R&D eﬀ ort in the development of GR’s bio-
technology pipeline. Gedeon Richter Plc. is engaged in the development and 
manufacture of both bacterial cell fermentation based and mammalian cell fer-
mentation based biosimilar products. GR has R&D, analytical & manufacturing 
capabilities in multiple locations in Hungary & Germany. Dr. Bogsch, has a Natu-
ral Sciences degree from the University of Cambridge and a PhD in cell biology 
from the University of Warwick. Following a brief postdoctoral academic re-
search career, he worked in the food industry for many years in R&D, Quality & 
Manufacturing roles in the UK, Hungary & Germany. He joined Gedeon Richter 
Plc. in 2012, as commissioning lead for GR’s biotechnology factory in Debrecen, Hungary, before mov-
ing into his current role in 2014.
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Gustav Boije af Gennäs
University of Helsinki, Finland
Dr. Gustav Boije af Gennäs is a Principal Investigator of the Drug Discovery 
Group at the Faculty of Pharmacy, University of Helsinki. His main research in-
terests include regenerative medicine, inhibitors of pathogenic parasites, cancer, 
therapy of Alzheimer’s and Parkinson s´ diseases and the development of micro-
chip technology. Dr. Boije af Gennäs has published over 20 peer-reviewed scien-
tifi c articles, two patents, and supervised 5 PhD and 18 MSc students. Currently 
he leads a group of 4 PhD and 2 MSc students in the Synthetic Medicinal Chem-
istry group that uses state-of-the-art methods in the design and synthesis of nov-
el drug-like compounds, such as stem cell inducers as well as kinase and other 
enzyme inhibitors and activators. In addition, he develops microchips for novel 
applications such as bioanalysis and organic reaction analysis. Dr. Boije af Gennäs has been the head of 
several research projects including those funded by the Academy of Finland and the University of Hel-
sinki, and is involved in projects funded by the Finnish Funding Agency for Technology and Innovation 
(TEKES), EU, Jane and Aatos Erkko Foundation etc. He has had several invited plenary and keynote 
presentations in international and national scientifi c conferences. Dr. Boije af Gennäs is a board member 
in international scientifi c committ ees, evaluation panels and societies. In 2012 he was granted the highly 
distinguished Academy of Finland postdoctoral project that was continued by the Key Project Funding 
in 2016. In addition, he received the University of Helsinki Three-year-grant in 2016 and obtained the 
Finnish Society of Sciences and Lett ers Award by the Ruth and Nils-Erik Stenbäck Foundation as well as 
the Young Researcher Award by the University of Helsinki, both in 2016.
István Greiner
Research Director, Gedeon Richter Plc.,
István Greiner graduated at Technical University of Budapest in 1984 as chemical 
engineer (M.Sc.). He works at Gedeon Richter Plc. since there, at the beginning as 
research scientist. He got his Ph.D. at Institute of Organic Chemistry of the same 
university. In 1992 he was appointed as Deputy Head of Chemical and Biotech-
nological Research and Development. He got his MBA degree at Open University 
in 1997. He is a patent att orney too, and from 1996 he also headed the Intellectual 
Property Department at Gedeon Richter Plc. for two and a half year. In 1998 he 
was appointed to the Director of Chemical and Biotechnological Research and 
Development, and from 2001 he works for the company as the Deputy of the Re-
search Director too. His responsibility was all the API (Active Pharmaceutical In-
gredients) research and development activities including new chemical entity, generic and biotechno-
logical projects. He directed chemical R&D during discovery and development of the FDA approved 
cariprazine. From 1st of August 2014 he was promoted to Research Director of the Company. He is in-
ventor of seven patents, invited as plenary speaker for international and domestic conferences and has 
more than 90 publications in well known peer reviewed international journals.
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Mojca Kerec-Kos 
University of Ljubljana, Slovenia
Since 1999 she has been working at the Chair of Biopharmacy and pharmacokinet-
ics. Her recent scientifi c work is focused on drugs pharmacokinetics in special pop-
ulation, such as elderly and children, with the aim to optimise the safety and eﬃ  ca-
cy of pharmacotherapy. She is also actively involved in research activities in the 
area of clinical pharmacy. Her other research focus is on  bioadhesive polymers, 
which increase the permeability of urinary bladder epithelia and enhance drug per-
meation into the bladder wall or by desquamation of superfi cial urothelial cells pro-
vide a promising treatment of bacterial cystitis and superfi cial bladder cancer. 
Müge Kilicarslan
Ankara University, Faculty of Pharmacy, Department of Pharmacutical Technology, 06100 Tandoğan, Ankara, Turkey
Muge Kilicarslan is Associate Professor of Pharmaceutical Technology at Ankara 
University, Faculty of Pharmacy, Turkey. She is graduated from Ankara University 
Faculty of Pharmacy in 1990. She received her M.Sc. degree on Pharmaceutical 
Technology with her thesis on the formulation of some drugs conserve in plastic 
syringes in the same university. She obtained her Ph.D. degree in 1999 on the prep-
aration of multiparticulate oral controlled release dosage form of verapamil HCl. 
She studied on the in situ implants at College of Pharmacy, Institute of Pharmaceu-
tical Technology, Freie Universitat, Berlin for post-doctoral research. Dr. Kilicarslan 
worked as Assistant Professor from 2010 to 2015 and received her Associate Profes-
sor title in 2015 at the same faculty and department. She studied at several research 
projects as assistant researcher and research manager. She is currently continuing her research work at 
the same department. Her current research interest revolves around micro and nanoparticulate drug de-
livery systems, micromeritics, dental and periodontal drug delivery systems and in situ implants. Her in-
terests also include Good Manufacturing Practices, Quality Assurance and Quality by Design. She is writ-
er of a national book chapter and one of the writers of national book. She has more than twenty papers in 
the international and national journals and has given several poster presentations and invited lectures. 
She is also serving as Vice Dean of Faculty of Pharmacy at Ankara University since June 2016.
Petra Kocbek
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Petra Kocbek is Associate Professor in Pharmaceutical Nanotechnology at Uni-
versity of Ljubljana, Faculty of Pharmacy. She received her Ph.D. in Pharmaceuti-
cal Sciences in 2008. Her main research interests include nanomaterials for the 
delivery of small molecular weight drugs as well as biomacromolecules. Her re-
cent scientifi c work is focused on the drug-loaded electrospun polymer nanofi -
bers for application in oral cavity and on the magnetically responsive nanocarri-
ers based on superparamagnetic iron oxide nanoparticles for the targeted cancer 
therapy. The results of her research have been presented at numerous scientifi c 
meetings and have been published in more than 20 peer-reviewed articles that 
have already received over 800 pure citations. P. Kocbek received Krka Prize for 
special research achievements in 2008 and Jožef Stefan Golden Emblem award for outstanding contribu-
tions made to science in the doctoral thesis in 2011.
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Karin Kogermann 
Institute of Pharmacy, University of Tartu, Nooruse 1, 50411 Tartu, Estonia
Dr. K. Kogermann is a pharmacist specialized in pharmaceutical technology and 
physical pharmacy. She received her master degree at the University of Tartu 
(UT). She completed her PhD at the University of Helsinki, Finland in 2008 enti-
tled: „Understanding solid-state transformations during dehydration: new in-
sights using vibrational spectroscopy and multivariate modeling“. After the de-
fense she continued her scientifi c career at the UT. In 2012 she received a Mobili-
tas Postdoctoral Research Fellow grant and continued her studies in the fi eld of 
biotechn ology at the Institute of Technology, Antibiotics Laboratory (UT). The 
main aim of her postdoctoral research was to develop in vitro and in vivo infec-
tion models in mice and understand the action mechanisms of antibiotics. Cur-
rently she is working as an Associate Professor and senior researcher at the Institute of Pharmacy. 
K. Kogermann has been acting as a grant holder/principal investigator in several Estonian Science 
Foundation Projects. Her research interests include the physical pharmacy and solid state analysis-relat-
ed as well as infection and antibacterial therapy-related topics. Her present research is focused on com-
bining these two branches and develop antimicrobial nanofi brous dressings as controlled drug delivery 
systems for eﬀ ective wound care and investigation of their performance. The main goal is to understand 
the eﬀ ects of the solid-state, mechanical and technological properties on the bioactivity of wound dress-
ings. Hence the drug release, antimicrobial activity, and biofi lm formation studies are the main part of 
the study. 
She has (co-)authored 24 original peer-reviews research publications and more than 100 conference 
proceedings. She has supervised 3 PhD students and currently is supervising 5 PhD students. K. Koger-
mann is acting as an expert at the European Pharmacopoeia Commission Expert Group G12, Estonian 
State Agency of Medicine and is a chairman of the Estonian Academical Society.
András Kotschy
Servier Research Institute of Medicinal Chemistry
András Kotschy is the managing director of the Servier Research Institute of Me-
dicinal Chemistry in Budapest, Hungary. After completing his PhD degree in 
1995 he joined the staﬀ  of Eötvös Loránd University where he rose through the 
ranks to associate professor also completing his habilitation and obtaining a DSc 
degree. His research interests included the development of new synthetic meth-
odologies, transition metal catalysis in particular, and  their application to hetero-
cyclic chemistry. 
In 2007 he joined the newly established Servier Research Institute of Medicinal 
Chemistry as director of the Discovery Chemistry division and in 2015 he became 
managing director of the institute. Since 2007 he has been in charge of multiple 
research projects in oncology and metabolism. András Kotschy is the author of 56 refereed publications 
that received over 1000 citations, 1 book, 2 book chapters, and 10 patents. He is also the recipient of mul-
tiple scientifi c awards and fellowships.
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Andres Lust
Institute of Pharmacy, Faculty of Medicine, University of Tartu, Estonia
Dr. Andres Lust received his MSc (Pharm) degree in 2010 and PhD (Pharm) in 
2015 at the University of Tartu, Estonia. The title of his PhD thesis is “Water me-
diated solid state transformations of a polymorphic drug – eﬀ ect on pharmaceu-
tical product performance”. In 2012, he received a research mobility grant from 
the Academy of Finland and has also acted as a researcher in several other scien-
tifi c research projects. His main research areas are Pharmaceutical technology 
and Physical pharmacy, and the current research interests include e.g., solid-state 
properties of pharmaceutical substances, phase transformations, drug-excipient 
interactions, and electrospraying/spinning as nanofabrication techniques. Cur-
rently, Dr. Lust is acting as a Research Fellow and Scientist in the Institute of 
Pharmacy, University of Tartu.
Aleš Mrhar
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
After fi nishing his pharmacy internship, Ales Mrhar (PhD, MPharm) became as-
sociated with the Faculty of Pharmacy, University of Ljubljana, Chair for Bio-
pharmaceutics and Pharmacokinetics as Assistant Professor in 1976 and Full Pro-
fessor  for Pharmaceutical Technology and Biopharmaceutics with Pharmacoki-
netics in 1994. He has worked as post-doctorate fellow at the NCTR in Jeﬀ erson 
(Arkansas, USA) in July 1984 and three times (September 1988, June 1990 and Oc-
tober 1992) at the University of Trieste (Italy). For 4 years (1991-1995) he has served 
as the Dean of the Faculty of Pharmacy at the University of Ljubljana and for 8 
years (2001-2009) as the Head of the Biopharmaceutic and Pharmacokinetic Chair. 
Additionally he has been engaged from 2006 to 2008 as a visiting professor for 
pharmacology at the Medical Faculty of the Univeristy of Maribor. He has acted as a mentor to more 
than 180 diplomants, 23 specializants, 24 master degree and 17 PhD students. His research interests in-
clude development of in vitro and in vivo tests in biopharmaceutics and pharmacokinetics, develop-
ment of experimental models for studying interactions, transport and metabolism of drugs in biological 
systems of increasing complexity, pharmacokinetic-pharmacodynamic analysis using compartmental 
and hybrid models, statistic and computer aided design of drug delivery systems, development of site-
specifi c microspheres for intravesical and colonic delivery, pharmacoepidemiologic and pharmacoeco-
nomic analysis, and fi naly outcomes research (clinical, economic and humanistic outcomes in relation to 
drug medical treatments). Ales Mrhar is author and co-author of 167/206 articles published in interna-
tional peer-reviewed journals with 1029/1288 pure citations (source: WoS/Scopus, status: 21 February 
2017). He is recipient of the national award for the achievements in research on the fi eld of mathematical 
modeling and computer simulation in pharmacokinetics, in 1990. Moreover, from the very beginning he 
has been developing strong collaboration with national and international pharmaceutical industry in 
terms of running more than 50 basic and applied projects in the fi elds of pharmaceutical technology, bi-
opharmaceutics and pharmacokinetics, and pharmacoeconomics. He is also the member of editorial 
board of Acta Pharmaceutica, an international journal that publishes articles dealing with pharmaceuti-
cal sciences and related fi elds. Since 2001 he acts also as a guest editor of International Journal of Phar-
maceutics and European Journal of Pharmaceutical Sciences. In 1996 Ales Mrhar was elected president 
of the Section for Pharmaceutical Sciences of the Slovenian Pharmaceutical Society. In this capacity he 
joined EUFEPS, European Federation of Pharmaceutical Sciences, fi rst as a Council member, later as 
Committ ee for Congresses and Conferences member and fi nnaly as Executive Committ ee member for 
the term 2002-2004. At the same time he was appointed President of The Central European Symposium 
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on Pharmaceutical Technology and Biotechnology, which has been organized under the patronage of 
EUFEPS biennialy since 1995, lastly in 2016 for the 11th time in Beograd (Serbia).  Since 2001 Ales Mrhar 
is actively involved in research and eductions activities in the area of clinical pharmacy with the aim to 
implement the principles of rational drug usage in healthcare systems. In this capacity he is responsible 
for collaboration between academic institutions and hospitals on national and international levels. He 
has managed more than 10 successful projects and published more than 30 articles in peer-reviewed na-
tional and international journals proving that clinical pharmacist with knowledge from the areas of me-
dicinal chemistry, drug delivery systems, clinical pharmacokinetics and pharmacogenetics is an indis-
pensable healthcare provider. Moreover, the results of these studies clearly show that by this support 
clinical, humanistic and economic outcomes are signifi cantly improved.
Jessica Rosenholm
Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku, Finland
Jessica Rosenholm holds a docentship in biomedical nanotechnology at Åbo Aka-
demi University, Finland, from where she also received her MSc(Tech) degree in 
chemical engineering in 2002. Her doctorate period included a four-year funded 
position in the national Biomaterials and Tissue Engineering Graduate Sch ool, 
from which she graduated her DSc(Tech) degree in 2008. Her thesis work “Modu-
lar Design of Mesoporous Silica Materials: Towards Multifunctional Drug Deliv-
ery Systems” has been awarded national and international prizes, e.g. the Akzo 
Nobel Nordic Research Prize 2009 for best doctoral thesis and research activity in 
colloid and surface science in the Nordic countries. In 2009-2010 she spent a post-
doctoral period at the Nano Biomedical Research Centre, Med-X Research Insti-
tute, Shanghai Jiao Tong University in China. Since returning to Finland in 2010, she heads her own 
group, the BioNanoMaterials group. The group’s activities are centered on the development of nano-
medicines for drug delivery and/or imaging, for the enabling of a variety of diagnostic and therapeutic 
applications. The designed systems are largely based on mesoporous silica and its composite nanostruc-
tures. Since 1.1.2015 she is appointed professor in pharmaceutical development at the Pharmaceutical 
Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University (www.pharmscilab.fi ). 
Currently the group is further involved in formulating the already developed nanosystems into diﬀ er-
ent dosage forms including dermal patches, antibacterial coatings and varying 2D/3D printed formula-
tions e.g. for tissue engineering.
Sándor Szalma
Institute of Takeda Pharmaceutical Company
Sándor Szalma is senior director of biomedical informatics within the Data Sci-
ence Institute of Takeda Pharmaceutical Company. Most recently, he was head of 
Translational Informatics and External Innovation, R&D IT in Janssen Research 
& Development, LLC. He serves as a member of the industry advisory committ ee 
of ELIXIR. Previously, he was member of the board of the Pistoia Alliance, mem-
ber of the Translational Medicine Advisory Committ ee of the PhRMA Founda-
tion and led the Data & Knowledge Management Strategic Governance Group of 
Innovative Medicine Initiative. His past positions included president of MeTa In-
formatics, general manager of QuantumBio and senior director of Computational 
Biology and Bioinformatics at Accelrys, Inc. He was co-founder of Acheuron 
Pharmaceuticals, Inc. He lectured at UCSD Extension and was adjunct professor at Rutgers University 
in the Computational Biology and Molecular Biophysics program. He is the author of more than 40 sci-
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entifi c publications and book chapters and two patents. He received his doctoral degree in chemistry 
from A. Szent-Györgyi Medical University in Szeged, Hungary.
He is married to Judit and they have two grown up children Dániel and Dorina. They live in Carls-
bad, CA, USA.
Mátyás Szentiványi
Roche Hungary Ltd. Budapest, Hungary
 
Mátyás Szentiványi MD PhD. graduated from Semmelweis University of Medi-
cine and received his MD degree in 1992. He worked six years as a researcher at 
the same university and  two years at the Medical College of Wisconsin in Mil-
waukee (USA). His fi eld of interest was vascular physiology, renal physiology, 
and hypertension. He received his PhD degree at the Semmelweis University of 
Medicine in 2002. The title of his PhD thesis was „Adaptive control mechanisms 
of the saphenous region”. 
Since 2000 he works in pharma business, in the fi rst fi ve years at a big CRO 
(Quintiles), while in the last twelve years at a multinational pharmaceutical com-
pany (Roche). Currently he is the medical director of Roche in Hungary. He has 
broad experience in clinical research and signifi cant medical aﬀ airs experience working in oncology, 
haematology, and hepatology. Current responsibilities include heading the medical department and 
overseeing its diﬀ erent units (medical aﬀ airs, clinical trials, regulatory, pharmacovigilance). Additional 
responsibilities include taking part in the company’s leadership team and compliance board. Since 2011 
he is a member of the Communication Ethics Committ ee of the Hungarian Pharma Associations. 
Mátyás Szentiványi is fi rst author of 6 articles in international scientifi c journals and second author of 
5 articles. He presented 21 scientifi c presentations in international scientifi c meetings. 
Main publications: 
 – Szentiványi M Jr et al. Am J Physiol. 271: H2238-H2245. 1996
 – Szentiványi M Jr et al. Circ. Res. 81: 988-995. 1997
 – Szentiványi M Jr et al. Hypertension 33: 440-445. 1999
 – Szentiványi M Jr et al. Hypertension 35: 418-423. 2000
 – Szentiványi M Jr et al. Hypertension 35: 740-745. 2000
 – Szentiványi M Jr et al. Am J Physiol 283: R266-R272. 2002
György  Thaler
Development Director, Gedeon Richter Plc., Hungary
György Thaler joined Gedeon Richter Plc in 1983 as a chemical engineer. After 
spending some years as a medicinal chemist he completed his Ph.D. at the Tech-
nical University of Budapest in synthetic organic chemistry. After holding diﬀ er-
ent management positions he is Development Director of the Richter Group since 
1992. His current responsibilities are product development and regulatory af-
fairs. He is the chairman of the Legal Aﬀ airs Committ ee of Medicines for Europe, 
since its establishment in 2002. He is also serving as Executive Board member of 
Medicines for Europe.
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Irem Yenice
Head of Biotechnology and R&D Director, Arven, Turkey 
Irem Yenice graduated from Hacett epe University in 2007 with a Ph.D. degree in 
Pharmaceutical Technology. After working as a researcher at Hacett epe Universi-
ty, she joined Sanovel in 2007, a Turkish Pharmaceutical Generic Company of 
TOKSOZ Group.  She has played leading roles in in the company’s biosimilar 
program. Over the last nine years, she set up the biotechnology division for bio-
similars comprising manufacturing and characterization experts.  In 2014, Dr. 
Yenice and her team moved to ARVEN, a company of TOKSOZ Group, with a vi-
sion to develop high-tech products committ ing to requested quality standarts to-
ward global recognition. Dr. Yenice and her team developed  the fi rst biosimilar 
of Turkey, biosimilar fi lgrastim, from cell line to product.  She has been working 
as the head of Biotechnology Department and R&D Director at Arven since December 2016.
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Plenary Lectures
Pl-1
 Trends of drug research 
and development in Europe
 BILENSOY, E.
President of European Federation of Pharmaceutical Sciences 
(EUFEPS)
Department of Pharmaceutical Technology, Hacett epe
University, Faculty of Pharmacy, Ankara, Turkey
Drug research and development has been under 
focus since the last century globally, as the world is 
moving towards an aging population. In the mean-
time, in-depth novel techniques incorporating 
pharmacogenomics, allow the diseases to be bett er 
elucidated than before. This breakthrough paved 
the way to a more integrated approach based on 
systems pharmacology for drug research and de-
velopment. In this lecture, new trends in drug de-
livery, drug development and research will be dis-
cussed in the light of recent reports and strategic 
research and innovation agenda from European 
Technology Platform. It has to be noted that drug 
research and drug development is becoming more 
and more concentrated on the patient and individ-
ualized/precision medicine is the driving force in 
today’s pharmaceutical research in all disciplines 
in this fi eld. This eﬀ ect is starting to diﬀ use into 
the pharmacy practice and even more into the 
pharmacy education in Europe. This lecture will 
focus on current trends in pharmaceutical research 
and give an insight on EUFEPS initiatives to sup-
port these new trends in pharmaceutical research 
and innovation. EUFEPS is a federation of 18 mem-
ber societies from diﬀ erent countries in Europe as 
well as individual members and member institu-
tions. Based on Frankfurt Germany, EUFEPS is a 
an organization active in scientifi c events, educa-
tion and training for professionals in pharmaceuti-
cal sciences, regulatory activities about medicines 
and medical devices with position papers and re-
ports on drafts guidelines by EMA. EUFEPS has 
established Networks to bring together individu-
als supported by member societies on Bioavailabil-
ity/Biopharmaceutics, Pharmacogenomics, Quality 
by Design/Process Analytical Technology, Nano-
medicine, Safety Sciences, Veterinary Drugs. Sys-
tems Pharmacology and Regulatory Sciences.
Pl-2
Challenges of the pharmaceutical industry: 
Where are we heading?
 THALER, GY.
Gedeon Richter Plc., Budapest, Hungary
Many people think that the pharmaceutical in-
dustry reached its golden era some decades ago 
and those opportunities we had then, will never 
return again. There are several factors which 
tend to support that statement. During the 
course of the presentation we will hear some of 
them including the investors’ view and demo-
graphic changes which impacted the behaviour 
of social security systems (the payers). Political 
level infl uences in some countries also may ef-
fect the room for operation of the companies. 
The declining eﬃ  ciency of the classical pharma-
ceutical R&D and the rise of biotech products 
also shape the future of the industry. What are 
the growth opportunities for the pharmaceutical 
industry today? What are the global market 
trends that help or are against growth? What re-
alistic chances a mid-sized company has in Hun-
gary to survive? What are the most pressing lim-
itations we have? What kind of strategic direc-
tions we may consider and what are the key ele-
ments of growth? These questions will be tack-
led in the presentation.
Pl-3
New chemical enrtity research and development 
in Hungary: challenges and opportunities
 GREINER, I .
Research Director, Gedeon Richter Plc., Budapest, Hungary
BACKGROUND: During the past twenty fi ve years 
new chemical entity research delivered very limited 
results in Hungary. This was not only becasue com-
panies would like to hide their results, if any, before 
their competitors, but also because academic re-
search  did not publish any related paper or article. 
During the last two years something started to 
change. 
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AIMS: Based ont he last two years results hav-
ing listed and analysed future opportunities and 
trends will be discussed.   
RESULTS:  As it is well known from the litera-
ture Gedeon  Richter plc. granted positive opinion 
from EMA CHMP to its original drug, cariprazine 
for schisophrenia indication. FDA has approved 
the same product nearly two years ago for the pre-
vious and one more (bipolar mania) indication. 
This is defi nitely the fi rst drug which was discov-
ered, and developed with diﬀ erent partners by a 
CEE company and approved on 70% of the world 
market [1]. Beside this result two small Hungarian 
companies called Avidin adn Soneas announced 
that phase I. study had been successfully fi nished 
with their investigational drug against cognitive 
disorders[2]. Last year Hungarian chemist at Servi-
er (Budapest) publish a Nature paper [3] about a 
new clinical candidate and it was also revealed that 
a unique cooperation between academia and two 
SMEs resulted a clinical candidate SzV-1287 [4].
CONCLUSIONS: Based ont he latest results of 
Hungarian pharma R&D present position of Hun-
gary in this fi eld can be regarded as special in this 
region and further support of this inspirative en-
vironment can strengthen its role in the world 
pharma R&D.
REFERENCES: 
1. www.richter.hu (2017-05-25, 10 pm)
2. htt p://www.soneas.com/hu/sikeres-fazis-i-vizsgalatok-
a-q134r-k-gyogyszerjeloltt el-2/ (2017-05-25, 10.30 pm)
3. Kotshy, A. et al. Nature 538, 477-482 (2016) 
4. Horváth, Á. et al. Nature Scientifi c Reports, doi: 10.1038/
srep39863
Pl-4
Supporting health market innovation 
by OGYEI
 SZOLYAK, T.
National Institute of Pharmacy and Nutrition, Budapest, 
Hungary
The majority of new pharmaceutical develop-
ments, as well as innovations in the fi elds of medi-
cal devices and health-focused nutrition products 
are initiated by academic research groups. How-
ever, translating basic research into applied re-
search is often problematic. Realizing this chal-
lenge has inspired the foundation of the EU Inno-
vation Network, and the Innovation Oﬃ  ce of 
OGYEI as one of the fi rst innovation oﬃ  ces estab-
lished by European pharmaceutical agencies. The 
Innovation Oﬃ  ce aims to support early develop-
mental programmes in order to promote that re-
search groups execute their innovative approach-
es. Upon developing the core concepts of the Inno-
vation Oﬃ  ce we have realized that the scope of 
our activities should be widened to include pro-
viding advice to pharmaceutical companies, and 
also supporting that developers get a bett er access 
to the resources oﬀ ered by the European Medi-
cines Agency. Besides, the Innovation Oﬃ  ce is 
aimed to serve as a methodological centre of 
OGYEI, and hereby aims to foster conversation 
between Hungarian stakeholders committ ed to 
health development.
Pl-5
Restoring programmed cell death – a new 
approach in cancer therapy
 KOTSCHY, A.
Servier Research Institute of Medicinal Chemistry, Budapest, 
Hungary
Tumour cells that harbour genetic mutations and 
are recognised as abnormal should be naturally 
eliminated but they maintain their existence by a 
combination of multiple activities – also known as 
the hallmarks of cancer. One of these hallmarks is 
the evasion of apoptosis, the programmed cell 
death. The restoration of the apoptotic cascade in 
tumour cells has long been recognised as a prom-
ising way to treat cancer but the major members of 
this protein family, BCL2, MCL1, and BCL-xL have 
long remained elusive targets decades long for 
drug discovery. Recently the decade long eﬀ orts of 
the pharmaceutical industry have been rewarded 
by the identifi cation of potent and selective inhibi-
tors for some family members.
The presentation overviews the principal phar-
macological and chemical challenges of targeting 
this protein family and presents the recent scien-
tifi c [1] and pharmacological achievements in this 
area.
REFERENCES: 
1. Kotschy A. et al. Nature, 538, 477-482 (2016).
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Pl-6
Next generation sequencing: the future of 
personalised healthcare (PHC 2.0)
 SZENTIVÁNYI, M.
Roche (Hungary) Ltd., Budaörs, Hungary
Innovative drugs signifi cantly contribute to the 
success of our healthcare including to the fi ght 
against cancer. Some drugs act in specifi c pa-
tient populations which require diﬀ erent diag-
nostic tools. This is called Personalised Health-
care (PHC) where a given proportion of the pa-
tients can be chosen who will have bett er chance 
to respond to a given drug. Evidence shows that 
personalised targeted therapies are associated 
with signifi cantly bett er outcomes than cytotox-
ic agents. However, this approach is unable to 
treat a signifi cant portion of the patients and 
many patients do not have access to novel diag-
nostics and medicines. Therefore a new method 
is necessary to give an even higher chance to 
cancer survival with a good quality of life. The 
technology of Next Generation Sequencing 
(NGS) combined with sett ing up new databases 
enables us to fi nd the ways how a single patient 
can be treated. With NGS more genetic altera-
tions associated to diﬀ erent cancer types can be 
found than with single gene testing, the current 
method. This is called PHC 2.0 which provides 
new treatment options to 70 % of the patients in-
cluding oﬀ -label use of current treatments and 
targeted enrollment into clinical trials. This lat-
ter can improve the recruitment of the trials re-
sulting in faster and more accurate drug devel-
opment which will save money for the society. 
In addition PHC 2.0 shows to appr. 10 % of the 
patients that no current treatments are available 
for them saving them from the side eﬀ ects and 
other complications of any drug currently avail-
able on the market. In conclusion, new genomic 
sequencing technology (NGS) together with ad-
vanced bioinformatics and reporting are avail-
able to help physicians understand patient tu-
mour profi les and improve personalised patient 
care.
REFERENCES: 
1. Schwaederle et al. Mol Cancer Ther (2015) 
2. Frampton et al. Nat. Biotechnol. (2013)
Pl-7
“It is in your hands” – How healthcare 
professionals can ensure their safety when 
handling hazardous drugs
 BATKA, G.
Szent Rafael Hospital of Zala County, Zalaegerszeg, Hungary 
BACKGROUND
Handling chemotherapy drugs constitutes high 
risk to the healthcare professionals. Compounds 
with carcinogenic, mutagenic, reprotoxic (CMR) 
potency should fully be removed from work envi-
ronments. Unfortunately, these carcinogens do 
not have a defi ned safety level. Depending on in-
dividual sensitivity, one molecule may cause a se-
rious and irreversible health impact. Assessing en-
vironmental contamination and keeping it below 
detection limits are critical.    
AIMS
To assess contamination due to cytotoxic drugs in 
hospital pharmacies, to evaluate the eﬃ  cacy of a 
Closed System Transfer Device (CSTD, Tevadap-
tor) in reducing cytotoxic contamination and in 
preventing pharmacy staﬀ  from exposure of haz-
ardous drugs.  
RESULTS
We carried out a study in 13 Hungarian Hospitals 
where cytotoxic drugs prepared using the tradi-
tional needle/syringe methods and then using a 
CSTD (Tevadaptor) to assess the diﬀ erence in lev-
els of contamination in main areas, such as vial 
surface, laminar box - preparation area, infusion 
bag surface, gloves of pharmacists. Two sets of 
wipe samples were taken following the ESOP 
study protocol: the fi rst to establish baseline con-
tamination and a post intervention measure to as-
sess the eﬃ  cacy of Tevadaptor to reduce environ-
mental contamination. The samples were sent to a 
validated laboratory (IUTA in Duisburg, Germa-
ny) for chromatography analysis. Higher levels of 
contamination were found at baseline, while us-
ing CSTD (Tevadaptor) to manipulate cytotoxic 
drugs signifi cantly decreased contamination.  
CONCLUSIONS
Contamination was reduced to below the level of 
detection after a CSTD (Tevadaptor) was imple-
mented and both the environment and healthcare 
professionals remained contamination free. These 
results showed that the use of a CSTD in handling 
hazardous drugs is highly recommended.  
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Pl-8
Biosimilars landscape – Development, 
regulatory & market access challenges
 BOGSCH, E. JR.
Biotechnology R&D, Gedeon Richter Plc., Budapest
The past decades have seen the breakthrough of 
biologics within the pharmaceutical sector. As 
many of these blockbuster biological products’ 
patents expire, there is an enormous opportunity 
for biosimilar products to make these, often life-
saving, medicines accessible to considerably more 
patients, particularly in the fi elds of oncology and 
immunology.
The objective of the presentation is to give an 
overview of biosimilar products, their develop-
ment challenges, the regulatory requirements they 
must adhere to and a view of their market poten-
tial.
Development and manufacture of biologics is 
very diﬀ erent to traditional small molecule phar-
maceuticals. Stable expression of large protein 
molecules and their purifi cation are the key chal-
lenges for drug substance development and man-
ufacture. Most biologics are parenteral products 
requiring appropriate fi nal formulation develop-
ment and specifi c fi ll & fi nish manufacturing tech-
nologies.
The precise characterisation of biologics poses 
an exciting challenge for analytical teams the 
world over, and is of pivotal importance in the de-
velopment of biosimilars. In fact, the very strin-
gent regulatory requirements applied to biosimi-
lar developments are in part due to the diﬃ  culty 
posed in precise characterisation of such macro-
molecule based medicines. Signifi cant clinical de-
velopment programmes are expected of biosimi-
lars, very diﬀ erently to small molecule generic de-
velopments.
Further to development and regulatory chal-
lenges, market access requirements also diﬀ er and 
present new challenges as well as opportunities 
for companies with biopharmaceutical portfolios. 
Development, manufacture and commercialisa-
tion of biologics, including biosimilars, have a 
higher entry barrier than small molecule develop-
ments due to diﬀ erentiated know how require-
ments, high capital investment, development and 
manufacturing costs in addition to changing regu-
latory and commercial landscapes.
Pl-9
Focus on biosimilar fi lgrastim development 
 YENICE, I .,  YILMAZ, E.,  UZGUN, M., ET AL. 
Head of Biotechnology and R&D Director, Arven İlaç ve San. Tic. 
A.Ş., İstinye Mah. Balabandere Cad. No:14, 34460, Sarıyer, Istanbul
Biological medicines are made by or derived from a 
biological source, such as a bacterium, yeast or 
mammalian based cells. The active substances of bi-
ological medicines are larger and more complex 
than those of non-biological medicines. Develop-
ment of biosimilars is much more challenging than 
generic small molecules due to their complexity of 
structure and manufacturing processes and their 
potential risks for increased immunogenicity. 
Therefore, specifi c regulatory approval pathways 
and guidelines must be followed during the devel-
opment of biosimilars.   Determination of the bio-
similarity is based on the comparison of the candi-
date biosimilar product and its reference product 
with respect to structure (by using chromatograph-
ic, electrophoretic techniques , function (receptor 
binding and bioassay studies, etc), animal toxicity, 
human pharmacokinetics (PK) and pharmacody-
namics (PD), clinical immunogenicity, and clinical 
safety and eﬀ ectiveness.  A rigorous scientifi c pro-
cess for an evaluation of potential diﬀ erences be-
tween candidate biosimilar product and its refer-
ence product is essential to ensure quality, safety 
and eﬃ  cacy of the biosimilar.  This presentation 
will focus on a Arven’s fi rst biosimilar product (bio-
similar fi lgrastim) and it’s development history. De-
tailed manufacturing processes, in-process controls, 
material and product testing, also structural and 
functional in vitro characterization studies includ-
ing physical, chemical, biological tests, and compar-
ative studies against the reference licensed drug 
product, will be presented. Non-clinical studies in-
cluding in vitro and in vivo biological studies, and 
toxicokinetic study with biosimilar fi lgrastim, prior 
to initiating clinical development were carried out 
in accordance with related EMA guidelines.
REFERENCES:
1. Similar biological medicinal products, CHMP/437/04 
Rev. 1, 2015.
2. Biosimilar medicinal products containing recombi-
nant granulocyte-colony stimulating factor (Annex to 
guideline on similar biological medicinal products con-
taining biotechnology-derived proteins as active sub-
stance: non-clinical and clinical issues), EMEA/CHMP/
BMWP/31329/2005.
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Pl-10
Target and biomarker discovery in an open 
ecosystem
 SZALMA, S.
Global Research & Development Center, Takeda 
Pharmaceuticals, Greater San Diego Area, USA
One of the most important characteristics of a 
successful drug discovery enterprise is to be able 
to develop a treatment for the right target for the 
right disease and for right population. An addi-
tional aspect is that the developed solution has to 
be competitive and commercially viable so that 
the commercial success provides the means for 
the pharmaceutical enterprise to continue its 
R&D and commercial operation.  The Data Sci-
ence Institute has been on the forefront of trans-
forming the practice of drug discovery and devel-
opment within Takeda Pharmaceutical Company. 
Our R&D leadership is committ ed to explore 
ideas in a very open, pre-competitive biomedical 
ecosystem.  By converging external and internal 
best practices, we strive to renew the pipeline of 
novel potential treatments for multiple therapeu-
tic areas of focus such as CNS, gastroenterology 
and oncology. We are championing two main 
concepts. Sustainable target selection is the fi rst 
step – we should start by inspecting the heteroge-
neity of medical practice and patient pathways 
across target markets and to understand regula-
tory and market conditions so that the selected 
targets can be sustained through the arduous 
road of drug development and regulatory ap-
proval.  The other concept is to apply a multimod-
al approach to biomarker discovery so that the 
right disease and right population can be identi-
fi ed. We are generating deep biomolecular and 
phenotypic data from patients, harmonize and 
standardize the practice of data collection and 
processing and research novel algorithms and 
methods to extract meaningful information to en-
able evidence-based decision making. In this talk 
I will present several use cases describing how 
we transform the wealth of evidence derived 
from internal studies, academic collaborations, 
public-private partnerships and pre-competitive 
consortia into insights by applying machine 
learning and advanced analytics and informatics 
tools.    
Pl.11
Translational medicine taking discoveries to 
patients benefi ts
 HEGYI, P.
Centre for Translational Medicine, University of Pécs, Pécs, 
Hungary
Translational medicine forms a bridge between 
clinical and basic research. It is an umbrella term 
for ‘translating’ preclinical research fi ndings to 
everyday clinical practice and patient care, thus 
going from bench to bedside. It also involves ex-
periments that facilitate a bett er understanding of 
the development of diseases within basic re-
search, the discovery of pharmaceutical points of 
att ack, eﬀ ect studies applicable to human thera-
pies, the biological study of human diseases and 
new improvements in treating human diseases. It 
also includes non-human or non-clinical studies, 
which can even form the foundation for new clin-
ical applications and drug development trials in 
clinical phases 1–3. In the 21st century clinical 
medicine should be divided into two main cate-
gories: general and translational medicine. The 
central work of general medicine is to provide ba-
sic care and graduate training, while translational 
medicine – besides the good care - engages in 
clinically-oriented studies (thus increasing scien-
tifi c output), pharmaceutical phase trials (to dis-
cover new therapies and grow institutional in-
come) and postgraduate training (to raise the 
number of PhDs and other academic degrees). Pa-
tients are only aﬀ ected by translational medicine 
if they undertake to participate in a clinical study 
(based on the National Institutes of Health (NIH) 
model). Another feature of the system is its multi-
disciplinary nature; that is, it facilitates theoreti-
cal and clinical research in particular medical 
specialties in coordination with various fi elds (IT, 
mathematics, clinical research, theoretical re-
search and management). In this lecture I will 
drive through the audience from the bedside to 
the laboratory and backwards by presenting our 
recent discoveries in acute pancreatitis.
REFERENCES: 
1. htt p://www.pancreas.hu/en 
2. htt p://www.tm-pte.org/
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Oral presentations
O-1 
Design and synthesis of novel inhibitors 
targeting pathogenic protozoan parasites
 BOIJE AF GENNÄS, GUSTAV
Drug Research Program, Faculty of Pharmacy, University of 
Helsinki, Viikinkaari 5E, Helsinki, Finland.
Malaria and leishmaniasis are caused by protozo-
an parasites that are responsible of major morbidi-
ty and mortality across the world, and new specif-
ic therapies are greatly needed. Several of the dis-
eases associated to protozoan parasites are classi-
fi ed as “neglected diseases” by The World Health 
Organization (WHO). The protozoan parasites also 
cause health problems in developed countries, e.g. 
Toxoplasma causes congenital toxoplasmosis and 
infections in immunosuppressed individuals. 
Membrane-bound pyrophosphatases (mPPases), 
which have no human homologs, are essential in 
parasites. It was recently shown that mPPases 
present in protozoan parasites have a unique mo-
lecular structure.1 They are thus ideal drug targets.
At present, there are no pharmacologically rele-
vant inhibitors for mPPases.2 Here, our recently 
identifi ed hit compounds will be presented for the 
fi rst time. We decided to optimize one of the four 
mPPase hit compounds to improve the binding ac-
tivities and to enhance the drug-like properties. 
Furthermore, in-house compounds yielded three 
more compound classes that showed inhibition of 
mPPase. To date, we have developed novel com-
pounds showing IC50 values between 1 and 10 μM. 
These inhibitors have been subsequently screened 
against Plasmodium and Leishmania species, and 
preliminary results show that the best compounds 
inhibited Plasmodium falciparum with IC50 values of 
7-19 μM, and Leishmania donovani with GI50 values 
of 0.6-22 μM. Furthermore, cytotoxicity studies 
showed that these compounds are well tolerated. 
These compounds will be further improved with 
medicinal chemistry tools into viable lead com-
pounds showing favorable drug-like properties. 
Subsequently, the inhibitors will be validated in in 
vivo animal models. Therefore, the ultimate goal of 
this ground-breaking project will be novel drug-
like inhibitors of pathogenic protozoan parasites.
REFERENCES:
1. Kellosalo, J., et al. Science, 337, 473–476 (2012).
2. Shah, N.,  et al. AIMS Biophysics 3, 171-194 (2016).
O-2
Exploring protein kinase CK2 by designing 
heterocyclic compounds
 BOUAZIZ, Z.,  LOMBERGET, T., 
 MARMINON, C.,  ETTOUATI, L.,  COCHET, C., 
 JOSE, J .,  LE BORGNE, M.
EA 4446 B2MC, ISPB-Faculté de Pharmacie, Université Claude 
Bernard Lyon 1, Lyon, France
BACKGROUND: There is considerable interna-
tional att ention related to new inhibitors of ca-
sein kinase 2 (CK2), a highly conserved serine/
threonine protein kinase that is playing a key 
role in cell growth, proliferation and regulation 
of apoptosis.1 Inhibition of CK2 kinase activity is 
become an att ractive way to stop growth of can-
cer cells (e.g. glioblastoma, renal cell carcinoma, 
acute myeloid leukemia). In parallel, our aca-
demic Group mainly develops synthetic meth-
ods that provide access to biologically active 
compounds. Then we progressively optimized 
the relationships between structures and activi-
ties for CK2.2
AIMS: The objective of our study is to use and 
functionalize diverse chemical scaﬀ olds according 
to the structural features of CK2: ATP-binding site, 
CK2alpha-CK2beta interface, allosteric sites.  
RESULTS:  Indeno[1,2-b]indoles, aminothia-
zoles and indoles were used and developped to 
target CK2, with the use of an international Med-
Chem toolbox.
CONCLUSIONS: The presentation presents di-
verse strategies for the development of new bioac-
tive small molecules as CK2 inhibitors. Sharing re-
search also allows eﬃ  cient work...
REFERENCES: 
1. Jose J. et al. Pharmaceuticals (Basel), 10, 33 (2017)
2. Jabor Gozzi G. Et al. J Med Chem 58, 265-77 (2015)
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O-3
Stereoselective synthesis, synthetic and 
pharmacological applications of chiral 
aminodiols and diaminoalcohols
 SZAKONYI, ZS.
Institute of Pharmaceutical Chemistry, University of Szeged, 
Szeged,Hungary
BACKGROUND: Although pharmacologically ac-
tive aliphatic aminodiols and diaminoalcohols 
have been studied intensively, less att ention has 
been paid to the alicyclic analogues, even though 
they are useful synthetic building blocks for the 
synthesis of 1,3-heterocycles. Chiral aminodiols 
can also be successfully applied as catalysts in en-
antioselective syntheses.1
AIMS:  The goal of present lecture is to sum-
marise and overview the latest results on the fi eld 
of the synthesis and application of 3-amino-1,2-di-
ols and diaminoalcohols, building blocks pre-
pared from natural sources.  
RESULTS:  The synthesis of chiral aminodiols 
followed two strategies: nucleophilic ring opening 
of monoterpene-based epoxyalcohols or OsO4 cat-
alysed stereoselective dihydroxylation of protect-
ed allylic amines. Diaminoalcohols were prepared 
starting from pinane-based protected allylamines 
via stereoselective epoxidation followed by ami-
nolysis of the resulting oxyrane ring. Each synthe-
sis was started from commercially available natu-
ral monoterpenes, as chiral sources. Regioselectiv-
ity of ring closure of aminodiols was also studied 
in detail.
CONCLUSIONS: The obtained monoterpene-
based tridentate ligands were applied as chiral li-
gands in the enantioselective addition of diethylz-
inc to aromatic aldehydes.  Monoterpenic amino-
diol-based nucleoside analogues were investigat-
ed as highly selective novel  NCX (sodium–calci-
um exchanger) inhibitors.
This work was supported by Hungarian Re-
search Foundation (K112442).
REFERENCES: 
1. El Alami M. S. I., et al. Chem Eur J 21, 1398-1413 (2015)
O-4
Continuous-fl ow solid-phase synthesis of 
peptides with exceptionally low amino acid 
consumption
 MÁNDITY, I .,  SZLOSZÁR, A.,  FÜLÖP. F.
Institute of Pharmaceutical Chemistry, University of Szeged, 
Szeged, Hungary
BACKGROUND: The importance of synthesis of 
peptides is warranted by the need for peptide-
based medicines. Nowadays, peptide synthesis is 
performed almost exclusively on solid supports. 
The solid-phase peptide synthesis (SPPS) tech-
nique has subsequently been progressively devel-
oped. However, still a general drawback of these 
methodologies are the high number of amino acid 
equivalents required for total coupling.
AIMS: Continuous-fl ow (CF) approaches have 
recently gained in signifi cance among synthetic 
techniques. We show here that the number of ami-
no acid equivalents used for SPPS can be lowered 
drastically to around 1.5 equivalents through the 
application of a CF technique and by complete re-
action parameter optimization.  
RESULTS:  Under the optimized conditions the 
couplings of all 20 proteinogenic amino acids with 
1.5 amino acid equivalents proceeded with excel-
lent conversions. To demonstrate the eﬃ  ciency of 
the CF-SPPS methodology, known diﬃ  cult se-
quences were synthetized in automated way. The 
purities of the resulting crude peptides were com-
parable with literature result, but the CF-SPPS 
methodology requires much less amino acid and 
solvent. As further evidence of the eﬀ ectiveness, 
β-peptide foldamers, N-methylated peptides and 
protected sequences were synthetized in excellent 
yields.
CONCLUSIONS: A highly eﬃ  cient CF peptide 
synthesis technology was developed. Importantly, 
exotic and expensive artifi cial amino acids were 
incorporated into sequences by an automated way 
through the use of exceptionally low numbers of 
amino acid equivalents at low costs, thus the syn-
thesis of such sequences was carried out by a con-
siderable cheaper way.
REFERENCES: 
1.  Mándity, I. M., et al. ChemSusChem 7, 3172–3176 (2014)
2. Mándity, I. M., et al. Chem Rec 16, 1018–1033 (2016)
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O-5
Homochirality of β-peptides: a signifi cant 
biomimetic property of unnatural systems
 NEKKAA, I .,  MÁNDITY, I . M.,  FÜLÖP, F.
Institute of Pharmaceutical Chemistry, Szeged, Hungary
BACKGROUND: Homochirality, an interesting 
phenomenon of life, is mainly an unresolved 
problem and was thought to be a property of liv-
ing matt er. Numerous investigations have been 
carried out by several scientists in case of natural 
α-peptides.[1] Foldamers are artifi cial self-organiz-
ing systems, display considerable tendency to 
form high stable and versatile secondary struc-
tures, e.g. helices, strands, turns. The most promi-
nent representatives of these oligomers are the 
β-peptides of which possess additional biomimet-
ic properties mimicking natural α-peptides. In 
case of beta-peptides the stereodiscriminative 
chain-elongation is still ambiguous compared to 
natural α-peptides.[2]
AIMS: Our aim was to investigate how the sec-
ondary structure can aﬀ ect the stereochemical 
course of the homochiral oligomer formation in 
the stereochemically discriminated synthesis of 
β-peptides with various side-chains shape and 
secondary structures in order to gain some in-
sights into the origin of biological homochirality.  
RESULTS:  The preliminary results show, that 
there is a strong propensity for homochiral ho-
mooligomer formation. Furthermore, we found 
that the diastereoselecivity increases in the pres-
ence of water which can be explaining due to the 
water induced self-association of peptides. Note-
worthy, the diastereoselecivity was chain-length 
dependent. 
CONCLUSIONS: We conclude that the biologi-
cal homochirality as a biomimetic property is also 
occurring with unnatural compounds, like 
β-peptide foldamers. We confi rmed that the self-
association of peptides is a crucial fact behind the 
homochirality phenomenon.
REFERENCES: 
1. Saghatelian A. et al. Nature 409, 797-801 (2001)
2. Hill R R. et al. Org. Biomol. Chem, 965-972 (2003) 
O-6
Hypothesis driven versus Genome Wide 
Association Studies: Which one is more relevant 
for precision medicine?
 BAGDY, GY.1, 2 ,  PETSCHNER, P.1, 2 , JUHASZ, G.1, 2, 3
1Department of Pharmacodynamics, Semmelweis University, 
Budapest, Hungary 
2MTA-SE Neuropsychopharmacology and Neurochemistry 
Research Group, Hungarian Academy of Sciences, Semmelweis 
University,  Budapest, Hungary 
3MTA-SE-NAP B Genetic Brain Imaging Migraine Research 
Group, Hungarian Academy of Sciences, Hungarian Brain 
Research Program, Semmelweis University, Budapest, Hungary
With the revolution of our knowledge and genotyp-
ing techniques deep genotyping through GWAS 
(Genome Wide Association Studies) and NGS (Next 
Generation Sequencing) methods became preferred 
against traditional methods like hypothesis driven 
candidate gene studies. The gap between GWAS 
and candidate gene studies is becoming continuous-
ly wider. Theoretically GWAS oﬀ ers a favourable hy-
pothesis free approach that is relatively inexpensive 
and allows to collect data of tens of thousands pa-
tients and controls. Limitations are also evident, 
namely, only a few genome-wide signifi cant hits 
emerge, and even these risk variants are present 
only in an extremely low rate in the patient popula-
tion. An even more signifi cant problem is that we do 
not take into account personal details of the patients, 
such as specifi c symptoms, case history, detailed 
drug responses or environmental factors. For preci-
sion medicine we have to separate patient groups for 
diﬀ erent treatment regimens. The separation could 
be performed on the basis of genetic variants, phe-
notypic measurements (e.g., symptoms), environ-
mental  factors (e.g., exposure to drugs, stressors) or 
a combination of these.  Although traditional medi-
cal thinking suggests that these parameters could be 
used as distinct entities, there is accumulating evi-
dence that these parameters strongly interact with 
each other, and therefore a useful classifi cation and 
also the assignment of each individual requires all 
these information regarding each person. For exam-
ple, genes do not directly aﬀ ect the development of 
common disorders, but rather modify the eﬀ ect of 
risk environmental factors leading to disease symp-
toms in susceptible individuals. 
REFERENCES:
1. Juhasz G, et al. PNAS 111, E1666-1673. (2014)
2. Kovacs D, et al. Ann General Psychiatry 13, Paper 17. 
(2014)
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O-7
Characterization of the bacterial winged-helix 
domain of RecQ helicase. A novel antibacterial 
target. 
 TÖKÖLI A.,  BARTUS É.,  HEGEDÜS ZS., 
 SZAKONYI G.,  MARTINEK T.
Institute of Pharmaceutical Analysis, Faculty of Pharmacy, 
University of Szeged, Szeged, Hungary
BACKGROUND: Nowadays, most of the clinically 
relevant antibiotics are small molecular enzyme 
inhibitors, and the increasing appearance of mul-
tidrug resistant bacteria is becoming an urgent 
problem. Inhibiting bacterial protein-protein in-
teractions may provide a new tool for fi ghting 
against resistant strains, since developing point 
mutation on one target molecule is not enough for 
survivability. Artifi cial beta-peptide foldamers 
provide a good option due to their high molecule 
surface/atom number ratio, and potentially long 
half-life in vivo.
AIMS: A well-studied interaction between E. coli 
RecQ winged helix domain and the C-terminal 8 
amino acids of single-stranded DNA-binding protein 
(SSB) was described using NMR, provides a good 
model for studying this phenomenon (1). In order to 
study this interaction the recombinant production of 
RecQ winged helix domain was necessary.    
RESULTS:  Gene coding RecQ-WH was ampli-
fi ed from E. coli DH5α using PCR reaction, and was 
cloned into pET28 expression vector. The protein 
was overexpressed in E. coli BL21(DE3) strain, the 
system was optimized for M9 minimum media for 
further possible isotope labelled protein produc-
tion. Ni-NTA aﬃ  nity chromatography was used as 
fi rst purifi cation method. Second, the eluted pro-
tein samples were applied to cationic ion-exchange 
chromatography. Lastly, RecQ-WH was further 
purifi ed by size exclusion chromatography. There-
after, in order to map the protein, a pulldown assay 
was performed using a beta-peptide foldamer frag-
ments (2) in the presence or in the absence of the 
previously synthetized SSB-C-terminal peptide. 
The foldamer fragments (H12 or H14 helices) con-
tained aromatic, polar, apolar and charged groups 
on their proteogenic surfaces. The protein was 
found to bind diﬀ erent H12 and H14 helices. 
CONCLUSIONS: Further analysis of the inter-
action is needed between the protein and the se-
lected foldamer helices. Dissociation constant of 
each foldamer helix must be determined using 
ITC. The best binders, and the nature of the inter-
action are going to be investigated in NMR using 
isotope labelled protein.
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
REFERENCES: 
1. Shereda R. et al. J Mol Biol. 386, 612-625 (2009)
2. Bartus É. et al. ChemOPEN. 6, 236-241 (2017)
O-8
 Nanoscale analysis of prostate cancer tissue 
microarrays
 TURIÁK , L.1,  RÉVÉSZ, Á.1,  ÁCS, A.1,
  VÉKEY, K.1,  DRAHOS, L.1,2
1MS Proteomics Research Group;
2NAP B MS Neuroproteomics Group, Research Center for 
Natural Sciences, Hungarian Academy of Sciences, Budapest, 
Hungary
BACKGROUND: Cancer is the leading cause of 
death in the developed countries. Detecting altera-
tions at the molecular level linked to cancer is a 
key aspect in developing new strategies for treat-
ment and for diagnosis. For this purpose tissue bi-
opsies are analyzed using various analytical tech-
niques, such as mass spectrometry, and may re-
sult in the identifi cation of novel biomarkers. Tis-
sue microarrays (TMAs) contain a large number of 
biopsies prepared in an array format. The use of 
T MAs in biomedical workfl ows is signifi cantly in-
creasing in the past few years; the  main challenge 
is the limited amount of sample available (1.5 mm 
diameter cores). 
AIMS: The aim of our work is to apply advanced 
 nanoLC-MS(MS) techniques to reliably identify 
various glycans and proteins from histological tis-
sue surfaces and to apply the workfl ow for the 
analysis of prostate cancer TMAs. Integrating pro-
teomics data with glycan analysis has recently be-
come widespread. Glycosaminoglycans (GAGs) 
play crucial roles in cancer progression; however, 
their nanoscale analysis is still considered an ana-
lytical challenge compared to proteomics methods, 
which are relatively straightforward. 
RESULTS: Proteins and GAGs were analyzed us-
ing nanoLC-MS(MS) following enzymatic digestion 
and extraction from the surface of prostate cancer 
TMA slides. More than 500 proteins were identifi ed 
and quantifi ed using label free quantitation from the 
1.5 mm dia meter cores, including several proteogly-
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cans (e.g., perlecan, versican, lumican) that had been 
previously implicated in prostate cancer. For the 
analysis of the GAG disaccharides self-packed na-
noscale HILIC-WAX columns were packed and neg-
ative ionization mode was used. Strategies for the 
analysis of the limited amount of GAGs extracted 
from the surface of TMAs will be shown.
CONCLUSIONS: Label free quantitation 
showed that the amount of proteoglycans was in-
creased in cancer. Limited amount of GAG chains 
were successfully analyzed from TMA slides.
O-9
Analytical sciences: serving the changing 
pharmaceutical landscape
GANZLER, K., 
Analytical Department, Formulation Development, Gedeon 
Richter Plc., Budapest, Hungary
The pharmaceutical industry subsists in a highly regu-
lated environment where the regulatory and/or the GMP 
requirements set the standards higher in all related fi eld 
in order to ensure effi cacy, production consistency as 
well as to minimize patient risk under very competitive 
conditions. Analytical sciences serve the background of 
the pharmaceutical development from API/reference 
product characterization, to product development in-
cluding excipient and packaging selection and stability 
studies. Thus, the recent developments in the pharma-
ceutical landscape (continuous technology, biosimilar 
development, QbD technology development) need to be 
served by a well selected analytical arsenal. The present 
talk will show selected examples (without intended to be 
comprehensive) from the fi eld of the above mentioned 
areas with special focus how the correctly chosen ana-
lytical tool can speed up development. Finally the ex-
pense of such analytical solutions will also be discussed 
as “there is no free lunch” as the proverb says. 
O-10
Triple quadrupole or high resolution accurate 
mass: the quantitation conundrum
 HUMPHREY, P.
Thermo Fisher Scientifi c wissenschaftliche Geräte GmbH, Wien, 
Ausztria
For over twenty fi ve years, triple stage quadrupole 
(TSQ) mass spectrometers have been the default 
analytical instrument used in routine laboratories 
for accurate and precise, sensitive detection. The 
reason for this is based on the selectivity of TSQ 
instruments when operated in selective reaction 
monitoring (SRM) mode, providing the user with 
high quality data, which can be reported with 
confi dence.
There are however analytical challenges where 
TSQ mass spectrometers are not necessarily capa-
ble of providing the quality of data. This can be 
for many reasons, which one might address 
through sample preparation or chromatography. 
If however there are still issues, the desired sensi-
tivity, or more accurately signal to noise, might 
not be achieved.
With the advent of simple, user friendly high 
resolution accurate mass (HRAM) instrumenta-
tion such as the orbitrap, the analyst has another 
option to achieve the desired high quality sensi-
tive data with confi dence. With the use of HRAM, 
the user is able to achieve and often exceed the 
level of selectivity observed with a TSQ. This is 
particularly advantageous where fragmentation of 
compounds is problematic, or where there are is-
sues with matrix interference.
Orbitrap based instruments are being increas-
ingly accepted as complimentary to TSQ instru-
ments in the routine quantitation laboratory, ex-
panding the tool set available to the analyst. The 
presentation will focus and explore the use of TSQ 
and HRAM Orbitrap instruments for highly sensi-




Development and manufacture of biosimilar 
medicinal products 
 KOLLÁR, É.1,  GÁLOS, Z.2
1Gedeon Richter Plc. Biotechnology R&D, Budapest
2Gedeon Richter Plc. Injectable Development Department, 
Debrecen
BACKGROUND: Successful development and 
manufacture of biological medicinal products re-
quires specifi c knowledge from both the develop-
ment and manufacturing teams.
AIMS: One of the fi nal objectives of any bio-
pharmaceutical development is to develop a for-
mulation and manufacturing process, which result 
in stable drug products suitable for regulatory sub-
mission and market entry. The two presentations 
will give an overview about the entire develop-
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ment process illustrated with examples and their 
relevance regarding fi nal drug product quality.   
RESULTS:  Information coming from the devel-
opment phase supports designing plant scale 
drug product manufacturing procedures, howev-
er technology scale-up poses its own unforeseen 
challenges in the process of fi nalising the manu-
facturing technology. Product development focus-
es mainly on factors infl uencing protein stability 
and protein degradation. Formulation, compati-
bility and stress studies are all important aspects 
to take into account during development. GMP 
and other regulations have to be taken into con-
sideration while planning the manufacturing pro-
cedure in plant scale. Development and manufac-
ture of biosimilars requires considerable analytical 
support including a wide range of analytical 
methods. Another important aspect is that devel-
opment of drug substance and drug product man-
ufacturing technology have to proceed in parallel 
with analytical method developments. However, 
diﬀ erences between drug substance and drug 
product are less pronounced in the case of paren-
teral biologics than in the case of many small mol-
ecule pharmaceuticals.
CONCLUSIONS: Development of biopharma-
ceuticals needs to consider physico-chemical, bio-
chemical, biological, clinical, regulatory, GMP, 
marketing and fi nancial aspects all at the same 
time. Drug product development and manufac-
ture are impacted by drug substance development 
and proceed hand in hand. 
REFERENCES: 
1. Bee J. S. et al. J Pharm Sci 100, 4158–4170 (2011)
2. Rayfi eld W. J. et al. J Pharm Sci, In press, (2017)
O-12
Innovative approach to improve the fi lm coating 
eﬃ  ciency with applying of a continuous fi lm 
coater
 BAJDIK, J .
Meditop Pharmaceutical Ltd., Pilisborosjenő, Hungary
BACKGROUND: Increasing market need to coat 
sensitive products and fl exibility in batch size are 
major challanges to be considered during the de-
velopment and manufacturing of coated tablets.
AIMS: A new project had been initiated to 
build up a new internal approach to improve the 
eﬃ  cacy and quality of non-functional coating 
processes with possibilities to support the special 
market needs. Key elements of the project was the 
installation of a new machine with the following 
characters: diﬀ erent batch sizes can be coated 
without extensive scale up studies, adequate for 
short coating time to treat the heat sensitive prod-
ucts, gentle coating must be available and short 
changeover between batches is required to short-
en the time of the campaigns. Establishment of a 
new internal Ways of Working was also aimed.  
RESULTS: O’Hara FCC 75 continuous coater 
had been installed. It is the fi rst and currently the 
only this pilot size machine in EU Pharma sector. 
New approach had been eﬀ ectively developed 
and applied for diﬀ erent purposes. Soft tablets 
had been successfully coated with high quality. 
Tablets containing heat sensitive active were treat-
ed without the unacceptable degradation of the 
API, since the coating time was very short for the 
individual tablets. A comparative analysis of the 
time demand of a manufacturing campaign was 
carried out and the results exhibited relevant sav-
ing of time with the same order of magnitude en-
ergy consumption.
CONCLUSIONS: Using of unique continuous 
coater is advantageous for tablets suﬀ ering heat 
and mechanical sensitivities. Quality of these 
products is enhanced. Time and energy consump-
tion of the new system and the related approach 
are more eﬀ ective than for the existing pan coater 
system. The new approach is an exceptional op-
portunity to change and reorganize the existing 
products/processes. The associated fl exibility can 
be improved by the modifi cation of batch/cam-
paign sizes without any related development ac-
tivity and cost.
O-13
A novel insight into Fluid Bed Melt 
Granulation: Temperature mapping for the 
determination of granule formation with the In-
situ and spray-on techniques.
 KORTEBY, Y.1,2,  MAHDI, Y.2,  DAOUD, K.2, 
 REGDON JR., G.1
1University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs, Szeged, Hungary
2University of Sciences and Technology Houari Boumediene, 
Faculty of Mechanical Engineering and Process Engineering, 
Laboratory of Transfer Phenomena, Algiers, Algeria
BACKGROUND: Fluid Bed Melt Granulation has 
received wide interest in the research fi eld due to 
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its use of binders with low melting points, which 
makes the drying phase of the granulation unnec-
essary and hence proposes a more time and ener-
gy friendly process.
AIMS: The aim of this study is to give an ap-
proach to the conditions established in a conical 
fl uid bed granulator during the In-situ and Spray-
on techniques. The determination of temperature 
mapping will allow the characterization of the 
critical zones during the melt granulation and the 
prediction the thermal behavior of the meltable 
binders. Hence identify the physical state transi-
tions and the optimal growth mechanism areas. 
Two grades of Polyethylene Glycol (2000 and 
6000) were used as meltable binders in three bind-
er spraying rates and droplet sizes.  
RESULTS:  The treatment of data matrixes of 
temperature made their mapping possible by us-
ing the “Contour” function in Matlab software 
(1). The results showed the presence of intense 
heat exchange in the bott om of the bed during the 
In-situ technique where the binder is added in a 
solid state. The zone is delimited by a yellow 
band enabling the identifi cation of the transition 
between the diﬀ erent heat transfer zones. The 
shape of the zone had a characteristic fl ame shape 
expressing the hot stream air profi le. The results 
showed an important heating zone under the 
spraying nozzle for the Spray-on technique, 
which can be identifi ed as the melting zone. The 
shape of this zone depends on the process condi-
tions applied. The particle analysis of the fi nal 
product showed more spherically shaped gran-
ules using Spray-on than In-situ due to the spher-
ical shape of the drops.
CONCLUSIONS: The determination of temper-
ature profi les enabled the characterization of the 
critical melting zone and the conditions needed to 
establish the optimal design space for the suitable 
quality att ributes of granules.
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
REFERENCES: 
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O-14
Application of solid nanoparticle as emulsifi ers 
and surface modifi ers in controlled drug 
delivery
 SZÉCHENYI, A.1,2,  HORVÁTH, B..,
  ŠAFARIK, T.2,  SÁNDORI ,D.1,  NAGY, S.1,
  PÁL, SZ.1
1University of Pécs, Faculty of Pharmacy, Institue of 
Pharmaceutical Technology and Biopharmacy, Pécs, Hungary
2Josip Juraj Strossmayer University of Osijek, Department of 
Chemistry, Osijek, Croatia
BACKGROUND: Poor water solubility of drugs is 
a well-known problem to people involved in phar-
maceutical sciences. Because of their clinical and 
economic signifi cance huge eﬀ ort has been made 
to develop new strategies to enhance their solubil-
ity and bioavailability. The preparation of drug 
nanocrystals suspensions and nanoemulsions 
with lipophilic drug dissolved in oil phase are 
methods with a proven ability to enhance these 
properties (1). In both cases amphiphilic mole-
cules are used to stabilize the structures responsi-
ble for enhanced solubility and bioavailability. 
Drug release from this formulations is determined 
by enhanced solubility or partition coeﬃ  cient, be-
cause the stabilizing layer of amphiphilic mole-
cules do not form a diﬀ usion barrier for drug mol-
ecules (2). The stabilization of drug nanocrystals 
or emulsion droplets can be achieved by adsorp-
tion of solid nanoparticles on the lipophilic-water 
interface. The self-assembled layer of solid 
nanoparticles forms a diﬀ usion barrier for drug 
molecules, and the diﬀ usion gap can be controlled 
by fi ne tuning of size and surface properties of 
solid nanoparticles.
AIMS: Our aim is to prepare self-assembled lay-
er of solid nanoparticles as engineered diﬀ usion 
barrier for controlled drug release, and evaluate 
their drug release properties.  
RESULTS:  For this purposes a series of silica 
nanoparticles with controlled size have been syn-
thesized and used as stabilizing agent in prepara-
tion of drug nanocrystals suspensions and nano-
emulsions of Indomethacin model lipophilic drug. 
The self-assembly is driven by att ractive electro-
static forces between oppositely charged particles. 
The surface charge of solid nano particles have 
been controlled by chemical surface modifi cation 
and ionic strength adjustment.
CONCLUSIONS: Preliminary test shows a 
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strong correlation between applied stabilizing sol-
id nanoparticle size and dissolution properties. 
For time being we are working on the experi-
ments, and the fi nal results and conclusion will be 
shown at the conference
REFERENCES: 
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2. Simovic S. et al. Eur. J. Pharm. Biopharm.67 39–47 (2007)
O-15
Recent advances in Continuous Coating 
Technology
 LASZLO-HERBERT, R.
Colorcon Limited Hungary, Budapest, Hungary
Overview of Continuous Coating equipment and 
techniques using a novel tablet coating technology 
developed for high speed coating - Opadry® QX. 
Focusing on the Thomas Engineering CTC and 
ConsiGma™ coater and the Driam Conti coater. 
The studies looked at critical process parameters 
and their eﬀ ect on coated tablet critical quality at-
tributes using Opadry® QX. Placebo tablets, were 
coated and assessed for color development and uni-
formity, surface roughness and gloss.  Coating with 
Opadry QX on the Thomas Engineering CTC and 
ConsiGma coater and the Driam Conti coater was 
successful over a wide range of conditions giving 
excellent color uniformity smoothness and gloss. 
O-16
JASCO solutions for separation and purifi cation of 
pharmaceutical compounds with carbon-d ioxide
 STEFÁN, G.,  SZEPESI, I .
ABL&E-JASCO Hungary Ltd., Budapest, Hungary
Is Supercritical Fluid Chromatography a „New 
Technology”? Of course not; SFC looks back to a 
history of more than half a century, and has got 
into the focus of interest from time to time. It has 
proven to be a mainstream technology for chiral 
separations based on it is higher eﬃ  ciency, 
throughput, and wide applicability. Chiral SFC 
has lately att racted increased interest and applica-
bility, in some cases, becoming the method of 
choice. These are the most well known application 
fi elds. In this presentation I should like to show a 
few non-common applications for separation and 
purifi cation using carbon-dioxide. The coupling 
with other analytical technics (SFC-SFE, SFC-FT-
IR) results in a combined system and brings more 
reliable results. Simultaneous analyses of acid, 
neutral, basic, lipid and amphoteric substances be-
ing almost impossible to execute by conventional 
HPLC instumentation can be done using SFC. Col-
umn screening is a useful function in the method 
development for chiral substances. The stacked in-
jection method helps to turn combined prepara-
tive systems into high-throughput ones. The JAS-
CO SFE/SFC/HPLC „three in one” versatile system 
is able to give reasonable solutions, as shown by 
the mentioned examples. 
O-17
Multimodal nanoantibiotics for synergistic 
modes of action against infectious diseases and 
for biofi lm treatment
 ROSENHOLM, J . M.
Pharmaceutical Sciences Laboratory, Åbo Akademi 
University, Turku, Finland
The current global threat of increasing antimicro-
bial resistance (AMR), termed the “post-antibiotic 
era” by the WHO, as well as the recalcitrant na-
ture of biofi lm-associated infections call for the 
development of alternative strategies to treat bac-
terial diseases. Nanoparticles (NPs) have been rec-
ognized as one of the emerging and promising 
platforms in this respect, due their unique physi-
cal and chemical properties, which provide fi ne-
tuning of their interactions with bacteria. Antibac-
terial NPs, “nanoantibiotics”, can be designed to 
treat infectious diseases more eﬀ ectively than con-
ventional antibiotics by making use of their ad-
vantageous properties known from other nano-
medical fi elds. These include improved pharma-
cokinetics of incorporated drugs, site-targeted de-
livery, sustained or controlled release, improved 
drug stability and dissolution, and so forth. The 
perhaps most advantageous property of nanoanti-
biotics in combating AMR is the possibility to con-
struct multimodal NPs, providing synergistic ac-
tions [1] while making it diﬃ  cult for bacterial cells 
to become resistant. Namely, the thus incorporat-
ed multiple simultaneous mechanisms of action 
would, likewise, require multiple simultaneous 
gene mutations in the same bacterial cell for AMR 
to develop [2]. We have constructed nanoantibiot-
ics out of organic & inorganic components com-
posed of an antibacterial core material (metal or 
ACTA-1703-BBBB.indb   110 9/19/17   6:28 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Oral presentations 111
metal oxide) surrounded by a mesoporous silica 
shell in which antibiotic drugs are incorporated, 
coated with an antibacterial polymeric layer. The 
extent of in vitro bacterial growth inhibition 
caused by the produced nanoantibiotics has been 
investigated, whereas Drosophila melanogaster (fruit 
fl y) has been used as an in vivo animal model to 
study the antibacterial activity of the nanoantibi-
otics in the gastro-intestinal tract. The observed 
results revealed that multiple antibacterial con-
structs in the designed system can improve the 
antibacterial activity in a synergistic fashion. 
REFERENCES:
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Design and development of antimicrobial 
fi brous dressings for advanced wound care
 KOGERMANN, K.
Institute of Pharmacy, University of Tartu, Nooruse 1, 50411 
Tartu, Estonia
Chronic wound infections are responsible for con-
siderable morbidity and increased healthcare costs. 
Recently, it has been recognised that biofi lm forma-
tion is one of the main problems associated with 
chronic wounds and persistent infections causing 
delayed healing. The current therapies to treat bac-
terial infection in the wound rely mostly on the 
systemic administration of antibiotics, but the relat-
ed major concerns are the risk of toxicity during 
treatment and insuﬃ  ciently low local drug levels 
in the wound1. Alternative topical pharmaceutical 
formulations however require frequent application 
and are ineﬀ ective in the presence of wound exu-
date or biofi lm. Therefore, there is a need to fi nd 
bett er treatment options for infected wounds. 
We have started to develop antimicrobial-loaded 
electrospun dressings for local wound care. Elec-
trospun fi bers have several characteristics that fa-
vour their use in such application including (i) abil-
ity to mimic the fi brillar structure of natural extra-
cellular matrix, (ii) the high surface area to volume 
ratio, (iii) interconnecting porous structure with 
high permeability, and (iv) the ability to incorpo-
rate drugs and/or growth factors2. The talk will 
shortly cover the reasons for wound infection de-
velopment and its current treatment options. Then 
electrospinning (ES) state-of-the-art will be re-
viewed. We show that the ES and its recent advanc-
es (e.g. ultrasound-enhanced ES, USES) enable to 
design and prepare various antimicrobial medicat-
ed fi brous dressings. Deep solid state analysis, tex-
ture analysis, in vitro biofi lm/cytotoxicity and drug 
release tests enable to understand the physico-
chemical and mechanical properties as well as anti-
microbial/antibiofi lm eﬃ  ciency and safety of the 
developed mats. This knowledge is important for 
the development of novel antimicrobial fi brous 
dressings intended for advanced wound care.
REFERENCES:
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Nanofi bers – a promising delivery system for 
benefi cial bacteria
 ZUPANČIČ, Š.,  KOCBEK, P.,  RIJAVEC, T., 
 LAPANJE, A.,  KRISTL, J .
Faculty of Pharmacy, University of Ljubljana, Ljubljana, 
Slovenia
BACKGROUND: In the recent years, bacteria gen-
erated considerable research interest as a power-
ful weapon against various diseases. The funda-
ment for their eﬀ ectiveness is the number of via-
ble cells incorporated in a patient friendly drug 
delivery system (1).
AIMS: In our study, the main focus was encap-
sulation of model bacteria in form of vegetative 
cells or spores into diﬀ erent kinds of hydrophilic 
nanofi bers, presenting one of the newest and very 
promising nanomaterials. The eﬀ ect of electros-
pinning parameters on bacterial survival during 
electrospinning process as well as storage condi-
tions were closely monitored since they have been 
rarely studied in the past.  
RESULTS:  Prepared nanofi bers were beadless 
with average diameter below 300 nm. The vegeta-
tive bacterial cells as well as spores were success-
fully encapsulated within nanofi bers (1010 CFU 
per gram of nanofi bers), visible in SEM images as 
local widening of nanofi bers in the shape of bacte-
ria. The results revealed that vegetative cells could 
not survive in hypotonic solution used for nanofi -
ber preparation, whereas the same bacterial strain 
in form of spores showed high resistance against 
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hypotonic or acidic conditions, high voltage, and 
dehydration during electrospinning. Over 90% of 
spores remained vital after electrospinning and 
2-month storage at room temerature.
CONCLUSIONS: Nanofi bers represent an at-
tractive drug delivery system for various drugs as 
well as for live microorganisms, as shown in our 
study. Furthermore, the results clearly show that 
incorporation of spores is a successful approach 
for preparation of elecrospun nanofb ers with spo-
rogenic bacteria, since it assures high bacteria via-
bility after the electrospinning process and storage 
REFERENCES: 
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Development and characterization of self 
nanoemulsifi ying systems for oral delivery of  
peptides
 CELIK-TEKELI, M.1,2,  CELEBI, N.1,  AKTAS, Y.2
1Faculty of Pharmacy,  Department of Pharmaceutical 
Technology, Gazi University, Ankara,Turkey 
2Erciyes University, Kayseri,Turkey 
BACKGROUND: Self emulsifi ying drug delivery 
systems (SEDDS) are isotropic mixtures of oils, 
surfactants, solvents and co-solvents/surfactants 
which form oil-in-water (o/w) emulsions in gastro-
intestinal tract by mild agitation. SEDDS can be 
used for formulation of peptides to improve bio-
availability (1). In this study, ethyl oleate was used 
as oil phase, whereas Cremophor EL® and abso-
lute alcohol were used as surfactant and co-sur-
factant respectively. Pseudoternary phase dia-
grams were established by titration. Surfactant/co-
surfactant (S/co-S) was optimized using the fol-
lowing ratios: 1:1, 2:1, 3:1, 4:1 according to the pseu-
doternary phase diagrams. For further studies, a 
nanoemulsion composition was chosen around 
the center of gravity for the clear nanoemulsion 
formation (2). Statistical analysis were evaluated 
by one-way repeated measures ANOVA.
AIM: The aim of this study was to develop self 
nanoemulsifying system for oral peptide delivery. 
SEDDS were characterized for emulsifi cation time, 
droplet size, polidispersity index (PDI) and zeta 
potential under storage conditions for one month.
RESULTS: The emulsifi cation time of formula-
tions were below one minute with bluish white ap-
pearance referred as Grade B. The mean size, PDI 
and zeta potential of nanoemulsion ranged be-
tween 20-50 nm, 0.1-0.2 and -7 to -20 mV respec-
tively. During one month, the optimized formula-
tion displayed no signifi cant changes in both drop-
lets size, PDI and  emulsifi cation time (p>0.05).
CONCLUSION: In conclusion, the ratio of 
oil:surfactant:co-surfactant (30:52.5:17.5) was se-
lected for SEDDS formulation.
REFERENCES:
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Radiolabeling of targeted self assembled 
nanoparticles for positron emission tomography
 SZIKRA, D.,  NAGY, G.,  TRENCSÉNYI, 
GY.,  NAGY, T.,  FORGÁCS, A.,  SZABÓ, S., 
 KRIZSÁN, Á.,  GARAI, I . 
Scanomed Ltd., Debrecen, Hungary
BACKGROUND: A biodegradable polymer based 
self-assembled nanoparticle family was developed 
by our partner, BBS Nanotechnology Ltd.. Nano-
particles with approx. 120 nm size were prepared 
by ion-ion interaction using chitosan and poly-
gamma-glutamic acid (PGA), where PGA was 
modifi ed with Folic acid (FA) via PEG linker and 
NODAGA chelator was conjugated to the chitosan. 
AIMS: The aim of our work was the develop-
ment of radiometal labeling- and quality control 
methods of functionalized nanoparticles, and sup-
porting the development of new nanoparticle pro-
totypes for in vivo imaging aplication.   
RESULTS:  Extensive study of labeling condi-
tions with 68Ga was performed in order to maxi-
mize radiolabeling yield and compare the prop-
erties of various nanoparticle preparations. The 
information, gained from the labeling experi-
ments helped our partner to optimize the modifi -
cation of the chitosan polymer used for nanopar-
ticle synthesis and the conjugation protocol of 
the NODAGA chelator. Quantitative labeling 
could be reached in 15 minutes on room temper-
ature at pH 5, adjusted with 10 μl 0.5M sodium-
acetate buﬀ er and 90 μl 0.05M sodium-hydrox-
ide. Radiolabeling was monitored by radio TLC 
on ITLC-SG sheets using 0.1M citric acid as elu-
ent.  Purifi cation of labelled nanoparticles on 
PD10 size exclusion resin slightly decreased the 
radioactivity concentration without any real ad-
vantage, thus it was omitt ed in animal experi-
ments. Changes of nanoparticle size during la-
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beling was monitored with Zeta Sizer Nano, and 
also used as an important imput for prototype 
development. Light scatt ering methods can not 
be used for size determination in plasma sam-
ples, thus we applied Wide Bore Hydrodynamic 
Chromatography to monitor size stability. The 
labelled nanoparticles appeared in the convec-
tion peak, well separated from small molecules, 
eluted in the diﬀ usion peak.      
CONCLUSIONS: 68Ga labeling and folate tar-
geting are used for the evaluation of in vivo stabil-
ity and pharmacokinetics of the studied nanopar-
ticles using PET/MR imaging in folate positive tu-
mor bearing mice. After the selection of the opti-
mal nanoparticle, RGD and NGR targeting will be 
applied for imaging neoangiogenesis in diabetic 
animal models.        
O-22
Non-enzyme catalyzed metabolic 
transformations of xenobiotics
 PERJÉSI, P.,  ALMÁSI A.,  KENARI F., 
 KUZMA M.,  NYÚL E.
University of Pécs, Institute of Pharmaceutical Chemistry, Pécs, 
Hungary
BACKGROUND: A large body of evidence has 
been accumulating demonstrating importance of 
non-enzyme catalyzed metabolic transformations 
of xenobiotics. For example, infl ammatory and oth-
er pathological processes are often accompanied 
by oxidative stress increasing the reactive oxygen 
and nitrogen radicals on the site of infl ammation. 
Furthermore, endogenous thiols, e.g. reduced glu-
tathione (GSH) possess an intrinsic reactivity with 
electrophilic xenobiotics and metabolites.
AIMS: To review and demonstrate importance 
of non-enzymatic oxidative metabolism of pheno-
lic xenobiotics and reaction of reduced glutathi-
one (GSH) with electrophilic xenobiotics. Demon-
stration of non-enzymatic metabolism of selenite, 
estrogens, salicylate and chalcones.
RESULTS: Experimental results demonstrated 
that non-enzymatic oxidation of phenolic com-
pounds (e.g., estrogens and salicylate) plays im-
portant role in their metabolic feature and biologi-
cal actions. They can act as radical scavengers pro-
tecting oxidative damage of sensitive endogenous 
compounds (e.g., lipids, nucleic acids) The nucleo-
philic antioxidant reduced glutathione (GSH) is 
also involved in a variety of non-enzyme cata-
lyzed reactions. Such reactions can be manifested 
in both cytotoxic and cytoprotective eﬀ ects.
CONCLUSIONS: Exponential results support 
that non-enzymatic transformation of xenobiotics 
can play important role in biological eﬀ ects of the 
parent compounds.
REFERENCES:
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Gastrointestinal electromyographic signals 
during immobilization in rats: new possibility 
for the instrumental detection of stress
 GÁSPÁR, R.1,  SZŰCS, K. F.1,  GROSZ, G.2, 
 SÜLE, M.2,  SZTOJKOV-IVANOV, A.1, 
 DUCZA, E.1,  KOTHENCZ, A.1
1Department of Pharmacodynamics and Biopharmacy, Faculty of 
Pharmacy, University of Szeged
2MDE GmbH, Walldorf, Germany
BACKGROUND: Anxiety and stress frequently 
lead to functional gastrointestinal disorders. The 
existence of brain-gut axis is recently more than a 
simple hypothesis: the hormonal and neuronal in-
teractions between the GI tract and the CNS have 
been approved (1). We have developed a method 
for the in vivo detection of GI tract activity apply-
ing smooth muscle electromyography (SMEMG) 
in rats (2). Our hypothesis is that the acute stress 
events should have a trace in the GI tract activity 
AIMS: Our aim was to detect the GI tract activi-
ty during acute immobilization stress (30 min) in 
rats by SMEMG. Subcutaneous abdominal elec-
trodes were implanted into rats. The magnitude of 
the activity was expressed as maximum of power 
spectrum density (PsDmax).  
RESULTS:  In stress, the PsDmax values of 
stomach, ileum and cecum were increased by 186, 
144 and 148 %, respectively. The plasma corticos-
terone level was increased by 190%. Haloperidol 
(1 mg/kg) blocked both the stress-induced in-
crease in PsDmax and in plasma corticosterone 
level, while diazepam (5 mg/kg) only reduced 
these parameters. Initial diazepam plasma level 
was 416 ng/ml, and it was reduced to 115 ng/ml at 
the end of stress period. Haloperidol was not de-
tectable in plasma, but its high amount was found 
in brain before (299 ng/ml) and after (159 ng/ml) 
stress. The compounds were ineﬀ ective on the 
contractions of GI tract strips in vitro.
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CONCLUSIONS: The acute stress-induced in-
crease in corticosterone plasma level is refl ected in 
the SMEMG signals of rat GI tract. Our method 
may open up a perspective for the instrumental 
detection of psychic stress and anxiety.  
The work was supported by the project 
PIAC_13-1-2013-0201, National Research, Devel-
opment and Innovation Oﬃ  ce, Hungarian Gov-
ernment and by the EU-funded Hungarian grant 
EFOP-3.6.1-16-2016-00008.
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Eﬀ ect of thyme, cinnamon and citronella 
essential oils in in vivo mouse lung 
infl ammation model 
 HORVÁTH, GY.1,  ÁCS, K.1,  CSIKÓS, E.1, 
 ASHRAF, AR.1,  BÖSZÖRMÉNYI, A.2,
  KOCSIS, B.3,  KERESKAI, L.4,  CSEKŐ, K.5, 
 KEMÉNY, Á.5,  HELYES, ZS.5
1Department of Pharmacognosy, Faculty of Pharmacy, 
University of Pécs, Pécs, Hungary; 
2Department of Pharmacognosy, Faculty of Pharmacy, 
Semmelweis University, Budapest, Hungary; 
3Department of Medical Microbiology and Immunology, Medical 
School, University of Pécs, Pécs, Hungary; 
4Department of Pathology, Medical School, University of Pécs, 
Pécs, Hungary; 
5Department of Pharmacology and Pharmacotherapy, Medical 
School, University of Pécs, Pécs, Hungary
BACKGROUND: Respiratory tract diseases aﬀ ect 
a large number of people in every age group 
worldwide. Unfortunately, the anti-infl ammatory 
eﬀ ect of essential oils (EOs) is weakly studied in 
well-designed respiratory tract infl ammation in 
vivo models (1).   
AIMS: The purpose of our study was to examine 
the chemical composition of thyme, cinnamon bark 
and citronella EOs with GC-MS. Moreover, our 
study aimed at the investigation of anti-infl amma-
tory eﬀ ect of these EOs in endotoxin-induced acute 
airway infl ammation in vivo (mouse) model.   
RESULTS: Thymol (46.1%), trans-cinnamalde-
hyde (45.9%) and citronellal (42.3%) were the 
main compounds in thyme, cinnamon bark and 
citronella EOs, respectively. In in vivo experi-
ments, thyme oil could reduce the airway respon-
siveness in the treated groups compared to ani-
mals in the control groups, but it had no eﬀ ect on 
other investigated parameters (e.g. inspiration 
and expiration time, relaxation time, etc.). Thyme 
EO signifi cantly reduced neutrophil and macro-
phage MPO activity and also the extent of perivas-
cular edema and perivascular/peribronchial in-
fl ammation. Inhalation of cinnamon bark oil also 
signifi cantly reduced LPS-induced airway hyper-
responsiveness, but it had no eﬀ ect on neutrophil 
and macrophage MPO activity. It reduced the ex-
tent of perivascular edema, perivascular/peribron-
chial infl ammation and the number of macro-
phages. Contrary, citronella EO signifi cantly im-
paired the most of the respiratory parameters, and 
the MPO activity was also increased. The histo-
pathological measurements also supported these 
fi ndings.    
CONCLUSIONS: Based on our results, the in-
halation of thyme and cinnamon bark EOs de-
crease acute pneumonitis and airway hyperre-
sponsiveness. Therefore, they can be considered 
as a potential treatment in such conditions. How-
ever, the use of citronella oil should be avoided, 
because it may cause irritation in the respiratory 
tract and exacerbates the infl ammatory process. 
Further experiments are planned to measure the 
infl ammatory cytokine profi le and mechanism of 
action. 
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Prevention of caspase activation by resveratrol 
in non-transformed cells
 ULAKCSAI, ZS.,  BAGAMÉRY, F.,  SZÖKŐ, É., 
 TÁBI, T.
Department of Pharmacodynamics, Semmelweis University, 
Budapest, Hungary
BACKGROUND: Resveratrol is a natural com-
pound with complex pharmacological activities. 
Among others its cytoprotective and cytotoxic ef-
fects are reported in the literature depending on 
factors such as its dose, duration of treatment and 
the model system.
AIMS: In this research our goal was to examine 
the eﬀ ect of resveratrol on non-transformed cells 
as a potential cytoprotective agent against noxious 
insults.
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RESULTS: In our model system resveratrol 
showed concentration dependent protective eﬀ ect, 
as prevented caspase 3 activation in response to 
serum deprivation in primary fi broblasts. Its cyto-
protective eﬀ ect was further confi rmed by the re-
duced release of lactate dehydrogenase (1).
The mechanism of eﬀ ect was also studied. 
Among the major signaling pathways p38 stress 
kinase was found critical, as its inhibition elimi-
nated the eﬀ ect of resveratrol on caspase activa-
tion. Studying cellular stress revealed that resve-
ratrol increased rather than reduced it. The com-
pound augmented the generation of reactive oxy-
gen species and caused depolarization of mito-
chondria.
As autophagy can protect damaged cells its role 
was also examined. Chloroquine, the inhibitor of 
late stage autophagy not only eliminated the pro-
tective eﬀ ect of resveratrol, but turned it to delete-
rious. The improved autophagy fl ux in the pres-
ence of resveratrol was further confi rmed by the 
reduced level of p62 protein a marker of autopha-
gic degradation.
CONCLUSIONS: Our results suggest that res-
veratrol has a concentration dependent protective 
eﬀ ect in non-transformed fi broblasts subjected to 
a noxious stimulus. The compound however acts 
by augmenting cellular stress that in turn can acti-
vate cytoprotective machineries, primarily au-
tophagy. These results and hypothesis can help 
the understanding the contradictory eﬀ ects of this 
popular natural compound.
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Eﬀ ects of Momordica charantia (Bitt er melon) 
on ischemic diabetic myocardium
 LEKLI, I .,  CZOMPA, A.,  GYONGYOSI, A., 
 BAK, I .,  CSEPANYI, E.,  SZOKE, K.,  HAINES, 
D.,  TOSAKI, A. 
Department of Pharmacology, Faculty of Pharmacy, University 
of Debrecen, Debrecen, Hungary
A rat model is here used to test a hypothesis that 
Momordica charantia (Bitt er melon/BM) extract, fa-
vorably alters processes in cardiovascular tissue 
and systemically relevant to the pathophysiology of 
type 2 diabetes and related cardiovascular disease.
Body mass of both Lean and ZO rats and periph-
eral blood fasting glucose levels were unaﬀ ected by 
treatment. However, some BM treatment-related 
improvement was noted in postischemic cardiac 
functions when lean, BM-treated animals were 
compared with vehicle treated lean control rats. 
Treatment of lean, but not ZO rats signifi cantly re-
duced the magnitude of infarcted zone in isolated 
hearts subjected to 30 minutes of ischemia and 2 
hours of working mode perfusion (I/R). Immuno-
histochemical demonstration of caspase-3 expres-
sion by tissue of isolated hearts subjected to I/R, re-
vealed signifi cant correlation between BM treat-
ment and reduced expression of this enzyme in 
hearts from both Lean and ZO animals.   The hier-
archy of caspase 3 expression from highest to low-
est was as follows: ZO rats receiving mucin-water 
(5C) > ZO rats receiving BM extract (5D) > lean rats 
treated with mucin-water (5A) > Lean rats adminis-
tered BM extract.  Outcomes of analyses of periph-
eral blood content of cardiac-related analytes: with 
particular relevance to clinical application was a 
signifi cant elevation in blood of ZO and ZO BM-
treated, versus Lean rats of total cholesterol (high 
density lipoprotein HDL-c + low density lipopro-
tein LDL-c), with an inferred increase in HDL-c/ 
LDL-c ratio. BM extract failed to positively af-
fect T2DM- and cardiovascular- related outcomes 
at a level suggesting use as a standalone treatment. 
Nevertheless, the encouraging eﬀ ects of BM in en-
hancement of cardiac function, suppression of 
post-ischemic/reperfused infarct zone extent and 
capacity to modulate serum cholesterol, will likely 
make it useful as an adjuvant therapy for manage-
ment of T2DM and cardiovascular disease.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project, 
OTKA K-104017, OTKA-PD-111794, TÁMOP 
4.2.4. A/2-11-1-2012-0001 ‘National Excellence Pro-
gram’; GINOP-2.3.2-15; EFOP-3.6.1. 
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Investigation of anti-infl ammatory eﬀ ect of sour 
cherry anthocyanins on Caco-2 infl ammatory 
model
 VÁRADI, J .,  REMENYIK, J .,  FENYVESI, 
F.,  BÁCSKAY, I .,  FEHÉR, P.,  UJHELYI, Z., 
 VASVÁRI, G.,  VECSERNYÉS, M. 
Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary
BACKGROUND: The high biological value of an-
thocyanins is based on their antioxidant, anti-in-
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fl ammatory and antiproliferative activities. High 
anthocyanin containing, thermostable sour cherry 
extract was produced at the University of Debre-
cen. The excellent properties of the sour cherry ex-
tract predict its expansive application.  
AIMS: The aim of this study was to investigate 
of anti-infl ammatory eﬀ ect of sour cherry extract 
on infl ammatory model of bowel diseases with 
Caco-2 intestinal epithelial cells. The examination 
of cytotoxicity of anthocyanin extract was per-
formed by real-time cell analysis (RTCA). Mono-
layer permeability after pro-infl ammatory cyto-
kine (TNF-α, IL-1β) stimulation was tested by 
transepithelial electric resistance (TEER). IL-6, IL-8 
production and activation of NF-κB pathway were 
also examined. The antioxidant capacity of antho-
cyanin extract was tested in Caco-2 cells by gluta-
thione peroxidase (GPx) assay.   
RESULTS:  Decreased TEER values were mea-
sured after the pro-infl ammatory cytokine treat-
ment, however anthocyanin pre-treatment elevat-
ed the TEER values to the control level. Increased 
IL-6, IL-8 concentrations were detected in pro-in-
fl ammatory cytokine treated samples which was 
reduced in anthocyanin pre-treated samples. The 
NF-κB nuclear translocation indicated by high nu-
cleus/cytoplasm intensity ratio was observed after 
pro-infl ammatory cytokine treatment, which was 
signifi cantly inhibited by anthocyanins. Reduced 
GPx activity were determined in anthocyanin pre-
treated Caco-2 cells after the cytokine treatment 
compared to stimulated cells.  
CONCLUSIONS: Protective eﬀ ect of sour cher-
ry extracted anthocyanins on pro-infl ammatory 
cytokine induced infl ammatory activation in 
Caco-2 monolayers was investigated for the fi rst 
time in this study. These results verify the eﬀ ec-
tive anti-infl ammatory and antioxidant capacity of 
sour cherry anthocyanins in Caco-2 cells. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.
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New drug delivery systems for the oral cavity 
and periodontal therapy
 KILICARSLAN, M.
Department of Pharmaceutical Technology, Faculty of Pharmacy, 
Ankara University, 06100 Tandogan, Ankara, Turkey
In this lecture especially the drug delivery from 
periodontal pocket and new systems will be de-
scribed after discussing the systemic and local 
drug delivery through oral mucosa and key consid-
erations in the design and development of a drug 
delivery systems intended for use of oral cavity. 
Periodontal diseases are several pathological condi-
tions in oral cavity and in recent years local drug 
delivery into the periodontal pocket has been in-
vestigated to overcome the disadvantages of sys-
temic antimicrobial therapy.The periodontal pocket 
provides a natural reservoir, which is easily acces-
sible for the insertion of local drug delivery devic-
es. In my researches clindamycine phosphate 
(CDP) and metronidazole benzoate (MNZ) have 
been chosen as model drugs. CDP loaded mic-
roparticles were prepared by spray drying method-
using chitosan at one of my research and delayed 
drug release more than one week and minimum of 
7 days’ sustained antimicrobial activity could be 
obtained. It can be concluded that the easy scale up 
of spray drying method, the appropriate particle 
size, bioadhesive properties of chitosan were ap-
propriate characteristics of these formulations for 
application into periodontal pocket (1). In situ im-
plants containing MNZ for periodontal therapy 
were prepared at the other research by using PLGA 
502H and 502S with diﬀ erent solvents. Using some 
adhesive polymers was novelty for in situ implants 
to maintain the longer retention time (2). MNZ 
loaded ethyl cellulose microspheres and NaCMC, 
Methocel K15M and K100M fi lms were also stud-
ied. Than microsphere embedded adhesive fi lms 
were prepared due to the diﬃ  culty of insertion of 
microspheres alone and burst release of drug could 
be decreased by that combination. Furthermore, 
CDP loaded chitosan fi lms, CDP loaded chitosan-
alginate complex fi lms were studied. Our studies 
on periodontal nanoparticles are in progress. 
REFERENCES:
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Design and characterization of mucoadhesive 
hydroxypropyl cellulose oral fi lms 
 GOTTNEK, M.1,2,  KELEMEN, A.3,  FARKAS, G.2, 
 SOVÁNY, T.2,  SÜVEGH, K.4,  PINTYE-HÓDI, 
K.2,  REGDON JR, G.2
1Abacus Medicine Hungary Kft., Budapest, Hungary
2University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs, Szeged, Hungary
3 University of Szeged, Department of Applied Informatics, 
Szeged, Hungary
4 Eötvös Loránd University, Laboratory of Nuclear Chemistry, 
Budapest, Hungary
BACKGROUND: Before their technological use, it 
is very important to determine the mechanical 
properties of mucoadhesive fi lms because the free 
fi lms are exposed to large mechanical stress dur-
ing the preparation process, unpacking and stick-
ing to the oral mucosa.
AIMS: Hydroxypropyl (HPC) cellulose free 
fi lms were investigated as potential buccal drug 
delivery system. The eﬀ ects of excipients on the 
polymer matrix were characterized in a wide 
range. In vitro mucoadhesion measurement meth-
od, equipment and software developed and opti-
mized, and accelerated stability test was evaluated. 
RESULTS:  Tensile strength and PALS suggested 
that Xylitol (Xyl) forms hydrogen bonds. Thermal 
study suggested that excipients in low concentra-
tion incorporated into the system. Carbon dioxide, 
acetic acid and/or isopropyl alcohol formed during 
TG-MS study. The tested systems were thermally 
stable, below 100°C only water loss was detected. 
FTIR confi rmed that both excipients incorporated to 
the polymer system via hydrogen bonds. Water up-
take and migration were detected. XRPD also con-
fi rmed the incorporation of the excipients used, the 
system remained amorphous. Water uptake and 
migration were detected and confi rmed via the 
changes of shape and angle halo of patt erns. TGA 
confi rmed the presence of bulk water. Tensile 
strength highlighted the softening behaviour of wa-
ter and the over plasticization eﬀ ect of it with Gly.   
CONCLUSIONS: PALS demonstrated that Gly 
increases and Xyl decreases the free vacancies of the 
HPC fi lms via moving the polymer chains. Tensile 
strength measurement and FTIR highlighted the so-
called ‘synergic’ eﬀ ect of Gly and Xyl used together. 
FTIR highlighted the potential novel application of 
Xyl as a plasticizer in pharmaceutical technology.  
REFERENCES: 
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Development of an orphan drug medicinal 
product for the treatment of maligant 
mesothelioma
 SONVICO, F.,  AMPOLLINI, L., 
 CARBOGNANI, P.,  COLOMBO, P.
Interdepartmental Centre for Innovation in Health 
Products, Biopharnanet TEC, University of Parma, Parma, Italy
BACKGROUND: Mesothelioma is a rare lung ma-
lignancy characterized by a long latency period of 
20-50 years after exposure to the main aetiology 
agent asbestos. In general, mesothelioma patients 
have three options: surgery, chemotherapy, and ra-
diation therapy. Due to the high proportion of 
therapeutic failures in the treatment of MPM, and 
the high percentage with which recurrences mani-
fest themselves, in particular after the postopera-
tive chemotherapy, new approaches are needed (1).
AIMS: The aim of the research was to develop 
an implant for intrapleural or intraperitoneal ap-
plication of cisplatin to be used during surgery for 
tumour resection to prevent local recurrence. The 
implant developed was a polymeric fi lm of hyal-
uronic acid loaded with cisplatin (2).  
RESULTS:  Cisplatin fi lms produced were charac-
terized for physico-chemical, mechanical and drug 
release properties by means of various in vitro tech-
niques. In addition, eﬃ  cacy and toxicity studies 
were carried out in an orthotopic rat recurrence 
model of malignant pleural mesothelioma and in 
sheep respectively. Films produced were thin, fl exi-
ble and assured a controlled release of cisplatin for 
up to 96 hours. These in vitro results were confi rmed 
by a prolonged plasma levels of cisplatin in both ani-
mals models, as well as successful prevention in re-
cidivation and bett er tolerability compared to intra-
venous or intrapleural administration of cisplatin.
CONCLUSIONS: The product developed was 
sccesfully submitt ed for orphan drug designation 
both by EMA and FDA. In addition, a clinical 
study protocol for a Phase I-II study has been de-
veloped in collaboration with the Scientifi c Advice 
Working Party of the CHMP of EMA.
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Development of a novel formulated, pulmonary mic-
roparticle (new generation DPI) containing antibiotic 
agent with improved aerosolization eﬃ  ciency
 AMBRUS, R.1,  BENKE, E.1,  FARKAS, Á.2, 
 BALÁSHÁZY, I .2,  SZABÓ-RÉVÉSZ, P.1
1Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
2Centre for Energy Research, Hungarian Academy of Sciences, 
Budapest, Hungary
BACKGROUND: Inhaled antibiotics are of key im-
portance in the treatment of cystic fi brosis-related 
lung diseases.  Therefore the formulation of dry 
powder inhalers (DPIs) containing antibiotics 
could oﬀ er a potential way in drug therapy.  The 
traditional carrier-based procedures (physical 
mixture of lactose and active agent) and a carrier-
free (active agent with modifi ed habit) alternatives 
can be applied to reach bett er aerosolization be-
haviours. The surface of the carrier and the habit 
of ciprofl oxacin HCl (CIP) can also be aﬀ ected by 
diﬀ erent technological methods. 
AIMS: Our recent work introduced a novel 
combined formulation method, where the surface 
modifi cation of the inhaled lactose and particle 
engineering of the drug were used before the 
blending. Therefore the eﬀ ect of magnesium stea-
rate and sodium stearate on the fi nal formulation 
was investigated.      
RESULTS:  A constant concentration of mag-
nesium stearate was used by interactive physical 
mixing (4h Turbula mixing) to cover the active 
places of the carrier. Sodium stearate (0-2 w/w%) 
was applied during the spray drying procedure 
to get suitable habit of the drug. A traditional 
formulation containing raw micronized CIP was 
prepared as a reference sample. The selected 
particle engineered formulation was then blend-
ed with modifi ed lactose for 0.5 h. During a mi-
crometrical (size, morphology, density) and 
structural (DSC, XRPD) characterization, spheri-
cal, ~ 2 μm sized particles of CIP with low densi-
ty and amorphous characters were detected. In 
vitro aerodynamic measurements revealed a 
high lung deposition (more than 70%) of the 
products. By applying a newly determined in 
silico model, the suitable inhalation manoeuvre 
was also predicted. 
CONCLUSIONS: A new generation DPI formu-
lation of CIP was prepared by a fi rst applied com-
bined method, which could help to improve the 
eﬃ  cacy of pulmonary therapies. 
This project was supported by GINOP-2.3.2- 15-
2016-00036 program and ÚNKP-17-4-III-SZTE-3 
New National Excellence Program of the Ministry 
of Human Capacities..
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Dissolution extent decrease of amorphous 
drug due to magnesium stearate induced 
crystallization
 DÉMUTH, B.,  GALATA, D. L.,  MAROSI, GY., 
 NAGY, ZS. K.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
BACKGROUND: By the aid of amorphous solid 
dispersions, extremely poor dissolutions of lypo-
philic drugs can be enhanced, often to 100%. 
However, downstream processing (and/or storage) 
may deteriorate this advantegous dissolution by 
crystallization or in other, yet unknown way. It is 
important to avoid these phenomena to maximize 
dissolution, and possibly bioavailability.
AIMS: Our aim was to reveal how magnesium 
stearate (MgSt) lowers dissolution extent of per-
fectly amorphous itraconazole in course of in vitro 
dissolution test. Furthermore, possible ways are 
searched to eliminate this issue.  
RESULTS:  Based on the experiments, dissolu-
tion extent of itraconazole (incorporated in amor-
phous solid dispersion with PVPVA64) from tab-
let formulation depends on the temperature and 
MgSt content. MgSt can be dissolved in acidic dis-
solution medium where it forms stearic acid. 
NMR examination and elemental analysis showed 
that itraconazole, a weak base, formed an insolu-
ble salt with stearic acid (itraconazole-stearate). 
This previously unreported phenomenon can be 
avoided by the application of other lubricant (so-
dium stearyl fumarate) or polymer matrix in the 
dispersion (HPMC). 
CONCLUSIONS: MgSt can deteriorate the dis-
solution of amorphous itraconazole through a salt 
formation phenomenon. It is yet to be evaluated if 
this aﬀ ect other amorphous, basic drugs or it is 
specifi c for itraconazole.
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Behaviour of medicated inks on porous 
substrates – The eﬀ ect of viscosity and surface 
tension on printing parameters
 SASS, A.,1  KELEMEN, A.,2  KÁDÁR, A.,2 
 REGDON JR., G.,1  PINTYE-HÓDI, K.,1 
 SOVÁNY, T.,1
1Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
2Department of Applied Informatics, University of Szeged, 
Szeged, Hungary
BACKGROUND: 2D and 3D printing methods are 
of emerging interest in the pharmaceutical indus-
try, since their oﬀ er enormous advantages from 
the aspect of dosing accuracy, modifi cation of the 
drug release kinetic and personalized medicine 
[1]. Genina et al. revealed that the ink parameters 
(e.g spreading on non-porous substrates) may in-
fl uence both printing accuracy and the behaviour 
and stability of the printed drugs [2]. 
AIMS: Current project is focusing on the inves-
tigation how the physicochemical characteristic of 
the applied medicated ink infl uence the printing 
and dosing accuracy, the penetration into and the 
distribution inside a porous substrate.   
RESULTS:  PVP K25 and Polysorbate 80 was used 
for sett ing of the viscosity and surface tension of the 
ink according to 32 full factorial design, which con-
tained brilliant blue dye as model material to help 
to follow the ink distribution of the texture of carri-
er matrix. 13 mm in diameter tablets with diﬀ erent 
porosity were compressed from Pearlitol SD200 
(Roquett e, France) lubricated with 1% of magne-
sium stearate using a hydraulic press (Specac, UK) 
and 2, 3, 4 and 5 tons compression force. The sur-
face tension and spreading parameters of the ink on 
the substrate surface was tested with an optical con-
tact angle tester (OCA20, Dataphysics, Germany). 
The printing experiments were conducted with a 
self-developed printing apparatus. The results re-
vealed that the viscosity plays considerable higher 
role in the ink behaviour than surface tension, low 
viscosity promotes the ink penetration into the sub-
strates which acts positively on the printing speed, 
but negatively aﬀ ects the printing patt ern especially 
in highly porous substrates. 
CONCLUSIONS: There are complex interrela-
tions between ink parameters and properties of 
porous substrates, which allows multiple ways for 
tailoring individualized delivery systems. 
REFERENCES: 
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Challenges in equilibrium solubility 
measurements: poor solubility, low dissolution 
rate, low wett ability
 TAKÁCS-NOVÁK, K.,  VÖLGYI, G.
Department of Pharmaceutical Chemistry, Semmelweis 
University, Budapest, Hungary
BACKGROUND: Various methods are available for 
the measurement of equilibrium solubility but the 
saturation shake-fl ask (SSF) technique has still re-
mained the “gold standard” approach [1]. It is a 
very simple method, however to obtain high-quali-
ty data one has to pay att ention on several critical 
experimental conditions among them on the incu-
bation time. Substances which dissolve very slowly 
generally need long incubation times (days or 
weeks) to reach equilibrium.  However, long times 
may pose several problems. In 1979, the Facilitated 
Dissolution Method (FDM) was proposed to dra-
matically reduce incubation time [2]. It employs a 
small volume of water-immiscible organic solvent 
to partly solubilize the sample and thereby increase 
the surface area available for dissolution. The meth-
od has been used only rarely and never validated.
AIMS: The aim of the present study was to con-
duct a systematic validation of FDM using proges-
terone as model compound. Further goal was to 
identify a standardized protocol of this method 
and prove its applicability in case of compounds 
with slow dissolution rate.  
RESULTS:  Using progesterone as a benchmark, 
the conditions of the FDM were optimized by 
changing several experimental factors. Second, 
four drugs known to have low dissolution rate 
were studied: dexamethasone, digoxin, haloperi-
dol , and cosalane. The time dependence of solu-
bility equlibrium was measured by SSF and the 
results were compared with those obtained by 
FDM. 
CONCLUSIONS: Our study supports the valid-
ity of Higuchi’s method. Here we propose a stan-
dardized protocol for the FDM, where 1% v/v of 
organic solvent is used.  In the presentation other 
factors aﬀ ecting the accuracy of SSF method are 
also surveyed and recommendations for the best 
practice are committ ed.
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Targeted delivery of solid and vesicular 
nanoparticles across the blood-brain barrier
 VESZELKA, SZ.,  MÉSZÁROS, M.,  KISS, L., 
 PORKOLÁB, G.,  KÓTA, Z.,  PÁLI T.,  BOZSÓ, 
ZS.,  FÜLÖP, L., PILBAT, AM.,  TÖRÖK, ZS., 
 SZABÓ-RÉVÉSZ P.,  DELI, M. A.
Institute of Biophysics, Biological Research Centre, HAS, 
Szeged, Hungary
BACKGROUND: Therapy of neurological diseases 
is diﬃ  cult, due to the restricted drug delivery across 
the blood-brain barrier (BBB). Nanoparticles target-
ing transporters of the BBB are promising candi-
dates to increase the CNS penetration of drugs.
AIMS: To compare diﬀ erent ligands of BBB 
transporters as targeting molecules for solid and 
vesicular nanoparticles.  
RESULTS:  Fluorescent polystyrene nanoparticles 
were derivatized with biotin and biotinylated gluta-
thione. Niosomes were derivatized with glucopyra-
nose, alanin and glutathione, and loaded with albu-
min-Evans blue complex. Nanoparticles did not 
change the viability of brain endothelial cultures. 
Biotin and glutathione increased the uptake of solid 
nanoparticles by brain endothelial cells in a time-
dependent way. The cellular uptake was verifi ed by 
confocal microscopy. Targeting ligands also in-
creased the uptake of the cargo in the cells which 
was temperature dependent and could be decreased 
with a metabolic inhibitor. The permeability of both 
the solid nanoparticles and the cargo across brain 
endothelial monolayers was increased by targeting 
vectors. Glutathione-labeled solid nanoparticles 
crossed the BBB model bett er than the biotin-target-
ed ones. Treatment with niosomes increased plasma 
membrane fl uidity in endothelial cells suggesting 
fusion with the cell membranes. 
CONCLUSIONS: Biotin as a targeting ligand 
increases the uptake and the transfer of solid 
nanoparticles across brain endothelial cells. Gluta-
thione is eﬀ ective to increase nanoparticle perme-
ability through BBB models. Our data indicate 
that nutrient transporter ligands can potentially 
be exploited for CNS targeting of nanoparticles.
O-36




Transporters have important endobiotics among 
their substrates. Drug-mediated inhibition of 
transporters may alter homeostasis of transport-
ers and, thus, precipitate toxicity or adverse reac-
tions.  
Bile acids/salts are among the fi rst chemical 
class of endobiotics that has been associated with 
a pathological condition such as cholestasis. A ge-
netic impairment of function of the canalicular 
bile salt eﬄ  ux pump (BSEP/ABCB11) in humans 
leads to progressive familial intrahepatic cho-
lestasis type II (PFIC II). It has been long recog-
nized that drug mediated inhibition of BSEP may 
also lead to cholestasis. Other canalicular eﬄ  ux 
pumps such as multidrug resistance associated 
protein 2 (MRP2/ABCC2) has also been implicat-
ed in bile salt transport. More recently infl ux 
transporters, most importantly sodium-taurocho-
late co-transporting polypeptide (NTCP/SL-
C10A1) and organic anion transporting polypep-
tide 1B1 (OATP1B1/SLCO1B1) have been shown 
to play important roles in hepatic uptake of bile 
salts. If canalicular eﬄ  ux is blocked sinusoidal ef-
fl ux transporters MRP3/ABCC3 and MRP4/
ABCC4 get induced and eﬄ  ux bile salts into the 
blood.
Taurocholate is the prototype bile salt most of-
ten used to characterize these bile salt transporter 
functions. Taurocholate is a monovalent amidated 
bile salt and even among amidated bile salts it is 
not the most abundant bile salt in healthy hu-
mans. Moreover, it is a relatively hydrophilic tri-
hydroxy bile salt and, thus less toxic. 
We have profi led bile acid/salt transport of 
BSEP, MRP2-4, NTCP  and OATP1B1 using diﬀ er-
ent classes of bile acids/salts such as a bile acid, 
monovalent bile salt, sulfated bile acid and diva-
lent bile salt. Selectivity of bile salt transport by 
these transporters will be discussed.
Financial support: the work was supported by 
IMI consortium MIP-DILI.
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The role of biocompatibility investigations in 
pharmaceutical technological research
 BÁCSKAY, I .1,  FEHÉR, P.1,  RÓKA, E.1,
  ARANY, P.1,  NEMES, D.1,  FENYVESI, F.1, 
 VÁRADI, J .1,  VECSERNYÉS, M.1,  PERRET, F.2, 
 COLEMAN, A.2,  UJHELYI, Z.1,
1 University of Debrecen, Department of Pharmaceutical 
Technology, Debrecen, Hungary
2 University of Claud Bernard, Department of Supramolecular 
Chemistry, Batiment Raulin,  Villeurbanne Cedex, France
BACKGROUND: BACKGROUND: Pharmaceutical 
excipients are widely used for the preparation of 
diﬀ erent dosage forms. The simultaneous pres-
ence of these materials can often result in drug-ex-
cipient or excipient-excipient interactions, which 
can possible be advantageous (e.g. solubility en-
hancement) or even harmful (e.g. allergic reac-
tion). Thus, the profound safety screening of ex-
cipients (such as CDs, preservatives, tensides etc.) 
are always indispensable, including their pharma-
cokinetic and toxicological profi le (1). Diﬀ erent in 
vitro cell culture biocompatibility tests were devel-
oped to simulate and predict biological reactions 
to materials when placed into or on tissues in the 
body (2). 
AIMS: Our objective was to investigate various 
group of pharmaceutical excipients using diﬀ er-
ent cytotoxicity methods on Caco-2 and HeLa cell 
lines.  Further aim was to prove the applicability 
of MTT cell viability, LDH and hemolysis tests in 
the routine toxicological investigation and to de-
termine relationship between their chemical struc-
tures and cytotoxicity profi les.    
RESULTS:  Nine α-CD derivatives on Caco-2 
cell lines and on human erythrocytes were investi-
gated. Chemical modifi cation on the free hydroxyl 
groups have a defi nite impact on toxicity. Toxicity 
depends on the number of building units. The rate 
of toxicity depends on the exposition time. The in-
tensity of CD cytotoxicity varies on diﬀ erent cell 
types. We also tested tensides with various chemi-
cal structures. There were signifi cant diﬀ erences 
in the cytotoxic properties of surfactants in a con-
centration-dependent manner. Polyoxyethylene 
glycol based tensides are more toxic surfactants 
than propylene glycol esters. If we combined sur-
face active agents with preservatives and/or with 
polymers, in some cases polymers showed a cell-
protective eﬀ ect, but tensides can decrease the bio-
compatibility of preservatives and polymers in 
liquid pharmaceutical dosage forms. 
CONCLUSIONS: It can be concluded that in vi-
tro biocompatibility test can predict the tolerabili-
ty of pharmaceutical excipients and may ensure 
useful information about the interactions of excip-
ients.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.  
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Examination of pharmacokinetic properties 
of fl uorescently labelled hydroxypropyl-beta-
cyclodextrin
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Debrecen, Debrecen, Hungary
BACKGROUND: A new renaissance started in the 
research and application of cyclodextrins a few 
years ago. The number of novel derivatives are in-
creasing and new applications has been appeared. 
Fluorescent cyclodextrin derivatives are new tools 
in cyclodextrin research. By the help of these mol-
ecules the cellular interactions of cyclodextrins 
can be visualized and their biological activity can 
be monitored by fl uorescent techniques.      
AIMS: The aim of our study was to test the 
pharmacokinetic properties of fl uorescein-isothio-
cyanate labelled hydroxypropyl-beta-cyclodextrin 
(FITC-HPBCD) and to study its internalization on 
diﬀ erent cell lines.    
RESULTS:  FITC-HPBCD pharmacokinetic anal-
ysis was carried out on BALB/c mice. The blood 
concentration decreased rapidly after i.v. adminis-
tration in the function of time, showing fast elimi-
nation. Accumulation of FITC-HPBCD in diﬀ erent 
organs could not be measured in tissue homoge-
nates at the end of the experiment. In vivo imag-
ing technique confi rmed fast elimination. The cel-
lular internalization of FITC-HPBCD was detected 
by fl uorescent microscopy on Caco-2, HaCaT and 
HUVEC cells. Endocytosis of FITC-HPBCD in the 
primary human endothelial cell line, HUVEC can 
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explain the fi rst step of tissue distribution of cy-
clodextrins.  
CONCLUSIONS: The in vivo behaviour of fl uo-
rescent cyclodextrins can be easily examined by 
fl uorescent techniques, thus these derivatives are 
suitable for pharmacokinetic measurements. Our 
data are in accordance with earlier results and re-
veals that HPBCD can be internalized by several 
cell types. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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Diarylheptanoid composition of several 
European Betulaceae species
 ALBERTI, Á.,  MALCSINER, P., 
 VESZTERGOMBI, D.,  TÓTH, CS.,  PÉNZES, R., 
 TÓTH, A.,  RIETHMÜLLER, E.,  BÉNI, SZ.
Department of Pharmacognosy, Semmelweis University, 
Budapest, Hungary
BACKGROUND: Diarylheptanoids are a group of 
phenolics bearing a 1,7-diphenylheptane skeleton. 
Due to the anti-infl ammatory and antitumor ac-
tivities of diarylheptanoids, the search for new 
plant sources is gaining signifi cance. 
AIMS: The aim of our work was to study and 
compare the distribution of diarylheptanoids in 
several species of the Betulaceae family.  
RESULTS:  Alnus glutinosa (L.) Gaertn., Alnus 
cordata (Loisel.) Duby, Alnus incana (L.) Moench, 
and Carpinus betulus L. (Betulaceae) were evaluat-
ed. Leaf, bark, involucre and catkin samples, ad-
ditionally, in vitro callus cultures of A. glutinosa 
were investigated by HPLC-DAD-ESI-MS/MS. For 
the separation of the constituents RP-HPLC meth-
ods using linear gradient elution with acetic acid 




ten-3-one] were detected as the main diarylhep-
tanoids for the Alnus samples, similarly to the 
Corylus species investigated in our previous works 
[1-2]. In C. betulus hexosides and glucuronides of 
linear-type diarylheptanoids, as well as macrocy-
clic constituents were detected.
CONCLUSIONS:  Diarylheptanoid composition 
of leaves, involucres and catkins of the above 
mentioned Alnus and Carpinus species has been 
studied for the fi rst time. Our further aim is the 
isolation and structural identifi cation of the de-
tected compounds, in order to investigate their in 
vitro cytotoxic activity. 
The fi nancial support from NKFIH K 120342 is 
highly appreciated.
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Melt electrospinning of fi bers from the molten 
mixtures of a carrier material and drug 
 LUST, A.
Institute of Pharmacy, Faculty of Medicine, University of Tartu, 
Estonia
Electrospinning is a one-step continuous process 
in which an electrical fi eld is used to “draw very 
fi ne fi bers from a viscous solution, suspension, or 
molten material. Electrospinning has been used 
for fabrication of medicinal scaﬀ oldings and 
amorphous solid dispersions of carrier polymers 
and active pharmaceutical ingredients [1]. The 
drawback of electrospinning from the polymeric 
solvent systems is that organic solvents used are 
usually toxic or harmful. Melt electrospinning can 
directly produce polymer nanofi bers at elevated 
temperatures, thus avoiding the use of expensive 
and hazardous solvents. However, only few stud-
ies have used this technique to date [2].
The aim of the present study was to develop 
melt electrospinning methods applicable for pre-
paring microfi bers composing of a binary or ter-
nary mixture of drug and polymer(s) or sugar(s). 
The ultimate goal was to improve the overall solu-
bility and dissolution rate of a poorly water-solu-
ble drug (indomethacin as a model drug). It is ex-
pected that the increased surface area of the fi bers 
and rendering the material amorphous will have a 
positive eﬀ ect on the dissolution characteristics of 
drug. The chemical stability of the materials dur-
ing melt electrospinning, molecular interactions 
and solid-state changes were studied using a sol-
id-state nuclear magnetic resonance spectroscopy 
(NMR), thermogravimetric analysis, diﬀ erential 
scanning calorimetry (DSC), Raman spectroscopy 
and Fourier Transform infrared spectroscopy 
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(FTIR). The morphology of the fi bers was investi-
gated with optical and scanning electron micros-
copy (SEM).
REFERENCES:
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Development of hollow nanostructures for 
magnetically-assisted drug delivery
 KOCBEK, P.1,  POTRČ, T.1,  KRALJ, S.2, 
 MAKOVEC, D.2
1Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 
7, 1000 Ljubljana, Slovenia
2Department for Materials Synthesis, Jožef Stefan Institute, 
Jamova 39, 1000 Ljubljana, Slovenia 
Inorganic nanobiomaterials generally exert higher 
thermal and chemical stability as well as bett er re-
sistance to physiological conditions compared to 
the organic counterparts, thus nowadays they at-
tract special att ention in biomedical fi eld. Among 
them magneto-responsive materials based on su-
perparamagnetic iron oxide nanocrystals (SPIONs) 
are especially interesting, since they enable mag-
netic drug targeting i.e. the remote control over the 
distribution and accumulation of the nanocarrier 
in the body [1]. However, preparation of eﬀ ective 
and robust magnetically responsive nanocarriers 
still represents a great scientifi c challenge, due to 
physical limit of individual SPIONs, namely the 
too small magnetic force acting on individual 
nanocrystals exposed to magnetic fi eld gradient, 
resulting in their ineﬀ ective spatial guidance. The 
solution to this shortcoming could be assembly of 
numerous individual SPIONs into superparamag-
netic nanoparticle clusters, which exert good mag-
netic responsiveness, due to the increased volume 
of magnetic phase. In well-defi ned magnetic fi elds 
the clusters can form various hierarchical nano-
structures (i.e. nanobundles, nanochains), having a 
great potential for the preparation of innovative 
magneto-responsive nanodelivery systems [2].
The presentation will briefl y describe the syn-
thesis of well-defi ned magnetic nanoparticle clus-
ters and their assembly in hierarchical nanostruc-
tures. Then the development of magneto-respon-
sive delivery system based on such clusters will be 
presented. The special att ention will be paid to the 
method of drug loading, drug release studies and 
in vitro biocompatibility evaluation. 
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Development and characterisation of a gel 
formulation containing ibuprofen-loaded 
nanostructured lipid carriers 
 SÜTŐ, B.1,2,  BERKÓ, SZ.2 ,  CSÁNYI, E.2 
1Egis Pharmaceuticals Plc, Budapest, Hungary 
2Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
Faculty of Pharmacy, Szeged, Hungary 
 
BACKGROUND: Ibuprofen is a potent NSAID 
used for treating diﬀ erent forms of pain. Its low 
water-solubility and low bioavailability are great 
challenge in the development of dermal prepara-
tions.1 Nanostructured lipid carriers (NLCs) can 
overcome this problem.2 The dermal use of NLC 
systems oﬀ er many advantages: physical stability 
of the formulations, increased chemical stability 
of the incorporated drugs, improved skin bioavail-
ability, fi lm formation on the skin accompanied 
with controlled occlusion, skin hydration.1,2  
AIMS: The aim of this work was to develop ibu-
profen-loaded NLC (IBU-NLC), to achieve in-
creased transdermal API penetration. The opti-
mized formulation was incorporated in a gel; ex 
vivo and in vivo penetrations were compared to a 
conventional ibuprofen formulation.   
RESULTS:  Characterization of the IBU-NLC 
dispersion proved appropriate size range and 
morphology. XRD measurements and the high en-
trapment eﬃ  ciency (98.51%) both confi rmed the 
presence of IBU as a molecular dispersion in the 
lipid matrix of the fi nal formulation. The homoge-
neous distribution of IBU in the lipid matrix and 
the weak interactions between the drug and the 
excipients predicted rapid drug liberation. The ex 
vivo, in vivo penetration studies demonstrated sig-
nifi cantly higher drug permeation from the IBU-
NLC compared to the reference formulation. 
CONCLUSIONS: It can be concluded that the 
IBU-NLC gel is of great potential to increase drug 
permeation through the skin and enhance the eﬃ  -
cacy of the treatment for osteoarthritis and other 
musculoskeletal infl ammations compared to a 
conventionally prepared ibuprofen gel. 
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Formulation and characterisation of 
nanofi brillar cellulose consisting nanofi brous 
mats intended for novel wound dressings
 PAAVER, U.,  HEINÄMÄKI, J ., 
 KOGERMANN, K.
Institute of Pharmacy, University of Tartu, Tartu, Estonia
BACKGROUND: Cellulose nanofi brils, also 
termed as nanofi brillar cellulose (CNF), have sev-
eral unique material properties for excipient use 
in both immediate-release and controlled-release 
dosage forms. CNF is non-toxic, has high surface 
area and excellent mechanical strength that could 
be used to improve the mechanical properties of 
the dosage forms (1). CNF absorbs a lot of water 
and readily forms a gel which makes it a suitable 
candidate to be used also as a wound protective 
material (2). 
AIMS: The aim of the present study was to in-
vestigate the electrospinning (ES) of CNF and to 
fi nd optimal process conditions and solvent sys-
tems for fabricating CNF-based nanofi brous mats. 
The fi ber size, size distribution, surface morpholo-
gy, and physical solid-state properties of the nano-
fi bers were studied.  
RESULTS:  The formulations consisting CNF 
and a water-soluble polymer (polyethylene oxide, 
PEO) in various concentrations were tested. The 
process parameters of ES were varied to improve 
the processability of the nanofi bers. It was found 
that the 1:1 ratio of CNF (0.135 w/v% aqueous dis-
persion) and PEO (8 w/v%) solution in ES pro-
duced the nanofi bers with an uniform structure. 
The mean diameter of the fi bers was less than 200 
nm, and the fi ber diameter was dependent on the 
voltage used. When CNF was added to the PEO 
solution, the diameter of the fi bers decreased com-
pared to that obtained with the pure PEO fi bers. 
Higher concentration of CNF impaired the ES pro-
cess, and consequently, several beads were detect-
ed on the nanofi brous mats. 
CONCLUSIONS: CNF can be successfully elec-
trospun with PEO. Further studies will reveal the 
mechanical properties, stability, swelling and deg-
radation behavior of the present nanofi bers.
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In vitro investigation of antimicrobial 
electrospun wound dressings based on 
chloramphenicol and biodegradable polymers
 SAKS, L.,  MEOS, A.,  LAIDMÄE, I .,  PUTRINŠ, 
M.,  TENSON, T.,  KOGERMANN, K.
Institute of Pharmacy, University of Tartu, Tartu, Estonia
BACKGROUND: Infection and biofi lm formation 
are increasingly associated with non-healing and 
chronic wounds [1]. In order to develop novel 
wound dressings/drug delivery systems to tackle 
with this problem and understand their potential 
eﬀ ectiveness, full physicochemical, mechanical 
and biopharmaceutical characterization needs to 
be performed in addition to the antibacterial and 
cytotoxicity studies.  
AIMS: To develop chloramphenicol-loaded 
electrospun dressings and investigate properties 
important for the successful treatment of wound 
infections.  
RESULTS:  Chloramphenicol-loaded matrices 
using diﬀ erent carrier polymers were developed 
and characterized morphologically (scanning elec-
tron microscopy, atomic force microscopy, mercu-
ry intrusion porosimetry and BET analysis), phys-
icochemically (XRD, FT-IR, DSC), and biopharma-
ceutically (drug release). Also mechanical and 
swelling properties of the matrices and physical 
stability in biorelevant liquid medium were stud-
ied. Antibacterial properties of the dressings were 
revealed and compared using disc diﬀ usion as-
says and also biofi lm studies in a novel artifi cial 
wound model. Safety of the matrices on eucaryot-
ic cells was confi rmed with cytotoxicity testing on 
NIH 3T3 fi broblasts.  
CONCLUSIONS: Two potential wound dress-
ings with diﬀ erent structural, physicochemical 
and mechanical characteristics as well as diﬀ erent 
drug release behavior were developed. Both were 
biocompatible and had adequate antibacterial ac-
tivity, but diﬀ ered greatly in drug release profi les 
and swelling properties. It was possible to investi-
gate and confi rm the antibiofi lm properties of the 
dressings using an artifi cial wound model.
REFERENCES: 
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A science based approach for Topical drug 
Classifi cation System (TCS) 
 SHAH, V. P.
Consultant (Formerly with US FDA), North Potomac, Maryland, USA
Determining the bioequivalence of topical drug 
products is challenging, complicated and also cum-
bersome. We have developed a Classifi cation sys-
tem for Topical Drug Products, TCS, based on es-
tablished scientifi c principles specifi cally devel-
oped for semisolid topical drug products (SUPAC-
SS) and is combined with the in vitro release (IVR) 
of the drug product.  The TCS classifi cation is simi-
lar to the well-established Biopharmaceutics Clas-
sifi cation System (BCS) for immediate release oral 
drug products. TCS considers the qualitative (Q1) 
and quantitative (Q2) composition of inactive in-
gredients and microstructure arrangement of topi-
cal semisolid products.  The IVR refl ects the com-
bined eﬀ ects of several physico-chemical character-
istics, particle or droplet size, viscosity, the micro-
structure arrangement of the matt er (Q3) and the 
state of aggregation of the dosage form.   Based on 
composition (Q1 and Q2) and IVR similarity (Q3), 
the topical drug products are classifi ed as TCS class 
1, 2, 3 and 4.  Under the proposed classifi cation - 
only TCS class 1 and TCS class 3 drug products are 
eligible for biowaiver;  TCS class 2 and TCS class 4, 
are not eligible for biowaiver and will require ap-
propriate in vivo BE studies for drug approval. The 
TCS simplifi es the regulatory requirements and re-
duces the regulatory burden, and maintains the 
drug product quality.  It will also make the drug 
products more aﬀ ordable to consumers. 
REFERENCES:
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Some bioequivalent (BE) modifi ed-release 
(MR) formulations with multiphasic 
concentration profi les are not interchangeable
 ENDRĖNYI, L.,  TÓTHFALUSI, L.
Department of Pharmacology and Toxicology, University of 
Toronto, Toronto, Canada
BACKGROUND: It is widely assumed that if the 
bioequivalence of two drug products is approved 
then (provided that they are also pharmaceutical-
ly equivalent) they are therapeutically equivalent 
and, consequently, interchangeable.  It has been 
shown in several cases that these assumptions 
have not been satisfi ed.  
AIMS: To demonstrate that MR, multiphasic 
methylphenidate (MPH) formulations are not in-
terchangeable even when they have been declared 
to be BE.   
RESULTS:  The time profi les of concentrations 
in several MR, multiphasic MPH preparations are 
very diﬀ erent even though they have similar max-
ima and areas under the curve.  Consequently, 
they have diﬀ ering pharmacokinetic features even 
though they satisfy the regulatory criteria for bio-
equivalence. 
CONCLUSIONS: The diﬀ ering characteristics 
of apparently BE formulations raise doubts about 
their interchangeability.   Similar questions persist 
also for other classes of drug products. 
REFERENCES: 
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Navigating the regulatory 
information maze
 PÁLFI- GOÓTS, H.
Gedeon Richter Plc., Budapest, Hungary
BACKGROUND: In  the pharmaceutical industry 
as well as for health care professionals and pa-
tients it is important to identify the information 
and documents relevant to their everyday work, 
activities, life, etc.
AIMS: Aim of the presentation is to introduce 
what type of information and documents are pub-
licly available and how to search for  them.  
CONCLUSIONS: The pharmaceutical regulato-
ry environment is continuously evolving and has 
become very complex by today. Transparency is 
an important feature of this environment that has 
reached a never-before level in  the recent past. 
Medicines agencies are public authorities and are 
obliged to be open as for their operations as well 
as for information on clinical trials, medicinal 
products and for access to documents. The benefi t 
of the transparent operation is, but not limited to, 
strengthening the scientifi c, technical and admin-
istrative competencies in the pharmaceutical en-
vironment,  the eﬀ ective information sharing and 
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collaboration of the stakeholders. The European 
Union law sets the minimum level of transparen-
cy that the European Medicines Agency must ap-
ply. However, in many areas, the Agency has de-
cided to go beyond what the law requires provid-
ing as much information publicly available as 
possible. The presentation identifi es the type and 
source of information that the Agency releases ei-
ther mandatorily or proactively and how the pub-
lic can navigate in the enormous amount of infor-
mation. In addition the presentation summarises 
where health care professionals and patients can 
source their information from. 
REFERENCES: 
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Long-term dissolution method for poor water-
soluble parenteral suspension
 
 LEHOCKÝ, R.1,  PĚČEK, D.2,  ŠTĚPÁNEK, F.1
1University of Chemistry and Technology, Prague, Czech Republic
2Zentiva, k.s., Prague, Czech Republic
BACKGROUND: Sustained release (SR) injectable 
suspensions are already used in clinical practice 
because they have advantages: lower frequency of 
administration, blood levels remain within thera-
peutic range, greater eﬀ ectiveness and reduced 
side eﬀ ects. Such suspensions may be adminis-
tered in the form of a low soluble drug, but the re-
lease time of such medication is dependent on the 
particle size and the specifi c surface area. 
AIMS: In drug development, it is very impor-
tant to have reliable method how to evaluate drug 
dissolution profi le in in vitro conditions before 
clinical trials on animals and humans. In the case 
of low soluble drug, common dissolution tests are 
not applicable because of drug insolubility. There-
fore, we have developed a new in vitro dissolution 
method to evaluate the dissolution profi le of such 
medication. Moreover, this method is also useful 
for the development of generic drugs, to compare 
their dissolution profi le to those of the reference. 
Enzymatic dissolution tests of our drug suspen-
sions were conducted with various PSD by the en-
zyme serine esterase.
RESULTS: For each sample taken at various 
time intervals, the increase of API concentration 
and reduction of PSD of the suspension were eval-
uated using HPLC and laser diﬀ raction, respec-
tively. Based on the results of this work, the rate of 
kinetic release was found to correlate directly with 
an increase in the specifi c surface area of the parti-
cles in the suspensions. The proposed in vitro 
method is used to predict the pharmacokinetics of 
the medication under in vivo conditions. 
CONCLUSIONS: Thus, it can serve as a cheaper 
and faster alternative for bioequivalence studies 
(BES) on animals used in generic drug develop-
ment. However, further validation studies will be 
required to relate our method quantitatively to 
real in vivo conditions.
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New advances in continuous pharmaceutical 
technology
 MAROSI, GY.,  FARKAS, A.,  HIRSCH, E., 
 BORBÁS, E.,  DÉMUTH, B.,  DOMOKOS, A., 
 NAGY, B.,  FULOP G.,  BALOGH, A.,  NAGY, ZS. K.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
BACKGROUND: Continuous manufacturing of 
pharmaceuticals, being especially suitable for in-
stantaneous quality monitoring and control, al-
lows sudden reaction to market changes and cut 
development and upscaling costs. The choice of 
available scalable integrated continuous technolo-
gies is, however, limited.
AIMS: A complex research program aiming to 
widen the choice of techniques applicable for con-
tinuous formation of amorphous solid dispersion 
(ASD) was started recently.  The design of each 
step considered the application of process analyti-
cal technology (PAT) tools and feedback control in 
order to ensure output of stabile quality through 
fl exible and robust production.  
RESULTS:  Extrusion process being able to oper-
ate under wet, melt or supercritical (Sc) circum-
stances was developed and evaluated using vari-
ous polymers such as PVPVA64, Soluplus and oth-
ers. The role of parameters and components on the 
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amprphicity, homogeneity and dissolution charac-
teristics was evaluated.  Sc-extrusion allowed 
milder processing parameters and resulted in fast 
dissolution. Nanofi ber production with enhanced 
productivity could be developed applying various 
techniques such as high speed (HSES), alternating 
current (ACES), fi bre blowing and melt blowing. 
Further improvement in dissolution rate of drugs 
(of BCS II. type) could be achieved in all cases. 
Considerable challenge was to match appropriate 
downstream steps to these continuous production 
lines and combine them with in-line Raman sensor 
supporting real time release.  Novel feedback con-
trol was developed for powder blending and drug 
crystallization using UV and/or Raman sensors. 
These steps were integrated with drug synthesis in 
fl ow reactor resulting in end to end continuous 
pharmaceutical technology.
CONCLUSIONS: Development of new integrat-
ed continuous technology with in line control re-
sulted in several advantages. Higher bioavailabili-
ty was predicted for the formed ASDs of enhanced 
dissolution. The developed spectroscopy-based 
process control with well-designed chemometric 
techniques allowed adjusting the control strategy 
and process parameters to the required stable 
product quality. Real time release helps to avoid 
production losses resulting in more economic and 
safe manufacturing of pharmaceuticals.
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Application of the Quality by Design 
methodology in the R&D phase: 
implementation of „co-creation” with regulatory 
agencies, pharmaceutical industry partners and 
patients
 CSÓKA, I .
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Faculty of Pharmacy, Szeged, Hungary
BACKGROUND: Quality by Design (QbD) is a 
concept introduced by Dr. Joseph M. Juran, em-
phasizing the design of quality into products and 
services (1). This QbD approach is a risk and 
knowledge based holistic and systematic way of 
pharmaceutical developments as well, and it is 
highly recommended by the regulatory authori-
ties. The elements of the QbD methodology are 
described in the ICH Q8 (R2) international guide-
line dedicated for the industry (2).
AIMS: The aim of this work was to collect all rel-
evant stakeholders and evaluate their quality expec-
tations concerning the active agent, dosage form 
composition and manufacturing process; as well as 
the choice of the administration route. This work 
was followed by creating and pilot testing of a mod-
ifi ed fl ow chart of Quality by Design methodology 
together with a guideline for formulators in case of 
diﬀ erent dosage forms and administration routes.   
RESULTS:  Based on the preliminary data, we 
experience (a) an increased need for the evalua-
tion of the „unmet clinical needs”, (b) special fo-
cus and implementation of the preformulation 
study design based on the inputs of regulatory 
agencies and also the feedback from industrial 
partners of the pharma sector, and (c) put more 
emphasis on control strategy. 
CONCLUSIONS: Based on our research experi-
ences in case of topically, nasally and pulmonary 
administered diﬀ erent dosage forms and diﬀ erent 
carrier systems; the “R& D - QbD” was found to 
be a useful tool – set to formulate products for 
quicker transfer to manufacturing and marketing 
authorization, meeting the requirements of the de-
fi ned key stakeholders.  
REFERENCES: 
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Optimization of fl urbiprofen nanosuspensions: 
The QbD approach
 OKTAY, A.,  KARAKUCUK, A., 
 ILBASMIS-TAMER, S.,  CELEBI, N.
Gazi University Faculty of Pharmacy - Department of 
Pharmaceutical Technology, Ankara, Turkey
BACKGROUND: Flurbiprofen (FB) is the one of 
non-steroidal anti-infl ammatory drugs which has 
low water solubility. Nanosuspensions (NS) are 
promising drug delivery systems consist of pure 
solid drug particles mainly. Due to their mean 
particle size below 1000 nm, they increase solubil-
ity, dissolution and bioavalibility of poorly soluble 
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drugs. Quality by design (QbD) is a systematic ap-
proach to predict quality of NS with desired and 
predetermined parameters (1). 
AIMS: The objective of this study was to pre-
pare fl urbiprofen nanosuspensions (FBNS) using 
DoE with 23 full factorial design. FBNS were pro-
duced using microfl uidization method and stabi-
lized with Plantacare 2000 (PL). Eﬀ ect of critical for-
mulation att ributes (CFAs), critical process parame-
ters (CPPs) and their interactions were determined.
RESULTS: The particle size (PS), polydispersity 
index (PDI) and zeta potential (ZP) were found 
630±10 nm, 0.210±0.032 and -34.7±0.586 mV, respec-
tively as a function of 2 level of FB:PL ratio (A) (1:1, 
1:2), homogenization pressure (B) (20000-30000 psi) 
and homogenization cycles (C) (10-30 cycle). All 
parameters were evaluated using univariate ANO-
VA at α=0.05 as the minimum level of signifi cance. 
The 3-way interaction between independent vari-
ables was found to be insignifi cant (p>0.05). There-
fore, the 2-way interactions and main eﬀ ect of   in-
dependent variables were evaluated. All main ef-
fects and 2-way interactions between A*B and A*C 
were found to be eﬃ  cient on PS and ZP values. 
FB:PL ratio and 2-way interaction between B*C 
were eﬃ  cient according to PDI. The infl uence of 
CFAs and CPPs for the optimization of FBNS was 
determined using QbD approach successfully. The 
optimum formulation and process parameters 
were found as 1:1 FB:PL ratio, 26000 psi homogeni-
zation pressure and 30 homogenization cycle.
CONCLUSION: This study demonstrated the 
usefulness of QbD approach using DoE to under-
stand the optimum homogenization process pa-
rameters of FBNS.
REFERENCE: 
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Application of fl ow techniques as a research tool 
in pharmaceutical area
 SOLICH, P.,  SKLENÁŘOVÁ, H., 
 CHOCHOLOUŠ, P.
Charles University, Faculty of Pharmacy,  Laboratory of Flow 
Analysis, Hradec Králové, Czech Republic  
BACKGROUND: Various fl ow techniques (FIA, 
SIA, SIC, MSA, MSC, LOV, etc.) are already well 
established analytical techniques, which are char-
acterised by simplicity of fundamental principles, 
inexpensive instrumentation, automated sam-
pling and analytical procedures, low sample con-
sumption and short analysis time. Flow methods 
oﬀ er several advantages, mainly the instrumental 
set-up is very fl exible and the hydrodynamic vari-
ables are easily controlled with high eﬃ  ciency, 
thus fl ow methods are becoming a convenient re-
search tool in pharmaceutical area.
AIMS: Automated fl ow analytical methods are 
recently more and more used as a simple sample 
preparation step (automation of various extraction 
techniques) or for long-term monitoring. Flow 
techniques can automate the analysis and control 
long-term measurements such as dissolution, lib-
eration or permeation tests of pharmaceuticals.  
RESULTS:  A fully automated system based on 
the SIA technique connected to the Franz cell (en-
ables to mimic real conditions in the human skin 
and penetration of the drug through the dermal 
barrier) can easily monitor on-line the release rate 
of pharmaceuticals [1].  Sequential injection chro-
matography (SIC) was introduced fi rstly in 2003 
[2] as an alternative of high performance liquid 
chromatography (HPLC) for fast analysis of rela-
tively simple samples. Implementation of short 
monolithic chromatographic column into SIA has 
expanded also to analysis of pharmaceutics.
CONCLUSIONS: An overview of the use of 
fl ow techniques as a research tool in pharmaceuti-
cal area either as a simple technique for automa-
tion and sample preparation or for monitoring of 
pharmaceutically important procedures or fi nally 
as a simple alternative for separation procedures 
will be discussed. The authors gratefully acknowl-
edge the fi nancial support of Grant Agency of the 
Czech Republic (GAČR), project No. 15-10781S.
REFERENCES: 
1. Zelená L. et al., Anal. Bioanal. Chem. 408, 971-979 (2016)
2. Šatínský D. et al., Anal. Chim. Acta 499, 205-2012 (2003)
O-53
Application of simultaneous dissolution-
absorption apparatus for screening formulations 
before bioequivalence studies
 SINKÓ, B.1,  BORBÁS, E.2,  TSINMAN, K.1, 
 MAROSI, GY.2,  NAGY, ZS. K.2
1Pion Inc., Billerica MA, USA 
2Budapest University of Technology and Economics, Budapest, Hungary
BACKGROUND: For generic drug development 
traditional dissolution tests have been used in the 
pharmaceutical industry to compare performance 
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of diﬀ erent drug product formulations before con-
ducting bioequivalence studies, even though the 
in vivo predictive power of these tests are ques-
tionable.1 Namely, when a poorly water-soluble 
API is formulated to enhance its dissolution, addi-
tives have an eﬀ ect not only on dissolution, but 
also on fl ux through the membrane.2  
AIMS: The aim of this study was to represent 
that a simultaneous dissolution-absorption test 
can be used as a predictive tool before bioequiva-
lence studies are conducted.   
RESULTS:  Telmisartan tablets were tested us-
ing MacroFLUXTM: Receiver chamber integrated 
with permeation membrane, overhead stirrer and 
UV probe was inserted in the standard 900 mL 
vessel of USP II apparatus. The dissolution and 
fl ux results of the brand name (Micardis) and ge-
neric (Actavis) Telmisartan 40 mg tablets were 
compared. Actavis showed a slower release kinet-
ics than Micardis, though reached the same maxi-
mum concentration after 110 min. The fl ux from 
the generic product was found to be 0.240 ± 0.011 
μg/(cm2min), which is only 71% of the fl ux of the 
brand name (0.337 ± 0.028 μg/(cm2min)). This in 
vitro result showed excellent correlation with the 
in vivo data from bioequivalence studies, where 
the appearence rate or the drug in blood from Ac-
tavis was 72 % of the rate from Micardis. 
CONCLUSIONS: The in vivo predictive power 
of the simultaneous dissolution-absorption test 
was demonstrated by comparing the in vitro fl uxes 
to in vivo rate of appearance in blood of brand 
name and generic formulation of telmisartan. 
REFERENCES: 
1. Buckley, S. T. et al. Eur. J. Pharm. Sci. 45, 235–250 (2012).
2. Borbás, E. et al. Mol. Pharm. 13, 3816–3826 (2016).
O-54
Translation of clinical pharmacy research into 
practice: a Slovenian case
 MRHAR, A.
Faculty of Pharmacy, University of Ljubljana, Ljubljana, 
Slovenia
Clinical pharmacists in Slovenia have succeeded 
in the development and application of all relevant 
research methodologies to maximize the clinical 
eﬀ ect of medicines, minimize the risk of treat-
ment-induced adverse events and minimize the 
expenditures for drug treatments. 
On the basis of numerous original research arti-
cles published in leading journals at the area of 
outcomes research (1,2), two types of clinical phar-
macy services are currently in the process of im-
plementation in community care and in hospitals.
In community care Medication use review is of-
fered in community pharmacies, while in commu-
nity health centres and in nursing homes a practice 
of pharmacist consultant service is available as Ad-
vanced medication review. Medication use review in-
cludes medication history and patient information, 
whereas Advanced medication review is based on 
medication history, patient information and clinical 
information, which is obtained from patient’s medi-
cal records. The practice of pharmacist consultant is 
started by a general practitioner who identifi es ei-
ther patients with potential drug adverse reactions 
or patients with potential drug-drug interactions in 
the case of polypharmacotherapy. These patients 
and their medical records are referred to the phar-
macist. The pharmacist’s report is sent back to the 
general practitioner who optimizes the pharmaco-
therapy in accordance with the patients. The accep-
tance rate of pharmacist’s proposals is approximate-
ly 70%. The practice of pharmacist consultant is fi -
nanced as the regular health program by the Health 
Insurance Institute of Slovenia since 2016.
A full scale model of clinical pharmacy activi-
ties in clinics and hospitals has been introduced 
as early as in 2007. They are performed in the 
wards at the patients’ bedside and in the hospital 
management system. Clinical pharmacists partici-
pate in medical rounds, perform Advanced medica-
tion review, implement Medication reconciliation 
process, perform Therapeutic drug monitoring ac-
tivities and prepare Drug formularies. Additional-
ly, they participate in hospital committ ees for 
drugs, antibiotics and hospital infections, take an 
active role in creating pharmacotherapeutic guide-
lines and start sett ing up clinical pharmacy de-
partments.
REFERENCES:
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2. Čufar A., et al. Artif Intell Med 64, 147-158 (2015)
O-55
Cariprazine, a new generation atypical 
antipsychotics: Clinical overview
 LASZLOVSZKY, I .,  NÉMETH, G.
Medical Division, Gedeon Richter Plc., Budapest, Hungary
BACKGROUND: Schizophrenia is a chronic and 
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disabling psychiatric disease characterized by 3 
core symptom domains: positive symptoms, nega-
tive symptoms, and cognitive impairment. Anti-
psychotics are generally eﬀ ective in treating posi-
tive symptoms, but the treatment of negative symp-
toms and cognitive impairment remains a clinical 
challenge and a major unmet need in the treatment 
of schizophrenia. Negative symptoms have a sub-
stantial impact on the day-to-day functioning of 
patients and constitute the main barrier to a bett er 
quality of life for patients with schizophrenia. 
AIMS: To develop new atypical antipsychotic 
targeting dopamine D2/D3 receptors with D3 selec-
tivity to provide solution on the unmet medical 
need to treat predominant negative symptom of 
schizophrenia.
RESULTS: Cariprazine is a new orally active and 
potent dopamine D3 and D2 receptor partial agonist 
with preferential binding to D3 receptors, which has 
demonstrated eﬃ  cacy in treating various symptoms 
of schizophrenia in short and long term treatment 
trials. Cariprazine is approved in the US for the 
treatment of schizophrenia and manic or mixed epi-
sodes associated with bipolar I disorder in adults. In 
the post hoc analysis of short term eﬃ  cacy trials, 
cariprazine demonstrated signifi cantly greater im-
provement over placebo in a subset of patients with 
high levels of negative symptoms. In an adequately 
designed clinical trial in predominant negative 
symptom patients cariprazine showed superiority 
over risperidone both on the symptoms and the 
personal and social performance of patients. Clini-
cal developments of cariprazine are ongoing for bi-
polar depression (BD) and major depressive disor-
der as adjunctive therapy (MDD).
CONCLUSIONS: Cariprazine with its partial ago-
nist property and D3 selectivity on dopamine recep-
tors as well as with marked eﬃ  cacy on predominant 
negative symptoms of schizophrenia is a unique 
representative of third generation antipsychotics.
O-56
Changes in pharmacokinetics in patients with 
chronic heart failure
 KEREC-KOS, M.1,  CVAN TROBEC, K.1, 
 GRABNAR, I .1,  VOVK, T.1,  LAINSCAK, M. 2, 3
1 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
2 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3 Department of Internal Medicine, General Hospital Murska Sobota
Chronic heart failure can lead to changed body 
composition and cachexia. Cachexia is a unique 
process of weight loss resulting from constant acti-
vation of infl ammatory processes caused by under-
lying chronic disease like cancer, chronic heart fail-
ure, chronic obstructive pulmonary disease, etc. In 
patients with chronic heart failure, the disease it-
self and changes in body composition and cachexia 
may infl uence drug pharmacokinetics. Additional-
ly, body composition may infl uence the estimation 
of renal function if it is based on serum creatinine 
concentration. Patients may lose their muscle mass 
despite unchanged total body weight and this may 
result in decreased serum creatinine concentration 
regardless of their renal function. On the other 
hand, renal function is one of the key clinical pa-
rameters to be monitored in heart failure patients. 
Besides predicting mortality, it can importantly 
change renal excretion of drugs. A signifi cant pro-
portion of patients with chronic heart failure devel-
op a rapid decline in renal function, regardless of 
their baseline renal function. In pharmacotherapy 
of heart failure, inhibitors of angiotensin conver-
tase enzyme and beta blockers are used to improve 
survival and reduce number of hospitalizations.
In patients with chronic heart failure we evalu-
ated the pharmacokinetics of bisoprolol and 
ramipril, including longitudinal changes, and the 
infl uence of changed body composition and ca-
chexia on drugs pharmacokinetics (1). Moreover, 
we assessed the performance of creatinine-based 
renal function estimating equations in monitoring 
changes of renal function in chronic heart failure 
patients, and the eﬀ ect of body composition on 
the equations performance (2).
REFERENCES: 
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O-57
Safety an eﬃ  cacy of vitamin D supplementation 
among elderly people 
 TOTH, B. E.,  CSASZAR, T.,  KADAR, K.
Dept of Pharm. Surveillance and Economy, Faculty of Pharmacy, 
University of Debrecen, Debrecen, Hungary 
BACKGROUND: Vitamin D is essential to maintain 
the health status and the normal funtion in multiple 
organs in human. The potential role in prevention as 
well as correlation in certain morbidities, have been 
revealed recently. Advanced age, four-wall trapped 
lifestyle, low exposure to sunlight and insignifi cant 
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dietary Vit-D intake are the major factors associated 
with VitD defi ciency. 
AIMS: An observational study conducted be-
tween 2015 -2017  included elderly patients hospital-
ized in geriatrics facilities at Zala-megyei Szt Rafael 
County Hospital. Patient characteristics by key med-
ical history parameters and diagnoses were analyzed 
by  the severity of VitD defi ciency. The eﬃ  cacy of 
standard dose with a combination of loading –main-
tenece Vit D supplementation were assessed.   
RESULTS:  Signifi cant Vitamin D defi ciency was 
observed among the elderly people. The defi ciency 
was over 90%, and half  of the subjects who had no 
prior vitamin D supplementation did not reach the 
level of  serious defi ciency. The eﬃ  cacy of Vit D treat-
ment elevating the 25(OH)D levels were observed in 
most patients receiving at least 1000ÍU daily doses in 
average. Treatment with slow uploading doses – 
30000 IU /week for 3 month signifi cantly increased 
the median 25(OH)D levels. over one year period. 
CONCLUSIONS: Vit D defi ciency among hospi-
talised elderly people are signifi cant and may have 
critical impact on their health status. Periodic sup-
port with Vitamin D may not provide enough sourc-
es to maintain the recommended 25(OH)D levels. A 
therapy starting with a slow loading dose of 30000 
IU/week for 3 month proven to be eﬃ  cient and to 
reach the targeted levels. A continuous maintanence 
doses are necessary even over the summer period.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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O-58
The eﬃ  cacy of ginger (Zingiber oﬃ  cinale) for 
the prevention of postoperative nausea and 
vomiting
 TÓTH, B.,  LANTOS, T.,  CSUPOR, D.,  VASAS, 
A.,  MATUZ, M.,  BENKŐ, R.,  HEGYI, P., 
 VIOLA, R.
Department of Pharmacognosy, University of Szeged, Szeged, 
Hungary
BACKGROUND: Postoperative nausea and vom-
iting (PONV) is one of the most common and dis-
tressing outcomes occurring within 24 hours af-
ter surgery, aﬀ ecting patients undergoing gener-
al anaesthesia. PONV may lead to several sec-
ondary complications, such as aspiration pneu-
monia, wound disruption, gastric herniation, 
dehydration and fatigue. Ginger has been used in 
the treatment of nausea and vomiting for thou-
sands of years. Recently several randomized, pla-
cebo-controlled clinical trials have been conduct-
ed in order to evaluate the eﬀ ects of ginger on 
PONV. 
AIMS: The aim of our work was to assess the ef-
fi cacy of orally administered ginger on PONV 
compared to placebo based on the available clini-
cal data. Literature searches were conducted 
through EMBASE, PubMed and WOS databases. 
Human, placebo-controlled clinical studies of pa-
tients undergoing any types of surgery, receiving 
pharmacological doses of ginger per os were in-
cluded. Only clinical studies with explicit descrip-
tion regarding the extract of ginger were ana-
lyzed..  
RESULTS:  Eleven randomized trials including 
a total of 1157 patients were pooled for statistical 
analysis. The investigated primary outcomes were 
1) presence of postoperative nausea or vomiting, 
2) request of rescue antiemetic drugs, and 3) 
changes in nausea and vomiting scores. Subgroup 
analyses were performed with diﬀ erent doses of 
ginger. To assess the eﬃ  cacy of ginger on PONV a 
frequentist approach random eﬀ ect analysis was 
performed, calculating 95% confi dence interval 
for the pooled eﬀ ect and two sided P value. Statis-
tical heterogeneity was explored by Chi square 
test and I-squared statistics.
CONCLUSIONS: The results of our analysis 
demonstrate that ginger intake may reduce the 
risk of postoperative vomiting, and ameliorate 
nausea scores. However, only doses of ginger not 
less than 1000 mg were signifi cantly bett er than 
placebo. The eﬀ ects of ginger on postoperative 
nausea and rescue antiemetic request were not 
statistically signifi cant.
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NOVEL DELIVERY SYSTEMS 1
P1A–1
Melt-electrospinning: a novel method for 
formulating and improving the solubility of 
poorly water-soluble drugs
 SEMJONOV, K.1,  LUST, A.1,  LAIDMÄE, I .1, 
 KOGERMANN, K.1,  HEINÄMÄKI, J .1
1 Institute of Pharmacy, Faculty of Medicine, University of 
Tartu, Estonia
BACKGROUND: Solution or melt electrospinning 
(MES) are eﬀ ective methods for fabricating nano- 
or micro-scale drug delivery systems (DDSs), or 
scaﬀ olds for biomedical applications. Formulation 
of melt electrospun fi brous solid dispersions is a 
novel approach to improve the solubility of poorly 
water-soluble drugs1. The combination of several 
factors related to the process (amorphization, sta-
bilization and void of any solvents) makes MES an 
att racking tool to be investigated to address poor-
ly soluble drugs.
AIMS: The objective of this study was to prepare 
and characterize DDSs fabricated by MES using in-
domethacin (IND) as a model drug, and polyvinyl-
pyrrolidone (PVP)/Soluplus (SOL)/xylitol (XYL) as 
carriers. Moreover, the eﬀ ects of formulation on 
the dissolution behavior of IND was investigated.  
RESULTS:  Melt spun fi bers (MSFs) were suc-
cessfully prepared and analyzed using XRPD, 
FTIR, DSC and SEM. The dissolution studies were 
carrier out at pH 6.8. Solid-state characterization 
confi rmed the presence of amorphous IND. The 
dissolution (drug release) from MSFs was superi-
or compared to that obtained with pure crystalline 
IND alone, or with the corresponding physical 
mixtures (PMs).  
CONCLUSIONS: The results demonstrate that 
MES can be used as an eﬀ ective tool for fabricat-
ing micro-scale fi bers (fi brous solid dispersions) 
for poorly-water soluble drugs. The dissolution 
rate of IND can be signifi cantly improved com-
pared to that of pure drug and PMs. 
REFERENCES: 
1. Nagy et al. J Pharm Sci 102 (2), 508-513 (2013).
P1A–2
Evaluation of techniques and possibilities for 
oral delivery of antidiabetic peptide drug – 
liraglutide – in a novel delivery system 
 RUBA, I .,  CSÓKA, I . 
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
Faculty of Pharmacy, University of Szeged, Szeged, Hungary. 
 
BACKGROUND: Liraglutide (NN2211) is a long 
acting Glucagon like peptide-1 (GLP-1) analog 
with 97% homology to human GLP -1. It is ap-
proved by FDA for the treatment of diabetes melli-
tus type 2 and for chronic weight management of 
adults delivered through subcutaneous injection1. 
Since this invasive route is associated with many 
problems leading to insuﬃ  cient patient compli-
ance, the oral route should be aimed, providing a 
patient friendly administration in addition to 
mimicking the physiological route of GLP-1 from 
intestine to circulation2. However researchers 
should overcome the major obstacles concerning 
the oral liraglutide delivery, including the low sta-
bility through GI tract and low intestinal permea-
bility. 
AIMS:  The aim of this presentation is fi rstly to 
evaluate the up to date strategies for oral peptides 
delivery, especially GLP-1 and its analogs and sec-
ondly to share a development plan according to 
Quality by Design (QbD) methodology for the 
early development of these dosage forms, and 
thirdly to give a report on the preformulation 
studies prior designing a fi nal dosage form.    
RESULTS:  The following solutions can be 
evaluated to be a good selection for enhancing 
the oral bioavailability of the peptide drug by ei-
ther protecting the drug from the harsh environ-
ment through the GI tract or improving its intes-
tinal permeability: polymeric nanoparticles and 
cell penetrating peptides. These solutions in a 
proper combination could lead to a promising re-
sult, according to the results of the literature re-
view. Quality Target Product Profi le is to be de-
fi ned as well as Critical Material Att ributes and 
Critical Process Parameters as a part of QbD 
methodology. As a part of the preformulation 
study PLGA, Eudragit RS PO and Eudragit RL 
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PO were selected as polymers for preparing 
nanocarriers; the suitability of the double emul-
sion evaporation method is under evaluation at 
present.     
CONCLUSIONS: According to the evaluation 
of the available literature and industrial data, evi-
dences were found, that the achievement of the 
oral delivery of liraglutide leads to an improved 
patient adherence. As there are many critical steps 
in formulation as well as a careful selection of ad-
ditivies is also a challenge in case of this type of 
products; authors strongly emphasize the applica-
tion of QbD methodology in the early develop-
ment stage as well as doing careful preformula-
tion studies prior to dosage form design.  
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
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P1A–3
Development of a fl oating gastroretentive 
dosage form by melt foaming 
 HAIMHOFFER, Á.,  VASVÁRI, G., 
 FENYVESI, F.
Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary
Introduction: Gastroretentive drug delivery is ad-
vantageous in such cases when the active ingredi-
ent has narrow absorbtion window or gastric tar-
geted release is aimed. Based on the retentive 
mechanism we can distinguish categories like 
low- or high density based, mucoadhesion-based , 
size dependent or magnetic anchored forms.1
Aims: We aimed to develop and create a drug 
delivery system based on its high-porosity and 
low-density by foam formation after melting the 
components. We were also interested to determine 
the key factors aﬀ ecting the elementary properties 
of the carrier, such as fl oating ability, foam prop-
erties by electron microscopic imaging. We also 
tested the in vitro drug release and texture chang-
es during dissolution. As a possible API we used 
metronidazole.
Results: At start we designed and built a lab 
scale agitator and a suitable vessel to melt and to 
dose the molten mixture into size 00 gelatine cap-
sules.  After selecting the possible excipients we 
revealed, that the presence of lipids and surfac-
tans such as PEG 4000, stearic acid or Labrasol 
was essential for the foam formation beside heavy 
agitation. Our EM pictures confi rmed that we suc-
cessfully created a carrier with closed cell struc-
ture. The prepared foams showed a hard structure 
even on body temperature. PEG and Labrasol 
alone was not enough to prepare foams with de-
sired fl oating ability. From the initial density of 
1,22-1,29 g/ml we decreased it to 0,78-0,92 g/ml 
target values. The dissolution studies showed that 
the more stearic acid was added to the mixture the 
slower drug release was detected. The 90% of the 
API was released within 10 hours. 
Conclusion: We can summarize that we devel-
oped a novel method to prepare solid and low 
density drug delivery system with zero fl oating 
lag-time. The prepared samples showed pro-
longed drug release and hard structure with the 
ability to remain in the stomach for several hours. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.
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P1A-4
Formulation and evaluation of innovative, 
chitosan based mucoadhesive buccal drug 
delivery fi lms
 MÓDRA, SZ.,  KATONA, B.,  SOVANY, T., 
 AIGNER, Z.,  PINTYE-HÓDI, K.,  KRISTÓ, K., 
 REGDON JR., G.
University of Szeged, Institute of Pharmaceutical Technolgy and 
Regulatory Aﬀ airs H-6720 Szeged, Eötvös u. 6., Hungary
BACKGROUND: Nowadays, the buccal adminis-
tration of mucoadhesive fi lms is very promising. It 
provides convenient dosing and patient compli-
ance is good, considering its small size and easy 
application.
AIMS: Our aim was to produce chitosan based 
fi lms, which can provide a small amount of active 
substance absorption through the buccal mucous 
membrane, thereby avoiding the hepatic fi rst pass 
eﬀ ect. During the formulation, we used ascorbic 
acid (AscA) in diﬀ erent concentrations (2-5%). It 
provided acidic pH, and it has permeation en-
hancer properties as well. We compared the AscA 
eﬀ ects on the properties of fi lms with fi lms pre-
pared with acetic acid (AA). Each fi lm contained 
glycerol as plasticizer in the same quantity.
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RESULTS: We examined the identifi cation crys-
talline form in the fi lms with X-ray powder dif-
fractometry (XRPD).Spectra were recorded with a 
BRUKER D8 Advance diﬀ ractometer (Bruker AXS 
GmbH, Karlsruhe, Germany). The FTIR spectra 
suitable for structure analysis as well. The tensile 
strength was tested with a device and software 
developed in our Institute, the in vitro adhesion 
force of the fi lm on mucin solution as well. The 
mucoadhesion force was examined by calculating 
the fi lms’ surface free energies (SFE) based on re-
sults from contact angle measurement with OCA 
20 (DataPhysics Instruments GmbH). Higher 
AscA concentration caused higher plasticity in the 
fi lms against AA containing fi lms. AscA also mod-
ifi es the mucoadhesional force, compared to AA 
fi lms it is decreased to diﬀ erent extents. The XRPD 
spectra show us that the highest AscA amount did 
not build into the structure of the fi lms, same as 
the FTIR spectra. The surface free energy was 
higher when using AscA than with AA.
CONCLUSIONS: Using AscA is advantageous 
in case of surface free energy, and from the muco-
adhesion aspect the 4% of AscA composition 
proved the best.
REFERENCES: 
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P1A-5
Alternating current electrospinning, a novel 
method for preparing drug-loaded amorphous 
solid dispersions
 FARKAS, B.,  BALOGH, A.,  NAGY, Z. K., 
 MAROSI, G.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary 
BACKGROUND: Preparing amorphous solid dis-
persions of the growing number of poorly water 
soluble drugs can overcome the hurdle of reaching 
high bioavailability in the fi eld of oral dosage forms. 
Two-thirds of the marketed solid dispersion-based 
products apply cellulose ethers as carriers due to 
their ability to prevent the drug from precipitation 
during dissolution and maintaining the high ener-
gy amorphous form of the drug for a long time. Al-
ternating current electrospinning (ACES), the high-
yield version of the widely investigated direct cur-
rent method (DCES) is a promising novel way to 
prepare amorphous solid dispersions, although de-
spite its benefi ts, it has not come into great interest 
yet in the fi eld of pharmaceutics (1.). 
AIMS: ACES was explored to prepare im-
proved drug-release amorphous solid dispersions 
of poorly water soluble drugs with high produc-
tivity while maintaining excellent fi ber quality. 
Cellulose ethers of great importance in pharma-
ceutics were intended to use as polymer carriers, 
although their poor spinnability required the in-
vestigation and modifi cation of solution proper-
ties to improve the electrospinning process.  
RESULTS:  Conductivity of the polymer solu-
tion was found to be of great importance during 
ACES. After optimizing the solution conductivity 
and adding high molecular weight polyethylene 
oxides as active fi ber-forming agent, multiple 
times higher productivity was achieved with 
ACES compared to DCES while maintaining the 
same good quality fi bers. DSC and XRPD mea-
surements showed that the drug turned into 
amorphous in the electrospun samples. Dissolu-
tion tests showed remarkable increase in drug re-
lease rates.
CONCLUSIONS: The results demonstrate that 
alternating current electrospinning is a promising 
new technique to produce drug-loaded polymeric 
mats at high throughput rates than the conven-
tional direct current method.
REFERENCES: 
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P1A-6
Mesoporous silica nanoparticles within 
nanofi bers – novel antibiofi lm strategy
 SEN KARAMAN, D.1,  SAKS, L.2,  LANNO, G.-M.2, 
 GOUNANI, Z.1,  TENSON, T.2,  ROSENHOLM, J.1, 
 KOGERMANN, K.2
1Pharmaceutical Sciences Laboratory, Åbo Akademi University, 
Finland
2Institute of Pharmacy, University of Tartu, Estonia
BACKGROUND: Biofi lms are microbial communi-
ties together with polymeric extracellular matrix 
which are known to be the main reason for the de-
velopment of resistance to antimicrobial agents 
and persistent and chronic bacterial infections (1). 
Mesoporous silica nanoparticles (MSN) as drug-
carriers are able to pass through the cell mem-
branes as well as biofi lm matrices and provide 
bett er treatment outcome (2). However, the eﬃ  ca-
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cy of MSN in killing the bacteria within the bio-
fi lm can be increased by using novel delivery plat-
forms for the therapy such as MSN loaded electro-
spun nanofi ber matrices.
AIMS: To design and develop MSN loaded into 
electrospun nanofi ber scaﬀ olds as novel antimicro-
bial agent delivery systems used for the prevention 
and eradiction of mono/poly microbial biofi lms. 
RESULTS: Prepared MSN consisting FITC label-
ling for tracking and polyethyleneimine surface 
functionalization were prepared and characterized 
using fl uorescent microscopy, SEM and dynamic 
light scatt ering. Spherical shaped MSN had a mean 
size of approximately 250 nm and net positive sur-
face charge. Stable MSN dispersion was electros-
pun together with a hydrophobic carrier polymer 
obtaining fi bers mostly having a diameter of 260 
nm, but there were also some larger fi bers observed 
(diameters up to 1500 nm). The presence and distri-
bution of MSN within the electrospun fi bers was 
nicely shown using elemental analysis of SEM. The 
selection of appropriate polymers as well as sol-
vents is crucial for successful electrospinning and 
obtaining stable drug delivery systems. The antimi-
crobial agent incorporation into the MSN will al-
low understanding whether the burst release to-
gether with prolonged drug release from electros-
pun nanofi ber scaﬀ olds can be achieved important 
for successful antibiofi lm activity.
CONCLUSION: Mesoporous silica nanoparti-
cles (MSN) were successfully incorporated into 
nanofi bers using monoaxial electrospinning. Fur-
ther studies will investigate the incorporation of 
various antimicrobial agents and the antimicro-
bial eﬃ  cacy of the developed platform during in 
vitro biofi lm studies using relevant bacterial 
strains.
REFERENCES:
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The eﬀ ect of sodium stearate on the aerosol 
performance of meloxicam potassium using a 
carrier-free procedure
 BENKE, E.,  SZABÓ-RÉVÉSZ, P.,  AMBRUS, R.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: The development of dry powder 
inhalation systems (DPIs) led to the new genera-
tion of formulations. Instead of a traditional lac-
tose-base formulation, carrier-free alternatives can 
be applied to reach bett er aerosolization behav-
iour of the drugs. Our previous work focused on 
the DPI formulation of meloxicam potassium 
(MXP), which is a novel synthetized salt form of 
meloxicam. Diﬀ erent types of hydrophilic addi-
tives were used to improve its aerodynamic prop-
erties. The pulmonary application of MXP is a 
novelty for local anti-infl ammatory treatment be-
cause it does not exhibit aspirin-like hypersensi-
tivity reactivity. 
AIMS: The aim of our present work was the 
formulation and investigation of the DPI form of 
MXP containing sodium stearate in diﬀ erent con-
centrations (0-2 w/w%).  Spray dried formula-
tions were characterized in terms of size distribu-
tion, morphology, density, cohesivity, in vitro 
drug release in lung media and in vitro lung de-
position.  
RESULTS:  Because spray drying dos not 
overcome the hydroscopic and cohesive nature 
of the powder, the incorporation of a lipophilic 
agent could oﬀ er a solution to these problems. 
The produced particles exhibited 2-3 μm size, 
low density and spherical form. The fi ne parti-
cle fraction was more than 80 %, however, the 
fi ne particle dose converted to % was around 60 
%. 2% of sodium stearate resulted in the best 
product.
CONCLUSIONS: This study has shown that 
lung deposition could be influenced by modi-
fied morphology and size of the drug and the 
application of an adjuvant. The structure of the 
micronized drug (crystalline/amorphous) could 
affect the bioavailability and stability of the 
produced DPI, too. The pulmonary application 
of MXP is a novelty for local anti-inflammatory 
treatment; at present, MXP-containing DPI 
products are not marketed for pulmonary ther-
apy.
This project was supported by the János Bolyai 
Research Scholarship of the Hungarian Academy 
of Sciences (2014–2017) and by the ÚNKP-16-2-I 
New National Excellence Program of the Ministry 
of Human Capacities.   
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P1A-8
Microencapsulation of probiotics as 
biotherapeutic agents for their local delivery
 MIRTIČ, J . 1,  FAJDIGA Š. 1,  ZUPANČIČ, 
Š.1,  RIJAVEC, T. 2,  ZVONAR POBIRK, A. 1, 
 LAPANJE, A. 2,  KRISTL, J . 1
1Faculty of Pharmacy, University of Ljubljana, Slovenia; 
2 Institute Josef Stefan, Ljubljana, Slovenia
BACKGROUND: The delivery of probiotics to the 
diﬀ erent sites of action within the human body can 
help to prevent or even treat several diseases. The 
action of priobiotics is either based on the shaping 
of local microbiota or interacting with host cells re-
sulting in the reversal of disease progression (1). 
AIMS: The primary aim was to develop a deliv-
ery system for the probiotic bacteria, which were 
isolated from healthy individuals and to deliver 
them localy. The goal was to encapsulate probiot-
ics into chitosan-coated Ca-alginate microcapsules 
produced by the prilling of lamellar liquid jet by 
membnane vibration technology. This enable ade-
quate delivery of the probiotic bacteria as well as 
to increase their stability during storage.  
RESULTS:  Using diﬀ erent alginate concentra-
tions (0.75 – 1.6 %), various excipients: lactose (fi ll-
er), glycerol and trehalose (cryo- and lyoprotec-
tants), chitosan (polyelectrolyte coating), micro-
capsules of 120 - 150 μm in diameter were pro-
duced, which were then additionally stabilized by 
freeze-drying. Their zeta potential switched from 
negative (- 10 mV) for uncoated to positive (+ 10 
mV) for chitosan coated microcapsules. Stereo and 
scaning electron microscopy allowed us to exam-
ine the infl uence of chitosan-coating on surface 
morphology modifi cation. The probiotic encapsu-
lation eﬃ  ciency was high; up to 1×109 of colony 
forming units per gram of dry microcapsules. A 
delay of probiotic release for at least 3h was 
shown for the coated microcapsules. The viability 
and stability of incorporated probiotics in such 
freeze-dried microcapsules has been shown to last 
at least for one month. 
CONCLUSIONS: Chitosan-coated Ca-alginate 
microcapsules were proved as a promising deliv-
ery system for probiotics, enabling their sustained 
relese and providing easier handling  as well as 
increased stability of encapsulated bacteria com-
pared to those thar were only freeze-dried. 
REFERENCES: 
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P1A-9
Development of a lipid based drug delivery 
system containing antibiotics for the treatment 
of periodontitis
 LÉBER, A.,  BUDAI-SZŰCS, M.,  VÁLYI, P., 
 URBÁN, E.,  CSÁNYI, E.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: Periodontitis – caused by an-
aerob Gram-negative bacteria – is the chronic in-
fl ammatory disease of the gingiva, which without 
proper treatment may lead to tooth loss. Antibiot-
ics have been widely used in the treatment of peri-
odontitis and could help eliminate pathogens re-
sponsible for the disease.
AIMS: Our aim was to develop lipid based drug 
delivery systems containing antibiotics which can 
be administered subgingivally and can provide 
sustained release of antibiotic compounds for at 
least one week. Biodegradibility is a key property 
of the formulations because it is important to help 
the periodontal pockets disappear and to allow the 
tissue of the gingiva to return to its healthy state.  
RESULTS:  We investigated the eﬀ ect of the ra-
tio of diﬀ erent lipid bases and the eﬀ ect of the var-
ious concentrations of the surface active agents on 
the consistency, the wett ability of the systems, the 
swelling and degardation properties, and the drug 
release. A preliminary microbiological investiga-
tion was also carried out in order to measure anti-
microbial eﬀ ectiveness of formulations. On the ba-
sis of the results the optimal composition was de-
termined. The proper ratio of the lipid compo-
nents can provide a suitable structure and an ap-
propriate consistency with sustained release of the 
antibiotic agents.
CONCLUSIONS: We successfully developed a 
lipid based biodegradable drug delivery system 
containing antimicrobials for the treatment of 
periodontitis. With the adequate concentrations of 
the components, sustained release of the active 
components is possible.
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
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P1A-10
CharacterIsatIon and EVALUATION OF 
Targeted LIPOSOMES. I - In vItro studIes
 SAKA, O. M.,  OZ, U. C., 
 KUCUKTURKMEN, B.,  GULYUZ, S.,  
 YILMAZ, Ö.,  BOZKIR, A.
Pharmaceutical Technology/Ankara University, Turkey
BACKGROUND: Liposome-derived carriers have 
advantages such as their diverse range of morpholo-
gies, compositions, abilities to envelope and protect 
many types of therapeutic biomacromolecules, lack 
of immunogenic response, and their diﬀ erential re-
lease characteristics. Also, they can be used to deliver 
a molecular cargo such as DNA for therapeutic bene-
fi t1,2. This type of gene delivery systems for therapeu-
tic applications remains limited by their poor ability 
to escape from the endosomal compartment and to 
translocate DNA into the nucleus. Peptide carriers 
that combine DNA binding and membrane destabi-
lising properties have been demonstrated to promote 
gene transfer into cultured cells and living animals2. 
We have recently described a new peptide-based3 
gene delivery system, prepared by cationic polymer 
which was covalently linked to DOPE, and conjugat-
ed with peptide 18 and peptide 563 which are specif-
ic for breast and prostat cancer, respectively.  
AIMS: In our study we designed and prepared 
cationic liposomes for cancer treatment plasmid. We 
prepared liposomes with most widely used method4, 
named as lipid hydration method.  Their particle 
size and and zeta potential measurements were per-
formed using an aqueous dip cell in the automatic 
mode by Zetasizer Nano ZS.  The morphology of the 
lipoplexes were visualized by transmission electron 
microscopy. Encapsulation eﬃ  ciency and loading 
capacity of the formulations was calculated. In-vitro 
release and their cyctotoxity studies were also per-
formed.   
RESULTS:  The polymer which is as widely stud-
ied as PEG and shares many of the desirable features 
of PEG was synthesized by cationic ring opening po-
lymerization of 2-ethyl-2-oxazoline. The prepared 
polymer was covalently linked to DOPE, and conju-
gated with peptide. 
CONCLUSIONS: Lipoplexes of DNA may cause 
positive zeta potential (24 to 39 mV), low cytotoxicity 
(cells remaining 86-98%), with a proper particle size 
(around 100nm), that might contribute to the high 
transfection eﬃ  ciency and seemed to be more eﬃ  -
cient carriers for in vitro gene transfer. Further stud-
ies were carried on to determine their stability and 
eﬃ  cacy on animal model transfection process.  
Authors are grateful to TUBITAK, for providing 
fi nancial assistance to carry out the research work 
under Project (Ref. no. 2013M760).
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P1A-11
Formulation and characterization of dermal 
fi lms for wound healing
 ÜSTÜNDAĞ OKUR, N.,  HÖKENEK, N.
Department of Pharmaceutical Technology, School of Pharmacy, 
Istanbul Medipol University, İstanbul, Turkey
Wound healing is the natural process of regenerat-
ing the dermal and epidermal tissue of the body. It 
is the process that brings back the damaged part of 
the body as normal as possible [1]. The dermal fi lm 
technology has proven to be fastest, easiest, safest 
and most economical way to help wound to heal. 
Hydrogels are ideal biopolymeric pharmaceutical 
forms for the treatment of skin wounds [2]. 
The aim of this study is to prepare dermal 
patches and evaluate wound healing potential 
with various polymers to be used topically in 
wound infections. 
Diﬀ erent concentrations of sodium alginate and 
chitosan were used to prepare fi lms. Glycerin, 
propylene glycol or PEG 400 at the range of 1-20 % 
was used as plasticizers and fi lms were developed 
by solvent casting evaporation. Films were evalu-
ated with regard to percentage moisture loss, 
thickness, FTIR, weight variation, and pH. Also 
swelling studies were performed at diﬀ erent time 
intervals. Films were prepared successfully by sol-
vent casting technique. Films had homogeneous 
appearances and could be easily removed from 
the petri dishes, except K9-K16 code formulation 
(sodium alginate %1, glycerin and PEG 400). The 
fi lms had a thickness varying from 0.25+0.02 to 
0.90+0.05 mm. The thickness of inserts increased 
when the plasticizer concentrations were in-
creased. All prepared formulations indicated good 
physical stability. Moisture content of fi lms was 
studied in order to determine the degree of hygro-
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scopicity of the formulation. The moisture of the 
insert was found less than 1% at the end of 24 
hours. During the swelling test the fi lms swelled 
for 12 hours and the volume and weight of the 
fi lms increased. 
According to the obtained results, when the ra-
tio of plasticizer was increased, the thickness, 
weight, moisture loss and swelling rate of the for-
mulation were found to increase. Films developed 
with chitosan and propylene glycol may be of-
fered as appropriate vehicles for wound healing.
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P1B-1 
Steroid-harboring nanoparticles provide anti-
infl ammatory response with less adverse eﬀ ects
 KOLLAR, B.*,  HORVATH, B.*,  SZECHENYI, 
A.,  PAL, SZ.,  KVELL, K.
*fi rst authors with equal contribution  
Pharmaceutical Biotechnology, Faculty of Pharmacy, University 
of Pecs Hungary
BACKGROUND: Steroids are acknowledged anti- 
infl ammatory drugs used in multiple conditions, 
including autoimmune disease. Steroids provide 
strong suppression of infl ammation, however, 
their long-term utilization triggers numerous ad-
verse eﬀ ects including obesity, diabetes, osteopo-
rosis, edema retention etc. As a result, only in-
fl ammatory fl ares are treated with steroid com-
pounds, for short term. 
AIMS: Our collaborative research team has pro-
duced nanoparticles of specifi c size harboring ste-
roid compounds. In theory, due their specifi c size 
steroid-harboring nanoparticles trigger phagocy-
tosis in monocytes and macrophages, but leave 
other (non-phagocytic) cells unaltered.  
RESULTS: Our human in vitro data indicate that 
steroid particles show potent anti-infl ammatory 
eﬀ ect on monocytes / macrophages, equivalent to 
that of steroid solution. However, their adverse ef-
fects are reduced using non-phagocytic cells. Liver 
cells, for example, show increased viability with 
steroid particles as opposed to steroid solution.
CONCLUSIONS: Our working hypothesis was 
that steroid- particles of a specifi c size range can 
preferentially target monocytes / macrophages, 
the major mediators of infl ammation. Other (non- 
phagocytic) cell types shall largely be unaltered 
by steroid particles, as opposed to steroid solu-
tion. This is confi rmed by our data. Our technolo-
gy allows for the production of regular steroid 
compounds with signifi cantly reduced side ef-
fects, with the promise of long-term use in human. 
P1B-2
Preparation and evaluation of loratadine 
nanosuspension by using precipitaion 
ultrasonication technology
 AREEN, A.,  AMBRUS, R.,  KATONA, G., 
 CSÓKA, I . 
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Hungary
BACKGROUND: Nanoparticle engineering occu-
pies the top of applied techniques as new,and ef-
fective breakthrough in drug design and delivery. 
Nanosuspensions are nanoscale drug dispersions 
stabilized by minimum amount of steric or/and 
electrostatic stabilizers. Nanocrystals could pres-
ent enhancing saturation solubility and surface 
area, thus increased absorption and bioavailabili-
ty (1). The classical bott om up method used is pre-
cipitation from antisolvent, where drug nanopar-
ticles are formed by assembling of its molecules 
from organic solution. Loratadine (LOR) has been 
selected as API, it is a second generation H-antag-
onist frequently prescribed for treatment of aller-
gic rhinitis, and other allergic conditions,it is char-
acterized by poor water solubility, high perme-
ation, and pH dependent solubility.
AIMS: This study is aimed for preparation of 
LOR nanosuspensions by precipitation to enhance 
LOR solubility, followed by characterization by 
measuring particle size, PDI, and zeta potential. A 
statistical analysis was applied to evaluate the ef-
fects of surfactant and stabilizer concentrations on 
these properties. Freeze dried nanoparticles were 
characterized by DSC,XRPD,SEM, and in vitro re-
lease patt eren.  
RESULTS:  The mean particle size and PDI were 
in the range of 245-488nm and 0,08-0,24 respec-
tively with negative zeta potential ranged from-3 
to -27 showing their stability. DSC and XRPD in-
dicated LOR crystallinity reduction.
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CONCLUSIONS: Antisolvent precipitation 
with ultrasonication was a proper method to pre-
pare LOR nanosuspensions with stable homoge-
nous distribution. These nanoparticles can be 
used as intermediate products for furthur formu-
lations.
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
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P1B-3
Pickering emulsion of tea tree oil in water, 
stabilized with silica nanoparticles for 
onychomycosis topical treatment
 HORVÁTH, B.,  BÁRDONICSEK, N., 
 TAKÁCSI-NAGY, A.,  PÁL, SZ.,  SZÉCHENYI, 
A.
University of Pécs, Faculty of Pharmacy, Institue of 
Pharmaceutical Technology and Biopharmacy, Pécs, Hungary
BACKGROUND: Onychomycosis is the most com-
mon nail infective disorder, which may be treated 
by topical and/or oral therapy. Because of the risk 
of oral therapy, which is the hepatotoxic side eﬀ ect 
of antifungal drugs, topical therapy is usually rec-
ommended. The hard keratin and compact struc-
ture of nail plate act as a barrier to drug diﬀ usion, 
and the hydrophilic nature of the nail plates also 
reduces the delivery of lipophilic and high molec-
ular weight antifungal drugs (e.g. amorolfi ne, tio-
conazol) to the infection site. Owing to the afore-
mentioned problems the topical treatment takes 
long time (10-12 months) and has a low cure rate(1). 
Some of the essential oils can be used as the alter-
native in Onychomycosis topic therapy, because of 
its antifungal activity, but their lipophilic character 
faces the same drug delivery challenge. 
AIMS: Our aim is to prepare silica nanoparticle 
stabilized o/w type Pickering-emulsion (2) with 
antifungal active tea tree oil, investigate its diﬀ u-
sion in model membrane and nail plate and com-
pare it to that of pure oil.  
RESULTS:  Hydrophilic silica nanoparticles 
were synthesised by Stöber method in one-step 
synthesis, which were characterized with DLS and 
TEM. The size range of the silica nanoparticles is 
15 nm to 100 nm. We have performed a surface 
modifi cation of silica nanoparticles with diﬀ erent 
amounts of ethyltriethoxysilane to tailor their hy-
drophilic/lipophilic surface character. The ratio of 
oil, water and silica nanoparticle was optimized to 
obtain emulsion with desired droplet size. The 
emulsions are characterized regarding their stabil-
ity and droplet size. The variation of silica 
nanoparticle size, surface modifi cation and emul-
sion composition resulted emulsions with droplet 
size from 100 nm to 800 nm.
CONCLUSIONS: At present we are working on 
the experiments, and the fi nal results and conclu-
sion will be shown at the conference.
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P1B-4
Infl uence of oil and cholesterol as wall 
components on the mean vesicle size of 
liposomes
 JÓJÁRT-LACZKOVICH, O.,  BÓNIS, E., 
 SZŰCS, P.,  SZABÓ-RÉVÉSZ, P.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: Nowadays liposome formulations 
oﬀ er excellent possibilities for the development of 
nano drug delivery systems (nanoDDSs). A great 
number of patents and articles deal with these for-
mulations, and it is known that the mean vesicle size 
largely determines their applicability in therapy.
AIMS: Our aims were to investigate liposomes 
with diﬀ erent content of wall components and 
without active pharmaceutical ingredients. We 
were interested in how the mean vesicle size and 
distribution of liposomes can be infl uenced by the 
oil component and cholesterol content.  
RESULTS:  We produced the samples with dif-
ferent wheat germ oil (0-10 w/w %) [1] and choles-
terol (0-10 w/w %) contents [2] using lipoid fi lm 
hydration method on a laboratory scale. The inves-
tigations of the vesicle size of liposomes were per-
formed with the dynamic light scatt ering process 
and laser diﬀ raction particle sizing technique. 
5 w/w % of oil content results in small vesicles, and 
the further increasing of oil content increases the 
vesicle size and polydispersity, too. Furthermore, 
experimental data shows that 7.5 w/w % cholester-
ol content resulted in the smallest vesicles. In the 
latt er case d(0.5) is 147 nm, which is a good appli-
cable particle size during a liposomal treatment. 
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CONCLUSIONS: Our experimental work is a 
preliminary investigation, which shows that the 
wall components of liposomes as oil and cholester-
ol can infl uence the vesicle sizes and size distribu-
tion, too. With a systematic design, it is possible to 
produce specifi ed sized ‘empty’ liposomal form.
This project was supported by GINOP 
2.3.2_15_2016_00060 project.
REFERENCES: 
1. Rodríguez J. et al. Food Res Int 83, 41–59, (2016)
2. Sułkowskia W. W. et al. J Mol Struct 737–747, (2005)
P1B-5
Biocompatible low-energy nanoemulsions for 
curcumin dermal delivery – the eﬀ ect of terpene 
oil and drug content
 NIKOLIĆ, I .,  ILIĆ, T.,  CEKIĆ, N.,  SAVIĆ, S . M., 
 ARSIĆ, N.,  SAVIĆ, S . D.
Department of Pharmaceutical Technology and Cosmetology, 
University of Belgrade - Faculty of Pharmacy, 11221 Belgrade, 
Serbia
BACKGROUND: Low-energy nanoemulsions (LE-
NEs) are considered novel drug vehicles, able to meet 
the criteria of modern trends in designing drug carri-
ers for highly demanding molecules. Curcumin (CU) 
– a polyphenol of natural origin, is a potent antioxi-
dant, cancer chemopreventive and potential chemo-
therapeutic agent that appears opportune for the 
melanoma therapy. Due to its physicochemical char-
acteristics, CU represents a challenging model drug.
AIMS: The objective was to inspect the critical for-
mulation parameters and to develop a biocompatible 
LE-NE as delivery systems for CU, stabilized by 
polysorbate 80 and soybean lecithin, suitable for der-
mal application with potential to overcome the stra-
tum corneum barrier. Knowing that terpenes are 
powerful chemical penetration enhancers, the goal 
was to investigate the infl uence of the eucalyptol 
(EU), as terpene oil, on performances of selected LE-
NEs, by varying its concentration. Additionally, the 
eﬀ ect of CU incorporation in the chosen formula-
tions was aimed to be evaluated in terms of physico-
chemical and in vitro release properties, using verti-
cal diﬀ usion and immersion cells.  
RESULTS:  Developed formulations were hydro-
philic, low viscous vehicles, with a mean droplet size 
(Z-ave) around 100 nm (depending on surfactant-to-
oil ratio – SOR), narrow size distribution, desirable 
zeta potential and pH values, stable during short term 
monitoring. EU induced remarkable Z-ave reduction, 
but, contrastingly, CU incorporation increased this 
value. Diﬀ erent CU and EU contents had decisive in-
fl uence on CU release from investigated samples.
CONCLUSIONS: Oil phase composition, SOR, as 
well as CU content proved to be the critical formula-
tion parameters in LE-NE design. Next step should 
be evaluation of CU in vitro/in vivo penetration/per-
meation behaviour from developed LE-NEs, both 
with and without EU.
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Investigation of folate-targeted Ga-68-labeled 
nanoparticles as imaging agents for positron 
emission tomography
 TRENCSÉNYI, GY.1, 2,  SZIKRA, D.1, 2,
  NAGY, G.1,  KEREKES, K.3,  KÖRHEGYI, Z.3, 
 RÓZSA, D.3,  GARAI, I .1, 2
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BACKGROUND: Folate receptor (FRα) is one of 
the promising tumor associated targets for imag-
ing of cancer, because these receptors are overex-
pressed on several cancer cell types, and their ex-
pression is limited in normal, healthy tissues. 
Nanoparticles from biodegradable and biocom-
patible biopolymers provide a robust nanoplat-
form with appropriate surface modifi cation for 
both targeting molecules and even for PET radio-
nuclides in a highly eﬃ  cient and reliable manner. 
Biodegradable nanoparticles using tumor associ-
ate-receptor ligands (e.g. folate) for targeting have 
remarkable potential as diagnostic imaging agents 
in Positron Emission Tomography (PET) (1). This 
work focused on the development of folate target-
ed biopolymer based nanoparticles for preclinical 
PET/MRI imaging.
AIMS: The aim of this study was to evaluate the 
tumor targeting properties of the Ga-68-NODA-
GA-nanoparticle under in vitro and in vivo condi-
tions using FRα positive KB (human cervix carci-
noma) and FRα negative MDA-MB-231 (human 
breast cancer) cell lines.   
RESULTS:  In our in vitro Ga-68-NODAGA-
nanoparticle uptake studies signifi cant diﬀ erences 
(p≤0.05) were found between the folate receptor 
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positive and negative cell lines after diﬀ erent incu-
bation times. The 68Ga-NODAGA-nanoparticles 
showed high specifi city and binding aﬃ  nity for fo-
late receptor overexpressed KB tumor cells, never-
theless the cell survival was more than 98% based 
on MTT assay. These results showed strong corre-
lation with our fl ow cytometric measurements 
where the number of FRα receptors were investi-
gated. The in vivo biodistribution and the tumor 
uptake of Ga-68-NODAGA-nanoparticles were 
also studied in KB and MDA-MB-231 tumor-bear-
ing SCID female mice using PET/MRI imaging. 
The in vivo PET/MRI studies indicated high tumor 
uptake with 6.31±0.25 T/M ratio and demonstrated 
that the 18FDG positive tumor areas and the Ga-
68-NODAGA-nanoparticle positive areas over-
lapped using folate receptor positive KB tumor xe-
nograft. 
CONCLUSIONS: In conclusion, the Ga-
68-NODAGA-labeled nanoparticles are promising 
candidates for imaging folate receptor overex-
pressing tumor cells using positron emission to-
mography. 
REFERENCES: 
1. Zwicke GL. et al. Nano Rev 3, 18496 (2012)
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Development and evaluation of micellar 
curcumin intended for the treatment of 
cutaneous T-cell lymphoma
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 KONSTANTINOV, S.3
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BACKGROUND:  Curcumin is a natural molecule 
possessing variety of pharmacological eﬀ ects but 
its poor solubility and stability limited its clinical 
use. Incorporation of curcumin into nanoparticu-
late delivery systems could overcome these draw-
backs. This approach might enhance therapeutic 
potential of encapsulated curcumin for the treat-
ment of cutaneous T-cell lymphoma as orphan 
disease.  
AIMS:  The aim of the study was to encapsulate 
curcumin in micellar nanoformulation and to 
evaluate its eﬃ  ciency for the treatment of cutane-
ous T-cell lymphoma (CTCL).   
RESULTS:   Micellar formulation containing cur-
cumin was developed using Pluronic as polymeric 
carrier. Incorporation of curcumin into micelles 
was performed applying diﬀ erent methods aim-
ing to obtain optimal encapsulation eﬃ  ciency. The 
resulted micelles possessed an average diameter 
less than 200 nm and negative surface charge. In 
vitro release tests showed an achievement of sus-
tained release of curcumin. Cytotoxic studies in 
three CTCL cell lines (HuT 78, MJ and HH) re-
vealed that micellar curcumin achieved lower IC50 
values and is more suitable for combinations with 
other antineoplastic drugs than free curcumin. 
Fluorescence microscopy visualized that the mi-
cellar curcumin penetrated through the mem-
branes of CTCL cells faster than free curcumin. 
CONCLUSIONS:  The encapsulation of curcum-
in in micellar formulation could provide bett er cy-
totoxic eﬀ ect at lower dose, that might be consid-
ered advantageous taking in account the poor sol-
ubility and absorption of curcumin. 
ACKNOWLEDGEMENTS: The study was sup-
ported by Grant DN03/3, Bulgarian National Science 
Fund. The cytotoxicity tests were performed on labo-
ratory equipment donated by the Alexander von 
Humboldt Foundation. 
P1B-8
Pickering foam formulation by wet nano-milling 
 LEHOCKÝ, R.1,  PĚČEK, D.2,  ŠTĚPÁNEK, F.1
1University of Chemistry and Technology, Prague, Czech Republic
2Zentiva, k.s., Prague, Czech Republic
BACKGROUND: Pickering foams or emulsions 
are very interesting formulations because they are 
stabilized by solid particles instead of surfactants. 
We observed during formulation of a nano sus-
pension of a hydrophobic API by wet ball milling 
spontaneous undesirable formation of a viscous 
foam, which was stabilized by solid nanoparticles 
dispersed in water. 
AIMS: We have prepared a Pickering foam by 
the milling of a hydrophobic API suspension in a 
fl ow-through ball mill Netsch LabStar by zirconi-
um dioxide balls as the milling media. We have 
characterized the particle size distribution (PSD) 
of the API particles in the foam by static light scat-
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tering and Scanning Electron Microscopy (SEM). 
We have studied the 3D structure of the foam and 
calculated its porosity using micro CT and confo-
cal optical microscopy. 
RESULTS: A Pickering foam produced by the 
ball nano-milling process is stabilized by the solid 
particles of the hydrophobic API. The foam forma-
tion time is dependent on the initial surfactant 
concentrations used in the milling process. Me-
chanical properties such as viscosity are depen-
dent on the milling time and increase because of 
increasing number of stabilizing particles and 
their surface area.
CONCLUSIONS: Solid nanoparticles can be 
used as emulsifi ers for the stabilisation of the 
Pickering foams or emulsions, which have advan-
tages compared to surfactant stabilized formula-
tions. Sometimes the formation of a Pickering 
foam can be a spontaneous and unwanted phe-
nomenon, which causes a change of mechanical 
properties of the material and makes the techno-
logical process more challenging.  To avoid unde-
sired complications of the technological process, it 
is important to know what causes the changes and 
to know how to avoid them. This was achieved by 
studying the undesirable Pickering foam pro-
duced by the formulation of a nanosuspension. 
The foam creation is signifi cantly dependent on 
the surfactant concentration relative to the specifi c 
surface area of the hydrophobic API.
REFERENCES:
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P1B-9
Development of magnetically-responsive 
SPION-based drug delivery system
 POTRČ, T.1,  KRALJ, S.2,  KOCBEK, P.1
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BACKGROUND: The targeted drug delivery 
based on remote control over the distribution and 
accumulation of the nanocarrier in the body is 
very att ractive in current pharmaceutical research 
and development, especially in the fi eld of cancer 
treatment (1). Thus, nanostructures based on su-
perparamagnetic iron oxide nanocrystals (SPI-
ONs) represent a novel, very promising platform 
for development of novel delivery system, howev-
er, they still face some obstacles, which should be 
overcome to achieve optimal eﬀ ectiveness. The 
main limitation of individual SPIONs is the too 
small magnetic force acting on them, when ex-
posed to magnetic fi eld gradient, thus resulting in 
their ineﬀ ective spatial guidance. This challenge 
can be overcome by assembly of multiple SPIONs 
into nanosized SPION clusters or magnetic nano-
chains (2). Magnetic nanostructures are usually 
coated with porous silica which oﬀ ers unique 
properties for drug loading and, at the same time, 
it improves the compatibility of the nanosystem 
with biological environment. Therefore, such 
magnetically responsive nanosystems represent, 
due their multifuntional properties the great po-
tential for the cancer treatment (3).    
AIMS: The main aim of the present research 
was the preparation of (i) hollow magnetic SPI-
ON-based clusters and nanochains that form sta-
ble colloidal suspension and (ii) the development 
of a method for model anticancer drug loading 
and controlled release.
RESULTS: In the scope of the current study the 
hollow nanostructures based on well-defi ned SPI-
ON-based clusters of about 150 nm in diameter 
and magnetic nanochains with length of about 
300-500 nm were successfully fabricated. To 
achieve colloidal stability of prepared nanosys-
tems in physiological environment, their surface 
was additionally modifi ed with hydrophilic poly-
mers and the stability of the prepared system was 
evaluated in phosphate and HEPES buﬀ er in vi-
tro. The zeta potential measurements revealed the 
suﬃ  cient surface charge (between-25mV and 
-40mV) that is required for colloidal stability of 
nanodispersions. The initial results of drug load-
ing experiments showed promising drug loading. 
The loading was performed by particle incuba-
tion in drug solution, however, the drug release 
experiments revealed very fast drug release from 
prepared nanodelivery system (total release ≤ 30 
min).  
CONCLUSIONS: The research revealed that 
hollow SPION-based nanostructures represent a 
promising nanomaterial for development of a 
magneto-responsive drug delivery system, how-
ever, the drug loading procedure should be fur-
ther optimized in order to achieve bett er drug in-
corporation into the hollow particle nanostruc-
tures and controlled drug release.
ACTA-1703-BBBB.indb   142 9/19/17   6:28 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters 143
REFERENCES:
1. Kralj S. Makovec D. ACS Nano. 9, 9700-9707 (2015)
2. Kralj S. et al. Curr. Med. Chem. 23, 1-16 (2016)
3. Pérez-Herrero E. Fernández-Medarde A. Eur. J. Pharm. 
Biopharm. 93, 52-79 (2015)
POSTER SECTION 1C 
PHARMACEUTICAL TECHNOLOGY 1
P1C-1
 Parameter optimization of spherical 
agglomeration method  
 GYULAI, O.,  AIGNER, Z.,  CSÓKA, I . 
University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs, Szeged, Hungary, gyulai.orsolya@
pharm.u-szeged.hu 
 
BACKGROUND: In the industry area, direct com-
pression is one of the most important techniques 
for the formulation of solid form drugs. For this 
the applicaqtion of this method, the active agent 
should possess appropriate parameters for exam-
ple increased fl ow rate generated by large-size 
(>100 mm) and spherical crystals. For improving 
the morphology, spherical crystallization tech-
niques can be used. These can be categorized into 
two groups: non-typical [1] and typical ones [2]. 
From our previous work it became clear that the 
non-typical methods, such as spherical agglomer-
ation, are suitable for improving the morphology 
of ambroxol hydrochloride (AMB-HCl).   
AIMS: This work aims at the optimization of 
the parameters of spherical agglomeration meth-
od. For this, a factorial design was applied and 
then the results were evaluated with STATISTICA 
for Windows program.    
RESULTS:  The potential critical parameters 
were as follows: agitation type and time, tempera-
ture diﬀ erences between the solvent and the anti-
solvent, composition of the solvent system, satura-
tion rate and feed rate. The average size, aspect 
ratio and roundness of the products were deter-
mined, then the ones with proper morphology 
were chosen for further experiments. Signifi cant 
eﬀ ects on morphology were revealed. The prod-
ucts were also examined by an individually-devel-
oped hardness test. 
CONCLUSIONS: The application of horizontal 
shaker with shorter mixing times and lower tem-
perature diﬀ erences had a positive impact on the 
morphology of AMB-HCl. With the help of spheri-
cal agglomeration, the particle size increased up 
over an order of magnitude and roundness and 
aspect ratio improved, too. The hardness of the 
products was large enough to keep the spherical 
particles stable. 
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
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P1C-2
Aggressive conditions during primary drying as 
a new approach to optimize freeze-drying cycle 
of biopharmaceuticals
 BJELOŠEVIĆ, M.,  BOLKO SELJAK, K., 
 BRUS, B.,  ĆATIĆ, S .,  AHLIN GRABNAR, P.
Faculty of Pharmacy, University of Ljubljana, Ljubljana, 
Slovenia
Lek d.d., Mengeš, Slovenia
BACKGROUND: Freeze-drying is the method of 
choice to dry formulations with biopharmaceuti-
cal drugs, typically unstable in aqueous media. 
This is usually done below glass transition tem-
perature of maximally freeze-concentrated solu-
tion (Tg’) to maintain physical stability, avoid the 
aggregation and preserve the activity of the pro-
tein, resulting in a lengthy and energy consuming 
process. However, it was recently shown that dry-
ing above Tg’ or even above collapse temperature 
(Tc) is not necessarily detrimental for the stability 
of biopharmaceuticals, providing an att ractive op-
tion for freeze-drying cycle optimization [1, 2].
AIMS: The aim of the present study was to re-
duce the primary drying time of a model mono-
clonal antibody IgG formulations (20 mg/ml) us-
ing aggressive conditions which were achieved by 
varying the shelf temperature and the chamber 
pressure, both directly impacting the product 
temperature (Tp).  
RESULTS:  In conventional freeze-drying cycle 
the Tp was -30 °C which is close to Tg’. With the 
implementation of the aggressive primary drying 
we managed to increase Tp to -24 °C which is 
above Tg’ and Tc. Consequently the time of the 
freeze-drying process was reduced by up to 40 % 
(from 48 to 30 h) as opposed to conventional 
freeze-drying cycle. Although the Tp was in some 
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cases above Tc, macrocollapse was not observed. 
Additionally, other product quality att ributes, 
such as reconstitution time and residual water 
content were also acceptable.
CONCLUSIONS: Aggressive conditions during 
primary drying present a prospective tool in 
shortening the freeze-drying time whilst ensuring 
quality att ributes of the biopharmaceutical formu-
lations. 
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Unique laser coding technology to fi ght falsifi ed 
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BACKGROUND: Counterfeit drugs pose a threat 
for health and they cause social and economic 
damage. According to WHO statistics, fake medi-
cines represent 10% of the global drug trade and 
50 % of medicines purchased over the Internet 
could be fake [1].
AIMS: According to Directive 2011/62/EU as re-
gards the prevention of falsifi ed medicines from 
entering into the legal supply chain, a unique iden-
tifi cation should be put on each box of drugs [2]. 
Our team is working on the development of a tech-
nology to mark an individual traceability code di-
rectly on the surface of the tablet. Anyone with a 
camera-enabled phone and a suitable application 
installed should be able to authenticate these drugs. 
RESULTS:  We coated tablets with HPMC and 
PMMA polymers. To mark the coated tablet, we 
used diﬀ erent types of lasers: high energy ArF 
excimer pulse laser, semiconductor laser and 
Nd: Yag laser. After marking polymer fi lms, we 
made an analytical quality control of them to 
check if there occurred any change during the la-
ser intervention. The Raman spectroscopy 
showed a structure crack in a fi lm treated with 
the semiconductor laser, while the excimer laser 
did not cause any signifi cant change. Thermo-
gravimetry showed that the decomposition of 
the material occurred sooner in fi lms marked by 
semiconductor laser, in higher temperature 
ranges, which is probably due to the decomposi-
tion process that had already started during the 
laser marking process. We did not experience 
anything like this in case of using excimer laser. 
The pre- and post-laser structure was examined 
by SEM as well. 
CONCLUSIONS: Results in this study showed 
that excimer laser could be the right instrument 
for marking the tablets with a unique code, which 
can be authenticated even by the patients them-
selves using a mobile phone.
The work was supported by Foundation for De-








The investigation of the connectability of 
continuous fl ow reactors and electrospinning
 DOMOKOS, A.,  BALOGH, A.,  RAPI, ZS., 
 NAGY, ZS. K.,  MAROSI, GY.
Department of Organic Chemistry and Technology, 
Budapest University of Economics and Technology, 
Budapest, Hungary
BACKGROUND: Despite the various examples 
from other industrial sectors pharmaceutical tech-
nology still relies on traditional batch methods in-
stead of continuous processes, albeit the invest-
ment and operating costs of the latt er are lower 
and constant product quality is obtainable.
There have been many synthetic studies of 
drugs using continuous fl ow reactors, however, 
the direct formulation of the drug after the synthe-
sis was found to be rather challenging. The only 
exemplary research on such an integrated system 
was conducted in the laboratory of the MIT [1]. 
Nevertheless, the way the interconnection was 
carried out was unfavorable for thermosensitive 
drug compounds.
Electrospinning provides a unique opportunity 
to convert the fi nal liquid fl ow of the synthesis 
into solid product immediately. During the pro-
cess micro- and nanofi bers are formed in a gentle 
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way under ordinary circumstances by applying 
high voltage.
AIMS: The aim of this study was the develop-
ment of a lab-scale production equipment in order 
to demonstrate the connectability of continuous 
fl ow reactors to electrospinning. The synthesis of 
acetylsalicylic acid was chosen as model reaction.
RESULTS: After the optimization of the reac-
tion, we investigated the processability of the re-
action mixture by electrospinning. As a result, 
highly water-soluble polymer fi bers could be ob-
tained. The purity, physical structure and state of 
the fi brous product was examined by diﬀ erent an-
alytical techniques.
CONCLUSIONS: Electrospinning was found to 
be connectable with continuous fl ow reactors, and 
could be applied not exclusively for formulation, 
but to purify the reaction mixture as well.
REFERENCES:
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Hot-melt technologies to develop modifi ed or 
targeted release hard capsules
 VASVÁRI, G.,  FENYVESI, F.
Department of Pharmaceutical Technology, Faculty of 
Pharmacy, Debrecen, Hungary
BACKGROUND: The convenience for patients and 
professionals to administer oral sustained-release 
capsules and tablets are well-known. 1 The en-
hancement of bioavailabilty and sustain drug re-
lease formulations can be achieved by using mol-
ten dispersions. PEGs, semisynthetic glycerides 
and their conjugates are favoured to be used as 
thermoplastic or meltable materials.   
AIMS: In eﬀ ort to develop modifi ed release hard 
capsules, novel approaches were developed com-
prising pulverised lipids, e.g. Gelucires, stearic acid, 
cetostearyl alcohol, ethylcellulose as a suspending 
agent. Our research was conducted to prolong drug 
release, furthermore to simplify solid dispersion fi ll-
ing into diﬀ ent size hard gelatin capsules.     
RESULTS:  Following the pulverization of the 
lipids a powder blend was made with suspending 
agent and APIs, such as diclofenace-sodium or ac-
etaminophen or metronidazole. Rational design of 
the compositions consisting of Gelucire 50/13, cet-
ostearyl alcohol and ethylcellulose made it possi-
ble to fi ll certain blends into hard capsules, then 
create a monolithic matrix by heating the closed 
shells. Drying and its unfavourable eﬀ ects, such as 
britt leness of the gelatin can be prevented if cap-
sules are sealed in fullfi lled conatiners which traps 
steam. The monolithic matrix succesfully sus-
tained drug release over 8 hours in SIF. Texture 
analysis revealed that the formed block inside the 
shells are resistant enough to be packed or blis-
tered. In an other series of experiments using met-
ronidazole, a fl oating system was created with 
zero lag-time and prolonged drug dissolution. 
Floating force measurements and texture analysis 
were performed to assess the characteristics of the 
fl oating formulation.   
CONCLUSIONS: Melt techniques are promis-
ing ways to formulated hard capsules with APIs 
showing diﬀ erent water solubilities and bioavail-
abilities. Our experiments confi rmed that no gran-
ulation, pelletization or melt-fi lling is required to 
produce sustain-release capsules. Drug dissolu-
tion can be tailored by wisely chosen auxillary 
materials to alter hydration of dosage form. In 
case of the fl oating formulation in vivo imaging is 
planned to confi rm gastric retention.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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Self- microemulsifying pellets prepared by fl uid 
bed coating technology 
 LUŠTRIK M.,  ŽGANC D.,  
ZVONAR POBIRK, A.
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
BACKGROUND: The results of modern approach-
es in the medicinal chemistry yield in the increas-
ing number of poorly water soluble active phar-
maceutical ingredients (API). Due to the enhanced 
dosing, transport, storage and patient compliance, 
the peroral application, especially of solid dosage 
forms, represents the most favourable root of ad-
ministration, where the water solubility and the 
drug bioavailability play an important role in 
achieving an adequate plasma concentration and 
therapeutic eﬀ ect. The various methods for en-
hancing water solubility, permeability and bio-
availability can be employed, where the increas-
ing focus is put to the solid lipid nano and/or mi-
cro particles and lipid based drug delivery sys-
tems (1).
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AIMS: The object of the study was to convert 
liquid self-(micro)emulsifying system (S(M)ES), 
containing carvedilol as a model BCS class II API, 
into a solid formulation by a Wurster fl uid bed 
coating technology.
RESULTS: The microcrystal cellulose pellets 
cores (Cellets 200) were subjected to the fl uid bed 
coating process in a chamber equipped with a 
novel swirl air fl ow generator (2). The coating dis-
persion was composed of liquid SMES and matrix 
materials (e.g. lactose), enabling the incorporation 
of liquid SMES into the coating layer. HPMC and 
PEG 6000 solutions were additionally used to pre-
vent the adherence of the pellets after each indi-
vidual coating stage. In order to obtain a suﬃ  cient 
layer of deposited material through three consecu-
tive coating stages, various process and formula-
tion parameters were tested. The coated pellets 
were subjected to the image analysis process 
where the average diameter and circularity were 
determined. Additionally the amorphous form of 
the API in the coating layer of the pellets was con-
fi rmed by the diﬀ erential scanning calorimetry. 
The pellet layer was dissolved in water and sub-
jected to the photon correlation spectroscopy, in-
dicating the spontaneous formation of (micro) 
emulsion. The dissolution profi les of the coated 
pellets indicate improved dissolution rate of the 
model drug in comparison to the crystalline form.  
CONCLUSIONS: It can be conclude that the 
fl uid bed pellet coating represents a promising 
technique for the SMES solidifi cation and the 
groundwork for further investigations and devel-
opment.  
REFERENCES: 
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Formulation of topical pharmaceutical foam to 
enhance cutaneous drug delivery
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BACKGROUND: Skin, particularly the uppermost 
layer-the stratum corneum-presents a formidable, 
largely impassable barrier to the entry of most 
compounds. There are two major challenges in 
topical drug delivery. Besides the drug solubiliza-
tion and adequate penetration of the stratum cor-
neum, the patient adherence to treatment is also 
important due to the particularly low compliance 
in topical drug administration. Pharmaceutical 
excipients are able to help address these challeng-
es. These compounds are able to deliver eﬀ ective 
drug solubilization and modulation of drug pene-
tration through the stratum corneum. These ex-
cipients can be very safe and highly tolerable. 
Moreover the applied components are enabling 
the formulation of diverse topical bases with ex-
cellent texture and sensorial properties which im-
prove patient experience and promote adherence.
AIMS: The objective of this study was to formu-
late safe dosage forms with enhanced cutaneous 
drug delivery.  
RESULTS:  Physical properties of the formula-
tions have been evaluated by various measure-
ments. A series of in vitro biocompatibility tests 
had been performed to ensure safety in applica-
tion. To complete our examination; HaCaT perme-
ability assays have been deployed as well. These 
studies have demonstrated that the formulated 
foam compositions have the ability to deliver the 
API at an increased rate compared with other ve-
hicles.
CONCLUSIONS: These results suggest that the 
these foams utilizes a nontraditional “rapid-per-
meation” pathway for the delivery of drugs. It is 
likely that components within the foam act as pen-
etration enhancers, and reversibly alter the barrier 
properties of the outer stratum corneum, thus 
driving the delivered drug across the skin mem-
brane via the intracellular route. This is in contrast 
to traditional topical delivery vehicles, which must 
fi rst rely on hydration of the intercellular spaces in 
the stratum corneum to achieve drug delivery
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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P1C-8
Formulation and investigation of baicalin 
in Self Emulsifying Drug Delivery Systems
 JAKAB, G.,  FÜLÖP, V.,  SZERŐCZEI, D., 
 AGHRABI, E.,  BALOGH, E.,  ANTAL, I .
Semmelweis University, Department of Pharmaceutics, Hőgyes 
Endre Street 7-9, Budapest, 1092 Hungary
BACKGROUND: Self-emulsifying drug delivery 
systems (SEDDS) are isotropic mixtures of oil, sur-
factant, co-surfactant and the lipophilic com-
pound, which are spontaneously form oil-in-water 
(o/w) emulsions upon mild agitation followed by 
dilution in gastro-intestinal fl uids1. Baicalin is a 
fl avone glycoside, extracted from the roots of Scu-
tellaria baicalensis Georgi. It was shown, that the 
poorly water soluble and poorly permeable poly-
phenolic fl avonoid has remarkable pharmacologi-
cal eﬀ ects including antioxidant, antimicrobial and 
anti-tumor actions. Baicalin is classifi ed as class IV. 
according to the Biopharmaceutical Classifi cation 
System (BCS)2.  
AIMS: The aim of the study was to investigate 
the thermodynamic solubility of baicalin in diﬀ er-
ent types of surfactants and oils. Optimising the 
ideal oil/surfactant/co-surfactant ratios to achive 
minimal droplet sizes and stabile nanoemulsions. 
Adding the best precontentrate to a solid carrier, 
and after drying preparation of pellets by extrusion-
spheronization method. After reconstitution of the 
pellets determine the droplet sizes and dissolution 
profi les in diﬀ erent pH dissolution medias.   
RESULTS:  Physical characterisations of matrix 
pellets were performed and all of the investigated 
parameters have met the Ph. Eur. 9. requirements. 
Reconstitution from the solid carrier was succes-
full in all three diﬀ erent dissolution medias, nano-
emulsion formulation of baicalin signifi cantly im-
proved its dissolution rate.  
CONCLUSIONS: The low aqueous solubility of 
baicalin can be improved by SEDDS, and the pre-
concentrate could be eﬀ ectively adsorbed to a sol-
id carrier.
REFERENCES: 
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P1C-9
Robust compression of multilayer enteric coated 
pellets enabled by dry powder layering
 DREU, R.,  MATJAŽ, D.,  LAVRIČ, Z.
Department of Pharmaceutical Technology, University of 
Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
BACKGROUND: Robust technology and particle 
formulation is needed in order to compress func-
tionally coated pellets into multiple unit tablets. 
Main challenges that have to be solved by design 
of formulation and technological process are min-
imization of polymer fi lm damage and assurance 
of tablet dose uniformity. Polymer fi lm damage 
stems from inter-pellet contacts and contacts of 
pellets with walls of tableting die and punches 
during compression. Drug dose variability is pri-
marily caused by segregation of pellets within 
tableting mixture.
AIMS: The aim was to develop multilayer de-
layed release pellet formulation and associated 
technological processes that would be applicable 
to pellet tableting process.  
RESULTS:  The concept of forming cushioning 
layer around fi lm coated pellets was employed [1]. 
However, compressibility of microcrystalline cel-
lulose as a cushioning agent was retained by dry 
powder layering process rather than via layering 
with organic suspension. Dissolution testing of 11 
mm biconvex tablets, comprised of enteric coated 
pellets with cushioning layer and extragranular 
phase, demonstrated less than 5 % of model com-
pound release after 2 h in acidic conditions or 
even less, if mutilayer pellets contained additional 
intermediate layers of HPMC and polyethylene 
glycol. Polyethylene glycol fi lm, that acts as a lu-
bricant and reduces shear between cushioning 
layer and enteric fi lm, enabled compression of 
sole powder layered pellets into tablets with im-
proved hardness, reduced friability and litt le 
change in delayed release behaviour.  
CONCLUSIONS: Powder layering approach 
and inclusion of intermediate lubricant layer 
proved to be successful strategies in designing 
multilayer delayed release pellets applicable to 
tableting process.
REFERENCES: 
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P1C-10
Taste masking of enalapril maleate by various 
techniques
  GEORGIEVA, Y.,  PILICHEVA, B., 
 KATSAROV, P.,  KASSAROVA, M.
 Department of Pharmaceutical sciences, Faculty of Pharmacy, 
Medical University-Plovdiv, Plovdiv, Bulgaria
High-technological Center of Emergency Medicine, Plovdiv, Bulgaria
BACKGROUND: Providing of a pleasant taste is of 
crucial importance for oral formulation especially 
those, intended for pediatric use. However, taste 
masking is a serious technological challenge. Enal-
april maleate is bitt er-tasting and could therefore 
be used as a model drug for this aim. In the pres-
ent study we compare two approaches for taste-
masking – spray drying and precipitation method, 
which results in a drug-polymer complex (DPC).
AIMS: The purpose of this study was to opti-
mize the technological parameters for the devel-
opment of DPC and spray dried microparticles of 
enalapril maleate for masking the bitt er taste of 
the active pharmaceutical ingredient (API).
RESULTS: Taste masking requires the use of 
polymer that is insoluble in the saliva pH = 6.8 but 
dissolves in the acidic pH=1.2-3.0 of the gastric 
juice. This polymer should also not aﬀ ect drug re-
lease profi le. Eudragit EPO features the men-
tioned characteristics and respectively was chosen 
as a carrier. Aqueous dispersion of enalapril and 
Eudragit EPO was spray dried in order to obtain 
fi ne particles. The experiment was carried out un-
der the following conditions: inlet air temperature 
70 oC, aspiration 50-55%, peristaltic pump 20-25%. 
DPC was prepared by precipitation method. Solu-
tion of enalapril and Eudragit EPO in absolute 
ethanol was injected into 0.1 N sodium hydroxide 
under constant stirring at 600 rpm. The obtained 
powders were further characterized in terms of 
size, shape, production yield, moisture content 
and drug release. Both models showed satisfacto-
ry yield; DPC had irregular shape while spray 
dried particles were spherical. Dissolution test did 
not reveal any drug release within 5 min which 
proved the accomplishment of taste masking.
CONCLUSION: Spray drying and precipitation 
method using Eudragit EPO are reliable tech-
niques for taste masking of enalapril maleate.
REFERENCES:
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P1C-11
Development of etoposide loaded poly(methyl 
methacrylate) and poly(hydroxyethyl 
methacrylate) tubular nanostructures
 ALGAN, A. H.,  KARATAS, A.
Department of Pharmaceutical Technology, Faculty of 
Pharmacy, Ankara University, Ankara, Turkey
BACKGROUND: Template-assisted synthesis, 
which provides a bett er of control of size and 
shape of materials, has become one of the most 
promising ways of fabrication polymer tubular 
nanostructures (1). Anodized aluminum oxide 
(AAO) membrane that contains highly ordered cy-
lindrical nanopores with high aspect ratios, is one 
of the most popular templates for nanorod/nano-
tube fabrication by template wett ing method
AIMS: In this study Etoposite loaded poly-
(methyl methacrylate) (PMMA) and poly(hyd-
roxyethyl methacrylate) (P(HEMA) tubular nano-
structures were prepared by template wett ing of 
porous AAO membranes and characterised for 
structural analysis and drug loading.  
RESULTS:  Examination of SEM images showed 
that PMMA/P(HEMA) nanostructures were ob-
tained successfully in nano dimensions in diame-
ter and with smooth surfaced tubular form. EDX 
analysis did not show any traces of template 
(AAO)material like aluminum (Al) verifying eﬀ ec-
tive removal of the template during the fabrica-
tion process. Drug entrapment eﬃ  ciency and drug 
loading were found as 25.1% and 4.1%, respective-
ly.
CONCLUSIONS: ETP was successfully loaded 
in polymeric tubular matrix. When the membrane 
was etched by mild aqueous acid, ETP loaded 
PMMA/P(HEMA) tubular nanostructures were 
liberated as drug carriers.
ACKNOWLEDGEMENT:  This work was sup-
ported by the Scientifi c and Technological Re-
search Council of Turkey (TUBITAK) under Grant 
113S201.
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P1C-12
Solidifi cation of the self-microemulsifying 
system by a fl uid bed granulation technique
 ZVONAR POBIRK, A.,  LUŠTRIK, M., 
 PIRNAT, V.,  GAŠPERLIN, M.
Department of pharmacetical technology, University of 
Ljubljana, Faculty of pharmacy, Ljubljana, Slovenia
BACKGROUND: Over the last decade self-(micro)
emulsifying systems (S(M)ES) are extensively inves-
tigated as one of promising technological approach-
es for improving bioavailability of poorly water sol-
uble and permeable drugs (1). In addition, the eﬀ ec-
tive methods for transformation of liquid S(M)ES 
into a solid formulations that merge the advantages 
of both systems are studied intensively (2).   
AIMS: The aim of the present research was to 
convert liquid S(M)ES into self-microemulsifying 
granules by employing fl uid bed technology that 
carries great potential for S(M)ES solidifi cation 
scaling up.  
RESULTS:  Various solid carriers, binders and 
process related parameters (inlet air temperature 
and airfl ow rate, nozzle diameter and positon, at-
omizing air pressure and spraying rate) were tested. 
The Neusilin® US2, as the most appropriate solid 
carrier, enabled the manufacturing of granulate 
with a high drug loading at a high process yield. 
PVPs and HPMC of various molecular weights 
were used as binders, where PVP K30 as low mo-
lecular weight binder additionally inhibited the pre-
cipitation of BCS class II drug. The fl ow property of 
the manufactured granulates were proven to be in a 
correlation with the S(M)ES absorption capacity of 
the solid carrier, where the excess S(M)ES loading 
yielded in the poor particle fl owability. The preser-
vation of self-microemulsifying properties upon so-
lidifi cation process was confi rmed by photon corre-
lation spectroscopy, whereas prepared self-micro-
emulsifying granules showed considerably in-
creased drug dissolution profi le as compared to 
crystalline form of BCS class II model drug.
CONCLUSIONS: Fluid bed technology equip-
ment was shown as eﬃ  cient and promising ap-
proach for transforming liquid S(M)ES into solid 
granulate, merging all the advantages of lipid 
based systems and solid formulations.  
REFERENCES: 
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P1C-13
The eﬀ ect of diﬀ erent excipients 
in the soild dispersion-formulation 
of poorly soluble material using 
melt technology
 KISS, O.,  AMBRUS, R.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: More than 40% of active agents 
are poorly water soluble drugs, therefore enhance-
ment of solubility, dissolution rate and bioavail-
ability of the drug is a very challenging task in 
drug development. Solid dispersion (SD) is a 
widely used method to form a stable amorphous 
product with improved physico-chemical proper-
ties, especially dissolution rate. SDs are the group 
of solid products consisting of at least two diﬀ er-
ent components, generally a hydrophilic matrix 
and a hydrophobic drug. A carrier/matrix should 
meet diﬀ erent criteria to be suitable for increasing 
the dissolution rate of a drug, such heat stable, 
chemically compatible, non-toxic, pharmacologi-
cally inert ect.
AIMS: During our work we introduced alterna-
tives for the preparation of melted matrix contain-
ing active pharmaceutical ingredient by ternary 
and binary systems of PVP, PVA, Poloxamer, PEG, 
Mannitol and Soluplus.
RESULTS: By the preparation of Ishikawa dia-
gram critical technological parameters were eval-
uated. Using XRPD and DSC the prepared sam-
ples were analysed compared with their physical 
mixtures. Amorphous and partial amorphous 
characters were detected. The hydrophilic excipi-
ents did not increase the dissolution rate of the 
API signifi cantly as wett ing agents through physi-
cal mixing. However the melted products present-
ed more than 3-fold improvement, mainly in the 
presence of Soluplus or PEG.
CONCLUSION: The applied compositions and 
presented technological factors could oﬀ er a novel 
formulation methodology in the fi eld of melt tech-
nology.
REFERENCES:
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P1C-14
Design of experiment of hydrophobic drug encap-
sulation using biopolymers : Particles size based study
 MANCER, D.,  AHMED ZAID, S., 
 ZANOUNE, Y.,  KORTEBY, Y.,  DAOUD, K.
Laboratory of Transfer Phenomena, Faculty of Mechanical and 
Process Engineering, University of Science and Technology Houari 
Boumediene, Algiers, Algeria.
BACKGROUND: Microencapsulation is a process that 
creates a protection of the encapsulated molecules; it 
provides stability to these compounds and releases 
them in a controlled manner under specifi c conditions.
Complex coacervation is widely used for encap-
sulating lipophilic compounds like Sodium Diclof-
enac (SD) which is a potent non-steroidal anti-in-
fl ammatory drug with analgesic and antipyretic 
eﬀ ects. However, due to its physicochemical action 
on the gastric mucous and infl ammatory action on 
the small bowel and the colon, it counts for a risk 
factor of relatively high incidence of gastrointesti-
nal side eﬀ ects. Because of the mentioned side ef-
fects and its short biological half-life, SD is an ideal 
candidate for prolonged release preparations.
AIMS: The objective of this work is to study the 
infl uence and the interaction of diﬀ erent factors 
(stirring duration, drug concentration and car-
boxymethylcellulose (CMC) concentration) on the 
process of microencapsulation using an experi-
mental design for the preparation of diclofenac 
microparticles by complex coacervation using gel-
atin and pectin as biopolymers.  
RESULTS: The microscopic visualization of the 
diﬀ erent preparations reveals the existence of sus-
pended particles as well as their irregular appear-
ance, then the granulometric analysis shows a par-
ticles size variation between 25,54 μm and 57,35 
μm. The statistical analysis reveals that the CMC 
concentration is the most important factor in this 
work; some of the interactions are also signifi ca-
tive such as stirring duration-CMC concentration 
interaction. Finally, the responses surfaces study 
gave us the experimental domain which allows 
the elaboration of the smallest particles.
CONCLUSIONS: The results obtained demonstrate 
the eﬀ ectiveness encapsulation of SD by complex co-
acervation in a pectin / gelatin polymer system.
REFERENCES:
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 Solid-state characterization of albendazole-
complex binary systems with pharmaceutical 
excipients
 TRANDAFIRESCU, C.,  LEDETI, A.,  BORCAN, 
F.,  SOICA, C.,  DEHELEAN, C.,  LEDETI, I . 
Pharmaceutical Chemistry, Victor Babes University of Medicine 
and Pharmacy, Timisoara, Romania
BACKGROUND: Albendazole is an active drug 
against helminth and Giardia lamblia infections. 
The drug has a poor oral bioavailability; one of 
the att empts made to overcome this drawback was 
the obtaining of binary systems with cyclodex-
trins. Pharmaceutical excipients infl uence the 
pharmacokinetic properties of a pharmakon. The 
evaluation of the interaction between the drug 
and pharmaceutical excipients is a very important 
aspect of the drug stability within the pharmaceu-
tical dosage form.
AIMS: The present study focuses on the evalua-
tion of compatibility/incompatibility between the 
components of binary mixtures containing alben-
dazole-cyclodextrin complexes and six pharma-
ceutical excipients. The binary mixtures were 
comparatively analyzed using thermal and spec-
tral methods.
RESULTS:The search for potential interactions 
were carried out in the spectral regions of reactive 
functional groups of albendazole, where shifting 
of peaks, dissapearance of some bands and ap-
pearance of new bands designated interactions be-
tween the drug and the excipient. Powder X-ray 
diﬀ raction patt erns of albendazole complex were 
searched in the patt erns recorded for binary mix-
tures. The infrared spectral data and the X-ray dif-
fraction patt erns indicated some minor interac-
tions between complex and some pharmaceutical 
excipients, whereas in most of the cases, no inter-
action under ambient conditions were observed. 
Thermal analyses were used to confi rm the results 
obtained by spectroscopic methods. 
CONCLUSIONS: In this study we investigated 
the compatibility of albendazole complex with six 
pharmaceutical excipients using spectral and ther-
moanalytical methods. The results indicated a 
good compatibility between complex and the ma-
jority of excipients under ambient conditions and 
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under the induced thermal stress.
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P1D-2
Comparison of the physicochemical and 
mechanical characteristics of alginate and 
chitosan based fi lms as wound dressings
 VIIDIK, L.,  LAIDMÄE, I .,  KOGERMANN, K., 
 HEINÄMÄKI, J .
Institute of Pharmacy, University of Tartu, Estonia
BACKGROUND: Chronic wounds are a great 
challenge for the medical care system with a 
growing number of people being aﬀ ected [1]. New 
strategies in wound care need to be considered to 
overcome this problem. Natural polymers have 
shown to have desirable characteristics for usage 
in wound dressings which accelerate the wound 
healing process [2].
AIMS: The aim of the present study was to in-
vestigate and compare the relevant physicochemi-
cal and mechanical characteristics of alginate and 
chitosan based fi lms intended to be used as 
wound dressings.  
RESULTS:  Alginate and chitosan fi lms with 
gelatin in diﬀ erent compositions were produced 
by a casting/solvent evaporation method. These 
conventional fi lms were compared with the corre-
sponding fi lms produced by 3D printing technol-
ogy. Physicochemical characterization of material 
blends and the fi nal fi lms showed good miscibility 
and suitable properties for wound healing appli-
cations.
CONCLUSIONS: Natural polymers are suitable 
carriers for wound healing platforms due to their 
particular characteristics, such as biocompatibili-
ty, biodegradability and nontoxicity. These mate-
rials also support a wound healing process and/or 
have intrinsic antimicrobial activity. Combining 
these polymers with additional antimicrobial ac-
tive substances and/or growth factors in the 
wound-care fi lms provides an exciting opportuni-
ty for the local wound treatment. 
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P1D-3
Mucoadhesion and rheological properties of 
poly(acrylates) gels for diﬀ erent mucosal drug 
delivery
 TUĞCU-DEMIRÖZ F.,  TORT, S.,  İLBASMIŞ-
TAMER, S.,   ACARTÜRK, F.
Department of Pharmaceutical Technology, Faculty of 
Pharmacy, Gazi University, Ankara, Turkey
BACKGROUND: Drug administration via muco-
sal routes is frequently used for enhancing the lo-
cal eﬃ  cacy or bioavailability of systemic drugs. 
Poly(acrylates) are widely used for the preparation 
of mucosal formulations due to their good physi-
cal, chemical, and biological properties. Carbopol 
974P and polycarbophil (Noveon AA-1) gels are 
found to be mucoadhesive and that they can rest 
on mucosal tissues for a long time (1,2).
AIMS: The aim of this study is to determine mu-
coadhesive and rheological and properties of 
poly(acrylates) gels for diﬀ rent mucosal tissues. 
The storage and loss modulus were used as mea-
surements for the rheological behavior. In addition, 
texture profi le analysis and back extrusion tests 
were performed using diﬀ erent features of the Tex-
ture Analyzer. Mucoadhesion measurements were 
performed using a Texture Analyzer to determine 
the maximal detachment force of the gels from the 
mucosa and their work of adhesion. Bovine muco-
sa was used for the model mucosa; specifi cally, 
cheek, nasal, vagina, uterus, rectum, stomach, eso-
pha gus, small intestine and colon mucosa.   
RESULTS: The storage and loss modulus of 
Carbopol 974P and polycarbophil gels are slightly 
reduced at low frequencies. It can be said that the 
Carbopol 974P gel has the best elastic character 
because it has the highest storage and loss modu-
lus value. According to the results of textural pro-
fi le analysis Carbopol 974P gel had an appropriate 
hardness and compressibility for application to 
mucosa, the highest elasticity showing good 
spreadability, and the highest cohesion to prevent 
the disintegration of the gel in the mucosa. The 
fi rmness, consistency, cohesiveness and index of 
viscosity were used to describe the texture charac-
teristics of gels. Carbopol 974P gel showed the 
best mucoadhesive properties to the uterus but 
low adhesion to the buccal mucosa and esohagus. 
While polycarbophil gel shows the best mucoad-
hesive property to vaginal mucosa, this property 
is very low in buccal mucosa.
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CONCLUSIONS: It was concluded that the rhe-
ological and mechanical properties of Carbopol 
974P and polycarbophil gels are suitable for mu-
cosal drug delivery.  Carbopol 974P gels shows 
good mucoadesive properties in uterus and poli-
carbophil is the best choice for the vaginal applica-
tions.
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P1D-4
Phenomenon of self-organized criticality in 
granule fl owability examinations
 FARKAS, GY.1,  HORVÁTH, B.1,
  SZÉCHENYI, A.1,  HÓDI, K.2,  PÁL, SZ.1
1Institute of Pharmaceutical Technology and Biopharmacy, 
University of Pécs, Hungary
2Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Hungary
BACKGROUND: Self-organized criticality is a 
phenomenon and an important property of dy-
namical systems, which have a critical state. In the 
pharmaceutics fl ow properties of powders and 
granules can be described by this theory. These 
systems have a specifi c augmentation and reach-
ing a critical point, avalanche behaviour of parti-
cles can be noticed.
AIMS: Our aim was to examine fl ow properties 
of medicated granules with classic methods 
which are supplemented by visual analysis tech-
nique to fi nd signifi cant contexts between fl ow 
properties and parameters of self-organized criti-
cality phenomenon. This examination can serve 
additional information improving the process 
and development of multiparticular drug formu-
lations. Our experiments were carried out using 
an experimental design including 22 samples. 
Variables of the design were: the type of the ac-
tive agent applying a hydrophilic (paracetamol) 
and hydrophobic one (prednisolone), granulation 
method (using high-shear and oscillating meth-
ods), average particle size and the amount of the 
glidant (talc) added to the granules. Examinations 
included self-organized criticality based fl owabil-
ity, porosity, compressibility and surface proper-
ties of particles.  
RESULTS:  Our results were still under evalua-
tion until the deadline of the transmission of the 
abstracts and will be presented on the conference.
CONCLUSIONS: Our conclusions were still un-
der construction until the deadline of the trans-
mission of the abstracts and will be presented on 
the conference.
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P1D-5
Evaluation of morphology of diuretic-
incorporated polymeric microspheres
 OSTRÓŻKA-CIEŚLIK, A.,  SARECKA-HUJAR, B.
Department of Pharmaceutical Technology, Chair of Applied 
Pharmacy, Medical University of Silesia in Katowice, School 
of Pharmacy with the Division of Laboratory Medicine in 
Sosnowiec, Poland
BACKGROUND: Microspheres are drug form with size 
between 1-500 μm, in which the active substance is incor-
porated into the polymer matrix. They are multicompart-
ment forms that allow to modify the release of the active 
substance.
AIMS: The aim of the study was to develop a 
technology for the preparation of microspheres 
containing the diuretic/furosemide incorporated 
into the Eudragit L30 D-55 matrix as well as the 
evaluation of their morphology.  
RESULTS:  Microspheres were prepared by 
spray drying technique using a Büchi Mini Spray 
Dryer B-191 (Büchi Labortechnik AG, Flawil, 
Switz erland). A standard nozzle with a diameter 
of 0.7 mm, pressure 3.5 bar and an air fl ow rate 
600 l/h were used. The optimal spray-drying pa-
rameters of furosemide with Eudragit L 30 D-55 
were as follows: aspirator capacity of 80%, Tin: 
140°C, pump capacity of 10% and were selected 
based on morphology of the obtained micro-
spheres, process eﬃ  cacy and particle size. Mor-
phological characteristics of microspheres were 
examined using scanning electron microscopy 
(SEM) analysis using Hitachi UHR FE-SEM SU 
8010 ultra-high resolution microscope (Tokyo, Ja-
pan). The distribution of microsphere sizes was 
analysed using the Mastersizer 3000 laser diﬀ rac-
tion particle size analyser (Malvern Instruments, 
UK) equipped with a dispersion unit. The particle 
size distribution was determined on the basis of 
the Fraunhofer model according to USP <429>. 
The analysed material of Furosemide-Eudragit 
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L30 D-55 in the 1:1 ratio contained the greatest 
amount (approx. 8%) of particles with 6.96 μm 
size. 90% of the particles were smaller than 21.4 
μm. Weighted residual for 1:1 ratio was <1%, 
which indicates a good fi t of the calculated data to 
the measured data.
CONCLUSIONS: The obtained results may al-
low to develop a new technological solution that 
optimizes furosemide therapy. The enteric form of 
this diuretic may also limit its side eﬀ ects.
P1D-6
Diﬀ erential scanning calorimetry and photon 
correlation spectroscopy as complementary tools 
for characterization of microemulsion hydrogels
 DJEKIC, L. 1,  MARTINOVIC, M. 2,  ČALIJA, B.1, 
 JANKOVIC, J .3,  PRIMORAC, M. 1
1Department of Pharmaceutical Technology and Cosmetology, 
University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia, 
2“Pharmacy Lekino Brdo“ , Belgrade, Serbia, 
3 “Pharmacy Jankovic“, Novi Sad, Serbia
BACKGROUND: Microemulsion hydrogels (MHs) 
show great potential as (trans)dermal drug deliv-
ery carriers combining semisolid consistency of 
the hydrogels and percutaneous penetration/per-
meation enhancement of the microemulsions (1, 
2). They consist of the biocompatible excipients in-
cluding the components of the oil and water 
phase, the surfactants, the co-surfactants, and the 
suitable hydrophilic polymers. The complex struc-
ture of such drug delivery systems is poorly in-
vestigated.
AIMS: The purpose of the current study was to 
assess the infl uence of the diﬀ erent hydrophilic 
polymers on structure and drug solubilizing ca-
pacity of the MHs by using diﬀ erential scanning 
calorimetry (DSC) and photon correlation spec-
troscopy (PCS).  
RESULTS:  The samples prepared with poloxam-
er 407 16% or xanthan 0.25% were homogeneous, 
clear to slightly opalescent viscous liquids, while a 
soft semisolid was obtained with chitosan 0.5%. For 
all samples the DSC analysis showed that the mod-
el drug ibuprofen was completely dissolved in a 
therapeutic concentration of 5%. Furthermore, the 
obtained endotherm patt erns of the samples indi-
cated that type and concentration of the polymer 
aﬀ ected signifi cantly the free and bound water ra-
tio in comparison with the polymer-free ibuprofen-
loaded microemulsion. Finaly, the results of the 
PCS analysis of the suitably diluted MHs demon-
strated the nanodispersion structure likely com-
prising the oil droplets (<100 nm) dispersed in the 
aqueous phase. The diﬀ erent infl uence of the poly-
mers on the droplet average size and distributions 
coresponded well with the DSC results.
CONCLUSIONS: The complementarity be-
tween the DSC and PCS results during the charac-
terization of the structure of the diﬀ erent MHs 
was observed. Three structure models for the in-
vestigated MHs comprising diﬀ erent hydrophilic 
polymers were assumed. 
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P1D-7
HPMC capsules as emerging solidifi cation 
approach for self-microemulsifying drug 
delivery systems (SMEDDS) 
 DJEKIC, L.1,  JANKOVIC, J .2,  SOLOMUN, L.3, 
 STANIĆ, D.4,  PRIMORAC, M.1
1Department of Pharmaceutical Technology and Cosmetology, 
University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia, 
2“Pharmacy Jankovic“, Novi Sad, Serbia, 3Hemofarm a.d., Stari 
Banovci, Serbia, 4Department of Physiology, University of 
Belgrade-Faculty of Pharmacy, Belgrade, Serbia
BACKGROUND: Development of the semisolid 
SMEDDSs is recently reported as a novel formula-
tion approach for improving oral drug absorption 
(1). Filling of the semisolid SMEDDSs in hard cap-
sules is scalable solidifi cation strategy, however, 
major considerations are related with physical sta-
bility of the formulated solid dosage form (2).  
AIMS: The semisolid SMEDDS fi lled in hard 
hydroxypropylmethyl cellulose (HPMC) capsules 
for oral delivery of the model drug acyclovir 
(ACV) was formulated by using the oil (medium 
chain length triglycerides), the surfactant (macro-
golglycerol hydroxystearate), the co-surfactant 
(polyglyceryl-3-dioleate), the cosolvent (glycerol) 
and the viscosity modifi er (macrogol 8000). The 
stability of the capsules fi lled with the semisolid 
SMEDDS was assessed during 3 months storage at 
20±5 °C and at 5±3 °C (RH~60%) by performing: 
organoleptic and light microscopy evaluation, de-
termination of ACV content by HPLC, and in vitro 
drug release study (after 0, 1, 2 and 3 months) us-
ing a rotating paddle method in phosphate buﬀ er 
pH 7.2, at 37±1oC for 60 min.  
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RESULTS:  Weight, colour and physical integri-
ty of capsule shells were not changed during the 
evaluation period, and there was no signifi cant 
change in drug particle size and content, at both 
temperatures. The drug release kinethics and the 
corresponding profi les of the ACV-loaded semi-
solid SMEDDSs, stored at both temperatures dur-
ing three months, were similar (0<f1<15). During 
the fi rst 10 minutes a lag phase was observed and 
over a period of 30 min the cumulative % release 
of drug was approximately above 70%. The entire 
amount of the ACV was released from the semi-
solid SMEDDS in 50 minutes.
CONCLUSIONS: The results showed satisfac-
tory physical and chemical stability of the investi-
gated semisolid SMEDDS fi lled in HPMC capsules 
for at least 3 months at 20±5 °C and at 5±3 °C 
(RH~60%).
REFERENCES: 
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P1D-8
Quantitative approach used Raman mapping for 
distributional homogeneity of diﬀ erent drugs in 
tablets
 FARKAS, A.,  NAGY, B.,  MAROSI, GY.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
BACKGROUND: Raman mapping is a suitable 
technique to examine the homogeneity in solid 
samples. Therefore it is used in the pharmaceuti-
cal fi eld increasingly. Two kinds of technique have 
been developed for evaluating homogeneity in re-
cent years.
AIMS: These two types of macropixel analysis 
were compared critically on samples prepared 
fi ve diﬀ erent manufacturing technologies.  
RESULTS:  Two kind of API, imipramine and 
spironolactone were applied in three conventional 
and two continuous processing technologies. The 
homogeneity of distributions of 10% API was de-
termined through Raman maps applying mac-
ropixel analysis method. Non-overlapping mac-
ropixel analysis (Poole-index) and calculation of 
distributional homogeneity indices (DHIs) were 
compared as a measure of homogeneity. Non-
overlapping macropixel approach proved to be 
more sensible than DHI evaluation. For enhancing 
eﬃ  cacy of DHI we suggest a correction by weight-
ing scores and considering relative standard devi-
ations. This way the capability of DHI can be im-
proved signifi cantly.
CONCLUSIONS: Using the modifi ed DHI val-
ues the very slight diﬀ erences between the contin-
uous methods (the homogeneity of which are 
much higher than that of conventional technolo-
gies) could be quantifi ed. Moreover the calcula-
tion of Poole-indices becomes unneccessary, of 
which calculation is time-consuming and needs 
more capacity than DHI.
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Experimental study of the eﬀ ect of the 
particles shape on the mixing performance in 
pharmaceutical V-blender
 BOUHAOUCHE, A.,  DAOUD, K.
Laboratory of transfer phenomena, Faculty of Mechanical 
Engineering and Process Engineering, University of Sciences 
and Technology Houari Boumediene, Algiers. Algeria
BACKGROUND:  the particles shape is a impor-
tant parameter having a signifi cative eﬀ ect on the 
powder properties [1]. It is therefore interesting to 
study  particles shape before any pharmaceutical 
formulation. 
AIMS: The aim of this work is to study the in-
fl uence of the particules shape on the mixing per-
formance. For this, two kinds of particles was 
used with diﬀ erents aspect ratio which represente 
the ratio of the maximum and minimum diameter 
of the particles [0.17 and 0.83] at two rotational 
speed levels [10 and 27 RPM], for three loading 
profi les; Top bott om (TB), Front back (FB), and 
Right left (RL] with 50 % of tracer, in laboratry 
scale V-blender. The experimental study was car-
ried out using disgn of experiments with Nem-
rodW software.   
RESULTS:  The mixing performance was evalu-
ated according the relative standard deviation 
(RSD) curves. It was found that the mixing time is 
very aﬀ ected by the aspect ratio for the three load-
ing profi les. Increasing the aspect ratio increase 
the mixing time for Top bott om loading profi le, 
and decrease it in case of Right left and front back 
loading profi les. Regarding the eﬀ ect of the rota-
tional speed, increasing rotational speed enhance 
the mixing homogeneity for Right left loading 
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profi le, and it was not signifi cant for the other 
loading profi les.
CONCLUSIONS: From the experimental study, 
it was found that, the homogeneity of a mixture 
depends strongly on the initial arrangement of 
particles in the mixer and thus the loading profi le. 
And the particles shape aﬀ ect signifi cantly the 
mixing time.  
REFERENCES: 
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Characterisation of polymer excipients by size 
exclusion chromatography and light scatt ering 
based detection 
 JANČAR, S.1,  PETERLIN, S.1,  GRAHEK, R.1, 
 SRČIČ, S .2
1Lek d.d., Ljubljana,
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BACKGROUND: Size Exclusion Chromatography-
Multi Angle Light Scatt ering (SEC-MALS) is one of 
the few absolute methods for characterizing the 
polymers in solution. In combination with concen-
tration refractive index detector the method addi-
tionally allows determination of average molecu-
lar weight, polydispersity and molecular weight 
distribution. Polyvinylpyrrolidon (PVP) and hy-
droxypropyl methylcellulose (HPMC), excipients 
from extended release matrix tablets, have been 
analysed by using SEC-MALS. 
AIMS: Characterisation of PVP and HPMC 
polymers in matrix tablets.  
RESULTS:  The SEC-MALS for PVP and HPMC 
characterization was set up, properly developed 
and validated too. Both polymers have been ini-
tially separated by selective dissolving. For deter-
mination of purity of separation and extraction ef-
fi ciency a RP-HPLC method was developed and 
successfully applied.   
CONCLUSIONS: PVP, either K25 or K30 as ex-
cipients in matrix tablets have been identifi ed. For 
the exact determination of PVP type the method 
of separation has to be refi ned as the diﬀ erence 
between their average molecular weight is small. 
Second polymer, HPMC, represents according to 
the weight average molecular weight and molecu-
lar weight distribution most probably HPMC 
K15M.
*Dedicated to the memory of Prof. Dr. Istvan 
Erös, Faculty of Pharmacy, University of Szeged, 
Professor, Researcher and Friend.
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Eﬀ ect of surfactants on microencapsulation with 
coacervation-phase separation method
 LENGYEL, M.,  STÖMMER, V.,  SZERŐCZEI, 
D.,  BERTALAN-BALOGH, E.,  ANTAL, I .
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Budapest, Hungary
BACKGROUND: Microencapsulation is an adapt-
able method for incorporating sparingly soluble 
active ingredients, oxidable substances, proteins 
from biotech origin or viable cells into a drug car-
rier. Microsphere and microcapsule diﬀ er in their 
structure, but both contain the active ingredient 
encapsulated by optional polymers, providing the 
beads with increased stability and depending on 
the polymer characteristics, modifi ed release. In 
combination with phase separation method Bü-
chi-390 apparatus is capable of laboratory scale 
microparticle formation within a wide range (noz-
zle diameter 80 um- 1000 um) using the vibration 
nozzle method (VNM), where the laminar jet of 
drug solution is broken into droplets by an axial 
vibrational force.
AIMS: As surfactants are capable of infl uencing 
the droplet formation, our study primarily aims 
the investigation of the eﬀ ect of diﬀ erent surfac-
tants (e.g. Polysorbate 20 and 80) on the formation 
of microparticles using VNM method. The experi-
ments also concern to observe the impact of the 
diﬀ erent process parameters (e.g. vibration fre-
quency, feed rate and voltage). The characteriza-
tion of microparticle formation involved the deter-
mination of droplet size and droplet size distribu-
tion using laser-diﬀ raction method (Malvern 2000, 
Malvern Instr.) and image analysis (Nikon 
SMZ1000, Image J). To evaluate the microencapsu-
lation eﬃ  ciency, drug release and its dependence 
on the physicochemical environment (e.g. osmo-
lality, pH) were investigated.   
RESULTS:  : A relatively low feeding rate and 
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alginate concentration favors optimal particle size 
distribution. The relationship between drug re-
lease kinetics and simulated environmental condi-
tions can be established taking also the formula-
tion parameters into consideration. 
CONCLUSIONS: Based on our results optimal 
production parameters were determined for the 
preparation of caﬀ eine-loaded alginate micro-
spheres.
REFERENCES: 
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POSTER SECTION 1E 
PHARMACOKINETICS, 
DRUG METABOLISM AND 
TRANSPORTERS
P1E-1
 Challenges in equilibrium solubility 
measurements: diﬃ  culties in phase separation
 VÖLGYI, G.,  TAKÁCS-NOVÁK, K.
Department of Pharmaceutical Chemistry, Semmelweis 
University, Budapest, Hungary
BACKGROUND: Knowledge of the physico-chem-
ical parameters of drug molecules is essential in 
the estimation of their pharmacokinetic proper-
ties. Solubility is used to predict the absorption of 
orally administered drugs.  Equilibrium solubility 
of drugs can be measured by diﬀ erent methods. 
The saturation shake-fl ask method is still the most 
frequently used procedure. The phase separation 
technique is a key part of this method. Three al-
ternative techniques (sedimentation, centrifuga-
tion and fi ltration) can be used for the separation 
of the solid from the saturated solution before ali-
quots can be taken out for concentration measure-
ment.
AIMS: The aim of the present study was to ex-
amine the eﬀ ect of the fi ltration on solubility. The 
equilibrium solubility of hydrochlorothiazide, di-
clofenac sodium and papaverine hydrochloride 
was determined at diﬀ erent pH values using satu-
ration shake-fl ask method. Hydrophilic and hy-
drophobic membrane fi lters as well as glass fi lters 
and analytical fi lter papers were applied.   
RESULTS:  In this study the eﬀ ect of hydrophil-
ic or hydrophobic type of membrane fi lters on the 
solubility results of ionizable molecules was prov-
en. The selection of appropriate fi lter type requires 
the knowledge of the acid-base chemistry of the 
sample. Hydrophobic fi lter can be recommended 
for the fi ltration of the ionized form of the com-
pound. For unionized drugs, hydrophilic fi lter can 
be recommended.
CONCLUSIONS: Sedimentation is the safest 
method for separation of the solid from the satu-
rated solution. For non-clarifying, opalescent col-
loid solutions the centrifugation can be used.  If 
fi ltration cannot be avoided, then it is essential 
that the proper fi lter type is selected. In this post-
er, a comprehensive, systematic investigation of 
the fi ltration and its infl uence on equilibrium sol-
ubility will be presented. 
P1E-2
Study of interaction of reduced glutathione 
(GSH) with chalcone and some cyclic chalcone 
analogues
 KENARI, F.,  PERJÉSI, P.
Institute of Pharmaceutical Chemistry, University of Pécs
BACKGROUND: Chalcones or 1,3-diaryl-2-pro-
pen-1-ones, are intermediary products and pre-
cursors of fl avonoid biosynthesis. Both natural 
and synthetic chalcone analogues are proven to 
have various therapeutical activity such as cyto-
toxicity, anti-infl ammatory, antitumor, and can-
cer-preventive properties. This class of com-
pounds have shown preference in reactivity with 
thiols. In our earlier experiments some cyclic chal-
cone analogues showed a signifi cant eﬀ ect of re-
duced glutathione (GHS) status of Jukat T lym-
phocyte cells.
AIMS: To demonstrate the relationship between 
GSH-reactivity and anti-cancer properties of the 
investigated chalcones. To study stereochemistry 
of the reaction. 
RESULTS: The investigated chalcones show an 
intrinsic activity towards GSH. This reversible Mi-
chael addition reaction yields maximum of two di-
asteromeric adducts in case of open chain chal-
cones or four ones in case of the cyclic analogues. 
The rate of the reaction depends on the proportion 
of deprotonated to protonated thiol function of 
GSH, as the deprotonated thiol is the more reactive 
form of it. Furthermore, reactivity depends on the 
ring size showing the open chain and the six-mem-
bered chalcones to be the most reactive. The rate of 
the reaction is also found to be depended on the 
nature of the 4’-substituents. The ratio of distereo-
meric adducts was found to be dependent on both 
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the pH and the ring size, as the mechanism and the 
stereochemical outcome of addition of the proton-
ated and deprotonated thiol is diﬀ erent.
CONCLUSIONS: Chalcones possess intrinsic 
reactivity with GSH which can play role in devel-
opment of their biological eﬀ ects.
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Anticipation of absorption in dog using in vivo/
in vitro/in silico tools to prepare fi rst in human 
studies
 HENRION, L.1,  LOUIT, G.1,  BRUEL, J-L.1, 
 NICOLAS, M-F.1,  ROUGEAUX, S.1, 
 VALENTE, D.2,  VICAT, P.2
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BACKGROUND: Animal studies with support of in 
silico PBPK absorption tools are valuable data to 
build knowledge of physiological behavior of a for-
mulated API to anticipate its pharmacokinetics in 
Human and to adapt the formulation when needed.
AIMS: This paper illustrates with six BCS II 
APIs examples how in vitro/silico/vivo studies 
conducted with a Beagle Dog model can be linked 
to rise understanding of the API behavior and 
propose an anticipation bioavailability (BA) in 
fi rst in Human studies.  
RESULTS:  The fi rst section presents for all com-
pounds the correlation between observed BA in the 
pentagastrin-Dog (pgDog) model and BA predict-
ed using in silico model built in GastroPlus v9.0 
(SimulationsPlus, Inc), as well as the Human BA 
prediction. The second section illustrates the use of 
pgDog model to contribute to the formulation 
strategy, linked to API physical form and size. In a 
fi rst example (compound A), an absorption increase 
obtained by reducing particle size was anticipated 
in silico and in vitro dissolutions on three batches 
with particle diameters varying from coarse (30μm) 
to micronized (3μm) ; the gain in AUC in pgDog 
was well correlated to this size reduction. The sec-
ond example (compound B) points up the impact 
of surfactant into the formulation on the absorption 
of two physical forms (B1 & B2). Recommendation 
from in silico and in vitro tests was to include a sur-
factant to the granules of form B1, but not into form 
B2. In vivo PK profi les in fasted pgDog model con-
fi rmed the validity of this suggestion. Compound 
C example relates to the value of vitro dissolution 
on PK profi les interpretation and the importance of 
transit times in the GI tract.
CONCLUSIONS: Combination of in vitro/sili-
co/vivo experiments on various compounds and 
formulation problematics around  pgDog model 
allows foreseeing absorption in Human and helps 
designing fi rst in man clinical studies by (1) orien-
tating formulation options and (2) targeting dose 
adjustment.
P1E-4
Investigation of absorption and metabolism of 
ibuprofen in small intestine and bile in the rat 
 ALMÁSI, A.1,  SZABÓ, A.1,  KOVÁCS, N. P.3, 
 SZENTE, L.4,  FISCHER, E.2,  PERJÉSI, P.1
1University of Pécs, Pharmaceutical Faculty, Institute of 
Pharmaceutical Chemistry, Pécs, Hungary
2University of Pécs, Medical Faculty, Institute of Pharmacology 
and Pharmacotherapy, Pécs, Hungary
3Farmacia Selena, Targu-Mures, Romania
4Cyclolab Kft, Budapest, Hungary
BACKGROUND: Per os administered drugs are 
absorbed from the gastrointestinal tract, reach the 
liver through the vena portae, and get to the site of 
action by the systemic blood circulation. Ibupro-
fen typically excreted as ibuprofen-glucuronide, 
hydroxyibuprofen and carboxyibuprofen and 
both enzymatic and spontaneous processes can be 
involved in formation of them.
AIMS: In vivo investigation of intestinal absorp-
tion and metabolism of ibuprofen as well as ap-
pearance its metabolites in the small intestinal 
perfusate and in the bile, under physiologic and 
pathologic (diabetic) conditions. Development of 
HPLC method for quantitation of ibuprofen and 
its Phase I and Phase II metabolites. Analysis of 
non-enzymatic oxidative ibuprofen metabolites 
formed in the Udenfriend and the Fenton tests.
RESULTS: It was found that the enentiomeric 
ratio of the racemic ibuprofen slightly altered in 
the intestinal perfusate during the experiments. 
Under hyperglycaemic conditions the non-metab-
olized ibuprofen and its glucuronide conjugate 
decreased, however the quantity of the excreted 
oxidative metabolites signifi cantly increased.
CONCLUSIONS: Hyperglycaemia increased 
the amount of oxidative metabolites that can be – 
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at least partly -the result of increased oxidative 
stress and/or elevated enzyme activities. Appear-
ance of excess of the (S)-(+)-ibuprofen can be the 
result of active excretion of the metabolite.
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In silico modeling of salbutamol deposition 
and absorption following intravenous and 
inhalation administration in rats
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BACKGROUND: Contemporary trends in drug 
development highlight the utility of in silico tools 
for the prediction of drug bioperformance in hu-
mans and diﬀ erent animal species (1). Rat has 
commonly been used as animal model to study 
drugs absorption; however, examples of rat physi-
ologically-based pharmacokinetic (PBPK) model-
ing for pulmonary drug delivery are rather scarce.
AIMS: The objective of this study was to devel-
op an in silico model for the prediction of salbuta-
mol deposition and absorption following intrave-
nous and inhalation administration. GastroPlus™ 
software (v 9.0.0007, Simulation Plus, Inc. USA) 
and MPPD model (v 3.04, ARA, Inc. USA) were 
used for computer simulations. The necessary in-
put parameters were obtained from literature or 
experimentally determined.  
RESULTS:  Drug-specifi c rat PBPK model was 
fi rst developed and validated for intravenous ad-
ministration, and further adjusted to simulate 
drug plasma profi le after inhalation of experimen-
tal dry powder formulation. Modeling results 
were validated by comparing the simulated val-
ues with data from the in vivo study (2). The ob-
tained results indicated that particle size, and con-
comitant  regional lung particle deposition, are the 
key factors that infl uence salbutamol absorption 
after inhalation. Also, changes in rat physiological 
parameters notably infl uence the absorption pro-
fi le of the inhaled drug.
CONCLUSIONS: In silico modeling of inhaled 
drug pharmacokinetics in preclinical species can 
facilitate the development of inhalation medicines. 
However, certain limitations such as incomplete 
knowledge of drug-related physiological mecha-
nisms, along with uncertainties regarding the pre-
diction of lung particle deposition, highlight the 
necessity for additional improvements in animal 
PBPK models.
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Semisolid self-microemulsifying drug delivery 
systems (SMEDDS): eﬀ ects on pharmacokinetics 
of acyclovir in rats
 JANKOVIC, J .1,  DJEKIC, L.2,  RAŠKOVIĆ, A.3, 
 PRIMORAC, M.2
1“Pharmacy Jankovic“, Novi Sad, Serbia, 2Department of 
Pharmaceutical Technology and Cosmetology, University of 
Belgrade-Faculty of Pharmacy, Belgrade, Serbia, 3Department 
of Pharmacology, Toxicology and Clinical Pharmacology, 
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BACKGROUND: Acyclovir (ACV) is an antiviral 
agent whose absorption from gastrointestinal 
tract is slow, bioavailability is low (~ 15-30%), and 
half-life short (t1/2 2.5h) (1). One of the potential 
ways to improve pharmacokinetic parameters of 
ACV is developing semisolid self-microemulsify-
ing drug delivery systems (SMEDDS) (2).
AIMS: Semisolid SMEDDS with ACV was pre-
pared by measuring accurate quantities of oil (me-
dium chain length triglycerides), surfactant (mac-
rogolglycerol hydroxystearate), cosurfactant 
(polyglyceryl-3-dioleate), co-solvent (glycerol) 
and a viscosity modifi er (macrogol 8000). The 
pharmacokinetic research was conducted on sexu-
ally mature white male Wistar laboratory rats (3). 
The animals were randomly divided into three 
groups and ACV was administered intravenously 
and orally in form of a suspension and semisolid 
SMEDDS, respectively. The animals were later 
treated orally with an aqueous solution of ACV, 
the self-dispersing formulation and ACV with the 
SMEDDS, during 7 and 21 days, respectively, in 
order to determine safety of semisolid SMEDDS 
by biochemical analysis.  
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RESULTS:  ACV administered with semisolid 
SMEDDS can reach signifi cantly higher maximum 
concentration in blood and has signifi cantly short-
er time reaching maximum concentration com-
pared to the suspension of ACV (Cmax 
247,31±28,7 ng/ml and 130,1±2,64 ng/ml; Tmax 
23,33±5,16 min and 38,33±14,37 min, for the semi-
solid SMEDDS with ACV and the suspension of 
ACV, respectively). The bioavailability of the ACV 
is twice higher when it is in the form of the semi-
solid SMEDDS. Biochemical parameters doesn’t 
show damage on function of liver and kidneys by 
administered formulation. CONCLUSIONS: 
Semisolid SMEDDS signifi cantly improves phar-
macokinetics of acyclovir and doesn’t show dam-
age on function of liver and kidneys.
CONCLUSIONS: Semisolid SMEDDS signifi -
cantly improves pharmacokinetics of acyclovir 
and doesn’t show damage on function of liver and 
kidneys.  
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Pharmacokinetic study of fl uorescently labelled 
hydroxypropyl-β-cyclodextrin 
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BACKGROUND: Cyclodextrins are cyclic oligo-
saccharides, which consist of α-D-gluco pyra nose 
units. These molecules have a cylindrical shape, 
their outer surface is hydrophilic, but the inner 
cavity is hydrophobic. Nowadays cyclodextrins 
has an increasing importance as drug carriers, but 
hydroxypropyl-β-cyclodextrin is also used in the 
treatment of Niemann-Pick disease type C.  
AIMS: The full characterization of biological 
properties of HPBCD has great signifi cance. Our 
fi rst aim was to test the safety of HPBCD by he-
molysis test in correlation with the number of sub-
stitution groups. We also aimed to examine the 
pharmacokinetic properties of fl uorescein-isothio-
cyanate labelled HPBCD (FITC-HPBCD) and eval-
uate its suitability for biological studies.     
RESULTS:  Our result showed that HPBCD has 
hemolytic eﬀ ect just at extremely high doses. The 
degree of substitution of HPBCD molecules has a 
litt le eﬀ ect on the hemolytic activity. FITC-HPBCD 
has fast elimination in BALB/c mice, but according 
to the pharmacokinetic model, tissue distribution 
could be also observed. The molecule was elimi-
nated by the urine and the degree of tissue accu-
mulation is insignifi cant at the end of the pharma-
cokinetic experiments. We studied the eﬀ ect of 
FITC-HPBCD on endothelial cells in the third 
phase of the experiment. We showed, that endocy-
tosis of FITC-HPBCD could be detected in HU-
VEC cells by fl uorescent microscopy and fl ow cy-
tometry. 
CONCLUSIONS: In conclusion, FITC-HPBCD 
is a suitable fl uorescent derivative for the pharma-
cokinetic analysis of HPBCD. The molecule can be 
used at high concentrations safely, and on the oth-
er hand the endocytosis in endothelial cells con-
tribute to the bett er understanding of the distribu-
tion process.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.  
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1Faculty of Pharmacy and Biochemistry, University of Zagreb, 
Zagreb, Croatia; 
2Faculty of Chemical Enginering and Technology, University of 
Zagreb, Zagreb, Croatia
BACKGROUND: A considerable research demon-
strates that entactogens have serious toxic eﬀ ects, 
both acute and chronic, that resemble those previ-
ously seen with other amphetamines. Among 
many others the four principal types of such seri-
ous toxicity are hepatic, cardiovascular, cerebral 
and hyperpyrexic.
AIMS: The aim of this study was to predict 
on- and oﬀ -targets as well as ADMET properties 
of selected phenylethylamine entactogens (n = 
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25) in order to get more insights in their toxic 
profi le.
RESULT: The sodium dependent serotonin or 
dopamine transporters and trace amine-associat-
ed receptors were revealed by Swiss Target Pre-
diction software as biological targets with the 
highest probability. Both, CYP inhibitor (1A2, 
2D6) and CYP substrate properties (1A2, 2B6, 2C9, 
2C19, and 2D6 and 2E1) have been predicted for 
majority of entactogens. QSAR studies, using 
computed molecular descriptors (LogP, Mr, TPSA, 
V) and topological indices (F, X, J, H, WW, W, Wp 
and Sz) with predicted ADMET properties com-
puted by ADMET PredictorTM 8.1 (Simulations 
Plus, USA) revealed the most signifi cant correla-
tions between ADMET Risk vs. CYP Risk (R = 
0.99), MLogP vs. TOX hERG (cardiotoxicity) and 
human plasma protein binding (R = 0.75 and R = 
0.92, respectively). 
Predicted ADMET risk were between 1 and 4 
(codes 1A, 2C19, 2D6, Mu or Hp), CYP risk be-
tween 1 and 2.72 (codes 1A2, 2D6 and 2C19) and 
TOX risk between 0 and 3.45 with codes of muta-
genicity (Mu) and hepatotoxicity (Hp). Mu was 
predicted for MDMEO or 1-(1,3-benzodioxol-
5-yl)-N-methoxypropan-2-amine (14) and MDOH 
or 3,4-methylenedioxy-N-hydroxyamphetamine 
(15) while both Hp and Mu were predicted for 
MDCPM or 3,4-methylenedioxy-N-cyclopropyl-
methylamphetamine (18).
CONCLUSIONS: The results of this study re-
vealed many unfavourable ADMET properties of 
evaluated molecules and MDCPM (18) as entacto-
gen with the worst toxic profi le.
REFERENCES: 
1. Aouidate A. et al., J Taibah Univ Sci 10, 787-96 (2016)
2. LeDonne Jr N et al., J Cheminf 3, 7 (2011)
P1E-9
Diabetic conditions and drug vehicles alter drug 
metabolism
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2University of Pécs, Faculty of Pharmacy, Department of 
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3University of Pécs, Faculty of Pharmacy, Department of 
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BACKGROUND: Type II diabetes mellitus is a 
chronic disease, characterized by hyperglycemia 
and impaired metabolism. In diabetes, several 
metabolic pathways are altered, thus the biotrans-
formation and pharmacokinetic of drugs can be 
infl uenced. According to epidemiological evidenc-
es, carotenoids are potent antioxidants and might 
have a protective role in chronic diseases. Because 
of their low solubility in water, cyclic oligosaccha-
rides, cyclodextrins can be used to improve the 
aqueous solubility of carotenoids. 
AIMS: We aimed to develop a method to inves-
tigate the eﬀ ect of cyclodextrins (2-hydroxypropyl-
β-cyclodextrin) and cyclodextrin-carotenoid com-
plexes in streptozotocin induced animal model of 
type II diabetes mellitus with, or without the ad-
ministration of insulin. Wistar rats were used in 
the experiments. During the method, the proximal 
jejunum of the diabetic and control rats is cannu-
lated and perfused with the substances in Krebs-
Tris buﬀ er. Samples are collected from the intesti-
nal perfusate and the bile. After the perfusion, dif-
ferent tissues (intestine, liver) were dissected and 
serum was collected for further investigations.
RESULTS: After the successful development of 
the method, the eﬀ ect of the cyclodextrin and the 
cyclodextrin-carotenoid complex on the appear-
ance of metabolites in the intestinal perfusate and 
bile, as well as the changes in the enzyme activi-
ties and drug transporter expressions in the tis-
sues during treated or untreated diabetes can be 
studied. There is also a scope for the investigation 
of signaling pathways connected to infl ammation 
during diabetes.
CONCLUSIONT: The applied method is suit-
able to investigate those alterations in treated and 
non-treated type I diabetes mellitus, which can in-
fl uence drug metabolism, therefore may change 
the eﬀ ect of agents. In addition, it can help to re-
veal the possible application of carotenoids in the 
treatment of diabetes in cyclodextrin-containing 
formulations.
ACKNOWLEDGEMENTS: The project was 
supported by the University of Pécs in the frame 
of the Pharmaceutic Talent Center program.
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P1F-1
 Chiral discrimination of fl uoxetine enantiomers 
by capillary electrophoresis
 KELEMEN, H.,  CÂRCU-DOBRIN, M., 
 BUDĂU, M.,  SZÉKELY-SZENTMIKLÓSI, B., 
 HANCU, G. 
Department of Pharmaceutical Chemistry, Faculty 
of Pharmacy, University of Medicine and Pharmacy 
Tîrgu Mureș, Romania
BACKGROUND: Fluoxetine (FLX) is a chiral selec-
tive serotonin-reuptake inhibitor, widely em-
ployed in therapy as an antidepressant. In chiral 
separation, capillary electrophoresis (CE) is con-
sidered to be an alternative for the more frequent-
ly used chromatographic techniques, with advan-
tages related to high separation eﬃ  ciency, low 
consumption of sample, reagents and chiral selec-
tors and especially with the high fl exibility in 
choosing and changing the chiral selector.
AIMS: FLX is used in therapy as a racemate, 
however stereospecifi city associated with its inter-
actions with the serotonin-reuptake carrier has 
been described and demonstrated; consequently 
development of analytical methods for its chiral 
separation become important for the pharmaceuti-
cal industry.
RESULTS:The study describes the development 
and optimization of a new CE method for the chi-
ral discrimination of FLX using cyclodextrins 
(CDs) as chiral selectors. A complex screening of 
11 native and derivatized, neutral and ionized 
CDs was carried out in order to establish the opti-
mum chiral selector. As a result of this process, 
heptakis(2,3,6-tri-O-methyl)-β-CD was selected 
for enantiomeric discrimination. A factorial analy-
sis study was performed by orthogonal experi-
mental design in which six experimental factors 
were varied at three levels in order to optimize the 
separation method. The optimized method was 
successful for baseline separation of fl uoxetine en-
antiomers within 5 minutes; the order of migra-
tion was established by spiking. The analytical 
performances of the method were verifi ed in 
terms of repeatability, precision, linearity, sensi-
tivity and accuracy. The method was applied for 
the determination of FLX enantiomers from phar-
maceutical preparations.
CONCLUSIONS: A simple, rapid and cost ef-
fective CE method has been developed for the en-
antioselective determination of FLX enantiomers. 
Acknowledgments:This work was supported by 
the Transylvanian Museum Society and Semmel-
weis University research Grant No. 63./P.2. EME-
OGYSZ 2015.
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P1F-2
Synthesis and biocompatibilty evaluation of 
new α-cyclodextrin derivatives
 PERRET, F.1,  ROKA, E.2,  BÁCSKAY, I .2
1Université de Lyon, Villeurbanne cedex, France
2Department of Pharmaceutical Technology, University 
of Debrecen, Debrecen, Hungary
BACKGROUND: The low solubility of drug candi-
dates cause a major problem in pharmaceutical 
formulations, as the aqueous solubility is an indis-
pensable criterion for appropriate bioavailability. 
Cyclodextrins (CDs) are widely studied organic 
host-compounds, and CDs have already been 
used as pharmaceutical excipients for solubility 
enhancement. The macrocycles’ chemical struc-
ture allows their versatile modifi cation, which 
eventuates changes not only in physicochemical 
characteristics, but in their eﬀ ects on living organ-
isms, as well. Thus, the biocompatibility evalua-
tion of the derivatives is fundamental.   
AIMS: Owing to the already performed assess-
ment of numerous β-CD derivatives’ biocompati-
bility, the aim of this research was to extend these 
experiments to commercially available α-CDs. 
They have been used less frequently, however 
several derivatives, which have not been tested 
yet in vitro, have the possibility of future pharma-
ceutical use. Their importance is also certifi ed by 
their benefi ts in nanoparticle formation. We have 
been interested in concrete structure-toxicity cor-
relations, thus alkyl ether α-CD derivatives were 
synthetized bearing increasing length alkyl chains, 
in diﬀ erent positions.  
RESULTS:  The cell viability and hemolysis tests 
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have allowed us to rank the α-CDs and to choose 
the safest derivatives, also to compare their toxic 
eﬀ ects in diﬀ erent systems. The comparison of α- 
and β-CDs bearing the same chemical modifi ca-
tions highlighted the importance of the number of 
building units. [2] Important information has been 
evaluated regarding the connection between the 
cytotoxic eﬀ ect and the number of free hydroxyl 
groups. Derivatives with long alkyl chains possess 
low solubility, which led us towards further 
chemical modifi cations. Sulfonation seemed to 
have benefi cial impact on the biocompatibility.
CONCLUSIONS: Our research concludes, that 
the structural changes on the macrocyclic rings 
may have major impact on the biocompatibility. 
As the modifi cation possibilities are practically 
unlimited, the evaluation of structure and activity 
cannot be avoided, facilitating the safest choice for 
further pharmaceutical use
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P1F-3
Preparation and antibacterial evaluation of some 
semisynthetic derivatives of teicoplanin and its 
hydrolysis products
 SZŰCS, ZS.,  OSTORHÁZI, E.,  KICSÁK, M., 
 BORBÁS, A.,  HERCZEGH, P. 
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 
University of Debrecen, Debrecen, Hungary
BACKGROUND: In a recent study, we have evalu-
ated diﬀ erent derivatives prepared from one of 
the pseudoaglycons of the glycopeptide antibiotic, 
teicoplanin, for in vitro antibacterial activity. One 
derivative displayed noticeably higher activity 
against numerous vancomycin and teicoplanin re-
sistant enterococci than the other compounds.
AIMS: The aim of this work was to study this par-
ticular molecule using well-known synthetic modifi -
cations in glycopeptide chemistry. We were interest-
ed to see if these transformations can infl uence the 
antibacterial activity in a similar way as it is de-
scribed in the literature for this group of antibiotics.  
RESULTS:  11 semisynthetic derivatives were 
prepared including the former compound. The 
transformations include the modifi cation of the N-
terminus by a diazotransfer reaction followed by a 
copper-catalyzed azide-alkyne click reaction to 
form a triazole derivative. This modifi cation was 
carried out on teicoplanin, its two pseudoaglycons 
and on the aglycon. The C-terminus was also 
modifi ed by PyBOP-mediated amide bond forma-
tion using 3-(dimethylamino)-1-propylamine and 
3-(diethylamino)-1-propylamine. The compounds 
have been characterized either by MALDI-ToF, 
HPLC-MS, 1D-, 2D-NMR or all of these tech-
niques. The measurement of antibacterial activites 
is in progress.
CONCLUSIONS: We have successfully synthe-
sized and characterized all of the derivatives we 
have planned to prepare. Although the antibacte-
rial activity of the molecules is not known yet, we 
will be able to present it on the conference along 
with structure-activity relationships.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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P1F-4
Novel synthesis of fl uorinated 1,2,3,4- 
tetrahydroisoquinoline derivatives
 ÁBRAHÁMI, R.,  KISS, L.,  FÜLÖP, F.
Institute of Pharmaceutical Chemistry, University of Szeged, 
Szeged, Hungary
BACKGROUND: Due to their high biological po-
tential, fl uorinated organic compounds have in-
creasing att ention in organic and medicinal chem-
istry. The replacement of one or more hydrogen at-
oms by fl uorine in biomolecules can generate 
changes in their physical, chemical and biological 
properties [1]. A number of isoquinoline deriva-
tives exist in nature, and most of them have vari-
ous biological activities [2].   
AIMS: Taking into consideration of the high 
biorelevance of 1,2,3,4- tetrahydroisoquinoline al-
kaloids and of organofl uorine scaﬀ olds our aim 
was to develop a novel and eﬃ  cient procedure for 
the access of fl uorinated 1,2,3,4- tetrahydroiso-
quinoline derivatives.   
RESULTS:  The novel synthetic route started 
from indene and some substituted indene deriva-
tives. They were oxidized with osmium tetroxide 
and these resulted vicinal diol derivatives  which 
were carried out by sodium periodate mediated 
oxidative ring opening in order to get the corre-
sponding diformyl intermediates. The unstable di-
aldehydes were subjected to reductive amination 
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with fl uorinated amines resulting in fl uor contain-
ing 1,2,3,4-tetrahydroisoquinoline derivatives. 
CONCLUSIONS: A  new convenient and eﬃ  -
cient procedure has been developed for the syn-
thesis of novel 1,2,3,4- tetrahydroisoquinoline de-
rivatives, based on the C=C bond oxidative ring 
cleavage of indene and diversely substituated in-
dene derivatives, followed by reductive ring clo-
sure of the diformyl intermediates using fl uorinat-
ed amines.
REFERENCES: 
1. Kiss, L. et al. Eur. J. Org. Chem. 26, 4951-4958 (2011)
2. Miyazaki, M. et al. J. Org. Chem. 76, 534-542 (2010)
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Catalytic deuterodehalogenation of haloarenes 
in continuous-fl ow
 ORSY, G.,  MÁNDITY, I . M.,  FÜLÖP, F.
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Szeged, Hungary
BACKGROUND: The deuterium labelled com-
pounds display widespread interest for scientists 
in many research areas. These compounds are 
used as internal standard in mass spectrometry, 
they are applied in the elucidation of biosynthetic 
pathways, they can be used to study reaction 
mechanisms. Nonetheless, deuteration can be 
used to increase metabolic stability of drugs.
AIMS: Continuous-fl ow (CF) technologies are 
of considerable current interest, since more eﬃ  -
cient and selective reaction can be carried out in 
continuous systems than those for regular batch 
operations.  Catalytic hydrogenation and deutera-
tion reactions are known in CF systems, however 
the deuterodehalogenation reaction is practically 
unexplored. We aim to develop a CF deuteration 
technology with which selectively deuterated aro-
matic compounds can be gained  
RESULTS:  First a reaction parameter optimiza-
tion was carried out. The results indicated that 
with regular supported Pd catalysts provide only 
law conversion rates even at harsh reaction condi-
tions. In case of Pt catalysts, the partial saturation 
of the aromatic ring was observed. Thus we shift-
ed our att ention towards polymer-based spherical 
activated carbon (PBSAC), of which is a novel sol-
id support for hydrogenation reactions. By a com-
plete reaction parameter optimization full conver-
sion was achieved with >95% deuterium incorpo-
ration. The reaction scope was extended to several 
haloarenes, including solely or multiply substitut-
ed chlorine and bromine substituted benzene de-
rivatives. Iodine substituted derivatives poisoned 
the catalyst.
CONCLUSIONS: A selective and eﬃ  cient CF 
catalytic deuterodehalogenation reaction was de-
veloped by the use of novel PBSAC supported Pd. 
Total conversions were gained a wide range of 
substances while high deuterium incorporation 
ratio was reached.
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Incubation time-, pH- and reagent ratio 
dependence of the product distribution in the 
Fenton reaction of salicylic acid
 NYÚL, E.1,  KUZMA, M.1,  MAYER, M.2, 
 PERJÉSI, P.1
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Pécs, Hungary
2University of Pécs, Department of Forensic Medicine, Pécs, 
Hungary
BACKGROUND: Infl ammatory and other patho-
logical processes are often accompanied by oxida-
tive stress. The reaction of reactive oxygen species 
with scavenger molecules can yield products that 
indicate their presence (and probably the underly-
ing reason of their formation) both in vivo and in 
vitro. Salicylic acid is a good model compound for 
the examination of non-enzymatic oxidative 
trans formation of phenolic compounds [1].
AIMS: We aimed to examine, how the change of 
the pH, the reaction time and the ratio of iron (II) 
to hydrogen-peroxide aﬀ ects the quality and 
quantity of the products in the Fenton oxidation 
of salicylic acid. 
RESULTS: The experiments were performed in 
at acidic (pH 3.0) and physiological (pH 7.4) pH 
with diﬀ erent iron (II) ion concentrations. The 
samples were analyzed at diﬀ erent time points of 
the incubations by a validated HPLC method. 
Similar to the in vivo results, in all incubates 2,3- 
and 2,5-dihydroxybenzoic acids were formed in 
the highest amount [2]. Furthermore, HPLC-MS 
analysis of the samples revealed presence of pre-
viously not identifi ed monohydroxylated and a 
dihydroxylated salicylic acid derivative. The ratio 
of the reactants was found to have a signifi cant 
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impact on the kinetics of the reaction and the ratio 
of the reaction products
CONCLUSIONS: Fenton reaction is a possible 
way of non-enzymatic oxidative transformation of 
phenolic compounds. Based on our in vitro results, 
the reaction can be a possible pathway of non-en-
zymatic oxidative biotransformation of phenolic 
xenobiotics under oxidative stress conditions.
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Concentration dependence of famotidine 
1H NMR chemical shifts in DMSO-d6
 MAROSI, A.1,2,  SZAKÁCS, Z.2,  NOSZÁL, B.1, 
 DEMETER, Á.2
1Semmelweis University, Department of Pharmaceutical 
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2Gedeon Richter Plc., Budapest, Hungary
BACKGROUND: In our previous work [1] 1H, 13C 
and 15N NMR spectral assignments of famotidine 
were clarifi ed in DMSO-d6. The results supported 
the predominance of extended conformers in this 
solvent in contrast to the previously supposed 
folded one. Furthermore, it was also revealed that 
besides the assignment, certain 1H NMR chemical 
shifts also diﬀ ered from previously published 
data [2], which raised the possibility of concentra-
tion dependence of 1H NMR chemical shifts in 
DMSO-d6, given the unknown solution concentra-
tion in Ref. [2].
AIMS: To explore the possible concentration de-
pendence of 1H NMR spectra in DMSO-d6.  
RESULTS:  The 1H NMR chemical shifts of the 
compound were measured in DMSO-d6 solutions 
at 13 diﬀ erent famotidine concentrations ranging 
0.29 mM to 2.96 M (1 g/ml). It was found that 1H 
NMR chemical shifts of the compound were sensi-
tive to concentration changes in solutions with con-
centrations exceeding ca. 15 mM, where the chemi-
cal shift values of all 1H NMR signals showed an 
almost linear change. However, the concentration 
dependence diﬀ ered signifi cantly for the individu-
al nuclei. Whereas the signals of the sulfonamide 
NH2 protons and the “free” proton of the amidine 
NH2 moiety suﬀ ered the largest chemical shift 
change with concentration (both 0.18 ppm), the 
smallest change (0.03 ppm) was observed for the 
other proton of the same amidine NH2 group. This 
is in accordance with our previous fi nding namely 
the involvement of the latt er proton in an intramo-
lecular hydrogen bond with the neighboring sul-
fonamide group, resulting in its relatively low af-
fi nity to intermolecular interactions.
CONCLUSIONS: Based on the nature of the ob-
served concentration dependence of the 1H NMR 
chemical shifts, disintegration of famotidine poly-
associates upon dilution can be assumed.
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Synthesis of 6-deoxy-l-talopyranoside-
containing analogues of the anticoagulant 
pentasaccharide idraparinux
 HERCZEG, M.,  DEMETER, F.,  BORBÁS, A.
Department of Pharmaceutical Chemistry, University of 
Debrecen, Debrecen, Hungary
BACKGROUND:  Heparin has been employed in 
the medical practice since the late 1930’s as a 
blood-anticoagulant. Enoxaparin, a low molecular 
weight oligosaccharides mixture (LMWH) drug, 
which made by the fractionation of heparin, have 
been among the world’s ten most traded drug. The 
synthetic analogues, such as Arixtra and Idra-
parinux(1,2), are more eﬀ ective than the heparin or 
Enoxaparin preparations but because of the com-
plexity of their synthesis are not able to compete 
to the natural-based derivatives in the pharma-
ceutical market. The most problematic part of the 
synthesis of heparin derivatives is the preparation 
of the L-iduronic acid unit, this unique sugar does 
not occur in free form.
AIMS: Our goal was the substitution of L-idu-
ronic acid with 6-deoxy-L-talopyranoside which 
has an essential fl exible structure such as iduronic 
acid, and has an eﬃ  cient and simple synthesis.
RESULTS: In our poster we will present the syn-
thesis of a methylated, a partially methylated and 
a partially acetylated 6-deoxy-L-talopyranoside-
containing idraparinux analogue pentasaccharides 
and the study of their anticoagulant activity.
CONCLUSIONS: We have successfully synthe-
sized potentially active Idraparinux analogue pen-
tasaccharides on shorter and more economical 
pathways. The anti-Xa activity measurements of 
these pentasaccharides are under way.
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P1F-9
Interaction of oligovalent alpha-L-
fucopyranosides with recombinant Photorabdus 
asymbiotica lectin 
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BACKGROUND: Photorabdus asymbiotica is one 
of the four recognized species of the Photorabdus 
genus, which consist of Gram-negative biolumi-
nescent bacteria. It causes diﬃ  culty treatable lo-
cally invasive soft tissue infection and disseminat-
ed bacteraemic disease characterized by multifo-
cal skin and skin tissues infection abscesses. A fu-
cose/galactose-binding lectin (PHL) was identifi ed 
from the bacteria and it was revealed that PHL 
has the ability to act as a host-cell recognizing 
agent. Therefore, PHL could be considered as a 
usable therapeutic agent. 
AIMS: In order to produce potential glyco-inhibi-
tors against PHL, alpha-L-fucoside containing mono-
, di-, tri- and tetravalent glycoclusters were prepared. 
RESULTS:  Several oligovalent fucoclusters 
were synthesized using multivalent scaﬀ olds by 
azide-alkyne click reaction. The interaction be-
tween fucoside derivatives and PHL was investi-
gated by diﬀ erent biophysical and biological 
methods: not only ITC, SPR, STD-NMR, X-ray dif-
fractometry were used but inhibition of agglutina-
tion and biofi lm formation were also studied.   
CONCLUSIONS: We have demonstrated that 
fucoclusters are able to inhibit the PHL lectin and 
the aﬃ  nity for multivalent ligands reach up to 
nanomolar values. Moreover, we proved that oli-
govalent ligands are able to cross-link the PHL 
lectin. These results may fi nd application in anti-
adhesion therapy. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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Development of HPLC method for estimation of 
18β-glycyrrhetinic acid phytosomes in carbomer 
based hydrogels 
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BACKGROUND: 18β-glycyrrhetinic acid phyto-
some® (GAP) is a complex of the highly pure ex-
tracts of Glycyrrhiza glabra rhizomes (27-31%) and 
phosphatidylcholine, with antiinfl ammatory, anti-
irritant and soothing eﬀ ects and well tolerated for 
topical application  in hydrogels (1,2). In general, 
the ingredients of plant origin are hygroscopic 
and prone to oxidation (1), thus formulation re-
quires careful consideration of their stability with-
in the specifi ed vehicle and under the defi ned 
storage conditions. 
AIMS: The study aimed to develop the HPLC 
method for determination of the GAP content in 
the carbomer based hydrogels.  
RESULTS:  The hydrogel with 1% of GAP was 
prepared by using Carbopol®Ultrez 10 (a gelling 
agent) (0.5%), sodium hydroxide (a neutralizing 
agent) (0.4%), glycerol (a humectant) (10%), Sepi-
cide® HB (a preservative) (1%), and water (up to 
100%). Chemical stability of GAP was evaluated 
by the developed and validated HPLC method. 
The chromatographic conditions were: Hypersil 
C18 150 ´ 4.6 mm, 5 μm, λ=220 nm, column tem-
perature 30°C, fl ow rate 1 mL min-1, and mobile 
phase: acetonitrile - 15 mM CTAB (20:80 v/v), pH 
2.5. Surprisingly, the content of GTP after 3 
months storage under ambiental conditions was 
190.35%. It was observed that although at the end 
of the third month the consistency was thicker 
compared to initial, the sample was homoge-
neous. Moreover, the centrifugation test could not 
indicate the syneresis phenomenon and the results 
of rheological characterization indicated that the 
hydrogel appearance was aﬀ ected by shrinkage 
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due to water evaporation (3). Therefore, the stabil-
ity of the investigated sample concerned satisfac-
tory, while the observed apparent increase in the 
GAP load was related with the decrease of the hy-
drogel mass due to evaporation loss. 
CONCLUSIONS: On the basis of the obtained 
results it has been concluded that the developed 
and validated HPLC method was suitable for 
chemical stability assessment of GAP loaded in 
the  hydrogel type formulations. 
REFERENCES: 
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P1G-1 
Endocannabinoid signalling in migraine
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1 MTA-SE-NAP B Genetic Brain Imaging Migraine 
Research Group, Budapest, Hungary
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Pharmacy, Semmelweis University, Budapest, Hungary
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of Manchester, UK and Manchester Academic Health 
Sciences Centre
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BACKGROUND: At the beginning of the last cen-
tury, the extracts of the Cannabis Indica plant were 
one of the suggested treatment of migraine. This 
branch of the traditional medicine led to discover 
the endogenous cannabimimetic compounds, the 
endocannabinoids.
AIMS: The purpose of this review was to determine 
the relevance of endocannabinoid system (ECS) in the 
evolution of migraine by using scientifi c literature.   
RESULTS:  Previous studies demonstrated the 
location of cannabinoid receptor 1 (CB1) in pain 
processing areas like trigeminal system, periaque-
ductal grey matt er, thalamus and others. In addi-
tion, animal studies reported the infl uence of AEA 
(anandamide), one of the best characterized CB1 
receptor endogenous agonist, on the activation 
and the sensitization process in the trigeminal sys-
tem. Some clinical studies underlie the phsysio-
logical analgesic eﬀ ect of ECs, next to its other 
regulatory roles in stress response regulation, ap-
petite control and motor learning. In addition, re-
duced concentration of AEA was measured in mi-
graineurs’ blood and  increased activity of AEA 
hydrolase and AEA transporter was detected in 
female migraineurs, but not in males. This latt er 
fi nding possibly explain the higher prevalence of 
migraine in women. 
CONCLUSIONS: In patients suﬀ ering from mi-
graine, an edocannabinoid system impairment is 
hypothesized but the exact nature of this is unkwon 
yet. Although, the ECS is an interesting avenue of 
antimigraine drug developement, there is still no 
medication on the market today that regulates ECS. 
ACKNOWLEDGEMENT: The study was 
supported by Hungarian Brain Research Program 
– Grant No. KTIA_NAP_13-2-2015-0001 (MTA-SE-
NAP B Genetic Brain Imaging Migraine Research 
Group) and by the Hungarian Academy of Scienc-
es (MTA-SE Neuropsychopharmacology and Neu-
rochemistry Research Group).
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P1G-2
Biocompatibility investigation of 
pharmaceutical excipients
 NEMES, D.,  PETŐ Á.,  ÚJHELYI Z.,  ARANY P., 
 BÁCSKAY, I .
Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary
BACKGROUND: Liquid pharmaceutical prepara-
tions are vulnerable to microbiological contamina-
tion and thus, must contain a broad-spectrum anti-
microbial agent which can prevent the reproduction 
of microbes, but these compounds have a signifi -
cant cytotoxicity on human cells as well. Addition-
ally it is important, what salt or derivative of the 
specifi c preservative has been used and there are 
other pharmaceutical excipients like surfactants, 
which have their own and synergetic cytotoxic att ri-
butes in diﬀ erent pharmaceutical preparations.
AIMS: Based on these eﬀ ects we aimed to create 
an experiment to determine the biocompatibility 
of preservatives and other excipients which are 
generally used in pharmaceuticals. We both want-
ed to test them on their own and in combinations. 
Also we tested diﬀ erent paraben derivatives, salts 
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of sorbic and salicylic acid to investigate the chem-
ical structures’ eﬀ ect on cell-damage. The other 
tested excipient groups were the thickener poly-
mers and various surface-active agents to observe 
the biocompatibility of a real pharmaceutical com-
pound which contains multiple excipients apart 
from the active substance.
RESULTS: In order to avoid the animal experi-
ments, we used human cell lines of Caco-2 and 
HaCaT. We determined the cytotoxicity with 
MTT-assay and RT-CES. The surfactants greatly 
increased the cytotoxicity of preservatives, but in 
some cases, the thickening agents could decrease 
this eﬀ ect. Also, the diﬀ erent preservative deriva-
tives acted in a diﬀ erent way given on what other 
excipients were in the test system and their disso-
ciations in the given pH values.
CONCLUSIONS: Overall, we can state, that no 
general IC50 value can be measured in case of 
pharmaceutical preservatives. The other compo-
nents of pharmaceuticals, like surfactants and 
thickeners can greatly modify the preservatives’ 
biocompatibility. During formulation, the cytotox-
icity must be assessed and cannot be calculated 
based on previous researches.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.
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Abdominal detection of uterine 
electromyographic signals in pregnant rat: 
strong correlation with mechanical contractions
 SZUCS, K. F.1,  GROSZ, G.2,  SULE, M.,  TISZAI, 
Z.1,  SAMAVATI, R.1,  GASPAR, R.1
1Department of Pharmacodynamics and Biopharmacy, 
University of Szeged, Hungary
2MDE GmbH, Walldorf, Germany
BACKGROUND: Premature labour is the major 
contributor to perinatal mortality and morbidity. 
There is a need for sensitive, reliable method to 
detect and follow the myoelectric activity of the 
pregnant uterus.
AIMS: Our aim was to develop an electromyog-
raphy method for pregnant rat myometrium in 
vivo and to separate them from other smooth 
muscle signals to predict premature contractions 
or other disorders.  
RESULTS:  The frequency of the electric activity 
was characterized by cycle per minute (cpm), the 
magnitude of the activity was described as power 
spectrum density maximum (PsDmax). In anaesthe-
tized rats, the frequency of the pregnant uterine 
activity was found at 1-3cpm that falls within the 
same range than that of caecum.[1]  Oxytocin (1μg/
kg) increased by 25-50%, while terbutaline (50μg/
kg) decreased the PsDmax by 25-40% measured by 
silver thread or subcutaneously placed disk elec-
trodes. We found a strong positive correlation be-
tween the alterations of PsDmax values and the 
strain gauge sensor-detected mechanical contrac-
tions (AUC). The GI specifi c compounds (neostig-
mine-atropine) mainly aﬀ ected the cecal activity, 
while myometrium specifi c drugs (oxytocin-terbu-
taline) infl uenced the myometrial signals only.[2]
CONCLUSIONS: The myoelectric activity of 
pregnant rat myometrium is measurable from the 
abdominal surface and well-characterized by cpm 
value. The PsDmax values express the intensity of 
contractions and refl ect contracting and relaxing 
eﬀ ects in the myometrium.  The overlapping myo-
metrial and cecal myoelectric signals are not sepa-
rable, but they can be distinguished based on their 
diﬀ erent activities and pharmacological respons-
es. Thus the early signs of contractions can be de-
tected and labour can be predicted in a fast and 
sensitive way. 
The work was supported by the project 
PIAC_13-1-2013-0201, National Research, Devel-
opment and Innovation Oﬃ  ce, Hungarian Gov-
ernment.
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P1G-4
Possible connection between heme-
oxygenase-1/CO system and autophagy in 
cardiomyocytes 
GYONGYOSI, A., LEKLI, I ., SZOKE, K., 
CZOMPA, A., TOSAKI, A.
Department of Pharmacology, Faculty of Pharmacy, University 
of Debrecen, Debrecen, Hungary
Several group have demonstrated that separately 
the increased activity of heme-oxygenase-1/CO 
system and autophagy could protect the myocar-
dium against ischemic events. However, it is still 
not clear whether a connection between HO-1/CO 
system and autophagy processes exists in the 
myocardium.
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In the current study we aimed to examine the 
possible connection between the two systems. 
H9c2 cardiomyoblast cells were treated with dif-
ferent dose of hemin or cobalt-protoporphyrin IX 
(CoPPIX) or vehicle (20mM NaOH solution) for 
24-h. After the treatment of the cells cytotoxicity 
was measured by MTT assay. Furthermore, stain-
ing was carried out to determine the alterations in 
cell size. To study the autophagic process CytoID 
staining was carried out and cells were studied by 
fl uorescence microscope. Moreover, Western blot 
analysis was performed to analyse the level of 
HO-1, certain autophagy related proteins and 
apoptosis markers.
We have detected a slight decrement in cell via-
bility in the hemin and CoPPIX treated groups, re-
spectively, which may indicate a toxic eﬀ ect of 
high concentration of heme-oxygenase-1 inducers. 
The cell size did not alter. As it was expected a ro-
bust induction of HO-1 were detected with both of 
inducer. An enhanced number of autophagosome 
were detected by CytoID staining, and elevated 
level of LC3B-II was found in the highest hemin 
and CoPPIX treated groups.
Taken together, our results show that, there is a 
connection between HO-1/CO system and autoph-
agy process, but further experiments needs to be 
carried out to precisely understand the nature of 
the connection. 
Acknowledgments: OTKA PD 111794, ’Nation-
al Excellence Program’: TÁMOP-4.2.4.A/2-11/ 
1-2012-0001, NTP-NFTÖ-16, GINOP-2.3. 2-15-
2016-00043, EFOP-3.6.1-16-2016-00022 „Debrecen 
Venture Catapult” project.
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eﬀ ects of beta-cyclodextrin derivatives on 
intestinal epithelial cells
 RUSZNYÁK, Á.,  MALANGA, M.,  FENYVESI, 
É.,  SZENTE, L.,  VÁRADI, J .,  BÁCSKAY, 
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Debrecen, Debrecen, Hungary
BACKGROUND: Cyclodextrins are widely used 
excipients for increasing water solubility, delivery 
and bioavailability of lipophilic drugs. Using fl uo-
rescent cyclodextrin derivatives we showed previ-
ously, that cyclodextrins are able to enter Caco-2 
intestinal cells by endocytosis, but the diﬀ erent 
fl uorescent labelling have not been compared on 
the same cyclodextrin derivative. On the other 
hand the consequences of the cellular internaliza-
tion of cyclodextrins have not been revealed yet. 
AIMS: Our aim was to compare the cellular in-
ternalization of fl uorescein and rhodamine labeled 
hydroxypropyl (HPBCD) and randomly-methylat-
ed beta-cyclodextrins (RAMEB). We also aimed at 
examining the eﬀ ect of these cyclodextrins on NF-
kappa B pathway and autophagy on Caco-2 cells.    
RESULTS:  Using fl uorescent microscopy and 
fl ow cytometry we tested the endocytosis of the 
fl uorescent cyclodextrins. Both fl uorescein and 
rhodamine labelled derivatives are able to enter 
the intestinal Caco-2 cells by endocytosis in a com-
parable manner. Cooling almost perfectly inhibit-
ed endocytosis, while the application of rott lerin 
inhibited signifi cantly the uptake of cyclodextrins. 
We investigated the possible activation of NF-kap-
pa B pathway, which is important in regulating 
cellular responses. Cyclodextrin pretreatment did 
not activate the translocation of the p65 subunit of 
NF-kappa B heterodimer into cell nuclei both in 
cell monolayers or undiﬀ erentiated cells. After 
HPBCD and RAMEB treatments the presence of 
autophagosomes is detectable on fl uorsecent mi-
croscopic images, similar to control samples.    
CONCLUSIONS: The type of fl uorescent label-
ling does not infl uence the internalization of 
HPBCD and RAMEB cyclodextrin derivatives. 
FITC and rhodamine conjugates showed similar 
intracellular localization. The endocytosis of cy-
clodextrin does not activate NF-kappa B pathway, 
while the examination of autophagy induction re-
quires further quantitative analysis.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.  
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The role of circulating extracellular vesicles on 
human in vitro osteoclastogenesis 
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BACKGROUND: Extracellular vesicles (EV) are 
subcellular sized signalosomes which carry wide 
variety of biomolecules and are present in various 
biological fl uids. Exosomes (EXO), the smallest 
EVs, originate from the endosome. Microvesicles 
(MV) are plasma derived vesicles. EVs may alter 
the recipient cells’ functions and will become nov-
el delivery systems in therapy in the future. 
AIMS: Our objectives were to investigate the 
role of blood-derived EVs on the human in vitro os-
teoclastogenesis and to characterise the serum EV 
profi le of healthy donors, rheumatoid arthritis 
(RA) and psoriatic arthritis (PsA) patients. RA is a 
chronic autoimmune disorder that primarily af-
fects small joints, PsA is a long-term infl ammato-
ry arthritis that occurs in patients with psoriasis.   
RESULTS:  Microvesicles did not alter the num-
ber of mature osteoclasts. By contrast, exosomes 
signifi cantly (p < 0.01) inhibited the osteoclast dif-
ferentiation of the healthy and RA donor-derived 
monocytes in vitro, but not those of the PsA pa-
tients’ monocytes. EXO and MV treated osteoclast 
samples contained less cathepsin K (CTSK) com-
pared to the untreated osteoclast samples, studied 
by Western Blot method. H- and RA-derived 
EXOs expressed signifi cantly more RANK com-
pared to PsA plasma-derived (p <0.05) EXOs mea-
sured by fl ow cytometry. H and RA plasma-de-
rived MVs did not carry RANK in contrast to PsA 
plasma-derived MVs.  
CONCLUSIONS: Our present data suggest that 
EVs profoundly regulate osteoclastogenesis. The 
plasma profi le of EVs is altered in diﬀ erent infl am-
matory arthropathies. 
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BACKGROUND: 3D printing is a modern method 
which can be used in numerous areas for example 
in the industrial pharmacology. With the use of 
3D printing complex and personalized products 
can be made on-demand. The examined implants 
are manufactured at the University of Claude Ber-
nard, Lyon.  
Biocompatibility is a very important question 
through the development because implanted de-
vices must be biologically compatible with the tis-
sues. The aim is to maximalise the benefi t and 
minimize the risk. [1.] 
AIM: Our aim was to determine the biocompat-
ibility of the implants. Biocompatibility can be ex-
amined by biofi lm formation and MTT cell viabili-
ty test.  Another aim is to gain information about 
the structure of the implants. Material structure 
can be examined by PALS (positron annihilation 
lifetime spectroscopy) this results will determine 
the free volume in the implants.   
RESULTS:  Nearly twenty samples were exam-
ined with MTT assay and based on the results all 
of the samples are suitable for further examina-
tions but a cytotoxic ranking can be set up: the 
lowest toxicity in the case of PLA, then PET and 
fi nally PMMA. 
Based on biofi lm formation we can select the 
best implants which are appropriate to further ex-
aminations. A biofi lm formation ranking can be 
set up: lowest in the case of PLA, then PET, diﬀ er-
ent PMMAs, PLA one and two. Nylon is inade-
quate to further examinations.  
PALS method determined the free volume in 
the implants which give us information about the 
further applicability of the samples.  
PLA samples have given the best results and 
this is advantageous because it is a biodegradable 
polymer.  
CONCLUSION: By determining the data and 
analyzing the results information can be provided 
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to the University of Claude Bernard to produce 
the most appropriate implants. Based on this the 
plan can be made for scale enlargement. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.
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Possible connection between the anti-aging 
klotho protein and autophagy
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BACKGROUND: According to the WHO, the average 
age of the population is increasing. Age is considered 
as main risk factor for the common diseases includ-
ing cardiovascular disease and cancer in the devel-
oped countries. Several studies show that autophagy 
plays an important role in aging. Numerous studies 
revealed that autophagy decreases with aging.
AIMS: In this study we have investigated the 
connection between autophagic process and the 
level of klotho protein.  
RESULTS:  To induce the klotho protein aged 
mice were treated with rapamycin. Thereafter the 
organs were isolated. The expression levels of an-
ti-aging klotho protein and autophagic, apoptopic 
proteins such as LC3B-II and p62 were evaluated 
by Western blot. We have noticed decreased lifes-
pan and body weight at the control group com-
pared to mice exposed to rapamycin, where the 
extended lifespan suggests that klotho functions 
as an anti-aging protein. We have investigated 
that the expression level of the klotho increased in 
most of the organs, especially in the kidney. Fur-
thermore, a decreased p62 protein level was found 
in the treated group, which is involved in the reg-
ulation of apoptosis and autophagy. 
CONCLUSIONS: Taken together our results 
suggest that in case of rapamycin induced klotho 
protein autophagy is increasing, which may help 
to reduce damaged protein organelles.  Acknow-
ledgements: OTKA-PD-111794, TÁMOP 4.2.4 A/2-
11-1-2012-0001, GINOP-2.3.2-15-2016- 00043, 
EFOP-3.6.1-16-2016-00022 „Debrecen Venture Cat-
apult” project.  
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Time course of gene expression changes in 
trigeminal neurones and peripheral blood 
mononuclear cells in a rat orofacial pain model
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BACKGROUND: The origin and precise 
pathomechanism of migraine are still being de-
bated. The headache and the referred hyperalgesia 
and allodynia on the face suggests that there is an 
underlying trigeminal nociceptor sensitization. 
Modelling complex mechanisms and symptoms 
accompanying primary headache disorders in an-
imals are challenging, however, a possible ap-
proach to study the mechanisms involved in the 
pain is to adapt infl ammatory pain models to 
the orofacial area.
AIMS: We aimed to investigate gene expression 
changes in trigeminal ganglia (TRG), central tri-
geminal nucleus caudalis (TNC) and peripheral 
blood mononuclear cells (PBMCs) evoked by 
Complete Freund’s Adjuvant (CFA) induced pe-
ripheral infl ammation in rats.    
RESULTS:  253 diﬀ erentially expressed genes 
were found between CFA-treated and contralater-
al TRG samples 7 days after CFA injection. The 
mRNA expression changes of G-protein coupled 
receptor 39 (Gpr39), kisspeptin-1 receptor (Kiss1r), 
Lkaaear1 and Otoraplin were validated. They 
were most upregulated on day 3 in TRGs of the 
CFA-treated side. CFA induced signifi cant orofa-
cial mechanical allodynia in one day with a maxi-
mum on day 3. This correlated with patt erns of 
neuronal (FosB), microglial (Iba1), and astrocyte 
(GFAP) activation markers in both TRG and TNC, 
and surprisingly in PBMCs. In TNCs, gene expres-
sion changes similar to TRGs were observed but 
Kiss1r transcripts were not signifi cantly altered.
CONCLUSIONS: The genes revealed by our 
study may participate in the cascade of events re-
sulting in the sensitization underlying migraine 
headache and the accompanying facial allodynia, 
thus may become potential targets for drug devel-
opment. The fi nding that there are corresponding 
mRNA changes in PBMCs is an intriguing result 
that might lead to the identifi cation of novel bio-
markers.
Support: KTIA_NAP_13-2014-0022, EFOP-
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Altered behavior, learning and memory 
functions in somatostatin receptor subtype 4 
gene-defi cient mice
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BACKGROUND: Somatostatin is an inhibitory 
neuropeptide regulating a variety of functions 
both in the peripheral and central nervous sys-
tems. Our team has previously discovered that 
among its fi ve Gi-protein-coupled receptors, soma-
tostatin receptor subtype 4 (sst4) mediates anti-in-
fl ammatory, analgesic and antidepressant eﬀ ects 
without endocrine actions.
AIMS: The aim of our study was to exam-
ine the role of the sst4 receptor in behaviors 
related to learning and memory processes 
(Y-maze, Open Field, Radial-Arm Maze and 
Novel Object Recognition Test) using gene-
defi cient (sst4-/-) male and female mice, and 
their wild-type (sst4+ /+) counterparts.  
RESULTS:  Female sst4+ /+ mice time spent signif-
icantly longer time in the middle of the OFT than 
their male wild-type counterparts, but the number 
of visited arms and arm combinations in the Y-
maze was not diﬀ erent. Furthermore, they visited, 
repeated and missed signifi cantly more arms, but 
found the same amount of rewards in the RAM, 
and they also spent signifi cantly longer time by 
exploring the novel object in NOR compared to 
male wild-types. Female sst4-/- mice visited and re-
peated less arms in both mazes, but they found 
the same amount of rewards and spent more time 
to explore the novel object in NOR compared to 
their wildtypes. In contrast, male sst4-/- mice found 
signifi cantly less rewards in the RAM and they 
were less interested to explore both objects in the 
NOR compared to their wild-types. 
CONCLUSIONS:  Based on these data, female 
mice showed greater spontaneous locomotor ac-
tivity, less anxiety, worse long-term learning abili-
ty and exploration skills than males. Sst4-defi ciecy 
resulted in faster short-term learning in females, 
but worse exploratory behaviour in both sexes. 
These results suggest that sst4 is an interesing 
complex regulator of behavior and cognitive func-
tions under healthy conditions, but further inves-
tigations are needed to determine its role in mem-
ory defi cits during aging or other pathological 
conditions.
Support: National Brain Research Program B 
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Transfer of Complex Regional Pain Syndrome 
to mice via human autoantibodies is mediated 
by interleukin-1-induced glia cell activation and 
central sensitization
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BACKGROUND: Complex Regional Pain Syn-
drome (CRPS) is a multifactorial disease character-
ized by severe, persistent pain accompanied by ab-
normal hypersensitivity, swelling and autonomic 
alterations of the skin. Although the ethiology is 
unknown, immune response against sensory 
nerve-derived antigens and complex neuro-im-
mune interactions are suggested to be involved in 
the development of this disease.
AIMS: Our aims were to investigate the eﬀ ects 
of the recombinant IL-1 receptor antagonist 
anakinra and corticosteroid prednisolone in the 
novel passive-transfer-trauma CRPS model. Small 
plantar skin-muscle incision to mimic the small in-
jury was performed in female C57Bl/6 mice. Ani-
mals were treated with serum-IgG from CRPS pa-
tients or healthy volunteers. Anakinra or prednis-
olone was also administered, saline-treated 
groups served as controls. The volume of the 
hindpaw was measured by plethysmometry, the 
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mechanonociceptive threshold by dynamic plan-
tar aesthesiometry. The neutrophil/macrophage 
myeloperoxidase (MPO) activity by luminescence 
in vivo imaging, infl ammatory cytokines by im-
munoassays, Iba1 microglia and GFAP astrocyte 
markers by immunochemistry in pain-related 
brain regions.  
RESULTS:  Following CRPS IgG injection we 
measured signifi cantly increased incision-induced 
swelling and MPO activity, but more pronounced 
enhancement and prolongation of hyperalgesia 
was observed compared to healthy IgG. CRPS IgG 
signifi cantly increased the density of both Iba1 
and GFAP immunopositivities. Anakinra treat-
ment abolished the CRPS IgG-evoked increased 
hyperalgesia and glia activation, but not the pe-
ripheral infl ammatory alterations. Prednisolone 
aﬀ ected neither edema nor hyperalgesia, and sur-
prisingly did not infl uence the MPO activity and 
cytokine production.
CONCLUSIONS: These results suggest that 
glia-mediated central sensitization mechanisms 
play a crucial role in the enhanced and prolonged 
hyperalgesia in CRPS. Anakinra is likely to act 
centrally by inhibiting IL-1-mediated neuroin-
fl ammatory pathways and might open new per-
spectives for its use in CRPS as a novel indication. 
KTIA_NAP_13-2014-0022 (PTE-NAP B); Pain Re-
lief Foundation; EFOP-3.6.1-16-2016-00004; GI-
NOP-2.3.2-15-2016-00050 –383 PEPSYS és GI-
NOP-2.3.2 STAY ALIVE 
P1G-12
Evaluation of fibroblast cell growth on 
3D printed polylactic acid based human 
auricular model in the presence of 
cyclosporine and co-enzyme Q10 loaded 
solid lipid nanoparticles 
 YALGIN, A.,  AYDIN, KÖSE, F.,
  GÖKÇE, EH.
Ege University, Faculty of Pharmacy, 
Department of Pharmaceutical Technology, Izmir, Turkey
BACKGROUND: Tissue engineering is an inter-
disciplinary fi eld which applies the principles of 
engineering and the life sciences toward the de-
velopment of biological substitutes [1]. Recently 
3D printing have been successfully used to fabri-
cate complex scaﬀ olds constructions [2]. These 
scaﬀ olds provide structural support as well as 
promoting att achment, proliferation, and diﬀ eren-
tiation with the ultimate goal of yielding function-
al tissues or organs.   
AIMS: The aim of this study was to use a com-
mercial 3D printer and combine them tissue engi-
neering techniques together for developing hu-
man auricular models. For this aim fi broblast cell 
growth on 3D printed PLA based human auricu-
lar model in the presence of cyclosporine and co-
enzyme Q10 loaded solid lipid nanoparticles 
(SLNs) were evaluated. The eﬀ ect on cell prolifer-
ation was investigated.   
RESULTS:  MTT assay was performed by 3T3 
dermal fi broblasts and a signifi cant poliferation 
was seen on 3D printed PLA auricular model.  Af-
ter determining the suitability of PLA, SLNs were 
added in culture media. Addition of nanoparticles 
did now show a cytotoxic eﬀ ect. The combination 
of nanoparticles were also suitable in terms of cy-
totoxicity. 
CONCLUSIONS: In this study it was shown 
that 3D printing, solid lipid nanoparticles and tis-
sue engineering techniques can easily be used to-
gether for human auricular defects.  
REFERENCES: 
1. Vacanti J.P. and Langer R, Lancet, 35, S32-S34 (1999)
2. Hutmacher D.W. et al. Trends in Biotech. 22, 354-362 (2004)
POSTER SECTION 1H 
NATURAL PRODUCTS
P1H-1
Determination and comparison of phenolic 
compounds of medicinal plants and veterinary 
herbal medicines 
 VARGA, E.1,  SCHMIDT, I .2,  SZÖVÉRFI, B.1, 
 FAZAKAS, M.2
1Department of Pharmacognosy and Phytotherapy, University of
Medicine and Pharmacy of Tîrgu Mures, Tîrgu Mureș, Romania
2 S.C. Promedivet S.R.L. Sovata, Romaniaa
BACKGROUND: Phenolic compounds from me-
dicinal plants have several biological eﬀ ects such 
as anti-infl ammatory and antioxidant properties 
which were well-known in phytotherapy and eth-
no-veterinary practices too. 
AIMS: We determined by screening the total 
phenolic and fl avonoid compounds from thirteen 
veterinary products and from fi fteen medicinal 
plants occurred in these products [1,2]. For fl avo-
noids we used the total and C-O glycosides deter-
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mination. The polyphenols and fl avonoids were 
determined by colorimetric methods. For these 
determination we prepared from investigated me-
dicinal plants methanolic, methanol and water 
(1:1), and ethanolic (70°) extracts. The mentioned 
compounds were determined directly from liquid 
veterinary products. 
RESULTS: The total polyphenolic (7 - 54 mg gal-
lic acid equivalent/100 g product and 4 - 44 mg 
gallic acid equivalent/100 g dry weight plant) and 
fl avonoid concentration (5 - 21 mg quercetin 
equivalent/100 g product and 4 - 39 mg quercetin 
equivalent/100 g dry weight plant.) were with 
highest concentration from ethanolic extracts. The 
C-O fl avonoid glycosides concentration showed 
lower value with these colorimetric determination 
(1.1 - 1.7 g hyperoside/100 g product and 1.2 –5.7 g 
hyperoside/100 g dry weight plant). 
CONCLUSIONS: We observed the great variabili-
ty of phenolics and fl avonoids compound. There are 
a wide variety of extraction methods for determina-
tion of phenolics and fl avonoids. The polyphenols 
have the potential to be integrated in these veteri-
nary products and used to promote animal health. 
ACKNOWLEDGEMENTS: The research was 
sup ported by the University of Medicine and 
Pharmacy of Tîrgu Mureș and SC Promedivet 
SRL, internal research grant number 
17972/07.12.2016.
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P1H-2
Antibacterial eﬀ ect of cinnamon bark, clove, 
thyme and peppermint oil against respiratory 
tract pathogens 
 BALÁZS, V. L.1,  ÁCS, K.1,  KOCSIS, B.2, 
 BÖSZÖRMÉNYI, A.3,  KRISCH, J .4, 
 HORVÁTH, GY.1
1Department of Pharmacognosy, Faculty of Pharmacy, 
University of Pécs, Pécs, Hungary
2Department of Medical Microbiology and Immunology, 
Medical School, University of Pécs, Hungary
3Semmelweis University, Faculty of Pharmacy, Institute 
of Pharmacognosy, Budapest, Hungary
4Department of Food Engineering, Faculty of Engineer-
ing, University of Szeged, Hungary
BACKGROUND: Essential oils (EOs) have been 
widely used for medicinal and cosmetic purposes. 
Nowadays in the health care EOs and their com-
ponents are becoming increasingly popular as 
naturally occurring antimicrobial agents.  
AIMS: Thus, the aim of this study was the evalu-
ation of antimicrobial properties of cinnamon bark 
(Cinnamomum verum J. Presl.), clove (Syzygium aro-
maticum (L.) Merr. and Perry), peppermint (Mentha 
x piperita L.), and thyme (Thymus vulgaris L.) EOs 
including their main components against respira-
tory tract pathogens especially Haemophilus infl uen-
zae (DSM 4690) and H. parainfl uenzae (DSM 8978).   
RESULTS:  The chemical composition of the 
EOs was measured with gas chromatography – 
mass spectrometry (GC-MS). Thin-layer chroma-
tography – direct bioautography (TLC-DB) and 
broth dilution (BD) method were used for the in 
vitro detection. In the case of TLC-DB the oils were 
diluted in absolute ethanol (20 mg/mL). An aque-
ous solution of MTT (3-[4,5-dimethyl-thiazol-
2-yl]-2,5-diphenyltetrazolium bromide) was used 
for the visualization of inhibition zones (expressed 
in diameter, mm). Standards of the main compo-
nents were also involved in the experiments. 5% 
emulsion was prepared from each EO with 10% 
solution of Tween 80 for the BD technique. Deter-
gent control was also prepared. All measurements 
were made in triplicate. The minimum inhibitory 
concentration (MIC) and minimum bactericidal 
concentration (MBC) values of the EOs were ex-
pressed in mg/mL. In TLC-DB cinnamon oil (19.5 
mm) and cinnamaldehyde (23 mm) were the most 
active agents against both bacteria. In comparison 
with peppermint oil (8 mm) EOs of thyme and 
clove were more eﬀ ective (11-12.5 mm). In BD as-
say cinnamon bark oil produced the lowest MIC 
value (0.06 mg/mL) which met the results of the 
other in vitro technique. In contrast with the TLC-
DB thyme oil showed bett er activity than clove 
and peppermint in the BD assay. 
CONCLUSIONS: To the best of our knowledge, 
we performed TLC-DB with Haemophilus species 
fi rstly. In our further studies, we are planning to 
extend our research including other pathogens 
and to determine the mode of action of the eﬀ ec-
tive oils in biofi lm-formation method. 
REFERENCES: 
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P1H-3
The antiviral properties of chamomiles on 
lentivirus
 SEPP, J .,  VANKER, M.,  ZUSINAITE, E., 
 KOGERMANN, K.,  HEINÄMÄKI, J .,  RAAL, A.
Institute of Pharmacy, University of Tartu, Estonia 
BACKGROUND: Lentivirus (i. e. HIV) is a genus 
of retroviruses, which are spread worldwide and 
cause serious diseases (i.e. AIDS). German chamo-
mile (Chamomilla recutita (L.) Rauschert) is one of 
the most popular medicinal plants in the world 
and has been used in traditional medicine as an 
antimicrobial, antiseptic, anti-infl ammatory medi-
cine etc. Our previous studies have shown that its 
chemical composition is similar to pineapple weed 
(Chamomilla suaveolens (Pursh) Rydb.).
AIMS: The aim of our study was to analyse the 
antiviral properties of the herbal extracts of the 
two species of chamomiles on HIV-1 based viral 
like particles (VLP) expressing Gaussia luciferase 
(Gluc) as a quantitative reporter.  
RESULTS:  For the experiments, 70% ethanol 
extracts of both chamomiles were prepared. First, 
the maximal noncytotoxic concentrations (dilu-
tions) of the extracts were determined using the 
tetrazolium dye MTT cell viability assay. The anti-
viral properties of chamomiles were analysed us-
ing ViraPower Lentiviral Expression System. 
Herbal extracts were preincubated with the VLPs, 
and were present in the infectious medium during 
the infection time as well as in the growth medi-
um during 48 h after infection. The antiviral eﬀ ect 
was determined by measuring the activity of 
Gaussia luciferase from infected cell lysates, 
which was normalized to the total cellular protein 
concentration. Both chamomiles demonstrated in-
hibitory eﬀ ect on the replication of HIV-1 based 
VLPs. The experiment with serial dilutions of the 
extracts downward of the maximal noncytotoxic 
dilution showed that the inhibitory eﬀ ect is dose-
dependent.
CONCLUSIONS: Both herbal extracts showed 
antiviral properties on HIV-1 based VLPs. Further 
analysis with essential oils and water extracts of 
chamomiles are being carried out at present.
P1H-4
Eﬀ ects of diﬀ erent parameters of herbal tea 
preparation on active compounds
 HORVÁTH, A.,  HORVÁTH, GY.,  BENCSIK, T.
Department of Pharmacognosy, University of Pécs, Pécs, 
Hungary
BACKGROUND: One of the oldest and most pop-
ular methods for preparation of herbal extracts is 
the preparation of a tea. However, some questions 
have arisen: How do diﬀ erent parameters of prep-
aration infl uence the amount of active compounds 
in a tea? Do we prepare our teas correctly today?
AIMS: To answer these questions, we examined 
three commercially available drugs oﬃ  cial in the 
Ph. Eur., namely Silybi mariani fructus, Uvae ursi 
folium, and Rosae pseudofructus.  
RESULTS:  For preparation of water extracts, 
we used three diﬀ erent temperatures and periods 
of time (hot water for 5 min, room temperature for 
2 hours, and room temperature for 10 hours) giv-
en by the manufacturers on the labelling. HPLC 
was used for determination of silybinin, arbutin, 
and hydroquinone contents, and spectrophoto-
metric methods were used for determination of to-
tal tannin and vitamin C contents. As expected, 
nearly no silibinin could be detected in the teas of 
Silybi mariani fructus, and the vitamin C content 
of Rosae pseudofructus was the highest in sam-
ples extracted at room temperature for 10 hours. 
Indeed, the arbutin and hydroquinone content of 
Uvae ursi folium increased with the longer time of 
extraction, but the tannin content (responsible for 
side eﬀ ects) also increased. 
CONCLUSIONS: To sum up, it is surprising 
that Silybi mariani fructus is commercially avail-
able for tea preparation, however, its hepatopro-
tective compounds are not water soluble. Con-
trary to the recommendation, 10-hour soaking is 
not appropriate for Uvae ursi folium, because tan-
nin content will also increase. However, it is well-
known, that the best method for extraction of vita-
min C from Rosae pseudofructus is the soaking 
for several hours at room temperature, most of the 
patients use hot water for 5-10 min in our acceler-
ated lifestyle, thereby reducing the eﬀ ectiveness of 
the therapy.
REFERENCES: 
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P1H-5
Investigation of topical formulations containing 
silybum marianum extract against UVB-
induced oxidative stress in guinea pig and on 
HaCaT keratinocytes
 FEHÉR, P.,  BÁCSKAY, I .,  UJHELYI, Z., 
 VÁRADI, J .,  FENYVESI, F.,  SINKA, D., 
 VASVÁRI, G., VECSERNYÉS, M.
Department of Pharmaceutical Technology, Faculty of 
Pharmacy, University of Debrecen, Hungary
BACKGROUND: Plants with high amounts of an-
tioxidants may be a promising therapy for pre-
venting and curing UV-induced oxidative skin 
damage. The topical application of Silybum mari-
anum extract has been already reported to have 
protective eﬀ ects against UVB-induced skin dam-
age [1]. However, the low solubility and low bio-
availability of silymarin limits extensive topical 
applicability [2]. Diﬀ erent compositions of silyma-
rin creams were formulated and the diﬀ usion of 
active substance was determined with Franz dif-
fusion cell. Antioxidant enzyme activities (gluta-
thione peroxidase, GPX; superoxide dismutase, 
SOD; catalase, CAT) were determined, lipid per-
oxidase tests were also performed and heme-oxy-
genase (HO-1) enzyme activity was measured on 
HaCaT keratinocytes and in skin tissue of guinea 
pigs in the pre and post-treatment of silymarin 
creams against UVB irradiation. 
AIMS: The aim of the present study was to de-
sign new hydrophilic topical formulations con-
taining Silybum marianum extract and to show 
the antioxidant activity of creams against UV-in-
duced oxidative stress in guinea pig model and 
HaCaT cells.  
RESULTS:  The results of in vitro membrane 
diﬀ usion studies justifi ed that Transcutol – which 
also helped in the dissolution of silymarin pow-
der- with sugar-ester type emulgents elevated the 
amount of active substance across the diﬀ usion 
membrane. The pre and post-treatment of creams 
containing silymarin powder in dissolved form 
showed suﬃ  cient antioxidant activity against UV-
induced oxidative stress in guinea pig model and 
HaCaT cells. 
CONCLUSIONS: Signifi cance of post-treatment 
is outstanding because silymarin creams may pro-
vide potential therapy against skin damages.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.  
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P1H-6
New perspectives on the antiaging 
dermocosmetic use of Salvia oﬃ  cinalis volatile 
oil 
 ANDREI, F.,  DRAGOMIRESCU, A.,  ALEXA, E.
Departement I, Faculty of Pharmacy, University of Medicine 
and Pharmacy, Timisoara, Romania
BACKGROUND: Reserchers`  eﬀ orts to fi nd active 
anti-aging substances focus on accepted and de-
sirable species of plants, although synthetic pep-
tides may be more targeted in this regard. Salvia 
oﬃ  cinalis is not only known in pharmacognosy 
but also recently researched as a colagen-synte-
tisuing and antiglycation species. In theory, block-
ing the dermal collagen glycation would provide 
elasticity and youthfulness to the skin.
AIMS: The study ainm s to evaluate by corne-
ometry, in vivo, on volunteers, the antiaging eﬀ ect 
of a pharmaceutical form for cutaneouse use con-
taining Salvia oﬃ  cinalis oil  
RESULTS:  The values obtained in corneometry, 
separately for photoaging and chronoaging, were 
statistically processsed with the StatPad applica-
tion. Analyzing the dispersion diagrams and the 
values of the correlation coeﬃ  ceients, it can be 
concluded that the use of the preparated creams 
containing Salvia oﬃ  cinalis oil leads to an increase 
in the hydration degree both in the cases of chro-
noaging and in the cases of photoaging as com-
pared to the whitness sample. In both situations 
there is a substantial improvement in the hydra-
tion of the skin. This confi rms also the traditional 
use of sage oil for beauty and skin rejuvenation in 
certain geographic regions. 
CONCLUSIONS: The encouraging results of 
this research deserve to be continued with cutom-
etry and skin-visiometry
REFERENCES: 
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P1H-7
Extraction, purifi cation and cristallisation of 
rebaudioside A, a sweetener from Algerian 
culitvated Stevia rebaudiana 
 BOUTRAA, W.,  BELKACEM, S.,  TOUBANE, A., 
 KORTEBY, Y.,  DAOUD, K.
Department of environmental engineering, Facutly of 
mechanical and process engineering, University of Science and 
Technology Houari Boumediene, Algiers, Algeria
BACKGROUND:  Diabete by its constant increase 
became the century desease, in Algeria mostly 12 
% of the population is touched by this plague. it is 
important for patient to be able to use medicines 
and beverages with a sweet taste but without any 
health risk. By cultivating Stevia rebaudiana, a 
sweet plant form Paraguay in Algeria, the sweet-
ener rebaudioside A could be obtained and acces-
sible for the common patient.   
AIMS: The Aim of this study is to optimize the 
extraction process (infusion) of rebaudioside A 
from Stevia rebaudiana cultivated in Algeria for 
pharmaceutical purpose.  
RESULTS:  the main factor that enhance extrac-
tion yield has been isolated and was identifi ed as 
the extraction temperature, among 3 temperatures 
the highest one (80°C) has shown the most eﬀ ec-
tive extraction with an extraction yield of 19%.  by 
using a purifi cation method that combine the use 
of calcium hydroxide and ion exchange chroma-
tography, we noticed a decrease in the total yield 
of extraction (4%) but with a product with a high-
er purity in rebaudioside A. to increase the purity 
of the isolated rebaudioside A, solvent cristallisa-
tion was performed using ethanol allowing to ob-
tain rebaudioside A cristals. the obtained products 
after extraction, ,purifi cation and cristallisation 
were characterized using microscopy, thin  layer 
chromatography and infrared spectroscopy, the 
results of both analyses compared to the reference 
products results have shown the sucess of the ex-
traction of rebaudioside A. 
CONCLUSIONS: this study has allowed to op-
timize the extraction of rebaudiosides by under-
standing the factors infl uencing the process. The 
product obtained and characterized  after purifi -
cation and cristallisation was Rebaudioside A the 
most powerful sweetener present in Stevia, this 
product could be presented as a good excipient 
for the preparation of liquid and suspension for-
mulations for diabetic patients.   
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P1H-8
Eﬀ ects of Prunus spinosa L. fruits on 
experimental wound healing
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BACKGROUND: A variety of medications and tra-
ditional approaches are used to improve the pro-
cess of wound healing. Prunus Spinosa L (Rosace-
ae) is a therapeutic plant known since the ancient 
times. Extracts from the fl owers  have been used 
as diuretic, anti-infl ammatory, spasmolitic and 
‘’blood cleansing’’ agents (1).
AIMS: We investigated the wound healing eﬃ  -
cacy of the Prunus Spinosa L. using an excisional 
cutaneous wound model in mice. For this purpose 
methanol extracts of fruits prepared.
RESULTS: We used 32 number C57/Black mice 
in total; equally divided into four groups. The fi rst 
group was set to be the control group to which we 
applied sunfl ower oil (Sunfl ower oil is known by 
its characteristic of being ineﬀ ective to the wound 
healing (reference molecule)). The second group 
was the vehicle group to which we applied glycer-
in and the third group was the Prunus spinosa L 
(Medicine) group. Lastly, the fourth group was 
named “Madecassol Group” to which we applied 
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a medical cream called Madecassol. The molecules 
were applied on the excisional wounds made on 
the back of the mice in all groups and the wound 
tissues were duly photographed. Through the in-
spection of the photographs taken, wound healing 
rates were calculated in digital measurement pro-
grams. Later, the wounded areas were cut out for 
fi xation, and the tissues were embedded in paraf-
fi n. Hematoxylin-eosin (HE) and immunohisto-
chemical (collagen type I, TGF β) staining and 
scoring were performed on fi ve μm thickness sec-
tions taken from the tissues. Tissue sections were 
evaluated for histopathology. Wound healing was 
scored based on epidermal regeneration, granula-
tion tissue thickness and angiogenesis (2). Less 
epidermal and dermal regeneration, medium-
dense granular tissue, four to fi ve veins in each 
section were observed in the control and vehicle 
group. For Madecassol and Medicine Group, we 
observed complete epidermal and dermal regen-
eration, dense granular tissue and more than sev-
en veins in each section. In the immunohistochem-
ical scoring, a few staining was observed in some 
of collagen 1, TGF β preparations of the control 
and vehicle groups. In those groups there were 
also some preparations which showed no stain-
ing. In the Medicine group, we observed statisti-
cally signifi cant increase in staining similar to our 
observations in Madecassol Group. 
CONCLUSIONS: Our fi ndings support the ben-
efi cial eﬀ ects of Prunus Spinosa L. for augmenting 
wound healing. The anti-infl ammatory activities 
of Prunus Spinosa L. increased collagen synthesis 
whereas the number of infl ammatory cells during 
wound healing was reduced and Prunus Spinosa L. 
may be benefi cial for treating skin wounds.
Keywords: Wound, healing, Prunus Spinosa L.
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POSTER SECTION 2A 
 NOVEL DELIVERY SYSTEMS 2
P2A-1 
Investigation of lidocaine base liposomes for 
transdermal delivery 
 BAKONYI, M.,  BERKÓ, SZ.,  CSÁNYI, E. 
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary 
 
BACKGROUND: Nowadays there is an increasing 
interest in new, nanostructured delivery systems 
for local anesthetics, especially for dermal applica-
tion because of its painless and easy application 
without the risk of systemic side eﬀ ects. Lipo-
somes are safe and eﬀ ective drug carriers for topi-
cal delivery of drugs oﬀ ering several advantages 
like biocompatibility, low toxicity, penetration en-
hancement of active ingredients and localization 
of the drug at the site of action. 
AIMS: The aim of this work was to formulate 
and evaluate liposome formulations containing 
0-10% w/w lidocaine. Large multilamellar vesi-
cles composed of 1,2-dimyristoyl-sn-glycero-
3-phosphocholine were prepared with the dry 
fi lm hydration method and investigated in terms 
of particle size, polydispersity index, zeta poten-
tial, encapsulation eﬃ  ciency and thermotropic 
behavior.   
RESULTS:  Particle size of the liposomes were 
in the range of 1844± 562.9 nm and 4842± 275.57 
nm, growing with increasing drug concentration. 
Polydispersity index represented heterogenous 
populations (0.279± 0.25 to 1.000± 0.00). Zeta-po-
tential value was barely infl uenced by the pres-
ence of the drug and altered around 0 mV. The de-
termination of encapsulation eﬃ  ciency with ultra-
centrifugation method, measuring the lidocaine 
content of the resuspended pellet, resulted 3.5-
10.1 % encapsulation eﬃ  ciency. DSC measure-
ments confi rmed the presence of lidocaine in the 
lipid bilayer of liposomes, as the main transition 
temperature of the liposomes shifted to lower 
temperature with the increasing drug concentra-
tion. 
CONCLUSIONS: We successfully developed 
and characterized a liposome encapsulated lido-
caine system, which could be a promising formu-
lation for topical administration, however, further 
investigations are needed the evaluate the eﬃ  cien-
cy of the product.  
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P2A-2
Characterization of prednisolone containing 
eye drop formulations by mucoadhesive – 
preservative system and cyclodextrin inclusion 
complex formation 
 BÍRÓ, T.,  HORVÁT, G.,  BUDAI-SZŰCS, M., 
 URBÁN, E.,  CSÁNYI, E.,  SZABÓ-RÉVÉSZ, P., 
 CSÓKA, I .,  AIGNER, Z.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: Topical administration of eye 
drops is restricted by the refl ex mechanisms and 
complex structure of the eye. In the treatment of 
several ocular infl ammations the applied, cortico-
steroid containing products are suspension formu-
lations, which have low bioavailability therefore 
more frequent application is needed [1]. To reach 
the microbiological stability, the most commonly 
used preservative is benzalkonium-chloride, 
which cornea-cell apoptosis and irritation induc-
ing eﬀ ects are known [2]. These unfavorable att ri-
butes result the decrease of the patient-compliance. 
Considering these facts, development of eye drop 
formulations with increased eﬃ  ciency and antimi-
crobial stability is necessary in the ocular therapy.
AIMS: Our aim was to develop and investigate a 
water-soluble prednisolone containing ophthalmic 
product by cyclodextrin inclusion complex formation, 
and mucoadhesive, preservative zinc-hyaluronate.  
RESULTS:  To solubilize the prednisolone the 
range of optimal cyclodextrin concentration was 
determined by phase-solubility test. The formula-
tions contained the prednisolone in water-soluble 
condition. The concentrations of cyclodextrins 
were set which induce increased in vitro penetra-
tion of drug through semi-permeable membrane. 
The measured viscosity and surface tension were 
on the acceptable level. All formulations have mu-
coadhesive properties, signifi cantly higher adhe-
sive force was measured by tensile-test at the zinc-
hyaluronate containing products. The microbio-
logical stability of zinc-hyaluronate containing eye 
drops was suﬃ  cient according to the require-
ments of European Pharmacopoeia.
CONCLUSIONS: Water-soluble prednisolone 
containing, mucoadhesive, properly preserved 
eye drops were formulated with increased in vitro 
penetration. These innovative products could be 
appropriate in the treatment of infl ammatory dis-
eases of eye.
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P2A-3
Printing and characterization of antiviral and 
anticancer drug loaded fi lm formulation by 
using inkjet printer
 VARAN, C.,  SEN, M.,  SANDLER, N.,  AKTAS, Y., 
 BILENSOY, E. 
Department of Nanotechnology and Nanomedicine, Hacett epe 
University, Ankara, Turkey
BACKGROUND: Research in the fi eld of personal-
ized medicine has been increasing every year. 
There is a need for new drugs developed with 
personalized medicine approach for the treatment 
of diseases such as cancer with high intrasubject 
variability. Inkjet printing technique is promising 
for the development of personalized drugs with 
appropriate dose and patt ern [1].
AIMS: The aim of this study was to prepare and 
characterize anticancer and antiviral drugs print-
ed fi lm formulation for the treatment of cervical 
cancer. Two diﬀ erent water-based ink formula-
tions containing anticancer or antiviral drug were 
developed and printed on hydroxypropyl cellu-
lose fi lm with appropriate dose and patt ern.  
RESULTS:  Diﬀ erent water-based ink formula-
tions containing anticancer-cyclodextrin complex 
or antiviral drug bound to nanoparticles were suc-
cessfully developed and printed on hydroxypro-
pyl cellulose fi lm with appropriate dose and pat-
tern. Drug amount and release profi le of fi lm for-
mulations were determined. Complete release of 
the anticancer drugs was reached within a period 
of 8h and the antiviral drug was reached within 
16h. Mechanical properties and in vitro cell cul-
ture studies were performed for determination of 
the safety, eﬃ  cacy and stability  of fi lms 
CONCLUSIONS: This study showed that inkjet 
printing technique is favorable for the develop-
ment of antiviral or anticancer drug-loaded per-
sonalized fi lm formulations. Developed fi lm seem 
to be a potential drug delivery system and good 
candidate for the treatment of cervical cancer. (Ac-
knowledgement: Financial support by TUBITAK 
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P2A-4
Formulation and study of fl uoxetine containing 
mucoadhesive fi lms
 REBEKA, T.,  SZABÓ, Z. I .,  RÉDAI, E.,  SIPOS, E.
Department of Pharmaceutical Industry and Management, 
University of Medicine and Pharmacy Tirgu Mures, Tirgu 
Mures, Romania
BACKGROUND: Considering that orally adminis-
trated fl uoxetine hydrochloride is mainly metabo-
lised by the liver, its bioavailability may be im-
proved by embedding into muco-bioadhesive 
pharmaceutical forms. 
AIMS: The main objective of this work was the 
formulation of buccal mucoadhesive fi lm contain-
ing fl uoxetine hydrochloride, using diﬀ erent poly-
mers in 5% concentrations. The eﬀ ect of polymer 
type on the properties of fi lms was also studied.    
RESULTS:  Three fi lms were formulated: the fi rst 
one containing only sodium-alginate, the second 
sodium-alginate and carboxymethylcellulose sodi-
um and the third one sodium-alginate, carboxy-
methylcellulose sodium and Carbopol 940. Each 
fi lm contained 100 mg fl uoxetine. The fi lm were 
prepared by solvent casting method. The diameters 
and weight was measured. Polymer type does not 
infl uence the diameter, but infl uences weight. 
Films containing only sodium-alginate possess the 
lowest weight, followed by those with combination 
two polymers. Results of drug content indicate ho-
mogenous dispersion of fl uoxetine in the fi lms, but 
concentrations vary depending on the polymer 
type. Highest values of swelling index and adhe-
sive force were shown by fi lms containing all three 
polymers. Dissolution curves demonstrate above 
90 % of liberated fl uoxetine in all cases, although 
diﬀ erences may be observed among formulations.    
CONCLUSIONS: Films containing three poly-
mers present proper physical properties and after 
5 minutes the dissolved amount of fl uoxetine is 
73%. In conclusion mucoadhesive fi lms with 
fl uoxetine hydrochloride containing sodium-algi-
nate, carboxymethylcellulose sodium and Carbo-
pol 940 may be used in clinical trials in order to 
develop a new pharmaceutical forms for the treat-
ment of depression. 
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P2A-5
 Cross-linked chitosan microspheres for 
sustained nasal delivery of doxylamine and 
pyridoxine 
 KATSAROV, P.,  PILICHEVA, B., 
 GEORGIEVA, Y.,  KASSAROVA, M.
Department of Pharmaceutical sciences, Faculty of Pharmacy, 
Medical University-Plovdiv, Plovdiv, Bulgaria
High-technological Center of Emergency Medicine, Plovdiv, Bulgaria
BACKGROUND: Spray-dried chitosan micro-
spheres loaded with the drug combination of dox-
ylamine succinate (DOX) and pyridoxine hydro-
chloride (PYR), intended for nasal delivery, were 
formulated in our previous study (1). The in vitro 
release of both drugs was fast, accompanied by an 
intensive burst eﬀ ect, which imposed further opti-
mizations of the particles release characteristics.
AIMS: The aim of the current study was to 
modify the polymer carrier by cross-linking the 
chitosan structure with glutaraldehyde before 
spray-drying in order to obtain microspheres with 
prolonged release of DOX and PYR.    
RESULTS: Three cross-linked drug-loaded 
models were formulated via spray-drying using 
diﬀ erent concentrations of glutaraldehyde (0.01, 
0.05 and 0.10 % w/v). The obtained microparticles 
were spherical in shape, with appropriate for na-
sal administration size (median diameter: 4.03 – 
4.10 μm) and high drug entrapment eﬃ  ciency 
(DEE: 82.24 – 93.14%). Only a slight decrease of 
the particle size and DEE was observed after the 
polymer cross-linking. With increasing the 
amount of the cross-linking agent both the swell-
ing capacity of the carrier and the drug release 
rate were decreased. The cross-linked particles 
showed substantially reduced initial burst eﬀ ect 
and prolonged release of DOX and PYR within 5h.
CONCLUSIONS: The cross-linking agent glu-
taraldehyde has a great infl uence on the swelling 
and drug release behavior of the spray-dried chi-
tosan microspheres. The formulated cross-linked 
particles oﬀ er sustained release of the drug combi-
nation doxylamine/pyridoxine and could there-
fore be a promising drug delivery system.  
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P2A-6
Microencapsulation of lavender essential oil 
via spray drying technique using chitosan and 
acacia gum as wall materials 
 PILICHEVA, B.,  KATSAROV, P., 
 GEORGIEVA, Y.,  KASSAROVA, M.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, 
Medical University-Plovdiv, Plovdiv, Bulgaria
Technological Center for Emergency Medicine, Plovdiv, Bulgaria
BACKGROUND: Lavender oil is an essential oil 
that has been widely used in food and aromather-
apy. It has a variety of cosmetic applications as 
well as therapeutic purposes in herbal medicine. 
Emulsifi cation and further microencapsulation of 
lavender oil is a reliable approach for the enhance-
ment of its stability in terms of oxidation, chemi-
cal interactions, or volatilization. The determina-
tion of the hydrophilic-lipophilic balance (HLB) 
value of lavender oil appears as a crucial step for 
the development of stable emulsions, which is a 
prerequisite for the eﬃ  cient oil encapsulation. 
AIMS: Evaluation of optimum HLB value for 
lavender oil was the primary aim of the present 
study. Furthermore, optimization of spray drying 
parameters for lavender oil encapsulation in dif-
ferent encapsulating agents was pursued.  
RESULTS:  A series of emulsions with varied 
HLB values (8÷12) were developed and the stabili-
ty of the formulated coarse disperse systems was 
evaluated in terms of droplet size distribution, de-
gree of creaming, eﬀ ect of centrifugation and tur-
bidimetry. According to the results, HLB=10 was 
selected as optimum for the development of emul-
sions of satisfactory thermodynamic stability. The 
formulated emulsions were further spray dried 
and the obtained powders were characterized in 
terms of particle size distribution and oil encapsu-
lation eﬃ  ciency. The infl uence of wall material 
type and concentration, as well as polymer/laven-
der oil ratio were evaluated. 
CONCLUSIONS: The assessed characteristics 
of the microcapsules were slightly infl uenced by 
the polymer/oil ratio. A major trend towards in-
creased encapsulation eﬃ  ciency was noted when 
higher polymer concentrations were used. Both 
wall materials appeared to be relevant for micro-
encapsulation of lavender essential oil.
REFERENCES: 
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P2A-7
Biotin and glutathione targeting of solid 
nanoparticles to cross human brain endothelial 
cells
 MÉSZÁROS, M.,  KISS, L.,  KÓTA, Z.,  PÁLI, T., 
 HOYK, ZS.,  BOZSÓ, ZS.,  FÜLÖP, L.,  DELI, 
MA.,  VESZELKA, SZ.
Institute of Biophysics, Biological Research Centre of the HAS, 
Szeged, Hungary
BACKGROUND: Pharmaceutical treatment of dis-
ease of the central nervous system is far from sat-
isfactory due to the poor penetration of therapeu-
tic drugs to the brain (1). Ligands of endogenous 
transporters of the blood-brain barrier (BBB), the 
major obstacle to prevent potential neuropharma-
ceuticals, can be used as targeting vectors for 
brain delivery of drugs encapsulated in nanopar-
ticles (2).  
AIMS: We tested biotin-labeled solid nanoparti-
cles for the fi rst time and compared to glutathi-
one-labeled nanoparticles in brain endothelial 
cells.  
RESULTS: Neutravidin coated fl uorescent 
polystyrene nanoparticles were derivatized with 
biotin and biotinylated glutathione. Cell viabili-
ty by MTT-test, uptake and transfer of the 
nanoparticles across hCMEC/D3 human brain 
endothelial monolayers were measured. The up-
take of the nanoparticles was visualized by con-
focal microscopy. The tested nanoparticles 
caused no change in cell viability. The uptake of 
biotin- and glutathione-labeled nanoparticles by 
brain endothelial cells was time-dependent and 
signifi cantly higher compared to non-labeled 
nanoparticles. The uptake was verifi ed by mi-
croscopy, targeted nanoparticles could be dem-
onstrated in hCMEC/D3 cells.The penetration of 
the glutathione-labeled nanoparticles across the 
endothelial monolayer was higher than the bio-
tin-targeted ones.  
CONCLUSIONS: : Biotin as a ligand increased 
the uptake and the transfer of nanoparticles across 
brain endothelial cells. Glutathione was more ef-
fective as a ligand to increase nanoparticle perme-
ability through endothelial monolayers support-
ing its use as a brain targeting vector. 
REFERENCES: 
1. Pardridge WM.  Expert Opin Drug Deliv 7, 963-75 (2016)
2. Rip J. et al. J Drug Target 5, 460-467 (2014)
ACTA-1703-BBBB.indb   180 9/19/17   6:28 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters 181
P2A-8
Targeted delivery of vesicular nanoparticles 
across a culture model of the blood-brain barrier 
 PORKOLÁB, G.,  MÉSZÁROS, M.,  KÓTA, 
Z.,  PÁLI, T.,  BOZSÓ, ZS.,  PILBAT, AM., 
 TÖRÖK, ZS.,  SZABÓ-RÉVÉSZ P.,  DELI, MA., 
 VESZELKA, SZ.
Institute of Biophysics, Biological Research Centre of the HAS, 
Szeged, Hungary
BACKGROUND: Eﬃ  cient drug delivery across 
central nervous system (CNS) barriers is a central 
problem in pharmaceutical treatment of neurolog-
ical diseases (1). Most pharmaceutical drug candi-
dates including hydrophilic molecules, biophar-
maceuticals, and eﬄ  ux transporter ligands have a 
low permeability across the blood-brain barrier. 
Targeted nanoparticles are new tools to increase 
drug delivery to brain (2).
AIMS: The aim of our study was to compare 
diﬀ erent ligands of transporters present at the 
blood-brain barrier for targeting vesicular nano-
particles.    
RESULTS:  Non-ionic surfactant and cholesterol 
based nanoparticles, so-called niosomes were de-
rivatized with glucopyranose, alanin and glutathi-
onen using lipid or PEG linkers. The cargo of the 
niosomes was Evans blue-albumin complex. 
Treatments with niosomes did not infl uence the 
viability of primary rat brain endothelial cells. The 
presence of targeting ligands on niosomes in-
creased the uptake of the cargo molecule in cul-
tured brain endothelial cells. The cellular uptake 
of niosomes was temperature dependent and 
could be decreased with a metabolic inhibitor in-
dicating an active transport process. Targeting li-
gands elevated the permeability of the cargo 
across brain endothelial monolayers.Treatment 
with niosomes increased plasma membrane fl uid-
ity in endothelial cells, suggesting the fusion of 
the nanovesicles with the cell membranes. 
CONCLUSIONS: Our data indicate that nutri-
ent transporter ligands can potentially be exploit-
ed for CNS targeting of nanoparticles.
REFERENCES: 
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P2A-9
Dexpanthenol/PCL nanofi bers for 
wound healing: Preparation and in-vitro 
characterization 
 TUNCAY TANRIVERDI, S.,  SUAT, B., 
 AZIZOĞLU, E.,  OZER, O.
Ege University,Department of Pharamceutical Technology, 
Izmir, Turkey
BACKGROUND: Dexpanthenol (DEX) has been 
widely used to treat mucous membrane lesions 
and skin wounds in traditional formulations (1). 
The nanofi ber mat covers the wounded area, pro-
tects the damaged skin and stimulates wound 
healing process by active agents (2). 
AIMS: In this work, DEX loaded PCL nanofi -
ber mats was prepared for the fi rst time.  The 
formulations were characterized by microscopic 
observations, measurement of thickness of nano-
fi ber mats. FT-IR analyses of formualtions were 
performed. Mechanical properties, swelling abil-
ity, loading capacity were investigated. In-vitro 
release behavior was studied with dialysis bags.  
RESULTS:  In this work, DEX loaded PCL nano-
fi ber mats was prepared for the fi rst time.  The for-
mulations were characterized by microscopic ob-
servations, measurement of thickness of nanofi ber 
mats. FT-IR analyses of formualtions were per-
formed. Mechanical properties, swelling ability, 
loading capacity were investigated. In-vitro re-
lease behavior was studied with dialysis bags.
CONCLUSIONS: DEX loaded PCL nanofi ber 
formulation was prepared successfully with suit-
able properties for topical application.
REFERENCES: 
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P2A-10
Development of inkjet printed 
levothyroxine formulations - towards 
personalized dosing
 WICKSTRÖM, H.1,2,  DE BEER, T.2, 
 SANDLER, N.1
1Pharmaceutical Sciences Laboratory, Åbo Akademi University, Åbo, Finland
2Laboratory of PAT, Ghent University, Ghent, Belgium
BACKGROUND: The advantages of digital print-
ing are well translated to the emerging trend of 
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personalized medicine in the pharmaceutical 
fi eld. Inkjet printing technology has shown to al-
low rapid, accurate and fl exible deposition of drug 
containing ink onto edible substrates. However, in 
depth understanding about formulation develop-
ment and production is still needed. 
AIM: The purpose of the study was to develop 
an ink formulation with levothyroxine (T4) and to 
print escalating doses onto a bilayered edible sub-
strate. Furthermore, dose repeatability of two par-
allel batches and the stability of the printed formu-
lations were evaluated at long-term (25°C, RH 60%) 
and accelerated (40°C, RH 75%) storage conditions.  
RESULTS: Stable drop formation, a prerequi-
site for dose uniformity, was demonstrated for 
the T4 (20 mg/ml) ink formulation having DMSO 
and propylene glycol (PG) as solvents. Thera-
peutic doses of T4 (40-590 μg) were prepared by 
printing two dose escalation sets with resolu-
tions of 200 and 400 dpi.  The doses were quanti-
fi ed by HPLC. Dose repeatability was studied 
for the 400 dpi samples and RSD of <4.1% was 
calculated for the parallel batches. Drug degra-
dation was evident for the T4 doses after 6 
weeks. The ink component PG contributed to 
prolonged drying times and therefore degrada-
tion of the drug.
CONCLUSIONS: Therapeutically relevant 
doses were printed. Remarkable drug degrada-
tion was observed between doses stored at dif-
ferent storage conditions. The viscosity increas-
ing agent, PG, contributed to prolonged drying. 
It would appear that the PG-% should be de-
creased or replaced in the ink formulation and 
more eﬃ  cient drying should be implemented to 
improve the stability of the printed drug deliv-
ery systems.
P2A-11
Brinzolamide microemulsions as alternative 
carriers against glaucoma disease
 SIAFAKA, P.,  ÜSTÜNDAĞ OKUR, N.
Department of Pharmaceutical Tecnology, Istanbul Medipol 
University,Beykoz, Istanbul, Turkey 
BACKGROUND: Glaucoma, is the second leading 
cause of the optic nerve damage and vision loss, 
internationally [1]. The main therapeutic agents of 
glaucoma are b-adrenergic blockers such as ateno-
lol, butanolol etc as well as carbonic anhydrase in-
hibitors. Brinzolamide, a carbonic anhydrase in-
hibitor lowers the intraocular pressure found in 
glaucoma but its low solubility limited its phar-
macological action. In addition to this, the fact 
that ocular concentional drug delivery systems re-
sults in poor bioavailability given  the lacrimal se-
cretion and nasolacrimal drainage of the eye leads 
the researchers to design novel ocular carriers 
such as microemulsions [2].  
AIMS: The aim of this work was the preparation 
of novel oil-in-water micromemulsions containing 
three diﬀ erent concentrations of Brinzolamide (0,2, 
0,5, 1% w/v). Pseudo-ternary phase diagrams were 
constructed for combination of isopropyl myristate 
as oil phase, Tween 80, Cremophor EL and Span 20 
as surfactants, ethanol as co-surfactant and dis-
tilled water as aqueous phase.  The drug was add-
ed to the oil phase and mixed vigorously. The 
properties of microemulsions, such as stability, FT-
IR spectrum, pH  in the absence or presence of 
Brinzolamide were evaluated. In vitro release stud-
ies were performed using simulated organic tears 
and the release time was 24 h.   
RESULTS:  In vitro release exhibited diﬀ erent 
release patt erns which diﬀ erentiated by the 
concentration of the drug as well as excipients 
presence. FT-IR spectroscopy studies showed 
that the microemulsions present some possible 
interactions which induced the enhanced re-
lease of brinzolamide. In further, pH values of 
the prepared microemulsions ranged between 
6.2-7 which are acceptable. Stability studies in 
terms of clarity and separation were found 
promising.   
CONCLUSIONS: In conclusion, Brinzolamide mi-
croemulsions were succcessfully developed and found 
to be an alternative option for glaucoma treatment.
REFERENCES: 
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P2A-12
Development of alginate microspheres 
containing essential oils microemulsions: Laser 
diﬀ ractometry characterization and loading 
capacity optimization by response surface 
methodology.
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 MANCER, D.1,  KORTEBY, Y.1,  NASRALLAH, N.1
1Laboratory of Reaction Engineering Faculty of Mechanical and 
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BACKGROUND: Due to the their multitude bioac-
tivities, the formulation of plant biomolecules, 
such as plant extracts and essential oils (EO), has 
been highly studied for a lot oﬀ  applications, from 
food fl avor industry to phytopharmaceutical and 
cosmeceutical applications; In aims of drug re-
lease control as response to several inductions, 
and also to bioactivities enhancing, Ionic Gelation 
(IG), a chemical method,  highly recommended for 
the encapsumlation of hydrophobic bioactive 
agents such as EO.
AIMS: To obtain small particles size allowing 
high drug loading capacity, the studied EO was, 
fi rstly formulated on microemulsion, then, sec-
ondly microencapsulated using biodegradable 
polymer; The Response Surface Methodology was 
applied to investigate fourth experimental param-
eters (polymer concentration, cross-linking agent 
concentration, mixing time and mixing velocity), 
considering multiple responses which are the 
loading capacity of the obtained microsphers and 
their related surface/volume parameters.   
RESULTS: The physical characteristics of the mi-
crospheres were assessed by laser diﬀ ractometry 
(Mastersizer 2000 Ver. 5.60, Malvern Instruments 
Ltd) and calculated on the basis of surface/ volume 
related parameters: Specifi c Surface Area, D[3,2] 
and D[4,3]. Also, Scatt ering Electronic Microscopy 
(SEM) observations were used to visualize the 
manner that the essential oil is microencapsulated.
The selected optimal conditions allow to mic-
roparticles with Specifi c Surface Area from 0.011 
to 10,1 m²/g; a mean Surface Weight with a range 
of 0.595 to 547.735 μm and a mean Volume Weight 
from 5.392 to 714.263 μm. The loading capacity of 
4,95 to 15,19% was allowed. The SEM observations 
showed that the studied EO was loaded according 
to the matrix solution system.
CONCLUSIONS: In conclusion, it is demon-
strated that EO microemulsions can be microen-
capsulated under alginate microspheres with ac-
ceptable particles size characteristics and an inter-
esting loading capacity for these volatile natural 
products.
REFERENCES:
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P2A-13
Assessment of etofenamate loaded 
microemulsion formulations for transdermal 
drug delivery: preparation, characterization, 
stability and in vitro release 
 ÜSTÜNDAĞ OKUR, N.,  ONAY, E.
Istanbul Medipol University School of Pharmacy Department of 
Pharmaceutical Technology, Istanbul/Turkey
BACKGROUND: Transdermal drug delivery sys-
tem was designed to sustain the release and im-
prove the bioavailability of drug and patient com-
pliance. Microemulsions are colloidal dispersions 
which have features to be chosen such as being 
thermodynamically stable, consist of oil, aqueous, 
surfactant and co-surfactant. The active substance, 
Etofenamate (ETF), works as analgesic, antirheu-
matic, antipyretic and anti-infl ammatory (1,2). 
AIMS: This study aimed to obtain and charac-
terize microemulsion containing ETF for transder-
mal delivery. Microemulsions were prepared by 
titration method. The ETF was incorporated in the 
proportion of 5% in microemulsions containing 
oleic acid as oil, Cremophor EL, Span 80, Tween 
20 as surfactants, ethanol and Transcutol HP as 
co-surfactant and distilled water as aqueous. All 
the formulations were subjected to droplet size, 
polydispersity index (PDI), zeta potential, ETF 
amount, pH and conductivity measurements and 
stability studies. Also, in vitro drug release was 
evaluated using Franz diﬀ usion cells.  
RESULTS:  Four diﬀ erent ETF loaded micro-
emulsions were developed successfully using 
phase diagrams. All formulations had appropriate 
observed pH values for dermal application. ETF 
loaded microemulsions exhibited low droplet size 
and PDI. Microemulsions were not electrically 
charged (zeta potential equal to 0 mV) due to their 
ionic characteristics. Regarding physicochemical 
values, no signifi cant changes in the values mea-
sured at the beginning of the study were obtained 
after the stability period. The obtained in vitro re-
lease results of microemulsions showed a slow re-
lease behavior. The cumulative drug release rate 
of M4 within 24 h was higher than other micro-
emulsions.
CONCLUSIONS: Consequently, these MEs re-
sult in a promising alternative for further in vivo 
evaluation. This study illustrated that ETF-micro-
emulsions have a good potential for dermal appli-
cation.
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POSTER SECTION 2B 
NANOPHARMACEUTICALS 2
P2B-1 
Development and evaluation of nanocomposite-
based “nanoantibiotics” in vitro and in vivo
 GOVARDHANAM P.,  ŞEN KARAMAN D., 
 MEINANDER, A.,  MOHAN, A., 
 ROSENHOLM, J . 
Åbo Akademi University, Pharmaceutical Sciences Laboratory, 
Faculty of Science and Engineering, Turku, Finland
BACKGROUND: Antibacterial nanoparticles are 
known to control infectious diseases in a more ef-
fective way by providing enhanced pharmacoki-
netics of drugs such as site-targeted delivery, con-
trolledrelease and bett er solubility, and also accu-
mulate to provide eﬀ ective therapeutic eﬀ ects, in 
contrast to the conventional antibiotics [1].
AIMS:  This study focuses on the development 
and investigation of the antibacterial activity 
“nanoantibiotics”, composed of inorganic & or-
ganic constructs..  
RESULTS:  The proposed nanocomposite-based 
nanoantibiotics were successfully prepared with 
in the range of 400 nm ,approved by TEM images. 
The success of nanoantibiotics design was proven 
in each step of preparation by zeta potential mea-
surements of the suspension of the prepared par-
ticles. The cytocompability of nanoantibiotics 
were determined by using CaCo-2 cell line as in 
vitro cell model with the WST-1 assay. In vitro 
bacterial growth inhibition results showed signifi -
cant inhibition by the improved design of antibiot-
ics from inorganic core to inorganic & organic 
nanocomposites. Ruptured bacterial cell mem-
branes was observed  when the bacteria were 
treated with the nanobiotics by TEM imagings 
The eﬃ  cient localization of the nanobiotics in the 
intestines of D.melanogaster was visualized 
through wide-fi eld fl uorescence imaging after 
feeding the fl ies with nanoparticle homogenized 
fl y food. 
CONCLUSIONS: The observed growth inhibi-
tion results from the in vitro experiments revealed 
that multiple antibacterial constructs in the de-
signed nanobiotics system helps to improve its an-
tibacterial activity. The operability of the nanobi-
otics in the in vivo animal model has been as-
sured.
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P2B-2
Sertaconazole loaded nanofi bers 
as topical drug carriers
 ESENTÜRK, İ.,  GÜNGÖR, S.,  ERDAL, MS. 
Department of Pharmaceutical Technology, Faculty of Pharmacy, 
Istanbul University, Istanbul, Turkey
BACKGROUND: Electrospun nanofi ber mats oﬀ er 
several desirable features as topical drug delivery 
systems. The high surface area to volume ratio of 
fi ber mats provide eﬃ  cient delivery of both hydro-
philic and hydrophobic drugs and, drug release 
can be modulated by functionalization of the 
nanofi bers (1).
AIMS: The purpose of this study was to formu-
late sertaconazole (a highly lipophilic antifungal 
drug) loaded polymeric nanofi bers by the electro-
spinning technique for topical administration. The 
morphology and size of polyurethane based nano-
fi bers were visualized by scanning electron mi-
croscopy (SEM) and drug-excipient interaction 
was studied by ATR-FTIR spectroscopy. In vitro 
skin penetration of sertaconazole from optimized 
nanofi bers was examined with tape stripping 
technique.  
RESULTS:  The electrospinnig process produced 
nanofi brous mats with uniform structure and with 
narrow size distribution. ATR-FTIR spectroscopy 
indicated interaction between the the drug and the 
polymer. In vitro skin penetration study revealed 
eﬀ ective sertaconazole accumulation in the pig 
skin from the polymeric nanofi bers. 
CONCLUSIONS: In conclusion, sertaconazole 
loaded homogeneous composite nanofi brous mats 
could be potential candidates in topical antifungal 
drug delivery. 
REFERENCES: 
1. Goyal R. et al. J Control Release 240, 77-92 (2016).
ACTA-1703-BBBB.indb   184 9/19/17   6:28 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters 185
P2B-3
Synthesis and characterization of apigenin 
loaded novel HSA/galactomannan/chitosan 
nanoparticles for pulmonary drug delivery 
 PÁPAY, ZS. E.,  FÜREDI, P.,  MIKE-KASZÁS, N., 
 BUDAI, L.,  BALOGH, E.,  ANTAL, I . 
Semmelweis University, Department of Pharmaceutics, 
Budapest, Hungary 
 
BACKGROUND: Pulmonary delivery of a phar-
macologically active ingredient oﬀ ers numerous 
advantages over other administration routes due 
to the large surface area, high permeability and 
low enzymatic activity of the lungs. Inhalable for-
mulations consisting of nanoparticles (NPs) are 
gaining interest in terms of controlling drug re-
lease and improving deposition. Serum albumin 
NPs are eﬀ ective tools for delivering poorly water 
soluble phytoconstituents1. Apigenin (Api), a poor-
ly water soluble fl avonoid, has remarkable health 
eﬀ ects such as antioxidant, anti-infl ammatory and 
anticancer properties and was classifi ed as Bio-
pharmaceutical Classifi cation System (BCS) II. 
drug2.  
AIMS: The aim of this work was to synthetize 
and characterize novel biocompatible HSA/galac-
tomannan/chitosan NPs, loaded with a poorly wa-
ter soluble Api.     
RESULTS:  The HSA-galactomannan conjugates 
were prepared by Maillard reaction at 60°C and 
80% relative humidity. As the next step, the chito-
san solution was added and stirred for 1 hour to 
obtain HSA/galactomannan/chitosan NPs. The 
physical properties of the NPs such as particles 
size, zeta potential and viscosity as well as drug 
loading eﬃ  ciency were measured. The samples 
were further lyophilized and dissolution of Api 
was determined with Franz cell apparatus. The re-
sidual water content was investigated by Karl-
Fischer titration. 
CONCLUSIONS: Our results indicate that the 
NPs have adequate size and apigenin could be ef-
fectively loaded into the nanoparticles with en-
hanced dissolution.    
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P2B-4
Development of a nasal powder preformulation 
process by Design of Experiment method
 GIESZINGER, P.1,  CASIAN, T.2,  TOMUTA, I .2, 
 RÉVÉSZ-SZABÓ, P.1,  AMBRUS, R.1
1 Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Faculty of Pharmacy, Szeged, Hungary
2 Department of Drug Analysis, Faculty of Pharmacy, Iuliu 
Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, 
Romania
BACKGROUND: The nasal delivery of drugs of-
fers a great alternative route to to increase patient 
compliance due to its advantageous properties. 
Nasal powders have bett er adhesion due to the ad-
ditive polymers that may be e.g. gelling or good 
wett ability agents, thus the bioavailability of pow-
ders is bett er compared to the liquid formulations. 
Using nanoparticles, innovative products can be 
achieved, which may lead to the improvement of 
diﬀ erent therapies. Co-milling is an economically 
and environmentally desirable method to produce 
nanoparticles. Lamotrigine (LAM) was used as a 
model drug and polyvinyl- alcohol (PVA) was 
chosen to provide a polymer matrix for the 
nanoparticles. 
AIMS: The aim of our study was to determine 
the optimal parameters of co-milling using Design 
of Experiment (DoE) as a part of Quality by De-
sign. By DoE it is possible to estimate the proper 
operating conditions of co-milling, which is called 
Design Space. Another goal is to investigate the 
prepared products that includes physico-chemical 
(XRPD, DSC, polarity, solubility), in vitro dissolu-
tion and Side-bi-Side horizontal diﬀ usion tests.   
RESULTS:  The dependent variables of DoE 
based factorial design are LAM:PVA ratio, milling 
time and speed, the independent variables are 
particle size and dissolution rate. The particle size 
determination shows that the size of LAM in the 
products is between 142 nm and 2.42 μm. The in 
vitro dissolution of LAM from the samples is be-
tween 43.38 and 100%. However, the Design Space 
of milling will be set up in the near future, and 
then the optimal parameters will be determined.
CONCLUSIONS: The results of particle size mea-
surement and dissolution investigations show a 
promising preparation method to produce powders 
that contain nanonized LAM for nasal application.
This project was supported by GINOP 
2.3.2_15_2016_00060 project. 
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P2B-5
Comparison study of nanonized meloxicam and 
its potassium salt containing peroral dosage 
form with fast release
 BARTOS, CS.,  JÓJÁRT-LAZCKOVICH, O., 
 SZABÓ-RÉVÉSZ, P.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: According to the guidelines de-
veloped by the World Health Organization, 
NSAIDs (non-steroidal anti-infl ammatory drugs) 
are used as initial treatment in both malignant 
and non-malignant pain therapy [1]. The solubility 
of NSAIDs is pH dependent (low solubility in 
acidic medium), and their permeability is relative-
ly high (logPapp 1-3). Therefore their particle size 
reduction or salt form can increase the dissolution 
rate/solubility to reach a fast analgesic eﬀ ect [2].
AIMS: Our aims were to produce nanonized 
meloxicam (MEL) as NSAID to achieve faster dis-
solution in order to prepare solid dosage form for 
peroral administration; moreover, to compare the 
dissolution characteristics with its potassium 
monohydrate (MELP) at pH 1.2.   
RESULTS:  Combined wet milling technology 
resulted in nanonized MEL (≈136 nm): stable in 
nanosuspension form. MEL containing nanosus-
pension was applied to develop solid drug deliv-
ery systems (DDSs). For comparison study, MELP 
containing DDS as an interactive physical mixture 
was used. It was found that the equilibrium solu-
bilities of MEL and MELP are the same; nonethe-
less, the diﬀ erence in their rates and extents of dis-
solution is considerable.
CONCLUSIONS: Our comparison study led to 
a new approach of developing MEL and MELP 
containing DDSs with fast release for pain thera-
py.
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged
REFERENCES: 
1. WHO Normative Guidelines on Pain Management: 
WHO Report 2007. WHO
2. Horváth, T., et al. Eur J Pharm Sci (2016)
P2B-6
Formulation and in vitro characterization of 
inhalable nano-structured dry powders
 CHVATAL, A.,  BARTOS, CSA.,  BARTOS, CSI., 
 SZABÓ-RÉVÉSZ, P.,  AMBRUS, R.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
Faculty of Pharmacy, University of Szeged, Szeged, Hungary
BACKGROUND: The formulation of inhalable dry 
powders aggregated of nanoparticles is gaining 
much att ention in the pharmaceutical research 
area. The appropriate particle engineering tech-
nique is the most important factor to get enhanced 
aerosolization properties and an improved thera-
peutic eﬀ ect. Not only the preparation method, 
but the exact aerodynamical characterization, too, 
gives important feedback for the further formula-
tion methods.
AIMS: Our aim was to produce inhalable nano-
structured powders, containing non-water-soluble 
active pharmaceutical ingredients (ACI), with a 
two-step wet mill (Bartos Cs., 2016) and co-spray 
drying technology (Chvatal A., 2017). We also 
aimed to characterize the eﬃ  cacy of the prepared 
samples with in vitro aerodynamical characteriza-
tion (Andersen Cascade Impactor).  
RESULTS:  We used a two-step inhalable 
nanoparticle preparation. First, the nanoparticle-
size pre-suspension was prepared with wet milling 
technology. The fi nal micro-sized powders were 
obtained with the co-spray drying of the diluted 
suspension and aerosolization enhancer excipients 
(L-leucine, ammonium carbonate). The electron mi-
croscopy pictures showed spherical particles, while 
the in vitro aerodynamic characterization gives an 
exact profi le of the powder dynamics.
CONCLUSIONS: We successfully worked out a 
nanoparticle preparation method by combining 
the wet milling and spray drying methods, with 
the use of which we could achieve the enhanced 
deposition of the samples.
This project was supported by the János Bolyai 
Research Scholarship of the Hungarian Academy 
of Sciences (2014–2017). 
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P2B-7
Application of dry milling technique in order 
to prepare intranasal powder with nanonized 
levodopa
 BARTOS, CS.,  SZABÓ-RÉVÉSZ, P., 
 MEHRNAZ, R.,  KATONA, G.,  KISS, T., 
 AMBRUS, R.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: Levodopa is the most commonly 
used medication in treating Parkinson’s disease. 
However, the delivery of oral levodopa is associat-
ed with adverse eﬀ ects. Intranasal administration 
is an alternative route for the delivery of levodopa 
to reach the systemic circulation due to the tran-
sepithelial absorption or directly the brain tissues 
through the axonal pathway (1).
AIMS: In the present work, the use of dry mill-
ing in order to increase the bioavailability of le-
vodopa, marked out for intranasal crisis therapy 
as dry powder, is reported. The aims of our work 
were to reduce the particle size of the drug to the 
nanometer range by using a planetary ball mill, 
with the optimization of the process parameters 
(milling time, speed of revolution) and excipients, 
and to study the eﬀ ects of milling on the physico-
chemical properties and in vitro diﬀ usion of le-
vodopa.  
RESULTS:  During milling, sodium hyaluronate 
and chitosan were used as additives. Various drug-
carrier ratios were treated. The average particle 
size of the products, detected by laser diﬀ raction, 
was reduced to the micrometer range in the pres-
ence of chitosan. The particle size of levodopa was 
obtained by analyzing several scanning electron 
microscopy (SEM) images with the ImageJ soft-
ware environment. It can be concluded that the 
size and morphology of the drug (~50-100 nm/
roundish) have changed due to milling. The deter-
mination of the structure of levodopa by diﬀ eren-
tial scanning calorimetry and X-ray powder dif-
fraction revealed the amorphization of the drug af-
ter milling (50-80% of the drug remained crystal-
line). In vitro permeability studies were carried out 
on a modifi ed horizontal Side-Bi-Side™ cell mod-
el, simulating the conditions of the nasal cavity.
CONCLUSIONS: The high specifi c surface area 
and rapid dissolution of levodopa nanoparticles 
resulted in the high permeability of the drug in 
case of milled products.
Supported by the ÚNKP-17-4-I-SZTE-3 New 
National Excellence Program of the Ministry of 
Human Capacities. 
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P2B-8
Eﬀ ects of diﬀ erent stability conditions on three-
layered doxycycline collagen loaded nanofi ber 
wound dressing
 TORT, S.,  ACARTÜRK, F.
Department of Pharmaceutical Technology, Faculty of Pharmacy, 
Gazi University, Ankara, Turkey
BACKGROUND: Electrospinning is the most used 
method to produce nanofi bers (1). Nanofi ber 
wound dressing have unique properties, such as 
high porosity and surface area. Nanofi bers can 
undergo diﬀ erent changes that will infl uence their 
structure and performance. Therefore, it is neces-
sary to determine the stability properties of the 
dressing in diﬀ erent conditions.
AIMS: The aim of this study is to determine 
physicochemical properties of nanofi ber wound 
dressing at three diﬀ erent conditions according to 
ICH guidelines (4°C/ambient humidity, 25°C/60% 
RH and 40°C/75% RH) for 12 months. At appro-
priate time intervals, some characterization pa-
rameters such as drug content, tensile strength 
and work of bioadhesion value were determined 
and SEM images of the nanofi bers were obtained.  
RESULTS:  Temperature and relative humidity 
aﬀ ect the fi ber structure negatively both at 
25°C/60% RH and 40°C/75% RH conditions due to 
moisture. The nanofi ber structure was completely 
deteriorated and the light yellow colored wound 
dressings turned to brown. For this reason, stabili-
ty studies were completed at only 4°C/ambient 
humidity conditions for 12 months. It was ob-
served that there were no signifi cant changes in 
the stability test parameters that could negatively 
aﬀ ect the use of wound dressing (p>0,05).
CONCLUSIONS: As a result of the stability 
studies, it was found that the morphological, me-
chanical, bioadhesion and wett ability properties 
and the amount of doxycycline remained stable 
for a period of 12 months at 4°C/ambient humidi-
ty condition. It is appropriate to carry out the sta-
bility studies with diﬀ erent packaging material so 
that the nanofi ber wound dressing can be stored 
at higher temperature and humiditiy condition. 
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P2B-9
Freeze-drying of Bovine Serum Albumin as 
potential nano drug delivery system
 KATONA, G.,  CSÓKA, I .,  SZABÓ-RÉVÉSZ, P.
Institute of Pharmaceutical Technology and Regulatory Aﬀ airs, 
University of Szeged, Szeged, Hungary
BACKGROUND: Bovine Serum Albumin (BSA) is 
playing an increasing role as a Drug Delivery Sys-
tem (DDS) in the clinical therapy. Due to its bio-
compatibility and non-toxicity, it can be used as a 
pharmaceutical carrier more safely versus many 
synthetic polymers. BSA is also an excellent mate-
rial to construct nanoparticles because it has good 
physicochemical stability, targetability, and chem-
ical functionality. Freeze drying is a suitable tech-
nique to improve the long-term storage stability of 
colloidal DDSs such as nanoparticles.
AIMS: Our aim was to apply the freeze drying 
technology, as commonly used method for pro-
tein stabilization to prepare nano DDS from BSA 
as model protein. Further aim was to characterize 
the physicochemical changes of the BSA and in-
vestigate the eﬀ ect of additives.  
RESULTS:  BSA based nano DDS was prepared 
using diﬀ erent concentrations of phosphate buﬀ -
ered saline (PBS), by means of coacervation meth-
od resulting in nano range preparation. After pu-
rifi cation of nano particles, freeze-drying was car-
ried out with trehalose as cryoprotectant. Consis-
tent with Fourier-transform infrared spectroscopy 
(FTIR) data trehalose partially prevented structur-
al perturbations in BSA upon freeze-drying. Ther-
mal analysis (TA) and X-ray powder diﬀ raction 
(XRPD) were used as physicochemical character-
ization methods. The desired particle size (130 
nm) and zeta potential ( -31,8 mV) was reached by 
optimization of the composition.
CONCLUSIONS: BSA based nano DDS can be 
prepared by means of coacervation and freeze-dry-
ing with desired properties (size, zeta potential, 
stability). The formulated BSA based nano DDS can 
be applied for drug conjugation and –delivery. 
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POSTER SECTION 2C 
QUALITY BY DESIGN
P2C-1
 Improving protein product quality through 
real-time bioprocess control based on Raman 
spectroscopy 
 
 PITTERS, A.1,  GILLIAM, S.2,  CUELLAR, M.2, 
 SRACHAN, D.2  
1Kaiser Optical Systems SARL, Saint-Priest, France  
2Kaiser Optical Systems Inc., Ann Arbor, USA
BACKGROUND: Raman spectroscopy is an opti-
cal spectroscopy technique that provides a molec-
ular fi ngerprint of a sample and enables nonde-
structive analysis of chemical composition and 
molecular structure. Applications of Raman spec-
troscopy in polymer, pharmaceutical, bioprocess-
ing, and biomedical analysis have strongly in-
creased in the past three decades as laser sam-
pling and detector technology has improved. Be-
cause of these technological advances, Raman 
spectroscopy is now well recognized as a practical 
analysis technique inside and outside the biophar-
maceutical laboratory. The quality of therapeutic 
CHO cell culture proteins is a result of the entire 
production process. Producing therapeutic pro-
teins with consistent characteristics is a challeng-
ing task which requires a high level of process un-
derstanding and maintaining process conditions 
within an optimal batch trajectory.  
 AIM: The goal of the case studies were to accel-
erate understanding of biopharmaceutical pro-
duction processes and integrate a robust real-time 
process control strategy.  
 RESULTS: Case studies in the presentation will 
illustrate the impact of Raman based bioprocess 
control to the cells, the cell culture environment, 
the yield, and fi nally to the quality of therapeutic 
proteins [1]. Results of the case studies will pro-
vide valuable insights into eﬀ ective control strate-
gies and explicate the successful transfer of ana-
lytical Raman methods from process development 
to GMP manufacturing.  
CONCLUSION: In situ Raman spectroscopy 
enables simultaneous monitoring of multiple 
product quality relevant parameter and allows for 
in-process corrections. Precise navigation and 
smart adaptation of critical upstream process con-
ditions based on Raman spectroscopy reduces the 
complexity of producing high quality products.  
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P2C-2
Initial Risk Assessment as part of the Quality by 
Design in peptide drug containing formulation 
development 
 PALLAGI, E.,  PAÁL,L. T.,  CSÓKA, I .
Department of Pharmaceutical Technology and Regulatory 
Aﬀ airs, University of Szeged, Szeged, Hungary
BACKGROUND: The Quality by Design (QbD) 
concept is a knowledge, risk based, holistic and 
proactive manner of pharmaceutical develop-
ments which results in a bett er product and pro-
cess understanding. The key element of the QbD 
method is the Risk Assessment (RA). The whole 
QbD thinking and RA are even more important 
and essential in case of biological products due to 
their complexity and nature1-2. 
AIMS: The aim of this study is the risk assess-
ment based planning and evaluation of an oral 
peptide delivery system; to develop a fl ow chart 
of necessary decision needed steps and also meth-
odology for evaluating potential risk factors.  
RESULTS:  The outcome of this development is 
the collection and presentation of parameters 
which infl uence the quality, safety and eﬃ  cacy of 
the aimed oral peptide containing product and its 
formulation process. The infl uencing factors (char-
acteristics of raw materials, environmental and in-
strumental factors, formulation characteristics, 
carrier system’s properties etc.) are presented by 
applying Ishikawa diagrams. The potential critical 
quality and process parameters are identifi ed as 
next step and the initial RA process is presented. 
The outcome of RA is resulted in the ranking of 
the critical factors according to their eﬀ ect and im-
portance. Ranking results are visualized in Pare-
to-, and severity-occurrence charts, by means of 
the RA software (Lean QbD®). 
CONCLUSIONS: Biological products, peptide 
containing drugs are special due to their bioactivi-
ty, immunogenicity, chemical diversity, safety as-
pects, etc. Their formulation is also more complex, 
therefore a more detailed planning, prior thinking 
and deep understanding of the risk factors will 
led to a proper product performance and quality. 
The key of this quality planning methodology is 
the QbD and RA based approach, which was 
found to be very useful in early phase develop-
ments in many cases3-4 and it also can be oﬀ ered in 
case of peptide containing formulations. 
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P2C-3 
In-line Raman spectroscopic monitoring and 
feedback control of a continuous pharmaceutical 
powder blending and tableting process
 NAGY, B.,  FARKAS, A.,  GYÜRKÉS, M., 
 MAROSI, GY.,  NAGY, ZS. K.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
BACKGROUND:  Spreading of continuous phar-
maceutical manufacturing is anticipated in the 
next decades [1]. However, the integration of Pro-
cess Analytical Technology (PAT) initiative into 
continuous processes is indispensable for reliable 
continuous production.
AIMS:  The aim of this study is to implement in-
line Raman spectroscopic monitoring and feed-
back control in a continuous blending and tablet-
ing process, two fundamental unit operations in 
the production of multicomponent solid dosage 
forms. This is the fi rst application of Raman-spec-
troscopy in continuous homogenization and the 
fi rst ever Raman-based feedback control in the 
formulation technology of solid pharmaceuticals.   
RESULTS:   Continuous blending and tableting 
experiments were conducted using a two-compo-
nent model system of caﬀ eine and glucose. The 
real-time analysis of API content in a two-compo-
nent blend, the blend homogeneity, and tablet 
content uniformity was performed using a Partial 
Least Squares (PLS) quantitative method. The in-
line Raman spectroscopic monitoring showed that 
the applied twin-screw continuous blender was 
capable of producing blends with high homogene-
ity, uniform composition. Furthermore, techno-
logical malfunctions could be detected by the pro-
posed PAT method. The Raman spectroscopy-
based feedback control of the API feeder was also 
established, which guarantees the required API 
content during the continuous blending. 
CONCLUSIONS:  The Process Analitically Con-
trolled Technology (PACT) approach presented in 
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this study proves the feasibility of Raman spectros-
copy for monitoring and control continuous pro-
cesses and could be extended to several manufac-
turing steps, therefore contributing to the develop-
ment of fully continuous manufacturing, minimiz-
ing the possibility of out-of-specifi cation products 
and the need for time-consuming oﬀ -line analysis.
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P2C-4
Quality by Design based approach in the 
development of dermatological dosage forms
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H-6720, Hungary
BACKGROUND: Dermal formulations receive 
more and more att ention in the pharmaceutical 
and cosmetic fi elds. Due to the fast market 
growth, a larger emphasis has been placed on 
proper planning of the product development and 
on using modern tools such as the Quality by De-
sign (QbD) concept [1]. In such a way the duration 
of the development process and its costs can be re-
duced, while being able to meet the requirements 
of the stakeholders, namely the patient, the indus-
try and the regulatory authorities more precisely.
AIMS: The aim of our present work was to 
adapt ICH Q8 guideline on the Quality by Design 
based approach for the development of dermato-
logical dosage forms.  
RESULTS:  The QbD concept involves identify-
ing the quality target product profi le (QTTP), the 
critical material att ributes (CMAs) and critical 
process parameters (CPPs) into the critical quality 
att ributes (CQAs) of a drug product at the begin-
ning of the development [1]. The quality manage-
ment tools (e.g. Ishikawa diagram, Pareto analy-
sis, risk estimate matrix etc.) and the Design of Ex-
periments (DoE) techniques within the risk assess-
ment process are key elements of QbD methodol-
ogy. LeanQbD Software and StatSoft. Inc. 
Statistica for Windows were applied to indentify 
the risks. The model system was a Nanostructured 
Lipid Carrier (NLC) preparation. The most critical 
CMAs and CPPs were chosen to be the indepen-
dent variables and the CQAs were chosen to be 
the dependent variables in the 23 factorial design 
process. Based on our experiments, an optimal 
formulation can be obtained [2].
CONCLUSIONS: The information received was 
very important for the pharmaceutical develop-
ment, on the basis of these results the control 
strategy can be designed and it ensures a safe and 
eﬀ ective dermal product that meets the quality ex-
pectations of the relevant stakeholders.
REFERENCES: 
1. ICH Guideline Pharmaceutical Development Q8(R2), 2009
2. Kovacs A. et al., Eur J. Pharm. Sci. 99, 246-257 (2017)
P2C-5
Preparation of orally dispersible tablets of 
ziprasidone hydrochloride monohydrate 
nanocrystals:  The Quality by Design (QbD) 
approach 
 TASHAN, E.1,2,  KARAKUCUK, A.1,  CELEBI, N.1
1Gazi University, Faculty of Pharmacy, Department of 
Pharmaceutical Technology, Ankara, Turkey
2Zoleant Pharmaceuticals International, Ankara, Turkey
BACKGROUND: Ziprasidone hydrochloride 
monohydrate (ZHM) is a poorly soluble active 
substance which is belong to BCS Class II drugs 
and used for schizophrenia treatment. Orally dis-
persible tablets (ODTs) are most common dosage 
forms for patient compliance and using QbD for 
development ODTs have advantages about estab-
lishing optimum composition. In this study ZHM 
nanocrystals were produced by high pressure ho-
mogenization using PVP K301 as stabilizer to solve 
solubility issues of ZHM. ODTs were prepared 
with ZHM nanocrystals and formulations were 
designed according to QbD to optimize tablet 
compositions in terms of disintegrating agent (Ac-
di-sol) and lubricant (Mg stearate) ratio. 32 full fac-
torial design was performed and tablets were pre-
pared by direct compression method. The eﬀ ects 
of interactions on dependent variables (hardness, 
friability and disintegration time) were investigat-
ed. Design spaces were obtained and disintegrant 
and lubricant amount were determined. 
AIMS: The aim of this study was to develop 
ZHM containing ODTs for treatment of schizo-
phrenia and enhancing water solubility of ZHM to 
improve oral bioavailability by developing nano-
crystals of ZHM. 
RESULTS: Nanocrystals characterized with 
400-600 nm particles size, 0.1-0.4 particle size dis-
tribution and >20 mV zeta potential values used to 
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prepare ODTs. Disintegration time was shorter in 
nanocrystal ODTs then physical mixture ODTs 
while similar results were observed in terms of fri-
ability and hardness. Friability, hardness and dis-
integration time values of nanocrystal ODTs were 
found 1.05%, 26.1 N and 6.0 seconds, respectively.
CONCLUSIONS: Nanocrystal ODT formula-
tions were developed successfully. The results 
showed that this new formulation could be an al-
ternative pharmaceutical form with improved wa-
ter solubility. 
REFERENCES
1. Krause, K. P et al.  Int. J. Pharm., 214, 21-24. (2001)
P2C-6
Raman spectroscopy based feedback control of 
the enzymatic hydrolysis of lactose
 HIRSCH, E.,  PATAKI, H.,  CSONTOS, I ., 
 NAGY, ZS.,  MAROSI, GY.
Department of Organic Chemistry and Technology, Budapest 
University of Tehcnology and Economics, Budapest, Hungary
BACKGROUND: Production of pharmaceuticals 
requires an eﬃ  cient process control strategy to en-
sure product quality. The Process Analytical Tech-
nology (PAT) initiatives have triggered the devel-
opment of real-time process monitoring and pro-
cess control in the pharmaceutical industry. Ra-
man spectrometry has special signifi cance as an 
analytical tool for inline monitoring of pharma-
ceutical processes. With the aid of real-time multi-
variate data analysis, the quantitative information 
extracted from the spectra can be utilized in a 
control system. There’s a great advantage in the 
use of Raman spectrometry in biotechnology for 
the monitoring and control of the production of 
biotechnology-derived medicines (e.g. monoclonal 
antibodies).
AIMS: In this work the enzymatic hydrolysis of 
lactose was chosen as a model bioprocess for de-
veloping closed-loop feedback control system 
based on inline Raman spectrometry. For this pur-
pose a real-time data analyser programm and an 
eﬀ ective control system was developed to main-
tain the lactose concentration.  
RESULTS:  Real-time Raman spectra evaluation 
was accomplished using classical least squares 
(CLS) and partial least squares (PLS) multivariate 
data analysis methods. After optimization of the 
lactose hydrolysis, the control of lactose concen-
tration could be achieved with CLS method. To 
improve real-time evaluation, PLS method was 
used resulting in bett er evaluation of spectra. 
Comparing the two chemometric methods, the 
PLS method gave bett er results in the control ex-
periment of lactose hydrolysis than CLS evalua-
tion method. 
CONCLUSIONS: Raman spectrometry based 
feedback control of the enzymatic hydrolysis of 
lactose shows the potential opportunities of Ra-
man spectrometry in other bioprocesses where the 
control of the medium component concentration 
is important. 
P2C-7
Defi ning of the design space and development 
of an in-line NIR monitoring method for the 
fl uidised bed granulation process of two APIs
 GÂVAN, A.,  IURIAN, S.,  CASIAN, T.,
  VOINA, I .,  TOMUȚĂ, I .
Department of Pharmaceutical Technology and 
Biopharmaceutics, University of Medicine and Pharmacy “Iuliu 
Hatieganu”, Cluj-Napoca, Romania
BACKGROUND: The modern drug development 
and manufacturing is expected to be carried out 
following a quality by design (QbD) approach and 
applying in-line monitoring methods as process 
analytical technology (PAT).
AIMS: Applying an experimental design in or-
der to optimise a fl uid bed granulation process of 2 
APIs simultaneously. Process optimisation 
through systematic evaluation of the infl uence of 
minor changes of the API / excipient sort or critical 
process parameters, on the process itself and the fi -
nal product quality. Development of an in-line 
near infrared (NIR) method which would allow 
the water content monitoring along the process.   
RESULTS:  The developed D-optimal experi-
mental design registered a G-eﬃ  ciency of over 70 
and a condition number of under 7.1, values 
which describe a good optimisation design. The 
design contained 2 critical process parameters as 
quantitative factors and diﬀ erent sorts of APIs and 
microcrystalline cellulose as qualitative factors. 
During the process, the relative humidity of the 
granules was between 1 and 19%. Those values 
were then used to calibrate the preprocessed NIR 
spectral data, developing an OPLS model with 
R2X greater then 0.9. The model allowed the in-
line process control by predicting the water con-
tent throughout the process and the establishment 
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of the granulation end point. Applying the de-
scribed experimental design, the design space 
could be specifi cally defi ned in accordance with 
all the possible changes of the API or excipient 
specifi cations, thereby providing an end product 
meeting the quality target product profi le. More-
over, during the in-line process monitoring, the 
changes of critical process parameters were well 
underlined, allowing the identifi cation of the 
granulation steps, facilitating the process control 
and ensuring a high reliability of the process. 
CONCLUSIONS: The described, systematic ap-
proach provided a thorough understanding of the 
fl uid bed granulation and its variables, allowing the 
development of a robust, fully controlled process.
P2C-8
Multivariate Data Analysis (MVDA) applied 
for the development, process understranding 
and real time monitoring of mannitol based 
granulates loaded with loratadine by solution 
layering 
 CASIAN, T.,  IOVANOV, R.,  ILYES, K., 
 TOMUȚĂ, I .
Iuliu Hatieganu University of Medicine and Pharmacy, Dept. 
of Pharmaceutical Technology and Biopharmacy, Cluj-Napoca, 
Romania
BACKGROUND: The development of a pharma-
ceutical product relies on the identifi cation and 
control of formulation and process variables that 
infl uence the product’s critical quality att ributes 
(CQAs). This objective can be fulfi lled by applying 
Design of Experiments (DoE) and by implement-
ing process monitoring instruments for real time 
quality testing as recommended by guidelines 
published for the industry.     
AIMS: The objective of this work was to devel-
op mannitol based granulates loaded with lorata-
dine by applying multivariate data analysis for 
process understanding and in-line monitoring via 
NIR technology.   
RESULTS: To identify most relevant formula-
tion and process variables fi ve factors (atomizing 
pressure, pulverization rate, %Water, %PVP, raw 
material particle size distribution) were screened 
through a Fractional Factorial Design with resolu-
tion V. Mean particle size was infl uenced by atom-
izing pressure, pulverization rate and water con-
tent of the pulverized solution. Diﬀ erences in 
granule fl owing properties could be att ributed 
mainly to atomizing pressure, water content and 
raw material particle size distribution. The PVP 
concentration mainly infl uenced disintegration 
and the size of the 0-300 μm granules fraction. 
OPLS models with good predictive properties 
(Q2>0.7)  were built from the NIR spectra of pul-
verization phase for the real time monitoring of 
loratadine and PVP granule layering.  Granule 
properties (% of sieve fraction size, PVP% and 
granule fl owing properties) were predicted using 
models built on NIR spectral data from the drying 
phase of the process.    
CONCLUSIONS: This work demonstrates the 
de way of applying Multivariate Data Analysis 
with Quality by Design paradigm for process un-
derstanding and product quality control of man-
nitol based granulates loaded with loratadine by 
solution layering 
REFERENCES: 
1. Guidance for Industry. Q8(R2) Pharmaceutical Devel-
opment.2009. [Accessed in:05.05.2017] Available at: 
http://www.fda.gov/downloads/Drugs/.../Guidances/
ucm073507.pdf 
2. Guidance for Industry PAT- A Framework for Innova-
tive Pharmaceutical Development, Manufacturing, and 
Quality Assurance.2004. [Accessed in:05.05.2017] Avail-
able at: htt p://www.fda.gov/downloads/Drugs/Guid-
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P2C-9
Texture assessment and multivariate data 
analysis: development of a predictive model for 
oral disintegration profi le and palatability of 
orodispersible tablets
 IURIAN, S.,  BOGDAN, C.,  CASIAN, T., 
 TARȚA, D.,  TOMUȚĂ, I .
Department of Pharmaceutical Technology and 
Biopharmaceutics, Faculty of Pharmacy, University of Medicine 
and Pharmacy ”Iuliu Hațieganu”, Cluj-Napoca, Romania
BACKGROUND: Among patient-centered dosage 
forms, orodispersible tablets were easily accepted 
both by patients and pharmaceutical industry, of-
ten as replacements for conventional tablets. Their 
development involves in vivo disintegration and 
palatability testing on healthy volunteers. Texture 
analysis was previously used to estimate oral dis-
integration time, with promising results.
AIMS: The aim of this study was to develop a pre-
dictive model to correlate texture analysis of orodis-
persible tablets with the oral disintegration time and 
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mouthfeel, by means of multivariate data analysis 
(MVDA).   
RESULTS:  Placebo tablets were prepared accord-
ing to an experimental design, by wet granulation. 
High formulation diversity regarding disintegration 
time and mouthfeel was achieved using two super-
disintegrants with diﬀ erent mechanisms, two fi llers 
(mannitol and microcrystalline cellulose),  two sweet-
eners (aspartame and sodium saccharine) and the 
granules were prepared at two levels of the average 
size (350 μm and 650 μm).  The classical pharmaceu-
tical evaluation targeted the measurement of weight 
uniformity, mechanical strength (between 28.60 ± 
4.74 N and 38.80 ± 2.89 N), friability, disintegration 
time (between 7.00 ± 1.09 s and 147.83 ± 19.97 s), 
wett ing time and water absorption ratio. In vivo eval-
uation on healthy volunteers revealed disintegration 
times between 34 s and 102.93 s and an exhaustive 
description of the palatability. Texture analysis plots 
of the load vs. time were recorded and their shape 
and surface were found as good indicators of in 
vivo tablet softening and disintegration behavior. 
Predictive models were developed using Partial 
Least Squares regressions for disintegration time, 
sweet taste, volume of residue and palatability (R2 
= 0.978, 0.978, 0.994 and 0.99, respectively). 
CONCLUSIONS: The study achieved the predic-
tion of the most important subjective characteristics 
of orodispersible tablets disintegration using an in-
strumental method and MVDA.
P2C-10
Design and development of multivitamin tablets 
with Quality by Design approach
 HOFFMANN, A.,  KRISTÓ, K.,  HORVÁTH, T., 
 PALLAGI, E.,  CSÓKA, I .
Institute of Pharmaceutical Technology and Regulatory Aﬀ aris, 
University of Szeged, Faculty of Pharmacy, Szeged, Hungary
Goodwill Pharma Ltd., Szeged, Hungary
BACKGROUND: The aim of pharmaceutical de-
velopment is to provide the safety, eﬃ  cacy and 
quality of the product. Instead of the traditional 
Quality by Testing method a new approach, the 
Quality by Design (QbD) is preferred nowadays. 
In this risk based method the critical parameters 
which have signifi cant infl uence ont he safety and 
quality of the product are defi ned right at the be-
ginning of the development. It can be especially 
useful by such complex formulations like multivi-
tamin tablets.
AIMS: The aim of this study was to design and 
formulate a multivitamin tablet for direct com-
pression, using the QbD approach, to fi nd the op-
timal parameters for production and composition 
and to defi ne the Design Space of the tablets. As 
model active ingredients water- and fat soluble vi-
tamins were selected.  
RESULTS:  All information from the literature 
and from preformulation studies were collected 
for the knowledge space development. Then the 
design and development process was performed 
by the QbD method. The Quality Target Product 
Profi le was defi ned and the critical factors (Criti-
cal Quality Parameters and Critical Process Pa-
rameters) were selected. According to the Risk As-
sessment (RA) results, factors of factorial design 
were selected. These were the amount of the fat 
soluble vitamins and compressing force. In the 
Design of Experiments phase 9 tablet samples 
were produced and examined and the Design 
Space was defi ned, namely ranges of the critical 
parameters where the quality of the product is 
suitable.
CONCLUSIONS: In this study the QbD method 
was successfully used in multivitamin tablet de-
velopment, which is a complex task with techno-
logical challenges. The QbD based prospective 
process resulted in an abbreviated but eﬀ ective 
development and it is useful by formulations with 
high diversity in composition (many components, 
chemical complexity, diﬀ erent ranges in dosage 
etc.)
REFERENCES: 
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P2C-11
Development and validation of NIR 
spectroscopic method for simultaneous 
quantifi cation of paracetamol and caﬀ eine in 
tablets
 MUNTEAN, D.,  ALECU, C.,  PORFIRE, A., 
 IURIAN, S.,  CASIAN, T.,  GAVAN, A., 
 TOMUȚĂ, I .
Iuliu Hatieganu University of Medicine and Pharmacy, Dept. 
of Pharmaceutical Technology and Biopharmacy, Cluj-Napoca, 
Romania
BACKGROUND: The Guidance for Industry im-
plemented by FDA starting with 2004  encourages 
the voluntary development of innovative pharma-
ceutical technologies based on Process Analytical 
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Technology (PAT).  In the last decade the Near In-
frared Spectroscopy (NIRS) became a widely used 
technique for direct and non-destructive analysis 
of solid samples as a PAT tool.      
AIMS: The objective of this work was to devel-
op and validate a NIRS method for direct and si-
multaneous quantifi cation of paracetamol and caf-
feine in intact tablets.   
RESULTS:  The calibration model was developed 
based on the NIR transmission spectrum recorded 
on 28 series of intact tablets samples prepared accord-
ing to an experimantal design with 2 factors and 5 lev-
els. The best predictive model for paracetamol was de-
veloped using standard normal variate pre-processing 
method and 2 PLS factors; the best predictive model for 
cafeine was developed using fi rst derivate followed by 
standard normal variate pre-processing method and 7 
PLS factors. The method was validated in terms of 
trueness, precision and accuracy and the results 
showed that the developed method is appropriate 
for prediction of paracetamol (ranging from 270 to 
330 mg/tablet) and caﬀ eine(ranging from 27 to 33 
mg/tablet) on intact tablets witout any sample 
preparation. Furthermore, the APIs content in tab-
lets was determined by means of NIRS-chemo-
metric methods and HPLC reference methods. A 
good correlation between predicted and deter-
mined results was found, the diﬀ erences being 
statistically insignifi cant and total prediction er-
rors were under ± 5%.
CONCLUSIONS: Considering the obtained re-
sults, the NIR spectrosopy proved to be a suitable 
tool for direct and simultaneous quantifi cation of 
the chemical composition regarding the APIs con-
tent of tablets with paracetamol and caﬀ eine. Such 
quick NIRS – chemometric method can be used 
for in line/at line monitoring of the manufacturing 
process of fi xed dose combinations tablets with 
paracetamol and caﬀ eine and is useful in achiev-
ing the goals of the PAT concept.
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P2C-12
Applying the principles of quality by design 
coupled with multivariate data analysis 
in establishing the impact of raw material 
variability for extended release indapamide 
tablets
 ILYÉS, K.,  CASIAN, T.,  HALES, D.,  RUS, L., 
 ȘTIUFIUC, R.,  TOMUȚĂ, I .
Department of Pharmaceutical Technology and Biopharmacy, 
Faculty of Pharmacy, University of Medicine and Pharmacy 
„Iuliu Hațieganu”, Cluj-Napoca, Romania.
Department of Drug Analysis, Faculty of Pharmacy, University 
of Medicine and Pharmacy „Iuliu Hațieganu”, Cluj-Napoca, 
Romania
Department of Pharmaceutical Physics-Biophysics, Faculty 
of Pharmacy, University of Medicine and Pharmacy „Iuliu 
Hațieganu”, Cluj-Napoca, Romania
BACKGROUND: The raw material is considered a 
source of variability, however the conventional, 
empirical development approach does not oﬀ er 
much information regarding the critical att ributes 
and how processes can be modulated as to remain 
in the constant quality region.
AIMS: The objective of the study was to devel-
op extended release hydrophilic matrix tablets 
with indapamide based on the quality by design 
concept, evaluating the impact of interchanging 
diﬀ erent types and suppliers of raw material on 
the fi nished product quality profi le.  
RESULTS:  Results showed signifi cant variabili-
ty within the in vitro release tests, the root cause 
being traced back to the API. The investigation 
was extended as to characterize the material from 
diﬀ erent physicochemical perspectives and using 
the multivariate data processing technique it was 
able to establish a network that can explain the 
global phenomena.  
CONCLUSIONS: Applying small, inevitable 
changes within the raw material proved to impact 
the fi nal product quality, highlighting the need to 
establish a risk based control strategy for the sup-
plied materials.  The impact of the raw material is 
complex, resulting from the simultaneous action 
of diﬀ erent physicochemical properties, suggest-
ing that the current approach of material selection 
and specifi cation establishment should be recon-
sidered as to include a multivariate data analysis.   
REFERENCES: 
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P2C-13
Continuous twin screw melt granulation and 
real-time imaging as a potential PACT tool
 FAZEKAS, Á.,  MADARÁSZ, L.,  DÉMUTH, B., 
 FARKAS, A.,  GYÜRKÉS, M.,  MAROSI, GY., 
 NAGY, ZS. K.
Department of Organic Chemistry and Technology, Budapest 
University of Technology and Economics, Budapest, Hungary
BACKGROUND: Continuous manufacturing com-
bined with real-time analytics and process control 
might be the new standard for newly developed 
pharmaceutical manufacturing processes in the 
next decades which is highly promoted by the au-
thorities besides to the big pharma companies. [1] 
The academia must support these eﬀ orts by devel-
oping new, innovative continuous technologies, 
real-time analitics and real-time control strategies 
to achieve Process Analitically Controlled Tech-
nologies (PACTs).
AIMS: The fi rst aim of this study is to develop a 
continuous granulation method without the use of 
water of organic solvent based on melting of 
excipient(s) during the process which can act as a 
granulation liquid. The other aim was to map the 
capabilities of real-time imaging combined with 
real-time image analysis for process monitoring 
and feedback control of contiunuous granulation 
as a PACT tool.  
RESULTS:  Solvent-free continuous melt granu-
lation and tableting experiments were conducted 
using a twin screw QuickExtruder as a continuous 
melt granulator and a Dott  Bonapace excentric 
tableting machine. Caﬀ eine as a model API and 
lactose as fi ller were granulated using PEG as 
granulating material which melts over 60°C and 
agglomerates the particles to form granules with 
larger size and bett er fl owability than the unpro-
cessed mixture. After the granulation process the 
fl owability and the tabletability of the caﬀ eine 
containing mixture were improved signifi cantly 
from an untabletable powder mixture to a well 
tabletable granule. Owing to the solvent-free gran-
ulation process there was no need for the time-, 
space- and energy-consuming drying of the gran-
ules. In-line imaging with the developed real-time 
image analysis can provide valuable information 
about the particle size distribution, the particle 
shapes and the change of them during the process. 
The obtained information can be a good base of 
the real-time control of the process.
CONCLUSIONS: Continuous melt granulation 
is a promising solvent-free granulation alternative 
with several considerable advantages (e.g. sol-
vent-free, drying-free, continuous). Real-time im-
aging combined with real-time can be a good de-
velopment tool for process understanding and can 
be used for process control as well.
REFERENCES: 
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P2C-14
Improving protein product quality through 
real-time bioprocess control based on raman 
spectroscopy
 PITTERS, A.2,  CUELLAR, M.1,  GILLIAM, S.1, 
 STRACHAN, D.1
1Kaiser Optical Systems, Inc., Ann Arbor, USA
2Kaiser Optical Systems, SARL, Saint-Priest, France
BACKGROUND: The quality of therapeutic CHO 
cell culture proteins is a result of the entire produc-
tion process. Producing therapeutic proteins with 
consistent characteristics is a challenging task which 
requires a high level of process understanding and 
maintaining process conditions within an optimal 
batch trajectory.  
AIMS: The aim was to enable - via in situ Raman 
spectroscopy - simultaneous monitoring of multiple 
product quality relevant parameter and allowing for 
in-process corrections.  
RESULTS:  Process development, pilot, and man-
ufacturing scale CHO cell culture batches were uti-
lized to demonstrate the feasibility of monitoring 
and eﬀ ect of controlling multiple critical process pa-
rameters in real-time using Raman spectroscopy. 
Case studies in the presentation illustrate the impact 
of Raman based bioprocess control to the cells, the 
cell culture environment, the yield, and fi nally to the 
quality of therapeutic proteins [1]. Results of the case 
studies provide valuable insights into eﬀ ective con-
trol strategies and explicate the successful transfer of 
analytical Raman methods from process develop-
ment to GMP manufacturing.  
CONCLUSIONS: Precise navigation and smart 
adaptation of critical upstream process conditions 
based on Raman spectroscopy reduced the complex-
ity of producing high quality products.  
REFERENCES: 
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P2C-15
Application of Quality by Design in 
orodispersable tablets development 
 SUCIU, Ş.,  IURIAN, S.,  BOGDAN, C., 
 IOVANOV, R.,  RUS, L.,  MOLDOVAN, M., 
 TOMUŢĂ, I .
Department of Pharmaceutical Technology and 
Biopharmaceutics, Faculty of Pharmacy, University of Medicine 
and Pharmacy “Iuliu Hațieganu”, V. Babeș 41, Cluj-Napoca, 
Romania
BACKGROUND: The actual concern of pharma-
ceutical product development relies on ensuring 
an adequate product quality through an eﬀ ective 
process. Quality-by-Design (QbD) concept was in-
troduced in drug formulation and development in 
order to achieve a good process understanding 
and to identify variability sources that infl uence 
the product features, respectively to build quality 
from development stage.
AIMS: The current work had the main purpose 
to develop and characterize orodispersable tablets 
containing ibuprofen, obtained through lyophili-
sation. Risk assessment evaluation was applied for 
this experiment. With a D-optimal experimental 
design with six factors and two levels, twenty-fi ve 
experimental formulations were prepared with 
the intent to evaluate the formulation factors that 
infl uence the desired quality target product pro-
fi le (QTPP): disintegration time, wett ing time, 
mean dissolution time, texture and bio-adhesive 
features of the orodispersable tablets.  
RESULTS:  The main observations are the fol-
lowing: the type of the matrix forming and bio-
adhesive agent infl uenced the disintegration time. 
All formulation factors had infl uences on the wet-
ting time, while no signifi cant infl uence was ob-
served for the bio-adhesive properties of the tab-
lets. The hardness and rigidity of the tablets was 
increased by gelatine, while the methylcellulose 
and xanthan gum conducted to opposite results. 
The fracturability of the tablets was infl uenced 
only by the quantitative factors, respectively the 
percentage of the matrix forming agent and the 
bio-adhesive agent. The dissolution profi le was 
slightly infl uenced by the  type of bio-adhesive 
agent.  Based on data analysis, the conditions for 
an optimum formulation were defi ned.   
CONCLUSIONS: The obtained results repre-
sent  a contribution in understanding the prepara-
tion and formulation processes of orodispersable 
dosage forms. According to the results orodispers-
able tablets with ibuprofen for paediatric use with 
desired pharmaceutical characteristics may be 
successfully obtained by lyophilisation. 
REFERENCES: 
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 Macro- and microstructural tracking of 
preformulation and ageing-related changes of 
papaverine hydrochloride-loaded electrospun 
nanofi brous buccal sheets
 KAZSOKI, A.,  SZABÓ, P.,  SÜVEGH, K., 
 VÖRÖS, T.,  ZELKÓ, R.
University Pharmacy Department of Pharmacy Administration, 
Semmelweis University, Hőgyes Endre St. 7-9, H-1092 
Budapest, Hungary
BACKGROUND: Papaverine hydrochloride has a 
non-specifi c direct relaxant eﬀ ect on smooth mus-
cles. One of its therapeutic indications is cerebral 
ischemia, but some unfavorable properties confi ne 
its clinical applicability. A nanofi brous buccal for-
mulation can improve the oral bioavailability of 
the drug as a result of the enhanced solubility and 
lack of the fi rst pass metabolism. The intra-and in-
ter-individual variability can also be decreased as 
well.
AIMS: The aim of this study was to prepare pa-
paverine hydrochloride loaded buccal nanofi -
brous sheets and to determine the optimum com-
position of hydroxypropyl cellulose (HPC) - 
poly(vinyl alcohol) (PVA)  gels (with 15 %(w/w) 
total polymer concentration) for electrospun fi ber 
formation with the combination of rheological, 
molar refl ectance, and scanning electron micros-
copy measurements (SEM). The further aim was 
to track the solid state changes relating to the 
stress induced physical ageing of the best compo-
sition system. Micro- and macrostructural altera-
tions were detected using Raman-, positron anni-
hilation lifetime- and Fourier transform infrared 
spectroscopy and SEM.     
RESULTS:  Correlation was found between the 
micro- and macrostructural properties of the gels 
and their electrospinnability. Gels of the lowest 
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elasticity and slightest intermolecular interactions 
and the more ordered intramolecular structure 
contributed to the best fi ber characteristics of the 
samples. During the stability test signifi cant 
changes were revealed at both supramolecular 
and macroscopic levels.  Two-step ageing process 
of the drug carrier and a partial phase transition 
of the active were observed. 
CONCLUSIONS: The combination of micro- 
and macrostructural characterization of the gels 
and the electrospun samples is an eﬀ ective way to 
achieve the optimum characteristics and follow 
the physical stability of the formulation. 
REFERENCES: 
1. Kazsoki A. et al. J. Pharm. Biomed. Anal. 138, 357-362. 
(2017)
P2D-2
The eﬀ ect of dilution and temperature on the 
viscosity of various ocular lubricants
 RAČIĆ, A.1,  KRAJIŠNIK, D.2,  ČALIJA, B.2, 
 NIKOLIĆ, I .2,  MILIĆ, J .2
1 University of Banja Luka – Faculty of Medicine, Department of 
Pharmacy, Banja Luka, Bosnia and Herzegovina 
2 University of Belgrade – Faculty of Pharmacy, Department of 
Pharmaceutical Technology and Cosmetology, Belgrade, Serbia
BACKGROUND: The main limitation of current 
ocular lubricants is the short duration of symptom 
control. An alternative approach is to use lubri-
cants with high viscosity.1 The viscosity of eye 
drops required to maintain precorneal residence 
has been reported to be in the range 15 – 150 
mPa·s.2
AIMS: To investigate the eﬀ ect of dilution and 
temperature on the viscosity of ocular lubricants 
prepared using various viscosity modifi ers. Com-
pounded ophtalmic vehicles containing Hyprom-
ellose (HPM) 0.3 %, MMW chitosan (CS) 1 %, hy-
droxypropyl guar gum (HP GG) 0.5 %, CS 0.5 %/HP 
GG 0.25 % and commercial eye drops (Hemo-
drops® (containing HPM 0.5 %), Systane® Ultra 
Lubricant (SU), and Systane® Gel Drops (SGD)
(both containing HP GG)) were investigated. The 
viscosity measurements were performed using a ro-
tational rheometer at 20 and 34 °C (after addition of 
the simulated tear fl uid (pH 7.4) in a ratio of 40:7).
RESULTS:The obtained results showed de-
crease in viscosity of compounded eye drops of 
about 2-fold i.e. from 14.15 to 8.85 mPa·s (for HPM 
0.3 %), 86.45 to 38.15 mPa·s (for CS 1 %), 91.45 to 
52.5 mPa·s (for HP GG 0.5 %) and 49.25 to 24.35 
mPa·s (for CS 0.5 %/HP GG 0.25 %). An increase in 
viscosity (from 2.7 to 19.1 mPa·s) was observed 
only for commercial (SU) drops. The highest val-
ues of viscosity were revealed for SGD sample 
(216 i.e. 136 mPa·s) under the stated experimental 
conditions.
CONCLUSIONS: The simultaneous increase of 
temperature and dilution of the prepared ocular 
lubricants induced changes in viscosity for all the 
samples. The samples containing CS and HP GG 
(alone or in combination) have shown higher 
starting values of viscosity and after the exposure 
to the stated experimental conditions, compared 
to the samples containing HPM. The viscosity of 
all the studied ocular lubricants was in the range 
recommended for topical ophthalmic prepara-
tions.
REFERENCES: 
1. Rhaman M.Q. et al. Eye 26, 1579-1584 (2012)
2. Baranowski P. et al. Sci World J (2014)
P2D-3
Stability study of acetylsalicylic acid during 
pharmaceutical operations 
 BOUHAOUCHE, A.,  BOURAI, I ., 
 BENAYACHE, A.,  DAOUD, K.
Laboratory of transfer phenomena, Faculty of Mechanical 
Engineering and Process Engineering, University of Sciences 
and Technology Houari Boumediene, BP32 El Alia Bab Ezzouar, 
16111 Algiers. Algeria
BACKGROUND: The Acetylsalicylic acid (ASA) is 
known to be sensitive towards moisture heat and 
pH changes[1] . The stability studies constitutes a 
decisive element during pharmaceutical devel-
oppement and guarantees quality of the product, 
which is the aim of this study.[2]
AIMS: The aim of this work is to study the sta-
bility of the Acetylsalicylic acid during fabrication 
and for pH changes.In one hand the degradation 
of the ASA was tested during pharmaceutical op-
erations such as, milling, compression and mix-
ing, which can generate a rise in temperature . 
And in the other hand, l’ASA was treated with 
chloridric acid and sodium hydroxid solutions 
with diﬀ erentes concentrations varing beween 0.5 
and 3 M, in order to test the eﬀ ect of the pH 
change on the ASA stability.  
RESULTS:  The ASA degradation was observed 
during milling at three speed levels ( 150, 350 and 
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700 RPM) for 1 hour. The ASA degradation is 
more pronouced at 150 RPM, where 13% of degra-
dation was obseved compared to 7% of degrada-
tion at 350 and 700 RPM. The addition of 10% of 
microcristallyne celluloce pH 102 during milling 
can reduce the drug degradation. The degradation 
was not observed either during compression or 
mixing. The acid treatment of ASA caused a deg-
radation of 4%, against the basic treatement 
caused a degradation of 10%.
CONCLUSIONS: From this study it can be con-
clude that the milling operation cause ASA degra-
dation resulting from the rise in temperature and 
the active ingredient can be protected during mill-
ing operation by adding the microcrystalline cel-
lulose pH102, which be used as fi ller in the formu-
lation.  The ASA in more sensitive to the basic pH 
changes then the acid ones. 
REFERENCES: 
1. Cahyadi C et al. Eur J Pharm Biopharm In press (2014)
2. Ranjit S et al.  J Pharm Educ Res 3, (2012)
P2D-4
Monitoring the stability and physichochemical 
changes of Suspensio anaesthetica  
 BOGNÁR, G.,  SZABÓ, P.,  ZELKÓ, R., 
 KOVÁCS-BALOGH, J . 
University Pharmacy Department of Pharmacy Administration, 
Faculty of Pharmacy, Semmelweis University, Budapest, 
Hungary 
 
BACKGROUND: Suspensio anaesthetica is an oﬃ  -
cial formulation of Formulae Normales Editio VII. 
used in the treatment of oncological patients for 
the anesthesia of the mouth, the throat, and the 
esophageal mucosa. The active substance, benzo-
caine belongs to the group of local anesthetics, 
which can be found in a suspended form in the 
magistral preparation because of its low aqueous 
solubility.  Swallowing the product often causes 
diﬃ  culties for oncological patients, especially for 
those who suﬀ er from head and neck cancer. The 
major issue surrounding this formulation lies in 
the high viscosity resulted from the use of hy-
droxyethylcellulose. Most of the patients prefer a 
drug with „water-like” consistency. 
AIMS: The aim of our research was to prepare 
suspensions of reduced Mucilago hydroxyaethyl-
cellulosi content to facilitate the administration of 
the medicine for oncological patients with swal-
lowing diﬃ  culties.   
RESULTS: As a result of the reduced amount of 
thickening agent, the preparations did not meet 
the zeta potential requirements. At the end of the 
4-week long storage period, the average particle 
sizes increased, the viscosity decreased, however 
the redispersability was retained. 
CONCLUSIONS: On the basis of the results we 
can state that the formulations tested do not have 
adequate physical stability. Zeta potential values 
and particle size characteristics clearly indicate 
that the stability of the composition is negatively 
aﬀ ected by the reduction of Mucilago hydroxya-
ethylcellulosi. Although, the lower the amount of 
Mucilago hydroxyaethylcellulosi, the lower the 
viscosity, in accordance with the hypothesis, fur-
ther stability tests are required. 
REFERENCES:  
1. Mats L. et al. Ann T Nord Rheol Soc 20, 209-214 (2012) 
P2D-5
Importance of freeze-thaw studies in 
biopharmaceutical development
 BALÁZS, B.,  GYURÁCZ, B.,  VÁSÁRHELYI, V. S.
Gedeon Richter Plc. Biotechnology R&D, Budapest, Hungary
BACKGROUND: Biopharmaceutical drug product 
quality should be controlled throughout manufac-
turing, storage, transportation, and delivery to the 
patients. Storage conditions are defi ned during 
stability studies in accordance with the ICH/WHO 
guidelines, but manufacture and transport are not 
covered by these guidelines. Additional such 
freeze-thaw studies are necessary to gather a full 
dataset in relation to the product’s stability profi le.
AIMS: Freezing of bulk protein solutions prior 
to drug product manufacture is common in the bi-
opharmaceutical industry. Freezing allows for 
prolongation of protein drug substance shelf life. 
However, freezing and thawing may cause chang-
es in the chemical and physical properties of bio-
pharmaceutical product solutions. The objective 
of the study was to determine the impact of sever-
al freeze-thaw cycles on product stability.  
RESULTS:  Several analytical methods such as 
Reverse Phase (RP), Size Exclusion (SE), Ion Ex-
change chromatography (IEX), Micro-Flow Imag-
ing (MFI), Capillary gel electrophoresis (CGE), 
Circular dichroism (CD) spectroscopy and other 
physical characterization methods were used to 
analyse protein stability after freeze/thaw cycles.
CONCLUSIONS: Based on the results from 
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these carefully selected analytical methods, in-
sights were drawn on the impact of freeze-thaw 
stress on the product stability of certain biophar-
maceutical proteins. 
REFERENCES: 
1. Ammann C. AAPS PharmSciTech 12, 1264-1275 (2011) 
2. Rayfi eld W.J et al. J Pharm Sci, In Press, (2017) 
P2D-6
Evaluation of biocompatible polymer gels 
before and after freeze drying
 SZERŐCZEI, D.,  FÜLÖP, V.,  JAKAB, G., 
 LENGYEL, M.,  BALOGH, E.,  ANTAL, I .
Semmelweis University, Department of Pharmaceutics, 
Budapest, Hungary
BACKGROUND: Freeze drying oﬀ ers many ad-
vantages in pharmaceutical technology. The pro-
longed physical, chemical and microbiological sta-
bility thanks to low moisture content ensures a 
long shelf-life. The product is porous and has high 
specifi c surface area, so it oﬀ ers improved dissolu-
tion rate. Freeze drying is used for formulation of 
injections, infusions, transfusions, vaccines and 
orally disintegrating tablets as well as for wound 
dressings or contact lenses containing drugs1. Hy-
drophilic polymers like chitosan, sodium alginate, 
hyaluronic acid, locust bean gum and Carbopol® 
polymers are biocompatible gelling substances for 
these lyophilized products2.
AIMS: The aim of this study was to evaluate bio-
compatible polymer gels before and after freeze dry-
ing, comparison of the polymers above.  
RESULTS:  Chitosan gels were prepared by dis-
solving chitosan in diﬀ erent organic acids. Sodium 
alginate gels were made using purifi ed water, as 
well as the locust bean gum and Carbopol® gels. 
Rheological properties of the gels were investigated 
using Kinexus Pro rheometer. The gels were lyophi-
lized in a Scanvac Coolsafe™ freeze dryer. Water 
content was determined by Karl-Fischer method us-
ing Metrohm 787 KF Titrino autotitrator.
CONCLUSIONS: The polymers can be lyophi-
lized to obtain a dry, porous structure with pro-
longed stability. The freeze-dried gel samples 
showed gelling ability after reconstitution. The rheo-
logical properties of gels are appropriate to formu-
late freeze dried drug delivery systems.
REFERENCES: 
1. Hansen, L. J. J. et al.  Vaccine 33, 5507–5519 (2015).
2. Krüger-Szabó, A. et al. J. Pharm. Biomed. Anal. 104, 12–16 (2015).
P2D-7
Evaluation of potential compressing of the 
microspheres containing losartan potassium
 SARECKA-HUJAR, B.1,  BALWIERZ, R.2, 
 MARCINIAK, D.3,  JANKOWSKI, A.1
1 Medical University of Silesia in Katowice, School of Pharmacy 
with the Division of Laboratory Medicine in Sosnowiec, 
Department of Pharmaceutical Technology, Sosnowiec, Poland 
2 Silesian Medical College in Katowice, Poland; 
3 Wroclaw Medical University, Department and Institute of 
Pharmaceutical Technology, Wroclaw, Poland
BACKGROUND: Microspheres are one of the drug 
forms which can provide prolonged release of the 
active substance. They are monolithic, porous or 
smooth micropellets, sized from 1 to 500 μm.
AIMS: In the present study we aimed to analyze 
the possibility of compressing microspheres with 
losartan potassium. Losartan was selected for the 
study due to its low bioavailability (33%) and 
short half-life in the human body (2h).  
RESULTS:  For the preparation of microspheres 
containing losartan potassium on the Eudragit 
L30D55  matrix, the method of spray drying was 
used. The tablets were prepared by direct com-
pression using the ERWEKA AR400 tablet press 
with 6 mm punches and a pressure force of 8kN. 
Five series of tablets containing microspheres with 
LOS:EUDRAGIT ratio of 1: 1 and 10% methylcel-
lulose, 30% methylcellulose and mannitol as a fi ll-
er were made. To assess the presence of micro-
spheres in the manufactured tablets the pictures 
of the tablets were also made using Scanning Elec-
tron Microscope (SEM, SUPRA25 Carl Zeiss com-
pany). The analysis of the photos justifi es the fact 
that with the increasing amount of methylcellu-
lose, the homogeneity of the surface increases as 
well as the more concentrated tablet surface is ob-
served. Compared to the standard (microspheres 
Los:Eu 1:1), microspheres contained in tablets 
have smaller particle size and less spherical mor-
phology.
CONCLUSIONS: Based on the performed stud-
ies we can conclude that the microspheres of 
losartan potassium with the size not exceeding 3.5 
μm do not deform during compressing while the 
larger microspheres are deformed and/or lost in 
the analyzed material. 
REFERENCES: 
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P2D-8
Atenolol ointment stability
 PILIPOVIC, B.1,  PILIPOVIC, S.2,  PASIC-
KULENOVIC, M.1   UZUNOVIC, A.2
1 Department of Pharmaceutical Development and Registration, 
Bosnalijek d.d. Sarajevo, Bosnia and Herzegovina
2 Agency for medicinal products and medical devices of Bosnia 
and Herzegovina, Sarajevo, Bosnia and Herzegovina
BACKGROUND: Atenolol is a known drug and it 
has been used for a number of years in the treat-
ment of cardiovascular diseases. For the purpose 
of testing potential local anti-infl ammatory activi-
ty of beta blocker containing ointments, a 1% aten-
olol ointment in the fatt y carbohydrate medium 
was prepared. The ointment was tested for stabili-
ty. Evaluations for physical and chemical stability 
were performed initially and throughout the stor-
age period of six months.
AIMS: The aim of the study is prepare and test-
ing stability of the 1% atenolol ointment prepared 
in the fatt y carbohydrate medium. 
RESULTS: Testing of the stability of the samples 
of fi nished ointment stored at the temperature of 
25°C and relative humidity of 60% and the tem-
perature of 40°C and relative humidity of 75% was 
performed with two analytical methods: UV spec-
troscopy and high pressure chromatography. By 
comparing the results obtained from these two 
methods no diﬀ erences of the said content were 
observed. The samples stored according to ICH 
guidelines did not show signifi cant degradation. 
In the tested ointment the atenolol content is with-
in the limits prescribed in monographs for oint-
ment (95,00 to 105,00%) in accelerated test on 
40°C, as well as in long-term test at 25°C, over a 
period of 6 months. The content of degradation 
products did not exceed the values of 0,04 for in-
dividual related substance.
CONCLUSIONS: The pre-formulation tests have 
shown a satisfactory quality of atenolol ointment in 
which this substance has been incorporated.  Aten-
olol is compatible with a fatt y medium used for 
production of 1% atenolol ointment. It has been es-
tablished that the ointment is stable for at least a 
year if it is kept at the temperature up to 25°C, i.e. 
at least six months at the temperature up to 40°C.
REFERENCES:
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HPLC determination of benzaldehyde in benzyl 
alcohol containing injectable formulations
 UZUNOVIC, A.1,  PILIPOVIC, S.1,  TUBIC, B.1, 
 SAPCANIN, A.2,  TAHIROVIC, I .3
1 Agency for medicinal products and medical devices of Bosnia 
and Herzegovina, Sarajevo, Bosnia and Herzegovina
2 Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
3 Faculty of Science, Sarajevo, Bosnia and Herzegovina
BACKGROUND: Benzyl alcohol is frequently used 
as a bacteriostatic agent or cosolvent in a variety 
of liquid pharmaceutical preparations. It can easi-
ly undergo oxidative degradation to benzaldehyde 
and benzoic acid. The presence of these potential 
impurities needs to be checked owing to its reac-
tivity and toxicity (neurotoxic and allergic reac-
tions) [1].
AIMS: The purpose of this work was to adapt 
and use the HPLC method proposed by Tan et al. 
for the assay of benzyl alcohol, benzaldehyde and 
benzoic acid in injectable formulations commer-
cially available from the local market [2].
RESULTS: A total of 10 diﬀ erent injectable 
products containing benzyl alcohol were analysed 
using a Shimadzu LC10-Avp system, equipped 
with a DAD detector, auto-injector (20 μL) and a 
Zorbax StableBond C18 column (250 X 4.6 mm, 5 
μm), at 25°C. HPLC was performed with an iso-
cratic mobile phase composed of water-acetoni-
trile-glacial acetic acid (760:240:5, v/v/v, pH 2.5) 
and peaks were detected at 254 nm. Flow rate was 
2.0 mL min-1. The new and simple HPLC assay 
method was validated for linearity (r> 0.99927), 
precision (repeatability: RSD< 0.96%; intermediate 
precision: RSD< 0.97%), accuracy (Rc= 98.76-
101.22%) and specifi city. Established HPLC meth-
od proposed for selective quantitation of neuro-
toxic benzaldehyde is suitable for application to 
the quality control analysis of benzyl alcohol con-
taining injection formulations. The results showed 
that three of the generic brands contained consid-
erable amounts of the toxic benzaldehyde (>0.05% 
of the benzyl alcohol content).
CONCLUSIONS: The developed HPLC method 
can be used to quantify benzaldehyde in injectable 
formulations. The fi nding that some injectable for-
mulations contain higher than acceptable levels of 
benzaldehyde, illustrates the need for stringent 
quality control in the manufacture of these solu-
tions.
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Comparison of pharmaceutical technological 
parameters of pharmaceutical equivalents
 HADŽIABDIĆ, J .1,  VRANIĆ, E.1,  RAHIĆ, O.1, 
 ELEZOVIĆ, A.1,  REGDON JR., G.2
1University of Sarajevo, Department of Pharmaceutical 
Technology, Sarajevo, Bosnia and Herzegovina
2University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs,Szeged, Hungary
BACKGROUND: Ranitidine hydrochloride is com-
mercially available as a generic drug. Pharmaceu-
tical equivalents may vary in their pharmaceutical 
technological characteristics due to the applica-
tion of diﬀ erent technological parameters in the 
production process, as a result of diﬀ erent excipi-
ents used in generic drugs production.
AIMS: In this study, we compared pharmaceuti-
cal technological characteristics of two generic drugs 
of ranitidine fi lm coated tablets (tablets 1 and tablets 2) 
from diﬀ erent manufacturers, which are available 
on the market of Bosnia and Herzegovina. Both ge-
neric drugs contain ranitidine hydrochloride, but 
diﬀ erent excipients in tablet core and fi lm coating.  
RESULTS:  Tablets have been evaluated using 
the same pharmaceutical technological tests (uni-
formity of dosage units, assay, dissolution test, fri-
ability test, disintegration and hardness testing) to 
determine whether the obtained data fulfi ll phar-
macopoeial requirements. The results of uniformi-
ty of dosage units, assay, friability testing and dis-
integration time of tablets for both generic drugs 
meet pharmacopoeial requirements. Signifi cant 
variations were observed in hardness testing for 
tablets 1 compared to hardness testing for tablets 2. 
Tested pharmaceutical equivalents may be consid-
ered bioequivalent because of in vitro dissolution 
testing of ranitidine tablets.
CONCLUSIONS: Based on pharmaceutical 
technological characterization of ranitidine fi lm 
coated tablets, tablets 2 would be drug product of 
choice. Because of lactose intolerance, tablets 2 can 
not be used in all patients.
REFERENCES: 
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P2D-11
Detection of interactions between active 
substance and excipients used in the 
formulation of lisinopril coated pellets using 
diﬀ erential scanning calorimetry
 RAHIĆ, O.1,  VRANIĆ, E.1,  HADŽIABDIĆ, J .1, 
 ELEZOVIĆ, A.1,  REGDON JR., G.2
1University of Sarajevo, Department of Pharmaceutical 
Technology, Sarajevo, Bosnia and Herzegovina
2University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs, Szeged, Hungary
BACKGROUND: Pellets are very popular solid 
dosage form, since they have numerous therapeu-
tical and technological advances. Their spherical 
shape and smooth surface make them ideal sub-
strate for coating, in order to achieve controlled 
release of active substance. If the active substance 
is highly water soluble it can migrate into the coat-
ing layer and lead to faster release rates. Men-
tioned migration can be a consequence of interac-
tion between active substance and excipients used 
in formulation. 
AIMS: TG/DSC investigation of the thermal be-
havior of lisinopril coated pellets and possible inter-
actions between the active substance and excipients, 
that may occur during the processing of pellets.  
RESULTS:  DSC thermograms of lisinopril coat-
ed pellets show broad endothermic peaks, of the 
active substance, but shifted towards higher tem-
peratures. No peaks characteristic for excipients 
can be observed in the DSC thermograms of lisin-
opril coated pellets. There can be seen a broad 
exothermic peak, not present in DSC thermo-
grams of any of the materials used.
CONCLUSIONS: The thermal analysis of lisin-
opril coated pellets shows that there are no inter-
actions between active substance and exipients. 
Exothermic peak present in DSC thermograms of 
coated pellets may be att ributed to partial solubili-
zation of the active substance in water during the 
DSC analysis.  
REFERENCES: 
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Rheological profi ling of sunscreen formulations 
– infl uence of main emulsifi er and thickener
 ELEZOVIĆ, A.1,  VRANIĆ, E.1,  HADŽIABDIĆ, 
J .1,  RAHIĆ, O.1,  REGDON JR., G.2 
1University of Sarajevo, Department of Pharmaceutical 
Technology, Sarajevo, Bosnia and Herzegovina
2University of Szeged, Institute of Pharmaceutical Technology 
and Regulatory Aﬀ airs, Szeged, Hungary
BACKGROUND: Rheological measurments oﬀ er 
an insight into internal structure of non-Newto-
nian fl uids, like liquid and semisolid preparations. 
Rheological properties of cosmetic products are 
crucial in their manufacturing as well as perfor-
mance.
AIMS: Investigation of the infl uence of main 
emulsifi er and the presence of a thickener on rhe-
ological properties of sunscreen emulsion formu-
lations.  
RESULTS:  Four sunscreen lotion formulations 
were developed containing anionic emulsifi er po-
tassium stearate (formulations A1 and A2) or non-
ionic emulsifi er glyceryl stearate/behenate (formu-
lations N1 and N2) as a main emulsifi er. A1 and N1 
contained thickener Carbopol 940, while A2 and N2 
did not. The rheological profi les of the formulations 
included: steady state viscosity, yield point, tixotro-
py, oscillatory amplitude sweep and oscillatory fre-
quency sweep. All formulations showed non-New-
tonian pseudoplastic fl ow. Formulations with an-
ionic emulsifi er had higher yield points. Formula-
tions containing thickener showed higher yield 
points. However, A1 had much higher increase of 
yield point compared to N1. All formulations 
showed low tixotropy. The hysteresis loop areas are 
larger in formulations containing thickener, and in 
formulation A1 it is manifold larger than in N1. Dy-
namic oscillatory sweeps of the formulations 
showed that the phase angle was constant and low, 
complex viscosity decreased logarithmically, elastic 
modulus (G’) was higher than viscous (G’’) and 
moduli were parallel. These characteristics imply 
internal gel-structure of the formulations.
CONCLUSIONS: Rheological characteristics of 
the formulations indicate pseudoplastic systems 
of structured emulsions that have stable inner gel 
stucture at rest. Small hysteresis loop areas imply 
fast recovery of the initial structure, thus creating 
homogenous fi lm on the skin surface that will 
serve its purpose in sun protection.  
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POSTER SECTION 2E 
BIOPHARMACY
P2E-1 
Melatonin: release studies from electrospun 
nanofi ber matrices for per os administration
 SIAMIDI, A.,  KIKIONI, S.,  TRAGOU, K., 
 KAPOTI, S.,  IOANNOU, E.,  VLACHOU, M., 
 ROUSSIS, V.,  TSOTINIS, A.
School of Health Sciences, Faculty of Pharmacy, Departments of 
Pharmaceutical Technology, Pharmacognosy and Chemistry of 
Natural Products and Pharmaceutical Chemistry, National and 
Kapodistrian University of Athens, Athens, Greece
BACKGROUND: Sleep problems are common, 
particularly among the elderly. Current hypnotic 
drugs are recommended only for short-term treat-
ment of insomnia, but concerns about “hangover” 
eﬀ ects and problems upon withdrawal persist. 
Melatonin, a hormone synthesized and released 
from the pineal gland at night, has been shown to 
have a hypnotic eﬀ ect in humans. During the last 
decade, we have developed novel pharmaceutical 
formulations suitable for treating sleep onset and 
sleep maintenance dysfunctions [1]. 
AIMS: Targeting at mimicking the physiological 
release of melatonin, we report herein on its re-
lease profi le in aqueous media from capsules 
loaded with electrospun nanofi ber matrices [2] in-
corporating melatonin.
RESULTS:  The results from the in vitro release 
experiments suggest that at pH 1.2, melatonin is 
almost instantaneously released from melatonin-
loaded nanofi bers, thus promoting sleep onset. In-
terestingly, melatonin’s release after this initial 
burst becomes well regulated at pH 6.8, exhibiting 
an ideal dissolution profi le for dealing with poor 
sleep maintenance. 
CONCLUSIONS: The electrospun nanofi bers 
used in this work are promising drug delivery 
systems for the per os administration of melatonin.
REFERENCES: 
1. Vlachou M. et al. Lett  Drug Des Discov 12, 259-262 (2015)
2. Kikionis S. et al. J Appl Polym Sci 132, 42153:1-5 (2015)
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P2E-2
In vivo performance study of fast inverted oil-
in-water emulsion and reference oil-in-water 
emulsion with incorporated dihydroquercetin
 MARTIĆ, R.,  KRAJIŠNIK, D.,  LUKIĆ, M., 
 SAVIĆ, S .,  NIKOLIĆ, I .,  MILIĆ, J .
Department of Pharmaceutical Technology and Cosmetology, 
Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
BACKGROUND: SWOP (Switch-Oil-Phase) emul-
sions are fast inverted oil-in-water (o/w) emulsions 
which invert into water-in-oil emulsions when ap-
plied to the skin (1). Dihydroquercetin (DHQ) is 
used in cosmetics as an antioxidant and shows ab-
sorption in the ultraviolet spectrum (2). Thus in-
corporation of DHQ into SWOP emulsion could 
result in new waterproof sun protection product. 
AIMS: The SWOP (SE) and the reference o/w 
(ROWE) emulsions without DHQ and with 5% of 
DHQ  (F1 and F3, respectively) were prepared to 
estimate their diﬀ erent eﬀ ects on the skin. For that 
purpose, an in vivo, short-term study which in-
cluded measurements of transepidermal water 
loss (TEWL), stratum corneum hydration (SCH), 
skin’s pH (pH) and the erythema index (EI) was 
performed.  
RESULTS:  There were no statistically signifi -
cant changes at any time point in SCH and TEWL 
values for any sample. Nevertheless, 1 hour after 
application, the sample SE showed the highest 
trend of increase in SCH. Furthermore, a trend of 
TEWL increase was noticeable after o/w emulsion 
application, and the results for SE and F1 samples 
were similar to the non-treated control. No chang-
es in the pH and EI values were noticed after the 
emulsions application. A specially designed 2-min 
study was performed on F1 sample to observe 
possible eﬀ ects of the SWOP emulsion on SCH, 
due to its inversion. It was determined that SCH 
was statistically increased comparted to the basal 
values even 20 s after application. However, 1 min 
after application, SCH levels returned to the basal 
values without further changes.
CONCLUSIONS: An in vivo performance study 
indicated bett er hydrating potential of the SWOP 
compared to the o/w emulsion. Additionally, 
emulsions with DHQ did not change the skin pH 
and EI values, which implys satisfactory irritation 
potential. The obtained results of SCH levels re-
vealed fast inversion of the SWOP emulsion. 
REFERENCES: 
1. Beuché M et al. EP1917954 A1 (2008).
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P2E-3
Antibacterial activity and safety testings of 
diﬀ erently designed electrospun matrices for 
periodontal diseases
 REPŠE, P.,  SAKS, L.,  ZUPANČIČ, Š.,  PUTRINŠ, 
M.,  TENSON, T.,  LAIDMÄE, I .,  KRISTL, J ., 
 KOGERMANN, K. 
Institute of Pharmacy, University of Tartu, Estonia
BACKGROUND: Patients with periodontal diseas-
es, caused by diﬀ erent bacteria (1), are often pre-
scribed antibacterial agents to avoid infection de-
velopment. It is a great challenge to deliver the 
drug locally into periodontal pockets. One solu-
tion would be to use electrospun drug-loaded fi -
brous matrices as delivery systems for antibacteri-
al agents locally.  
AIMS: To prepare electrospun drug-loaded ma-
trices and understand their antibacterial activity 
and safety for dental applications.   
RESULTS:  Electrospun nanofi brous matrices 
based on poly(ε-caprolactone) (PCL) together with 
diﬀ erent antibacterial agents metronidazole 
(MTZ) and ciprofl oxacin HCl (CPR) were success-
fully designed and investigated for their drug re-
lease, antibacterial activity and safety. Antibacte-
rial activity testings by agar diﬀ usion were per-
formed in aerobic as well as anaerobic conditions 
which allowed revealing the eﬀ ectiveness of de-
veloped matrices. Pathogenic bacterial strains im-
portant for periodontitis showed diﬀ erent antibi-
otic sensitivity against MTZ and CPR released 
from drug-loaded matrices. Combination matrices 
consisting both MTZ and CPR showed the inhibi-
tion of bacterial growth against all tested bacterial 
strains, CPR was more eﬀ ective against Actinomy-
ces weissii and MTZ against other anaerobic bac-
teria (eg Fusobacterium nucleatum subsp. poly-
morphum). All tested matrices were non-toxic to 
normal baby hamster kidney fi broblast cells . 
CONCLUSIONS: Combined metronidazole 
(MTZ) and ciprofl oxacin (CPR) loaded electros-
pun matrices are biocompatible and useful for the 
prevention and treatment of periodontitis. For the 
periodontitis treatment it is important to investi-
gate the activity of drug-loaded matrices on both 
aerobic as well as anaerobic relevant pathogenic 
bacterial strains.
ACTA-1703-BBBB.indb   203 9/19/17   6:28 PM
204 Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters  2017/3-4.
REFERENCES: 
1. Larsen and Fiehn, APMIS 125: 376–384 (2017)
P2E-4
Enhanced skin penetration of tacrolimus and 
fusidic acid from nano-sized colloidal carriers
 GÜNGÖRDÜK, S.,  ERDAL, MS.,  GÜNGÖR, S.
Department of Pharmaceutical Technology, Faculty of Pharmacy, 
Istanbul University, 34416 Universite, Istanbul, Turkey.
BACKGROUND: Tacrolimus and fucidic acid are 
highly lipophilic compounds used in topical treat-
ment of atopic dermatitis. In order to improve skin 
penetration of drugs nano-sized colloidal systems, 
namely microemulsions are widely used as topi-
cal carriers (1). 
AIMS: The aim of this work was to formulate 
microemulsions of both tacrolimus and fusidic 
acid and to examine skin uptake of these drugs 
from the optimized formulations.  
RESULTS:  Microemulsion components were 
consisted of Capryol 90 (oil phase), Labrasol (sur-
factant), Transcutol P (co-surfactant) and water. In 
vitro penetration of both drugs across pig skin 
from microemulsions was signifi cantly enhanced 
(up to 2.15 fold for tacrolimus and up to 1.86 fold 
for fusidic acid) compared to their marketed oint-
ment and cream formulations. ATR-FTIR analyses 
revealed the interactions between skin lipids and 
microemulsion components. CLSM studies dem-
onstrated the extension and depth of skin penetra-
tion of a model lipophilic fl uorescent dye from the 
optimised microemulsion.
CONCLUSIONS: Microemulsions could be a 
potential topical carrier to improve the skin up-
take of both tacrolimus and fusidic. 
REFERENCES: 
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P2E-5
Dissolution improvement of poorly water 
soluble model drug albendazole with surfactant 
assisted media milling process
 FÜLÖP, V.,  JAKAB, G.,  ENDRÉSIK, D.,  TÓTH, 
B.,  BALOGH, E.,  ANTAL, I .
Semmelweis University, Department of Pharmaceutics, 
Budapest, Hungary
BACKGROUND: Milling involves the application 
of mechanical energy to physically break down 
coarse particles to fi ner ones and is regarded as a 
“top–down” approach in the production of either 
micro-, either nanoparticles1. These particulates 
are mainly desired for the formulation of paren-
teral, respiratory and transdermal drug delivery 
systems. During a milling process we can im-
prove the solute drug’s dissolution rate can be im-
proved, by increasing its surface area and decreas-
ing the thickness of the diﬀ usion barrier. 
AIMS: The purpose of this study is to create 
nanosuspensions from the model drug albenda-
zole, which is a poorly water soluble BCS class II. 
drug, optimize the aﬀ ecting factors of the surfac-
tant assisted wet-milling process (milling speed, 
process time, diﬀ erent beads to powder ratios, 
types of diﬀ erent milling medias, diﬀ erent vol-
umes of the milling containers, diﬀ erent surfac-
tant types and concentrations)2. The optimized 
formula was then added to solid  carriers and 
dried. Both reconstitution from the solid carrier, 
dissolution profi le studies were investigated in ar-
tifi cial rumen fl uid and compared to the unmilled 
dispersion to demonstrate the eﬃ  ciency of the 
milling process.   
RESULTS:  Reconstitution studies demonstrat-
ed that, the released API’s PSDs are in the nano 
range. Surfactant assisted media milling signifi -
cantly improved the dissolution rate and water 
solubility of albendazole. 
CONCLUSIONS: Surfactant assisted media 
milling is an eﬀ ective technique to improve disso-
lution rate and water solubility of drugs, but we 
have many challenges to overcome, due to the 
several variable parameters infl uencing the pro-
cess. 
REFERENCES: 
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P2E-6
Improvement of solubility, dissolution rate 
and bioavailability of cilostazol using diﬀ erent 
technique of solid dispersion
 AGHRBI, I .,  FULOP,V.,  JAKAB, G., 
 SZEROCZEI, D.,  BALOGH, E.,  ANTAL, I .
Semmelwies University, Department of Pharmaceutics, 
Budapest, Hungary.
BACKGROUND: Solid dispersion is containing at 
least two diﬀ erent components one is hydrophilic 
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matrix and another is hydrophobic drug. Amor-
phous products and particularly amorphous solid 
dispersions are currently one of the most exciting 
areas in the pharmaceutical fi eld. This approach 
presents huge potential and advantageous fea-
tures concerning the overall improvement of drug 
bioavailability. Currently, diﬀ erent manufacturing 
processes are being developed to produce amor-
phous solid dispersions ranging from solvent 
evaporation to melting processes1,2.  
AIMS: The aim of this study was to improve 
dissolution rate, water solubility and stabilize 
amorphous form e.g. Cilostazol (CLZ) through 
formulation of binary and ternary solid dispersion 
systems (SDs) using diﬀ erent carriers and surfac-
tants by diﬀ erent techniques, solvent evaporation 
and fusion approaches. The prepared binary and 
ternary SDs were characterized using diﬀ erent 
imaging and spectroscopic methods, in vitro dis-
solution studies and physical characterization of 
powders.    
RESULTS:  Both SDs made by solvent evapora-
tion and fusion method is signifi cantly increased 
the dissolution rate compared to the physical mix-
tures. Imaging and spectroscopic studies con-
fi rmed the crystalline to amorphous transitions. 
Powder physical characterization studies demon-
strated that, all requirements of the Ph. Eur. 9.0 
have met. 
CONCLUSIONS: The above used techniques 
are all suitable for improving the dissolution rate 
and water solubility.
REFERENCES: 
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P2E-7
The eﬀ ect of selected terpenes on release and 
skin retention of quercetin from hydrogels
 DYJA, R.,  SARECKA-HUJAR, B., 
 JANKOWSKI, A.
Department of Pharmaceutical Technology, Medical University 
of Silesia in Katowice, School of Pharmacy with the Division of 
Laboratory Medicine in Sosnowiec, Sosnowiec, Poland
BACKGROUND: Quercetin is a fl avonoid provid-
ing  novel possibilities for the treatment and pre-
vention of oxidative-stress mediated skin diseases 
and premature skin ageing. However, quercetin 
skin penetration is limited and should be im-
proved to increase skin retention. One strategy to 
enhance the skin retention is use of penetration 
enhancers e.g. terpenes. 
AIMS: To assess the eﬀ ect of four diﬀ erent ter-
penes (camphor, linalool, menthol, pinene) on the 
porcine ear skin retention and on the release of 
quercetin from the hydrogels in in-vitro condi-
tions.    
RESULTS:  The signifi cant increase in the quer-
cetin skin retention was observed when camphor 
or menthol was used as a penetration enhancer. 
Linalool or pinene had no eﬀ ect on the quercetin 
skin retention. None of the used terpenes aﬀ ect 
the release of quercetin from hydrogels. The cor-
relation between the skin retention and the release 
rate was not observed.  
CONCLUSIONS: The eﬀ ect of the chemical 
structure of terpenes on the skin retention of quer-
cetin was reported. The most eﬀ ective skin reten-
tion enhancement was achieved with cyclic ter-
penes containing oxygen atom (menthol or cam-
phor). The acyclic terpene containing oxygen 
atom (linalool) or cyclic hydrocarbons (pinene) 
were ineﬀ ective in skin retention promotion. The 
mechanism of menthol or camphor skin retention 
enhancement is the interaction of that terpenes 
with the skin barrier but not the release rate en-
hancement. 
REFERENCES: 
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P2E-8
Investigating the driving force of membrane 
transport of Carvedilol from supersaturated 
solutions achieved by electrospun formulations
 BORBÁS, E.1,  SINKÓ, B.2,  TSINMAN, K.2, 
 MAROSI, GY.1,  NAGY, ZS.K.1
1Organic chemistry and technology department, Budapest 
University of Technology and Economics, Budapest, Hungary, 
2Pion Inc.,Billerica, MA, USA
BACKGROUND: When a poorly water-soluble ac-
tive pharmaceutical ingredient (API) is formulat-
ed to enhance its dissolution, additives, such as 
surfactants, polymers and cyclodextrins have an 
eﬀ ect not only on dissolution profi le, but also on 
fl ux through the membrane1understanding how 
solute thermodynamic activity varies with solu-
tion composition, particularly in the presence of 
solubilizing additives, is important in the context 
of passive absorption.\\n\\nMETHODS: In this 
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study, a side-by-side diﬀ usion cell was used to 
evaluate solute fl ux for solutions of nifedipine and 
felodipine in the absence and presence of diﬀ erent 
solubilizing additives at various solute concentra-
tions.\\n\\nRESULTS: At a given solute concentra-
tion above the equilibrium solubility, it was ob-
served that the solubilizing additives could re-
duce the membrane fl ux, indicating that the extent 
of supersaturation can be reduced. However, the 
fl ux could be increased back to the same maxi-
mum value (which was determined by the con-
centration where liquid-liquid phase separation 
(LLPS. In order to fully understand these eﬀ ects 
on fl ux, the driving force of membrane transport 
cannot be simplifi ed to the total concentration gra-
dient. 
AIMS: The aim of this study was to investigate 
the impact of formulation excipients, solubilizing 
additives and self-aggregation on dissolution, su-
persaturation and membrane transport of an API.   
RESULTS:  Carvedilol, an anti-hypertensive 
drug was chosen as a poorly water-soluble model 
drug and formulated in order to enhance its dis-
solution using solvent-based electrospinning. Two 
polyvinylpyrrolidone (PVP) derivatives (K30 and 
VA64) and Soluplus were used to create three dif-
ferent amorphous solid dispersions of the API. 
The eﬀ ect of various additives that can infl uence 
the characteristics of dissolution and permeation 
through artifi cial membrane were observed by 
carrying out a simultaneous dissolution-perme-
ation study with a side-by-side diﬀ usion cell, 
μFLUXTM.  Results showed that all amorphous sol-
id dispersions were eﬀ ective in dissolution en-
hancement of the poorly water-soluble API, name-
ly more than 90 % of the drug content was re-
leased from all formulations. Although the disso-
lution profi les of the formulations were found to 
be very similar, fl uxus diﬀ ered signifi cantly in 
case of Soluplus and PVP containing formula-
tions.  
CONCLUSIONS: The results show that the 
driving force of membrane transport cannot be 
simplifi ed to the concentration gradient. Supersat-
uration gradient, the diﬀ erence in degree of su-
persaturation (defi ned as the ratio of dissolved 
amount of the drug to its thermodynamic solubili-
ty) between the donor and acceptor side was 
found to be the driving force of membrane trans-
port.
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P2E-9
Improve stability and oral bioavailibility of 
Plantago lanceolata herb extract by using a Self-
Microemulsifying Drug Delivery System 
 KALANTARI,  A.1,  KÓSA, D.1,  NEMES, D.1, 
 UJHELYI, Z.1,  VECSERNYÉS, M.1,  GONDA, S.2, 
 VASAS, G.2,  BÁCSKAY, I .1  
1Department of Pharmaceutical Technology,University of 
Debrecen, Debrecen, Hungary
2Department of Pharmacognosy,University of Debrecen, 
Debrecen, Hungary
BACKGROUND: Plantago lanceolata (Ribwort 
plantain) possesses various pharmacological ef-
fects for human health including antioxidant, 
anti-inflammatory, hepatoprotective immuno-
regulation and neuroprotective properties with 
an excellent safety profile.The limitation of 
their formulation is the poor chemical stability 
due to hydrolysis. SMEDDS is frequently used 
for the sta bi li zation of natural product and 
these carrier systems may also increase the bio-
availability of natural bioactive materials (Eid 
et al. 2014).
AIMS: The aim of this work was to formulating 
a SMEDDS (selfmicroemulsifying drug delivery 
system) of Plantago lanceolata and assessing its in 
vitro and in vivo potential..This study was con-
ducted to develop SMEDDS containing Plantago 
L. extract to stabilize and for increasing its bio-
availibitity to improve its anti-infl ammatory eﬀ ect. 
Pseudoternary phase diagrams were used to eval-
uate the microemulsifi cation existence area.The ba-
sis of the formulation was the ternaryphase dia-
grams contained diﬀ erent surfactant/cosurfactants. 
RESULTS:  The developed SMEDDS was spon-
taneously forming microemulsion upon mild agi-
tation in distillated water at 25°C. The transmit-
tance percentage  and refractive index of the for-
mulations indicating the transparency of them. 
Moreover, the developed formulation has been 
stable for 1 month at 25°C . MTT test results 
showed that all the compositions were biocompat-
ible.The results obtained from acute cytotoxicity 
studies show 2 of the compositions resulted in fa-
tal consequences and these samples were elimi-
nated from further experiments. Our in vivo ear 
infl ammation test presents orally administered 
SMEDDS compositions signifi cantly decreased ear 
thickness in the complete period of time com-
pared to the untreated, positive control.     
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CONCLUSIONS: 8 SMEDDS compositions con-
taining Plantago L. prepared and were character-
ized by Dynamic Light Scatt ering method. Accord-
ing to our in Vitro cytotoxicity assay, every compo-
sition was accepted with no cytotoxicity by the ra-
tio of physical dilution. However, according to our 
in vivo toxicity studies, 2 compositions resulted in 
the death of mice due to high quantity of Transcu-
tol HP and Cremophore RH40. Other compositions 
have not been toxic and approved for the other test 
of eﬀ ectiveness. Ear thickness assay was measured 
to certify the eﬀ ect of these compositions.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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P2E-10
In vitro – in vivo characterization of simvastatin-
containing periodontal mucoadhesive 
nanoparticulate gel
 DINTE, E.,  BOROD, I . G.,  CÂMPIAN, R. S., 
 LUCACIU, O.,  TĂBĂRAN, F.,  BERCE, C., 
 TOADER, S.,  IONEL, A.
Department of Pharmaceutical Technology and 
Biopharmaceutics, Iuliu Hatieganu University of Medicine and 
Pharmacy, Faculty of Pharmacy, Cluj-Napoca, Romania
BACKGROUND:  Periodontitis is a chronic in-
fl ammatory disease characterized by gingival tis-
sue infl ammation, clinical att achment loss and al-
veolar bone destruction. Present scientifi c litera-
ture on simvastatin revealed its good applicability 
in the fi eld of periodontics as a local drug delivery 
agent due to its antiinfl ammatory and bone regen-
erative properties. Topical application of drugs di-
rectly into the periodontal pocket represents a sat-
isfactory approach, presents many advantages, 
and involves the use of a controlled release device 
with mucoadhesive properties. 
AIMS:  The purpose of the work was to formu-
late a topical simvastatin-containing mucoadhe-
sive periodontal gel (SVMPG) and evaluate in vivo 
eﬃ  cacy regarding clinical parameters, bone heal-
ing and systemic infl ammatory response in an ex-
perimental model of periodontitis in rats, and 
compare the eﬀ ects with oral administration of 
simvastatin  (SV). 
RESULTS:  The designed SVMPG formulation 
consisting of glyceryl monooleate and water, com-
bined in a ratio of 3 : 1 (containing SV in a concen-
tration of 2%) showed adequate viscosity 
(41672.40±68 mPa.s at 6 s-1 ) and adhesive charac-
teristics (a detachment force of 175±22 mN). X-ray 
diﬀ raction studies revealed that  the samples con-
tains cubosomes with the faces of cubes preferen-
tial orientated parallel with surface of the holder 
sample. The in vivo studies showed that the de-
gree of bleeding on probing as well as the dental 
mobility was statistically signifi cantly lower in the 
group where simvastatin was administrated topi-
cally (SMV-L) comparing to the periodontitis 
group without treatment (PG), (0% vs. 100%, 
p=0.018 for bleeding and (0% vs 100%, p=0.046) for 
dental mobility. The experimental results showed 
that SV applied either topically, through the de-
signed SVMPG, or administered by gavage re-
duced the local and systemic infl ammatory re-
sponse induced by periodontitis. 
CONCLUSIONS:  The results suggest that 
the prepared SVMPG may be favorable for topical 
application in periodontal therapy.
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P2E-11
Comparison of in vitro dissolution profi les of 
silymarin-cyclodextrin sustained release matrix 
tablets
 SINKA, D.,  HAGYMÁSI, A.,  FEHÉR, P., 
 UJHELYI, Z.,  FENYVESI, F.,  VÁRADI, J ., 
 VASVÁRI, G.,  VECSERNYÉS, M.,  BÁCSKAY, I .
Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary
BACKGROUND: Silymarin is the active ingredi-
ent of the plant Silybum marianum. It is used in 
medicine for curing or preventing liver and gall 
diseases for thousands of years. Silymarin has a 
low solubility and permeability. Current pharma-
cotherapy means conventional dosage forms such 
as capsules, which result in low bioavailability. 
AIMS: Our main goals through the research 
were to formulate matrix tablets with silymarin as 
active ingredient. We used diﬀ erent Carbopols as 
matrix-forming polymers. The complexation of si-
lymarin with diﬀ erent β-cyclodextrins was in-
tended to increase the solubility of the active in-
gredient. By achieving sustained release, our aim 
was to oﬀ er a bett er alternative than the conven-
tional therapy.  
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RESULTS:  We carried out MTT assay to exam-
ine the cytotoxicity of the matrix-forming Carbo-
pols to intestinal cells, which proved the biocom-
patibility of the carriers. Silymarin-cyclodextrin 
complexes were made by physical mixture meth-
od. Tablet ingredients were homogenized in mor-
tar after being measured. For compressing, manu-
al bench-top tablet press was used. We carried out 
weight uniformity, tablet friability and hardness 
test, and our products were proper according to 
Ph. Hg. VIII.
The medium used for the dissolution tests was 
artifi cial gastric juice in the fi rst hour and artifi cial 
intestinal juice for six hours. We took samples in 
every 15 minutes from the gastric and every 30 
minutes from the intestinal medium. Dissolution 
curves were displayed using the absorbance of the 
samples.
CONCLUSIONS: Comparing the results of our 
research, we could select the Carbopol-cyclodex-
trin combination with the optimal drug release of 
the 16 diﬀ erent compunds. With CD complexes, 
we could solve more than 85% of the silymarin. 
The biocompatibility of our product was proven, 
and the technology provided much bett er bioavail-
ability than the conventional silymarin therapy.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
P2E-12
Formulation and antioxidant investigation of 
creams containing diﬀ erent plant extracts
 JURCA, T.1,  PALLAG, A.1,  VICAS, L.1, 
 MARIAN, E.1,  BÁCSKAY, I .2,  FEHÉR, Z.2, 
 UJHELYI, Z.2,  DÁVID, S.2,  VECSERNYÉS, M.2
1University of Oradea, Faculty of Medicine and Pharmacy, 
Department of Pharamcy
2University of Debrecen, Faculty of Pharmacy, Department of 
Pharmaceutical Technology
BACKGROUND: Some plants can be incorporated 
into skin care products to treat conditions such as 
skin dryness and can function as an anti-oxidant.
AIMS: Creams were formulated from diﬀ erent 
plant extracts. Four kinds of plant extract were ex-
amined, black locust (Robiniapseudoacacia), cow-
slip (Primula veris), nasturtium (Centranthus) and 
crocus (Crocus longifl orus). 
RESULTS: Each extract was previously dis-
solved in Transcutol and then mixed in the same 
o/v cream basis containing Sucrose ester SP50 as 
an emulgent.In vitro drug release of diﬀ erent 
compositions was assessed by Franz diﬀ usion 
method (1).Creams containing black locust 
showed the highest diﬀ usion amounts. DPPH 
Radical Scavenging Activity of plant samples were 
also examined, according to methodology de-
scribed by Brand-Williams (2). 
CONCLUSIONS: According to our measure-
ments nasturtium showed the highest antioxidant 
activity. 
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POSTER SECTION 2F 
ANTICANCER DRUG RESEARCH
P2F-1 
Betulin-conjugated gold nanoparticles with 
antitumor activity
 SOICA, C.,  MIOC, M.,  CORICOVAC, D., 
 TRANDAFIRESCU, C.,  GHIULAI, R.,  PAVEL, 
I .,  DANCIU, C.,  PINZARU, I .,  MOACA, A., 
 DRAGOMIRESCU, A.,  POPOVICI, R. A., 
 DEHELEAN, C. 
Faculty of Pharmacy, „Victor Babes” University of Medicine and 
Pharmacy Timisoara, Romania
BACKGROUND: Gold nanoparticles exhibit large 
exterior surfaces and can be easily functionalized 
thus being adequate as highly eﬀ ective drug de-
livery agents [1] in cancer therapy.
AIMS: Synthesis of betulin conjugated gold 
nanoparticles with antitumor activity.  
RESULTS:  Betulin conjugated gold nanoparti-
cles were successfully synthesized and physico-
chemically analyzed. Their biological activity was 
tested against the A375 (human melanoma) tumor 
cell line using the pure compound as reference. 
Tests revealed a higher antiproliferative activity as 
a result of the betulin bioconjugation.
CONCLUSIONS: Betulin bioconjugation with 
gold nanoparticles leads to an improved antitu-
mor activity therefore representing a suitable op-
tion in drug delivery.
Acknowledgment. This work was supported by 
UEFISCDI grant PN-III-P2-2.1-BG-2016-0354.
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P2F-2
Hollow gold nanoparticles loaded with betulin 
as anticancer agents
 SOICA, C.,  MIOC, M.,  CORICOVAC, D., 
 TRANDAFIRESCU, C.,  GHIULAI, R.,  PAVEL, 
I .,  DANCIU, C.,  PINZARU, I .,  MOACA, A., 
 DRAGOMIRESCU, A.,  POPOVICI, R. A., 
 DEHELEAN, C.
Faculty of Pharmacy, „Victor Babes” University of Medicine and 
Pharmacy Timisoara, Romania
BACKGROUND: Hollow gold nanoparticles 
(HGN) display excellent properties in terms of 
biocompatibility and drug loading which makes 
them suitable carrier molecules for a variety of 
drugs used in cancer therapy [1]. In addition to an 
optimized therapeutic activity of the loaded drug, 
HGN also proved superior to other drug delivery 
systems such as liposomes [2].
AIMS: Synthesis followed by physico-chemical 
and biological analysis of hollow gold nanoparti-
cles loaded with betulin as anticancer agent.  
RESULTS: Hollow gold nanoparticles were suc-
cessfully synthesized by consecrated methods and 
physicochemically analyzed. Betulin was loaded 
as active antitumor agent and the resulting 
nanoparticles were in vitro tested against A375 
(human melanoma) cell line using the pure drug 
as reference. Hollow gold nanoparticles revealed a 
high drug load and improved antitumor activity 
compared to betulin alone.
CONCLUSIONS: The use of hollow gold 
nanoparticles as carrier for betulin improved its in 
vitro antitumor eﬃ  cacy thus oﬀ ering an alterna-
tive therapeutic option.
Acknowledgment. This work was supported by 
UEFISCDI grant PN-III-P2-2.1-BG-2016-0354.
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Expression of miRNA-21 and -221 in clear cell 
renal cell carcinoma (ccRCC) and their possible 
role in the development of ccRCC
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BACKGROUND: Clear cell renal cell carcinoma 
(ccRCC) is the third most common urological can-
cer after prostate and bladder cancer but has the 
highest rate of mortality aﬀ ecting over 40% of pa-
tients. microRNAs (miRNAs) are small non-cod-
ing RNAs that have become potential biomarkers 
and molecular targets for cancer treatment. Mo-
lecular markers such as miRNAs may have a role 
in the diagnosis of ccRCC. 
AIM: In this study, we examined the expres-
sions of miRNA-21 and miRNA-221 in renal can-
cer patients’ tumor and adjacent paired normal 
tissues investigating the possible role of these 
miRNAs in the development of ccRCC.
RESULTS: Renal tumors (n=24) and paired nor-
mal renal tissue (n=24) samples, obtained from the 
Department of Urology, University of Debrecen, 
were analyzed for miRNA-21 and miRNA-221 ex-
pressions with qRT-PCR. miRNA-21 and miR-
NA-221 expressions were signifi cantly upregulated 
in tumor specimens compared to normal tissue 
(p<0.05). miRNA-21 and miRNA-221 showed coex-
pression patt ern in 19 (79.2%) cases of tumor sam-
ples and 8 (33.3% ) cases of paired normal renal tis-
sues. Increased miRNA patt ern showed a positive 
correlation with pathologic TNM and Grade status.
CONCLUSIONS: Expression of oncogenic miR-
NA-21 and miRNA-221 in human ccRCC tumor 
tissue samples compared to adjacent nontumor-
ous tissues might suggest that these miRNAs are 
involved in the development of ccRCC. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project 
and GINOP-2.3.3-15-2016-00043
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P2F-4
Somatostatin receptors, as molecular targets in 
human uveal melanoma
 HARDA, K.1,  TRESZL, A.†1,  STEIBER, Z.2, 
 SZABÓ, ZS.1,  OLÁH, G.1,  HALMOS, G.1
1Department of Biopharmacy 
2Department of Ophthalmology, University of Debrecen, 
Debrecen, Hungary
BACKGROUND: Uveal melanoma is the most 
common malignancy of the eye. Independently 
from the currently available treatments, half of the 
patients develop metastatic disease and survival of 
patients with metastasis is only 2-8 months. Previ-
ous studies demonstrated that various analogues 
of somatostatin can inhibit tumor growth. So far 
fi ve subtypes of somatostatin receptors (SSTR1-5) 
have been identifi ed, all of them are G-protein cou-
pled receptors. Somatostatin and its synthetic ana-
logues display the highest binding aﬃ  nity to 
SSTR2 and SSTR5. In diﬀ erent human cancers and 
in cancerous vessels, the expression of SSTRs is 
higher than in normal tissues but their presence in 
human uveal melanoma has been investigated 
only in very limited number of samples.
AIMS: The aim of the present study was to in-
vestigate the mRNA expression of SSTRs in surgi-
cal specimens of 46 human uveal melanoma speci-
mens and normal uvea tissue samples by RT-PCR. 
We also aimed to investigate the presence of 
SSTRs on two human experimental uveal melano-
ma cell lines, OCM-1, OCM-3.  
RESULTS:  According to our results, the majori-
ty of uveal melanomas expressed mRNA for 
SSTR2 (67,5%) and SSTR5 (66,6%). Among the 
normal uvea tissues, only one sample showed 
mRNA expression for SSTR2. Our results showed 
correlation with clinicopathological data.
CONCLUSIONS: Peptide hormone analogues 
represent an advantageous alternative for receptor 
based targeted therapy based on their relatively 
easy production, fast internalization and clear-
ance, and suitable tumor penetration. Our results 
suggest that clinical use of subtype-specifi c SST 
analogues (i.e. in vivo scintigraphy, targeted thera-
py) might be benefi cial in the treatment of human 
uveal melanomas positive for SSTR2 and/or 
SSTR5. 
Grant support: GINOP-2.3.2-15-2016-00043 and 
EFOP-3.6.1-16-2016-00022 „Debrecen Venture Cat-
apult” project. 
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The mechanism of action of targeted cytotoxic 
Luteinizing Hormone-Releasing Hormone 
analog AN-152 in doxorubicin resistant human 
uveal melanoma cells
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BACKGROUND: Cytotoxic analogs of LHRH can 
be successfully used for the treatment of hor-
mone-dependent cancers (e.g.: prostate, ovarian, 
endometrial) but our knowledge on hormone-in-
dependent cancers such as human uveal melano-
ma (UM) is limited. Previously, we have demon-
strated that 46% of UM express full-length LHRH 
receptors. This fi nding has led us to further exam-
ine the mechanism of action of LHRH receptor 
based targeted therapies in this malignacy.
AIMS: In the present study a doxorubicin-re-
sistant human UM cell line (OCM3DOX320) was 
established to investigate cellular uptake of 
doxorubicin and AN-152 on OCM3 and OC-
M3DOX320 cell lines by confocal laser scanning mi-
croscopy. The LHRH receptor expression has 
been characterized by RT-PCR and immunocy-
tochemistry.
RESULTS: Our results demonstrate the expres-
sion of LHRH receptor spice variants and iso-
forms in OCM3 UM cell line and its doxorubicin 
resistant form OCM3DOX320.
It has been revealed by MTT assay that doxoru-
bicin as well as AN-152 inhibited cell proliferation 
in a dose dependent manner in OCM3DOX320 cells. 
Furthermore, receptor-mediated uptake of AN-
152 was demonstrated using confocal laser scan-
ning microscopy.
CONCLUSIONS: Our results suggest that the 
antiproliferative eﬀ ect of AN-152 can be carried 
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even if only LHRH receptor isoforms are ex-
pressed. Our study also demonstrates the LHRH 
receptor mediated uptake of AN-152 in doxorubi-
cin resistant OCM3DOX320 cells. Our experiments 
provide new insights for the targeted therapy of 
UM and give further details about the accumula-
tion of AN-152 in hormone-independent doxoru-
bicin resistant cells expressing splice variants of 
the LHRH receptors.
Grant support: GINOP-2.3.2-15-2016-00043 and 
EFOP-3.6.1-16-2016-00022 „Debrecen Venture Cat-
apult” project.
REFERENCES:
1. Treszl A et al: Oncotarget 4: 1721–8, (2013)
P2F-6
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BACKGROUND: Although the incidence of uveal 
melanoma (UM) is low, it is the most common pri-
mary intraocular malignancy. Previously, we have 
demonstrated that approximately 50 % of UMs ex-
press type-I receptor for luteinizing hormone-re-
leasing hormone (LH-RH-R). The gene encoding 
LH-RH-R is located in chromosome 4, however 
the occurrent numerical aberrations of chromo-
some 4 have never been studied in UM.
AIMS: In the present study we investigated the 
abnormalities of chromosome 3 and 4 and the pos-
sible correlation between them and also with LH-
RH-R expression. 46 specimens of UM were ob-
tained after enucleation. Numerical aberrations of 
chromosome 3 and 4 were studied by FISH.  
RESULTS:  Chromosome 4 could be detected in 
normal biparental disomy only in 14 (30 %) sam-
ples, however, 32 cases (70 %) showed more than 
2 signals/nucleus. Monosomy of chromosome 3 
could be found in 16 (35 %) samples. In 6 speci-
mens (13 %), more than 2 copies of chromosome 3 
were found, while normal biparental disomy 
could be detected in 24 (52 %) samples. Statistical 
analysis indicates signifi cant (p<0.05) correlation 
between the copy number of chromosome 3 and 4. 
Moreover, moderate diﬀ erence has been revealed 
in the survival rate of the UM patients with vari-
ous pathological profi les.  
CONCLUSIONS: Our results clearly demostrate 
abnormalities in chromosome 3 and 4 and the inci-
dence of the monosomy of chromosome 3 in hu-
man UM. Our study provides new information 
about the genetic background of this tumor. These 
fi ndings could contribute to a more precise deter-
mination of the prognosis of human uveal melano-
ma and to the development of new therapeutic ap-
proaches to this malignancy. Grant support: GI-
NOP-2.3.2-15-2016- 00043 (G.H.), TAMOP-4.2.2/ 
B-10/1-2010-0024 (E.S), the Gedeon Richter’s Talen-
tum Foundation (E.S.) and EFOP-3.6.1-16-2016-
00022 „Debrecen Venture Catapult” project. . 
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Antiproliferative evaluation of synthesized 
xanthene derivatives
 ZUKIĆ, S .,  VELJOVIĆ, E.,  ŠPIRTOVIĆ-
HALILOVIĆ, S .,  MURATOVIĆ, S ., 
 OSMANOVIĆ, A.,  ZAVRŠNIK, D. 
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 
University of Sarajevo, Sarajevo, Bosnia and Herzegovina
BACKGROUND: Xanthenes are important class of 
biologically active compounds due to their broad 
spectrum of pharmacological activities such as 
bactericidal, anti-infl ammatory, antiviral and anti-
proliferative activity.  
AIMS: The aim of study was to investigate anti-
proliferative activity of synthesized 2,2,5,5-tetra-
methyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthen-
1,8(2H)-dione derivatives and the eﬀ ect of sub-
stituent on investigated activity.     
RESULTS:  Five derivatives of  2,2,5,5-tetra-
methyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthen-
1,8(2H)-dione were synthesized as potential anti-
proliferative agents. The in vitro antiproliferative 
activity of the synthesized compounds was inves-
tigated against a panel of tumor cell lines includ-
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ing HeLa (cervical carcinoma), SW620 (colorectal 
adenocarcinoma, metastatic), HepG2 (human liver 
cancer), A549 (human lung cancer cell) and 3T3 
(mouse embryo fi broblast cell line by using MTT 
colorimetric assay. Among synthesized com-
pounds, 2,2,5,5-tetramethyl-9-(3’,4’-hydroxy phenyl) 
-3,4,5,6,7,9-hexahydro-1H-xanthen-1,8(2H)-dio ne 
(5)  showed the highest antiproliferative activity 
against all tested cell lines. The most potent com-
pound 5 were subjected to molecular docking sim-
ulations to preliminary fi nd out the potential mo-
lecular target and at the same moment further 
support the experimental cytotoxic tests. 
CONCLUSIONS: Structure-activity relationship 
studies revealed that substitution with two hy-
droxy groups on phenyl ring increase antiprolifer-
ative activity of xanthen-1,8 dione derivatives, 
while substitution with nitro or chloro group on 
aryl moiety do not aﬀ ect on antiproliferative activ-
ity. Docking studies for the most potent com-
pounds were carried out by taking amino terminal 
domain of topoisomerase II for anticancer activity 
against HeLa tumour cells. Docking study showed 
sites of importance in forming hydrogen bonds 
with receptors. 
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BACKGROUND: Uveal melanoma (UM) is the 
most common malignant tumor of the eye. In re-
cent years, an exponentially growing number of 
studies have focused on identifying cancer stem 
cells (CSCs) in human melanomas1. If CSCs have a 
signifi cant role in tumorigenesis, their frequency 
in primary tumors might correlate with tumor in-
vasion, angiogenesis and metastasis- and in turn, 
with patient prognosis.
AIMS: Based on evidence for the existence of 
CSCs we investigated whether the expression of 
CSCs in UM is in correlation with survival or with 
the tissue subtype of the tumor or not. Clinical, 
pathologic and molecular data of 70 human uveal 
melanoma specimens were collected and the ex-
pression of CSCs were investigated in tissue sam-
ples. mRNA expression of CSC markers was stud-
ied in 18 UMs by RT-PCR and the protein expres-
sion of FZD6 CSC marker was evaluated in 52 
UMs by IHC using tissue microarray (TMA) 
blocks.  
RESULTS:  The expression of Nestin, FZD6 and 
SOX10 CSC markers was detected in 100% of the 
UM samples. PROM1 and NGFR genes were ex-
pressed in 11.1% of the specimens. To extend the 
RT-PCR results, protein levels of FZD6 have been 
examined in 66 UM specimens with IHC-TMA 
technique. Kaplan-Meier curves showed no signif-
icant correlation (p=0.867) between the FZD6 ex-
pression and the survival of the patients.
CONCLUSIONS: CONCLUSIONS: The biologi-
cal signifi cance of stem cell markers, such as FZD6 
in primary uveal melanomas remains unclear. 
Our results show a primitive neuroectodermal 
stem cell-like profi le in a signifi cant number of UM 
samples, which may indicate a higher risk for me-
tastasis2. Further studies are needed to clarify the 
importance of stem cell marker sin human uveal 
melanoma. Grant support: GINOP-2.3.2-15- 2016-
00043 (G.H.), the Gedeon Richter’s Talentum Foun-
dation (K.F.) and EFOP-3.6.1-16-2016-00022 „Deb-
recen Venture Catapult” project. . 
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Investigation of the eﬀ ect of cyclodextrin 
nanoparticles on MCF 7 breast cancer cell line 
by proteomics approaches
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BACKGROUND: Amphiphilic cyclodextrins (ACD), 
used in nanoscale as a drug delivery system, are 
molecules with the ability to spontaneously form 
nanoparticles. Paclitaxel loaded ACD have already 
been known as active against MCF 7 cells. There 
are also data available to show ACD have apoptot-
ic eﬀ ect on some cancer cell lines (1). However 
there is no information how the drug-free ACD 
have antiproliferative activity against MCF 7 cells 
on proteome level.
AIMS: This study aims to clarify the mechanism 
of anticancer activity of cyclodextrin nanoparticles 
on MCF 7 cells by proteomics studies.  
RESULTS:  Group T is MCF 7 treated with ACD, 
whereas C is not treated. T and C proteins in cyto-
solic fractions were separated by 2D gel electro-
phoresis. The spots having 1.5-fold change for T 
and C were analyzed by MALDI-TOF MS and 
identifi ed by peptide mass fi ngerprint. Overex-
pressed proteins were hepatomaderived growth 
factor, heterogeneous nuclear ribonucleoprotein, 
and chromosomal protein homologue I. Underex-
pressed proteins with the infl uence of ACD were 
found as D-3-phosphoglycerate dehydrogenase 
(PHGDH) and keratin.
CONCLUSIONS: PHGDH inhibition has al-
ready been known to reduce tumor growth in 
breast cancers. In our study, 2.8-fold reduction in 
PHGDH compared to the C group is insightful to 
indicate the tumor suppressor properties of ACD 
against MCF 7 cell line.
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BACKGROUND: Estrogens are traditionally regard-
ed as crucial factors of the reproductive systems, 
and it is well known that 17β-estradiol increases the 
proliferation of its target cells not only in the repro-
ductive system but also in gynecological tumors. 
Our previous results show that D-ring modifi ed es-
trogens including a triazol-substituted D-secoe-
stone derivative have pronounced anticancer and 
antimigratory eﬀ ects in diﬀ erent cell lines [1].
AIMS: Based on our previous D-secoestrone-
triazol results, our aim was to investigate the anti-
proliferative eﬀ ect of some newly synthetized and 
structurally related estrone dimer compounds.  
RESULTS:  The growth inhibitory eﬀ ects of 8 
newly synthesized D-secoestrone and 13- 
α-epiestrone linked dimer compounds were in-
vestigated by standard MTT assay on 9 diﬀ erent 
cell lines. Only one of them (DIM) has substantial 
antiproliferative action on all of the tested cell 
lines. The detailed investigation of the mechanism 
of action of DIM have been completed on three 
cerval carcinoma cell line with diﬀ erent HPV sta-
tus (HPV 18-positive (HPV 18-positive HeLa, HPV 
16-positive C33-A and HPV-negative SiHA cell 
lines). After 24 hours incubation the cells showed 
the morphological signs of apoptosis visualized 
by fl uorescent double staining. After 48 hours cell 
cycle analysis exhibited signifi cant increase in the 
number of cells in G2/M phase, followed by a G1 
phase reduction, also elevation of the apoptotic 
subG1 population was observed regardless of the 
HPV status. The investigated DIM compound sig-
nifi cantly enhanced the cell independent tubulin 
assembly in vitro. The cell migrating capacity was 
observed by wound healing assay.
CONCLUSIONS: These results suggest that one 
of our new estrogen dimer derivatives is a potent 
anticancer agent with proapoptotic eﬀ ect proceed-
ed by G2/M blockade, microtube stabilization and 
changes in cell motility. 
Supported through the New National Excel-
lence Program of the Ministry of Human Capaci-
ties and János Bolyai Research Scholarship.
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BACKGROUND: Estrane analogs without hor-
monal activities (e.g. those with modifi ed in D-
ring) have been recently proposed as basic struc-
ture for innovative antiproliferative and antimeta-
static drug candidates.
AIMS: The aim of the present study was the in-
vestigation of the a set of 16-hydroxymethyl-es-
tranes for their anticancer properties. The most 
potent agent was selected for additional in vitro 
investigation in order to describe the mechanism 
of the action as well as to test its action on the met-
astatic ability of cancer cells.
METHODS: Growth inhibiting eﬀ ect of the es-
tranes were determined by MTT assay using hu-
man breast cancer cell lines (MCF-7, T47D, MDA-
MB-231 and MDA-MB-361). Fibroblasts were also 
used to determine the cancer selectivity. Cell cycle 
analysis was performed by fl ow cytometry. 
Wound healing assay and gelatin zymography 
were performed to evaluate the antimetastatic 
properties of the compounds. 
RESULTS: Benzyloxy function and their p-
substituted derivatives at position C-3 increased 
the antiproliferative potency. The most promising 
agents (IC50 values below 5 μM) exhibited a 
modest cancer selectivity. The selected molecules 
elicited a cell cycle disturbance with increased G1 
and decreased S and G2/M population after 24 h 
incubation. The same compounds blocked the cell 
migration at subantiproliferative concentration 
and inhibited the activity of matrix metallopepti-
dase 9.
CONCLUSION: Estrane skeleton with modi-
fi ed D-ring can be regarded as a promising struc-
ture for design lead molecules with direct antipro-
liferative as well as antimetastatic capacity. 
Supports from Hungarian Scientifi c Research 
Fund (OTKA K109293), GINOP-2.3.2-15- 2016-
00012 and Taiwan Ministry of Science and Tech-
nology Grant (MOST106-2911-I-037-504) are grate-
fully acknowledged.
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BACKGROUND: Antiproliferative properties of 
agents with steroidal backbone have been reported 
recently. Beyond their current therapeutic applica-
tions some 19-nortestosterone analogs with antican-
cer properties may be of high interest in early phase 
cancer research.
AIMS: The aim of our current work was the test-
ing of a set of novel 19-nortestosterone analogs and 
their growth inhibiting activities on a panel of hu-
man gynecological cancer cell lines by means of MTT 
assay. The tumor selectivity of the promising ana-
logues was determined by repeated assay on non-
cancerous fi broblast cells. The most eﬀ ective com-
pound was selected for further experiments in order 
to describe the possible mechanism of action. Its di-
rect cytotoxic eﬀ ect was measured by LDH assay. 
The induction of apoptosis was evidenced by fl uo-
rescent microscopy and determination of caspase ac-
tivities. The alterations in the cell cycle distribution 
were evidenced by fl ow cytometry. The infl uence on 
microtubule system elicited by the selected com-
pound was determined using tubulin polimerization 
assay.  
RESULTS:  Three compounds (17α-chloro- (1), 
17α-bromo- (2), 17α-iodo-19-nortestosterone (3)) 
showed substantial antiproliferative eﬀ ect on HeLa 
cells (IC50: 1.2–1.7 μM) with remarkable tumor selec-
tivity (IC50 > 30 μM on fi broblast). The most potent 
analogue (1: IC50: 1.2 μM) can cause moderate mem-
brane damage and cell cycle blockade due to accu-
mulation of the cells in S or G2/M phase. The in-
crease of hypodiploid population (subG1) demon-
strates the proapoptotic capacity of the agent. The 
induction of intrinsic pathway of programmed cell 
death has been proved by increasing activities of cas-
pase-3 and -9 with unchanged caspase-8 activity. 
The selected compound exerted a direct action on tu-
bulin dinamics by increase of the rate of polimeriza-
tion in vitro.
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CONCLUSIONS: According to our results the 
C17α substitution of the 19-nortestosterons with hal-
ogens is responsible for the antiproliferative eﬀ ect. 
The most potent compound is capable of inducing 
apoptosis and has a temperate cytotoxic eﬀ ect. This 
agent also causes a disturbance of cytoskeleton due 
to its infl uence on tubulin polimerization which may 
resposible for both of cell cycle arrest and the induc-
tion of apoptosis.
Financial support from Bolyai János Scientifi c 
Scholarship (R. Minorics), Richter Gedeon Talen-
tum Foundation (N. Bózsity, A. Kiss) and the 
Hungarian Scientifi c Research Fund (OTKA 
K-109293, I. Zupko) and GINOP-2.3.2-15- 2016-
00012 are gratefully acknowledged. 
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P2F-13
Anticancer properties of sesquiterpene 
derivatives and their conjugates with estrogens 
on breast cancer cell lines
 KULMÁNY, Á.1,  KISS, A.2,  ZUPKÓ, I .1, 
 MINORICS, R.1,  OCSOVSZKI, I .3
1 Institute of Pharmacodynamics and Biopharmacy, University of 
Szeged, Szeged, Hungary
2 Department of Organic Chemistry, University of Szeged, 
Szeged, Hungary
3 Department of Biochemistry, University of Szeged, Szeged, 
Hungary
BACKGROUND: Breast cancer is a leading cause 
of death in female population worldwide. The het-
erogenous aspects and diﬀ erent types of resis-
tances necessiates the research of new drug candi-
dates. Since most of currently applied agents are 
of natural origin their semisynthetic derivatives 
may have higher potencies. 
AIMS: Our aim was to investigate the antican-
cer properties of newly prepared artemisinin de-
rivatives and estrogen conjugates with no hor-
monal activities.  
RESULTS:  Antiproliferative eﬀ ects of our origi-
nal compounds, combinations of them and their 
new conjugates were determined by MTT-assay 
on four diﬀ erent breast cancer cell line (MDA-
MB-231, MDA-MB-361, MCF7, T47D). Our inves-
tigations demonstrated that IC50 values of these 
new molecules were one order of magnitude low-
er than that of parent compounds which means a 
more potent antitumor eﬀ ect. Morphological signs 
of apoptosis were detected after 24h incubation 
with our most potent conjugate on the most sensi-
tive cell line (MDA-MB-361) by Hoechst-Propidi-
um iodide fl uorescent staining. Cell cycle analysis 
recorded by fl ow cytometry evidenced the in-
crease of the ratio of MDA-MB-231 cells in G0/G1 
phase followed by a decrease of the ratio of cells 
in S phase after 24h and 48h incubation indicating 
the inhibition of cell division. 
CONCLUSIONS: This study provides experi-
mental evidance that chemical conjugation of arte-
misinin derivatives and estrogens results in new 
molecules with more potent antiproliferative 
properties than their parent compounds. These 
new compounds can be considered as promising 
new candidates in the fi eld of anticancer research. 
Supports from OTKA (K109293), GI-
NOP-2.3.2-15-2016-00012 and János Bolyai Research 
Scholarship are highly appreciated.
P2F-14
Searching for specifi c and clinically relevant 
BCRP (ABCG2) probe
 MOLNÁR, J .,  BEER, E.,  TÓTH, B.,  RAJNAI, 
ZS., JANI, M.,  KIS, E.,  MAGNAN, R.,  MAKAI, 
I .,  FEKETE, ZS.,  BUI, A.,  KRAJCSI, P.
Solvo Biotechnology, Szeged, Hungary
BACKGROUND: Breast Cancer Resistance Protein 
(BCRP/ABCG2) belongs to the G subfamily of the 
ATP Binding Casett e (ABC) transporter proteins. 
BCRP localized at the apical membrane of epithe-
lial cells of barrier tissues, handling a broad vari-
ety of endogenous and exogenous compounds. 
BCRP plays a role in drug absorption, disposition 
and excretion and regulates clinically relevant 
drug-drug interactions. Testing for BCRP is rec-
ommended by the regulatory agencies (FDA/
EMA), although there is no widely accepted BCRP 
probe for the various in vivo and in vitro assays. 
AIMS: To fi nd a clinically relevant BCRP probe 
that is specifi c for BCRP, accepted by the regulato-
ry agencies, applicable for various in vivo and in 
vitro assays, and commercially available. 
RESULTS: Five candidates (chlorothiazide, ro-
suvastatin, sulfasalazine, terifl unomide and topo-
tecan) were selected based on literature data and 
in-house experience. First, all fi ve compounds 
were tested in vesiculare transport assay using 
BCRP, MDR1, MRP2, and MRP4 overexpressing 
Sf9 or Hi5 membranes. Four of these compounds 
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were then measured in vectorial transport assay 
on Caco-2 cells and BCRP overexpressing MDCKII 
cells. Chlorotiazide, sulfasalazine and terifl uno-
mide were selective for BCRP in the vesicular 
transport experiments. In the monolayer system 
both chlorothiazide and terifl unomide were spe-
cifi c for BCRP. 
CONCLUSIONS: Based on our results and lit-
erature data, chlorothiazide and terifl unomide 
meet all the required criteria for being a clinically 
relevant BCRP probe. However, further clinical 
data, for chlorothiazide in particular, are needed 
to establish these compounds as BCRP probes.
POSTER SECTION 2G 
PHARMACOLOGY
P2G-1
 Antimicrobial and in vitro antiproliferative and 
proapoptotic potential against B164A5 murine 
melanoma cell line of fl avonol fi setin
 DANCIU, C.,  AVRAM, S.,  BOJIN, F., 
 MUNTEAN, D.,  MINDA, D.,  PAVEL, I ., 
 SOICA, C.,  ROXANA, G.,  DEHELEAN, C.
Department of Pharmacognosy, University of Medicine and 
Pharmacy “Victor Babeş“, Timişoara, România 
BACKGROUND: Flavonoids represent one of the 
most studied classes of phytocompounds. Papers 
in the fi eld show their role in the prevention of de-
generative maladies including cancer, cardiovas-
cular and neurodegenerative diseases [1]. Fisetin 
can be found in strawberries, apples, persimmons, 
mangoes, kiwi, peach, lotus root, onions, cucum-
bers and other fruits and vegetables. The fl avonol 
was  depicted for its anti-oxidant, anti-cancer, an-
ti-angiogenic, anti-infl ammatory, anti-diabetic 
neuroprotective and neurotrophic eﬀ ects.
AIM: To analyse the antimicrobial and in vitro 
antiproliferative and pro apoptotic potential 
against B164A5 murine melanoma cell line of fl a-
vonol fi setin
RESULTS: Compared to standard antibiotics, 
the inhibition zones show that among the selected 
strains fi setin presents antibacterial activity 
against E.faecalis, S. pyogenes, S.aureus, S.pneumoni-
ae. After 72 h of incubation and at a concentration 
of 100 μM, fi setin conduced to an average viability 
for B164A5 melanoma cells of 71,5 ±10,60 % re-
spectively a percentage of 21,42±7,19 early apop-
totic cells and 9,56±2,83 late apoptotic cells.
CONCLUSION: The fl avonol fi setin can be re-
considered as a natural antibacterial agent against 
E.faecalis, S. pyogenes, S.aureus and  S.pneumoniae. 





1. Tsao R. et al. Nutrients 2, 1231-1246 (2010)
P2G-2
Antimicrobial and in vitro antiproliferative and 
proapoptotic potential against B164A5 murine 
melanoma cell line of fl avonol quercetin
 DANCIU, C.,  AVRAM, S.,  BOJIN, F., 
 MUNTEAN, D.,  MINDA, D.,  PAVEL, I ., 
 SOICA, C.,  ROXANA, G.,  DEHELEAN, C.
Department of Pharmacognosy, University of Medicine and 
Pharmacy “Victor Babeş“, Timişoara, România 
BACKGROUND: Quercetin can be found in ap-
ples, grapes, red wine, blue and black berries, red 
cherries, citrus, green leafy vegetables, onions, co-
coa, tea. Due to the plethora of biological activities 
it was described as a fl avonol with multifaceted 
therapeutic applications [1]
AIM: To analyse the antimicrobial and in vitro 
antiproliferative and pro apoptotic potential 
against B164A5 murine melanoma cell line of fl a-
vonol quercetin
RESULTS: Compared to standard antibiotics, 
the inhibition zones show that among the selected 
strains quercetin presents antibacterial activity 
against E.faecalis, S. pyogenes, S.aureus, S.pneumoni-
ae. After 72 h of incubation and at a concentration 
of 100 μM, quercetin conduced to an average via-
bility for B164A5 melanoma cells of 51,2 ±14,14% 
respectively a percentage of 18,4±4,24 early apop-
totic cells and 5,54 ±4,87 late apoptotic cells.
CONCLUSION: The fl avonol quercetin can be 
reconsidered as a natural antibacterial agent aga-
inst E.faecalis, S. pyogenes, S.aureus and S.pneu moniae 





1. D’Andrea G, Fitoterapia 106, 256-71. (2015)
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P2G-3
Increased anterior cingulate cortex activation 
in migraine patients in response to acute 
citalopram administration
 EDES, A.,  MCKIE, S.,  ZSOMBOK, T.,  BAGDY, 
GY.,  JUHASZ, G. 
MTA-SE-NAP B Genetic Brain Imaging Migraine Research 
Group, Budapest, Hungary
BACKGROUND: In spite the high prevalence of 
migraine we do not know the exact pathomecha-
nism yet. However, we know that specifi c abortive 
medications, triptans act through serotonergic 
system and serotonin neurotransmission is de-
creased in this condition. Neuroimaging studies 
also show functional and structural alterations of 
pain modulating brain areas in migraine. The an-
terior cingulate cortex (ACC) has important role in 
migraine by modulating top-down control of 
brainstem areas and receives dense serotonergic 
innervation from the raphe nucleus.
AIMS: In this study changes in ACC activation 
during and after 7.5 mg citalopram infusion, were 
measured in 27 healthy and 6 migraine volunteers 
using within-subject, placebo-controlled, double-
blind, randomized design with challenge pharma-
cological fMRI (phMRI). The images were acquired 
at a 3T MRI scanner using T2*-weighted echo-pla-
nar pulse sequence with 3 mm x 3 mm x 3 mm res-
olution. The analysis was made with SPM12 in 
MATLAB by region of interest analysis of ACC. 
RESULTS: We found signifi cant diﬀ erences in 
brain activation during and after citalopram chal-
lenge between migraine and control subjects in 
two clusters in the right ACC. The extracted time-
series showed that the activation of ACC in mi-
graine patients was signifi cantly higher than in 
controls, especially in the fi rst 8-9 minutes of drug 
administration. 
CONCLUSIONS: Our fi ndings clearly demon-
strate that migraine patients are more sensitive to 
acute elevation of brain serotonin level, since they 
have increased ACC activation compared to the con-
trol group during and after citalopram challenge. 
ACKNOWLEDGEMENT: The study was sup-
ported by the Hungarian Academy of Sciences 
(MTA-SE Neuropsychopharmacology and Neuro-
chemistry Research Group) and the Hungarian 
Brain Research Program (MTA-SE-NAP B GEN-
IMIG Research Group, Grant No. KTIA_NAP_13-
2-2015-0001).
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P2G-4
The eﬀ ect of acute escitalopram treatment on 
EEG gamma power during wakefulness and 
REM sleep
 PAPP, N.,  VAS, SZ.,  BAGDY, GY.
Department of Pharmacodynamics, Semmelweis University, 
Budapest, Hungary
BACKGROUND: Escitalopram, a widely used se-
lective serotonin reuptake inhibitor (SSRI) antide-
pressant, is known to infl uence the sleep-wake cy-
cle. Electroencephalography (EEG) enables to ob-
serve not only changes in the sleep architecture 
(e.g. time spent in diﬀ erent vigilance stages), but 
also alterations in diﬀ erent frequency bands 
which are related to specifi c brain functions. Gam-
ma oscillations, at relatively high frequencies, play 
an important role in certain sensory and cognitive 
processes. 
AIMS: We aimed to investigate whether acutely 
administered escitalopram caused EEG power 
changes concerning the slow gamma frequency 
band (30-60 Hz) in the relevant vigilance stages, 
wakefulness and rapid eye movement sleep 
(REMS). We used adult male Wistar rats equipped 
with electrodes, and registered EEG, electromyo-
gram (EMG) and motor activity following intra-
peritoneal injections of 10 mg/kg escitalopram, 
starting at light onset.  
RESULTS:  Our results show that escitalopram 
altered gamma oscillations in the two examined 
vigilance stages in a diﬀ erent manner. During 
REMS, the SSRI caused a signifi cant reduction in 
the gamma EEG power. In contrast, during wake-
fulness, escitalopram had no eﬀ ect in this frequen-
cy range.
CONCLUSIONS: Since memory processes are 
important functions related to gamma activity 
during REMS, the decrease of gamma power in 
this stage may refer to memory loss as a result of 
the treatment. On the other hand, during wakeful-
ness, gamma power remained unaﬀ ected, which 
implicates that brain functions connected to gam-
ma band in this stage, such as att ention and cogni-
tion, may not be aﬀ ected by acute escitalopram 
administration.
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P2G-5
Role of stress hormones in migraine
 TOTH, ZS.1,2,  GECSE, K.1,2, EDES, A.1,2,  SZABO, 
E.1,  KOCSEL, N.1,  GALAMBOS, A.1,  BAKSA, 
D.1,2,  KOKONYEI, GY.1,2,  BAGDY, GY.1,2,3, 
 JUHASZ, G.1,2,3,4
1 MTA-SE-NAP B Genetic Brain Imaging Migraine Research 
Group, Budapest, Hungary
2 Department of Pharmacodynamics, Faculty of Pharmacy, 
Semmelweis University, Budapest, Hungary
3 MTA-SE Neuropsychopharmacology and Neurochemistry 
Research Group, Budapest, Hungary
4 Neuroscience and Psychiatry Unit, The University of 
Manchester, UK and Manchester Academic Health Sciences 
Centre 
BACKGROUND: Migraine is a disabling headache 
disorder which aﬀ ects millions of people world-
wide. Numerous factors can contribute to the de-
velopment of migraine including stressors.
AIMS: Our aim was to review scientifi c knowl-
edge about the relationship of migraine and stress. 
RESULTS:  Stress response controlled by the hy-
pothalamo-pituitary-adrenocortical axis (HPA). 
Under stress corticotropine-releasing hormone 
(CRH) and aginine-vasopressine (AVP) are re-
leased from the hypothalamus and stimulates the 
secretion of adrenocorticotrop hormone (ACTH) 
from the pituitary gland. ACTH is the main hor-
mone which leads to the production of cortisol. 
Migraine att acks are stressful stimuli and the 
brain of migraine patients could not habituate 
properly to these frequent stressors. As a result of 
impaired habituation, stress response termination 
compromised. Under normal circumstances corti-
sol binds to glucocorticoid receptors, which act as 
a negative feedback on the HPA. However, during 
chronic stress cortisol level remains continually el-
evated, which results in glucocorticoid receptor 
resistance and diminish the negative feedback 
control of CRH release. It leads to impaired anti-
infl ammatory processes and excessive glutamate 
release and eventually neuroplastic changes in the 
pain processing system.
CONCLUSIONS: The above mentioned pro-
cesses, among others, play an important role in 
the development of chronic migraine. Therefore, 
understanding the interactions between chronic 
stress and pain processing may help in develop-
ing migraine preventive therapies.
ACKNOWLEDGEMENT: The study was sup-
ported by Hungarian Brain Research Program – 
Grant No. KTIA_NAP_13-2-2015-0001 (MTA-SE-
NAP B Genetic Brain Imaging Migraine Research 
Group) and by the Hungarian Academy of Scienc-
es (MTA-SE Neuropsychopharmacology and Neu-
rochemistry Research Group).
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P2G-6
Cardiovascular eﬀ ects of low- and high-dose 
beta-carotene treatment in Zucker obese rats
 CSÉPÁNYI, E.,  CZOMPA, A.,  SZABADOS-
FÜRJESI, P.,  DUONG, T.,  LEKLI, I ., 
 TÓSAKI, Á.,  BAK, I .
Department of Pharmacology, Faculty of Pharmacy, University 
of Debrecen, Hungary
BACKGROUND: Nowadays there is a growing in-
terest in the components of plants as potential 
pharmaceutical raw materials. Among these beta-
carotene is one of most intensively studied com-
pound. Numerous clinical studies have examined 
the cardiovascular eﬀ ects of it, but the results are 
quite contradictory. Beta-carotene could function 
as an antioxidant, however, many evidence show 
that it can act as pro-oxidant under increased oxi-
dative circumstances 1.
AIMS: In the present study we investigated the 
cardiovascular eﬀ ects of long-term, low and high 
dose beta-carotene treatment in hearts isolated 
from Zucker obese rats.   
RESULTS:  The glucose tolerance tests showed 
dose-independent reduction in blood glucose lev-
el. Furthermore, low dose treatment resulted in a 
signifi cant increase in postischemic cardiac func-
tion, which was followed by decreased infarcted 
area. Moreover, high-dose beta-carotene treat-
ment singnifi cantly increased the level of HO-1 in 
hearts subjected to ischemia/reperfusion. Interest-
ingly, the observed cardioprotective eﬀ ects are 
disappeared in case of high dose treatment, in 
spite of increased HO-1 level.
CONCLUSIONS: The observed controversial ef-
fects would be the result of formation of harmful oxi-
dative products of beta-carotene during reperfusion.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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P2G-7
Eﬀ ect of GSH synthetic analogue UPF1 on the 
activation of NRF2
 HANSEN, M.,  POROSK, R.,  MAHLAPUU, R., 
 KAIRANE, C.,  ZILMER, M.,  SOOMETS, U.
Department of Biochemistry, Institute of Biomedicine and 
Translational Medicine, Centre of Excellence for Genomics and 
Translational Medicine, University of Tartu, Tartu, Estonia
BACKGROUND: The synthetic analogue of GSH, 
a tetrapeptide UPF1 has recently developed by Eh-
rlich et al. which outperform free radical scaveng-
ing properties of GSH, while not showing any tox-
icity to the cells at 250 μM concentration [1]. We 
have previously observed that while UPF1 pep-
tide itself is not capable of crossing the plasma 
membrane, the intracellular GSH concentration 
was increased when K562 cells were treated with 
0.1 mM UPF1 peptide [2]. The expression of GSH 
is tightly regulated by the Nuclear factor (ery-
throid-derived 2)-like 2 transcription factor 
(NFE2L2) or simply Nrf2 which is released from 
its anchoring protein Keap-1and binds thereafter 
to the antioxidant response elements (ARE) dur-
ing the oxidative stress. 
AIMS: In the present study we investigated if 
the increase of the cellular GSH levels induced by 
the UPF1 peptide is related to the intracellular lo-
calization and expression of the ARE activating 
transcription factor NRF2.  
RESULTS:  We found that when HepG2 cells 
are incubated with 0.1 mM UPF1 peptide, the con-
centration of intracellular free Nrf2 increases al-
ready after 30 min. In K562 cells the Nrf2 concen-
tration increases in the cytoplasm after 45 min in-
cubation. At the same time, Nrf2 concentrations in 
the nucleus are at the minimum in both cell lines 
after 30 min incubation with the peptide.   
CONCLUSIONS: The results suggest that UPF1 
peptide activates the intracellular antioxidant de-
fence system and while the initial step of this acti-
vation remains to be determined, the key step in 
the process is the activation of Nrf2. 
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P2G-8
Vasoactive eﬀ ects of a new nitric oxide donating 
acetylsalicylic derivative
 CZOMPA, A.,  BAK, I .,  SZOKE, K., 
 SZABADOS-FURJESI, P.,  LEKLI, I .,  BORBAS, 
A.,  HERCZEGH, P.,  TOSAKI, A.
Department of Pharmacology, Faculty of Pharmacy, University 
of Debrecen, Hungary
BACKGROUND: According to the latest WHO 
mortality rates ischemic heart conditions are the 
main cause of death among non-communicable 
diseases.
AIMS: In the following investigation we have 
aimed to test the properties of a nitric oxide (NO) 
donating acetylsalicylic acid (ASA) derivative, which 
is stable, water soluble compound newly synthe-
tized at the University of Debrecen, Hungary.  
RESULTS:  In the fi rst part of our experiments 
we were tested the possible cytotoxic eﬀ ects of our 
ASA derivative in vitro in 10-4 – 10-7M concentra-
tions. MTT cell viability assay and hemolysis tests 
were performed on H9c2 cells and rat erythro-
cytes, respectively. Thereafter, we were measured 
the vasoactive eﬀ ects on female Sprague Dawley 
rats ex vivo according to the Langendorﬀ  method 
in the presence or absence of the NO donating 
molecule. Our new NO donating ASA derivative 
is not aﬀ ecting negatively to the cell viability in 
the tested concentrations. Furthermore, we have 
noticed a dose-dependent, out washable vasodila-
tion on coronaries.  
CONCLUSIONS: Based on the benefi cial obser-
vations through our experimental arrangement, 
the new molecule synthetized in our University is 
a powerful vasodilator with no signifi cant toxic ef-
fects. It may contribute to new therapeutic ap-
proaches against ischemic heart diseases and pos-
sibly related syndromes, but the molecular mech-
anisms needs to be clarifi ed. 
Acknowledgements: NTP-NFTÖ-16, OTKA-
PD-111794, TÁMOP 4.2.4. A/2-11-1-2012-0001 and 
GINOP-2.3.2-15-2016-00043, EFOP-3.6.1-16-2016-
00022 „Debrecen Venture Catapult” project.  
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P2G-9
The study of the fenugreek seed treatment and 
its eﬀ ects on certain methabolic parameters and 
on the mithocondrial functions
 PALLAG, A.,  BOMBICZ, M.,  HEGEDŰS, 
CS.,  KOVÁCS, D.,  VARGA, B.,  PRIKSZ, D., 
 KURUCZ, A.,  NÉMETH, J.,  JUHÁSZ, B.,  KISS, R.2
Pharmacy department, Faculty of medicine and Pharmacy, 
University of Oradea, Oradea, Romania
BACKGROUND: The Trigonella foenum-graecum, 
fenugreek is a medicinal plant used since ancient 
times, it is also listed in the Pharmacopoeia. It 
contains numerous biologically active com-
pounds. The fenugreek has a great impact on the 
metabolism of lipids and glucose, insulin-sensi-
tising, has antioxidant eﬀ ects, it contributes in 
keeping the energy balance. Mithocondrial en-
zymes, like citocrom c or sirtuins, have an impor-
tant role in this. The citocrom c enzymes also take 
part in oxidative processes and by being released 
from the mithocondria they can start the pro-
grammed apoptosis. Sirtuins are NAD+-depen-
dent proteins, regulates several cellular processes 
like aging, transcription, apoptosis, infl amma-
tion, stress resistance, energy balance, insulin 
sensitizing, circadian clocks and mitochondrial 
biogenesis.
AIMS: We conducted a chronic feeding study 
on rats. The goal of our study is to analyse the ef-
fects of the fenugreek seed (0,6 g/kg) on metabolic 
parameters (nutrients and water consumption, 
weight), on glucose metabolism and on mithocon-
drial energy production.   
RESULTS:  The studied rats showed a signifi -
cant increase in body weight after four days op-
posed to the control group, the same increase 
could also be observed in their lipid accumulation, 
this diﬀ erence was present until the end of the 
treatment. We have found no diﬀ erence in the in-
sulin’s eﬀ ectiveness and neither did the insulin 
sensitivity change. While studying the integrity of 
the external mithocondrial membrane, no signiﬃ  -
cant diﬀ erences were found between Control 
(47,56± 1,668) and Treated (47,33± 1,863) groups. 
Measuring the enzyme activity no signiﬃ  cant dif-
ferences were found between Treated (88,18± 
1,798) and Control (88,82± 2,110) groups either. 
CONCLUSIONS: All things considered, we can 
say that the treatment strengthened the weight in-
creasing eﬀ ects of chronic feeding with lipids and 
glucose. Although the calorie consumption of the two 
groups was the same, the body’s lipid content has in-
creased in the treated group. The integrity of the ex-
ternal mithocondrial membrane has not changed. The 
sirtuin activity has increased, however, the causes of 
this mechanism are not completely clarifi ed yet. 
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P2G-10
The cardioprotective eﬀ ect of metformin on 
doxorubicin-induced cardiotoxicity
 ZILINYI, R.,  LEKLI, I .,  CZOMPA, A., 
 MARTON, M.,  TOSAKI, A.
Department of Pharmacology, Faculty of Pharmacy, University 
of Debrecen, Hungary
Doxorubicin (DOX) is one of the most eﬀ ective 
chemotherapeutic agent, but its cardiotoxicity has 
been an important clinical limitation. However, 
molecular mechanisms underlying DOX cardio-
toxicity are still being uncovered, but known to 
involve, at least in part, mitochondrial dysfunc-
tion, oxidative stress and apoptosis. In recent 
years, a number of studies have investigated the 
role of autophagy on DOX-induced cardiotoxicity 
but to date it is not clear how DOX alters that pro-
cess and its consequence on cardiomyocytes.
The aim of our study was to investigate the pos-
sible protective role of the antidiabetic drug met-
formin (MET) and its eﬀ ect on autophagy in a 
model of DOX-induced cardiotoxicity. Sprague-
Dawley rats were randomly divided four group. 
The DOX group rats received doxorubicin (3 mg/
kg every second day, cumulative dose: 18 mg/kg) 
intraperitoneally. The MET group rats received 
metformin (250 mg/kg/day for two weeks) via ga-
vage. The DOX+MET group rats received doxoru-
bicin + metformin at the same dose. Control group 
rats received distilled water and saline. After the 
last dose of doxorubicin isolated working hearts 
were prepared and heart function parameters 
(aorta fl ow, heart rate, coronaria fl ow and aorta 
pressure) were evaluated. Serum level of LDH, 
CK-MB enzymes, Troponin-T, and cardiac MDA 
were measured. Heart tissue samples were histo-
pathologically examined. Western blot analysis 
was conducted for autophagy-associated proteins 
P62, LC3, beclin-1, mTOR and AMPK.
ACTA-1703-BBBB.indb   220 9/19/17   6:29 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters 221
 Results of our study revealed that treatment with 
metformin produced increased cardiac protection 
manifested by a signifi cant decrease in serum Tro-
ponin-T and cardiac MDA level, and remarkable 
improvement in the heart function and in the histo-
pathological features. Furthermore, by focusing on 
the contribution of LC3, P62, beclin-1, mTOR and 
AMPK pathways, we have found that metformin 
induced autophagy and increased the expression of 
AMPK which may help cardiomiocytes to survive 
during doxorubicin treatment. These results may 
suggest using metformin would be preferable drug 
for patients suﬀ ering from cancer and receiving 
DOX in their chemotherapy regimen. 
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project.
P2G-11
Investigation of the eﬀ ects of anthocyanins on 
human infl ammatory keratinocyte model 
 MADARÁSZ, V.,  FENYVESI, F., VASVÁRI, 
G.,  FEHÉR, P.,  UJHELYI, Z.,  BÁCSKAY, I ., 
 VECSERNYÉS, M.,  VÁRADI, J .
Department of Pharmaceutical Technology, University of 
Debrecen, Debrecen, Hungary
BACKGROUND: Psoriasis is a chronic infl amma-
tory skin disease in which IL-17 and TNF-α play 
an important role in its pathology. Anti-cytokine 
therapies are the most eﬀ ective methods nowa-
days, nevertheless natural products render adju-
vant treatment opportunities in psoriasis. 
AIMS: Keratinocytes are widely used for in-
fl ammatory modelling of psoriasis. In our recent 
study we investigated the role of TNF-α and IL-17 
in infl ammation and proliferation on human kera-
tinocyte (HaCaT) cell culture models. Our aim 
was to establish a sensitive psoriasis model to re-
veal the anti-infl ammatory and anti-proliferative 
eﬀ ect of anthocyanins.  
RESULTS:  The NF-κB immunostaining results 
show the role of cytokines in infl ammation in the 
applied concentration. Anthocyanins eﬃ  ciently 
blocked the activation of NF-κB pathway. We de-
tected diﬀ erent proliferative eﬀ ects of stimulants 
on real time cell analysis (RTCA) and confi rmed 
the anti-proliferative eﬀ ect of anthocyanins. Proin-
fl ammatory cytokines aﬀ ected cell proliferation in 
diﬀ erent extent; however anthocyanin pre-treat-
ment decreased the proliferation rate on cytokine 
stimulated HaCaT cells in wound healing assay.
CONCLUSIONS: The results indicate that an-
thocyanins could aﬀ ect and inhibit the prolifera-
tion and infl ammation on infl ammatory HaCaT 
cell model.
This work was supported by EFOP-3.6.1-16-
2016-00022 „Debrecen Venture Catapult” project. 
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P2G-12
Iron (II) chelator could prevent the loss of 
positive cardiovascular eﬀ ects of high dose beta 
carotene treatment
 CSEPANYI, E.,  DUONG, T.,  SZABADOS-
FURJESI, P.,  LEKLI, I .,  BAK, I .
Bioanalytical Chemistry and Pharmacology,  Faculty of 
Pharmacy, University of Debrecen, Hungary.
Background: Beta carotene (BC) is a good antioxi-
dant compound, however, there are increasing ev-
idences suggesting the prooxidant eﬀ ects of it un-
der heavy oxidative stress. Earlier we studied the 
eﬀ ects of it under ISA/REP-induced increased oxi-
dative circumstances. In that study we found that 
the cardioprotective eﬀ ects of BC are lost after 
ISA/REP when the agent was administered at high 
concentration. Although, BC treatment increased 
HO-1 expression, we did not observe a bett er heart 
function and/or decreased IS in case of high dose 
treatment. (1). HO-1 is an enzyme produced in re-
sponse to oxidative stressors and may contribute 
to loss of cardioprotection at elavated BC dosage. 
Fe2+ produced under normal HO-1 activity is a 
harmless metabolite and clears up spontaneously. 
As Fe2+ boosts the prooxidant characteristics of 
high dose BC, it possibly undermines the cytopro-
tective eﬀ ects of HO-1 and increase oxidative 
stress on a tissue. We hypothesize using a selec-
tive chelator of Fe2+, desferal, may negate the loss 
of cardioprotection at high dose of BC. 
Aims: In the present study we investigated if 
desferal, can prevent the loss of positive cardio-
vascular effects in high dose BC treatment in 
isolated rat hearts. Adult male rats were ga-
vage-fed BC for 4 weeks, at dosage of 150mg/
kg/day. The hearts were then excised from the 
animals and mounted in a working heart appa-
ratus and subjected to 30 min of global isch-
emia, followed by 120 min of reperfusion. The 
cardiac functions were evaluated and infarct 
size were assessed. 
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Results: We observed that desferal increases 
postischemic cardiovascular function alone or in 
combination with high dose beta carotene treat-
ment. Furthermore, the iron (II) chelator improved 
the cardiovascular recovery which is refl ected in 
reduced infarct size. 
Conclusion: Iron (II) chelators can possibly pre-
vent the loss of positive cardiovascular eﬀ ects in 
case of high dose BC treatment.
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P2G-13
Characterization of D-serine transport in 
SH-SY5Y cell line and cortical astrocytes
 VINCZE, I .,  BAGAMÉRY, F.,  LAKATOS, P., 
 TÓKA, D.,  TÁBI, T.,  SZÖKŐ, É.
Department of Pharmacodynamics, Semmelweis University, 
Budapest, Hungary
BACKGROUND: D-serine is a co-agonist of the 
NMDA-glutamate receptors. Hypofunction of 
NMDA receptors has been connected to several 
CNS diseases, e.g. schizophrenia and bipolar dis-
order. Decreased extracellular level of D-serine 
may contribute to their pathophysiology. Various 
transport systems, like sodium dependent ASCT1 
and 2, as well as sodium-independent asc1 were 
reported to be involved in D-serine uptake [1]. 
These transporters are potential targets for modu-
lation of intra- and extracellular D-serine level. 
AIMS: Characterization and comparison of D-
serine uptake into SH-SY5Y human neuroblasto-
ma cell line and rat primary cortical astrocytes.  
RESULTS:  Time- and dose dependent D-serine 
uptake was observed in both cell types. Main 
transport form was found sodium-dependent 
since about 80% less D-serine uptake was mea-
sured in a sodium-free buﬀ er. Neutral amino ac-
ids, substrates of these transporters, e.g. L-alanine 
and L-threonine concentration dependently inhib-
ited D-serine uptake, characterized by a two-step 
inhibition curve and complete inhibition at their 
highest concentration in both cell types. Accord-
ing to literature data ASCT1 can be selectively in-
hibited by trans-4-hydroxy-L-proline (t-proline), 
while L-glutamine was reported as a preferential 
inhibitor of ASCT2 [1]. In the studied concentra-
tion range t-proline reached only about 55% inhi-
bition of D-serine uptake in both types of cells. In 
the fi rst, selective step the inhibition was about 
25%, possibly indicating the contribution of 
ASCT1 to D-serine uptake. L-Glutamine provided 
more pronounced inhibition in two steps in SH-
SY5Y cells and astrocytes alike. The fi rst step, sup-
posedly related to ASCT2 was responsible for 
about 60% of D-serine uptake.
CONCLUSIONS: Both primary astrocytes and 
SH-SY5Y cell line show mainly sodium-depen-
dent D-serine uptake with at least two transporter 
systems involved. Further characterization of 
these transporters is needed. SH-SY5Y cells are 
likely to be appropriate for studying the opportu-
nities of D-serine transporter modulation. 
REFERENCES: 
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P2G-14
Comparison of the cytoprotective eﬀ ect of some 
resveratrol derivatives
 BAGAMÉRY, F.,  ULAKCSAI, ZS.,  VARGA, K., 
 TÓTH, G.,  SZÖKŐ, É.,  TÁBI, T.
Department of Pharmacodynamics, Semmelweis University, 
Budapest, Hungary
BACKGROUND: Previously we have found resve-
ratrol shows strong protective eﬀ ect against se-
rum deprivation induced caspase activation in 
non-transformed fi broblasts. According to our re-
cent results the role of mild intracellular stress 
that activates stress resistance machineries plays a 
crucial role in the protective eﬀ ect (1).
AIMS: In the present study we aimed at exam-
ining structure activity relationship by using res-
veratrol derivatives.   
RESULTS:  Apoptosis was induced by serum 
deprivation in primary mouse embryonic fi bro-
blasts. Caspase 3 activation was assayed by using 
its fl uorogenic substrate. Reactive oxygen species 
production and depolarization of the mitochon-
drial membrane were measured by fl uorescence 
methods. The eﬀ ect of oxyresveratrol, pinostil-
bene, pterostilbene, trimethyl resveratrol was 
compared to that of resveratrol.
We found that oxyresveratrol and pinostilbene 
(monomethyl resveratrol) with very similar chemi-
cal structure to resveratrol exerts a resveratrol-like 
protective eﬀ ect. However; pterostilbene, (dimeth-
yl resveratrol) was found to have strong cytotoxic 
property thus cannot be further analyzed. Tri-
methyl resveratrol also signifi cantly reduced cas-
pase 3 activation although its eﬀ ect was much less 
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pronounced. This latt er compound caused much 
more considerable depolarization of mitochondria 
and consequential free radical generation than res-
veratrol and its protective derivatives did.  
CONCLUSIONS: Oxyresveratrol and mono- 
and trimethyl resveratrol posses resveratrol like 
protective eﬀ ect, while the dimethyl derivative 
has strong cytotoxic activity. The reduced eﬃ  cacy 
of trimethylated derivative raises the possibility of 
importance of presence of antioxidant phenolic 
hydroxyl groups in the protective eﬀ ect.  
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P2G-15
In vivo hypoglycemic activities of ethanol 
and aqueous extracts of Capparis ovata var. 
Palaestina
 OKUR, ME.1,2,  ÇIÇEK-POLAT, D.3,  ÖZBEK, H.4, 
 ARSLAN, R.1 
1Department of Pharmacology, Faculty of Pharmacy, Anadolu 
University, Eskişehir, Turkey
2Department of Pharmacology, School of Pharmacy Istanbul 
Medipol University, Istanbul, Turkey 
3Department of Pharmaceutical Botany, Faculty of Pharmacy, 
Ankara University, Ankara, Turkey
4Department of Pharmacology, School of Medicine, Istanbul 
Medipol University, Istanbul, Turkey 
BACKGROUND: Diabetes mellitus (DM) is a glob-
al public health problem with expected 300 mil-
lion diabetics by the year 2030 worldwide. There is 
a need to search for safe, more aﬀ ordable and 
widely available or easy to produce medication for 
treatment of DM. Therefore investigating the eﬃ  -
cacy of plants could be a bett er alternative. Cappa-
ris ovata var. palaestina has wide natural distribu-
tion in Turkey (1,2).
AIMS: The aim of this study is to evaluate hy-
poglycemic eﬀ ect of C. ovata var. palaestina extracts 
in alloxan induced diabetic mice. For this purpose 
bud and fruit extracts of C. ovata var. palaestina 
were prepared. Glibenclamide and saline was 
used as control.
RESULTS:  Diabetic mice were administered 
with 100, 300, 500 mg/kg (i.p.) doses of bud and 
fruit’s ethanol and aqueous extracts. Fasting blood 
glucose levels were screened 60, 120, 240 and 360 
min after treatments. Statistical analysis results 
was performed using one-way ANOVA followed 
by Dunnett ’s post-tests. The administration of the 
glibenclamide (3mg/kg,GC) signifi cantly de-
creased blood glucose at 60 min (p<0.01), 120 min 
(p<0.01), 240 min (p<0.001) and 360 min (p<0.001) 
when compared with diabetic control (DC). The 
administration of the fruit-aqueous (FA) extracts; 
FA1 (100mg/kg) at 60 min (p<0.05), 120 min 
(p<0.05) and FA2 (300mg/kg) at 60 min (p<0.01), 
120 min (p<0.01), 240 min (p<0.05) and 360 min 
(p<0.05), signifi cantly decreased blood glucose 
level when compared with DC. On the other hand 
administration of the bud-aqueous (BA) extracts; 
BA3 (500mg/kg) at 60 min (p<0.001), 120 min 
(p<0.01), 240 min (p<0.001) and 360 min (p<0.001), 
signifi cantly decreased blood glucose level when 
compared with DC. None of ethanol extracts did 
not show any signifi cant changing on blood glu-
cose level.
CONCLUSIONS: The results of this study 
showed that the aqueous extract of C. ovata var. 
palaestina  may have potential hypoglycemic ac-
tivity. 
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POSTER SECTION 2H
HOSPITAL PHARMACY AND 
PHARMACOEPIDEMIOLOGY
P2H-1
 Bisphosphonate related osteonecrosis of the jaw 
in Hungary
 VESZELY-KOTÁN, E.,  LIEB, T.,  PARISEK, ZS., 
 MESKÓ, A.,  VASZILKÓ, M.,  HANKÓ, B.
Uzsoki Hospital Budapest, Hungary
BACKGROUND: Bisphosphonate (BP) related os-
teonecrosis of the jaw (BRONJ) is a serious side ef-
fect of the bisphosphonate group. As this disease 
has no independent code in The International Sta-
tistical Classifi cation of Diseases and Related 
Health Problems (ICD), it is hard to estimate how 
many bisphosphonate patients are aﬀ ected.
AIMS: The aim of our study was to fi nd epide-
miology data of Hungarian BRONJ patients. We 
also mapped the risk factors of BRONJ: main diag-
nosis of the BP treatment as well as medication 
administered besides bisphosphonate, and socio-
economic factors.
RESULTS: In our study we defi ned BRONJ pa-
tients treated from 2010 to 2014 with the help of 
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ICD codes and the International Classifi cation of 
Procedures in Medicine (ICPM) from the database 
of the National Health Insurance Fund of Hunga-
ry. We identifi ed the basic disease treated with 
bisphosphonate, whether it was malignancy or 
non-malignant disease. 236,207 bisphosphonate 
patients’ socioeconomic and medication data were 
analyzed, out of whom 340 developed BRONJ ac-
cording to our defi nition. Although more women 
developed BRONJ in our patient population, we 
found signifi cantly more men in the necrosis 
group than in the total patients’ group. We found 
that oncology patients are at the highest risk of de-
veloping BRONJ, especially if BP is administered 
intravenously. Therapy change has no proven ef-
fect on the number of our patients developing 
BRONJ. Steroids and chemotherapy increase the 
risk of BRONJ, and we also found diﬀ erences be-
tween the BP groups.
CONCLUSIONS: In the group of bisphospho-
nate patients, oncology patients, intravenously ad-
ministered BP patients, and patients taking ste-
roids are at a higher risk of developing BRONJ. 
Diﬀ erences between our results and the interna-
tional data highlight the eﬀ ect of patient related 
other factors on the development of BRONJ. Our 
fi ndings confi rm that bisphosphonate patients 
need closer monitoring due to this serious side ef-
fect.
P2H-2
Cross-Cultural adaptation of the “Osteoarthritis 
Knee and Hip Quality of Life” disease specifi c 
questionnaire – methods and results of the Pilot 
phase I.
 FEKETE, H.,  FEKETE, R.,  CSOKA, I . 
University of Szeged, Faculty of Pharmacy, Institute of 
Pharmaceutical Technology and Regulatory Aﬀ airs, Szeged, 
Hungary
BACKGROUND: Osteoarthritis (OA) is highlighted 
disorder with important socio-economic factors affect-
ing the patient adherence and patients’ quality of life. 
WHO report handles this as one of the most important 
chronic disease. OA is counted as the leading cause of 
chronic disability and permanent loss of quality of life. 
There is an urgent need to focus on the main factors af-
fecting the disease state, and also to have an overview 
on the status of the Hungarian population. Lower limb 
osteoarthritis specifi c quality of life questionnaire is 
not available in Hungary.  
AIMS: The aim of this work was to develop the 
cross-cultural adaptation of the „Osteoarthritis Knee 
and Hip Quality of Life” questionnaire for the Hungari-
an population according to the relevant international 
guidelines and instructions of the French questionnaire 
development team.   
RESULTS:  Hungarian cross-cultural questionnaire 
was developed according to the adaptation and valida-
tion guidelines. The Pilot I. study was performed at The 
Rehabilitation Center in Kiskunfélegyháza; 34 question-
naires were evaluated of the fi lled 40. 70,58% of the 
sample was women, the mean age was 72,5. The educa-
tion level in most cases was primary school and 44,12% 
lived at the village area. Only one from the 43 items of 
the questionnaire was ignored, this was in connection 
with sexual activity of the patients (an item required to 
vacate, if more then 5% of the fi llers do not answer it).  
CONCLUSIONS: This study completed the Pilot I. 
part of the national implementation of the international 
questionnaire, measuring the quality of life in case of 
OA patients in Hungary.  The questionnaire measures 
the Hungarian arthritic population in four domains: 
physical activities, mental health, social functioning, 
and social support. The next step is a further pilot to 
evaluate reproducibility and construct validity.    
The work was supported by Foundation for De-
velopment of Pharmacy Education at University 
of Szeged.
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P2H-3
Screening potential interactions between drugs 
and supplementary products: Summarized 
experiences and recommendations based on the 
study of three Hungarian patient groups
 SOMOGYI-VÉGH, A.,  ÁBRAHÁM, E.,  BOTZ, L.
Department of Pharmaceutics and Central Clinical Pharmacy, 
Faculty of Pharmacy, University of Pécs, Pécs, Hungary
BACKGROUND: The increasing number of pa-
tients taking supplementary products (OTC medi-
cines, herbal remedies, dietary supplements, etc.) 
along with prescribed medicines has become a 
new challenge for health care systems. These 
products may infl uence therapy outcomes by in-
ducing unwanted eﬀ ects.
AIMS: Our aim is to summarize the results and 
practical observations from our previous studies.  
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RESULTS:  We studied the use of supplemen-
tary products with three diﬀ erent patient 
groups (patients of internal medicine – n=200, 
psychiatry – n=54, Parkinson’s disease – n=26). 
Potential drug-drug and drug-supplement in-
teractions were identifi ed and analyzed. The ra-
tio of supplement users varied between 46-91%. 
However, the prevalence of clinically relevant 
and potentially serious interactions may be 
about one order of magnitude less. The general 
risk of harmful interactions is hard to estimate 
because of the contradictions between the inter-
action databases, the numerous factors infl uenc-
ing the clinical relevance and the signifi cant dif-
ferences observed between the patient groups. 
Participants had diﬀ erent att itudes regarding 
supplements and prescribed medicines. The 
most common reason for taking supplements 
was that patients wanted to play an active role 
in their own recovery.
CONCLUSIONS: Although computerized inter-
action screening can be of great help, current data-
bases show great variability and have several limi-
tations. Lack of a comprehensive and verifi ed da-
tabase that includes all supplementary products 
and the lack of a generally accepted nomenclature 
of ingredients make the recognition and preven-
tion of drug-supplement interactions more com-
plicated. Standardized and transparent classifi ca-
tion of risk and clinical signifi cance of interactions 
can only be established through structured assess-
ment of underlying evidence.
P2H-4
Alarming patient safety concerns of the 
illegitimate online market of shortage oncology 
drugs
 VIDA, R. GY.,  FITTLER, A.,  BOTZ, L.
Department of Pharmaceutics and Central Clinical Pharmacy, 
Faculty of Pharmacy, University of Pécs, Pécs, Hungary
BACKGROUND: Shortages of oncology drugs 
mean a challenge to healthcare systems. Exposed 
patients or health care providers may seek alterna-
tive resources online. Unfortunately, consumers 
may be misled by unreliable information resourc-
es and the enormous number of illegitimate on-
line medication vendors. Illegally distributed 
medications may negatively infl uence the success 
of therapies, furthermore counterfeit medicines 
pose potential health hazard.
AIMS: The purpose of our study was to evalu-
ate the online accessibility of oncology drugs af-
fected by drug shortages at national and at inter-
national level in the past years. Patient- and medi-
cation safety issues were identifi ed to highlight 
the dangers of the unregulated sale of possibly life 
threatening products  
RESULTS:  Shortage oncology drugs are general-
ly available on the Internet and are accessible with-
out medical prescription by majority (73.4-78.4%) 
of the identifi ed (n=210) websites. Numerous 
(20.3%-26.9%) vendors do not display any contact 
information on their websites and in most cases 
(90.5%- 87.3% ) no healthcare professional is avail-
able for customers. None of the evaluated websites 
were approved/recommended by Internet pharma-
cy verifi cation databases, while 31.1% were defi -
nitely unregulated. Numerous Internet vendor 
sites (63,5%) operated in both evaluated years, indi-
cating illegitimate sellers’ continuous service.
CONCLUSIONS: The alarming illegitimate 
market of shortage oncology drugs has been iden-
tifi ed. The limited access to pharmaceuticals with-
in the traditional supply-chain is a challenge for 
healthcare but an opportunity for fraudulent on-
line sellers of medications. Managing illegal trade 
of pharmaceuticals and limiting access to poten-
tially counterfeit drugs must be a priority for gov-
ernments and drug supply systems. Future goals 
of the authors: identifi cation of the online avail-
ability of further active ingredients used in oncol-
ogy treatments, evaluation of the quality of thera-
py related information provided by online medi-
cation sellers.
P2H-5
The eﬀ ect of clinical pharmacy services on 
medication errors in a Hungarian regional 
hospital
 RICHTER, K.,  PÁZMÁNY, P.,  ATTL, O., 
 TOKAJI-NAGY, O.
„Szent Borbála” Hospital, Tatabánya, Hungary
BACKGROUND: Medication errors are a signifi -
cant and costly cause of injury during hospitaliza-
tion that can eﬀ ectively be mitigated by clinical 
pharmacist interventions. In October 2016, clinical 
pharmacy services were introduced in 4 depart-
ments of the „Szent Borbála” Hospital in order to 
facilitate patient safety and minimize medication 
errors.
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AIMS: To assess medication errors on 4 wards 
for an 8-month period and to investigate the po-
tential outcomes of implementing clinical phar-
macy services in those sett ings.   
RESULTS:  Since October 2016, 2189 patients 
were screened on 4 wards. Errors identifi ed dur-
ing the medication reconciliation and review pro-
cesses were classifi ed according to the Pharma-
ceutical Care Network v7.0 scheme. Pharmacist 
interventions and their acceptance rate were also 
recorded. Medication error rates diﬀ ered substan-
tially between medical specialties. The long-term 
care ward showed a markedly high, 32% error 
rate, while wards of internal medicine demon-
strated a moderate 6-8% rate and the department 
of surgery exhibited the lowest value at 5%. The 
most frequent errors were drug interactions (25%), 
followed by inappropriately high doses (13%), du-
plications (10%) and contra-indicated drug combi-
nations (6%).  The overall acceptance rate of phar-
macist interventions was 80%. Non-acceptance 
due to risk/benefi t assessments occurred in 11% of 
the cases, while no reason of refusal was provided 
in the remaining 9%. Reconciled medication errors 
of surgery patients were also referred to their pri-
mary care physicians. 
CONCLUSIONS: It was found that the imple-
mentation of clinical pharmacy services is a useful 
and eﬀ ective method of enhancing patient safety. 
Medication reconciliation and review has the capac-
ity to identify and resolve issues of the prescribing, 
dispensing and medication use processes. Direct in-
volvement of pharmacists in the clinical sett ing has 
also facilitated a highly functional, result-driven 
and multiprofessional approach of patient care.  
P2H-6
Assessment of some herbal products used to 
treat urinary tract diseases in Hungary
 GERNER, B.,  HORVÁTH, GY.,  BENCSIK, T.
Department of Pharmacognosy, University of Pécs, Pécs, 
Hungary
BACKGROUND: Due to the increased demand for 
herbal remedies, the number of products and dis-
tributors is also increasing worldwide. The quali-
ty, safety, and eﬃ  cacy of these products is not as 
well-regulated as in the case of medicines, howev-
er, the patients are not aware of this diﬀ erence.
AIMS: Because of popularity of herbal products 
in self-treatment of urinary tract infections in 
Hungary, we prepared questionnaires for both 
laypersons and professionals (pharmacists and 
pharmacy technicians) to assess their general 
judgement on them. Then according to the recom-
mendations of the Ph. Eur. (1) and another proto-
col (2), we investigated some herbal products con-
taining Solidaginis herba, Uvae ursi folium, Equi-
seti herba, and Vaccinium macrocarpon fructus.  
RESULTS:  Half of the laypersons (127 persons) 
answered, that they fi rst seek medical help in the 
case of urinary tract symptoms, about 30% (81 
persons) preferred self-medication with the help 
of the internet, and only 14% (37 persons) asked 
the help of a pharmacist. According to the TLC 
chromatograms, all products contained the mark-
er compounds of the medicinal plants, but the 
HPLC and spectrophotometric methods revealed 
considerable quantitative diﬀ erences between 
them. All products of Equiseti herba were of phar-
macopoeial quality, but the arbutin, fl avonoid, 
and proanthocyanidin content of preparations 
containing Uvae ursi folium, Solidaginis herba, 
and Vaccinium macrocarpon fructus, respectively, 
met the standards only in few cases 
CONCLUSIONS: All examined distributors had 
products with both bett er and worse quality, and 
we could not fi nd any correlation between the 
quality of the products and the popularity of the 
distributors among both laypersons and profes-
sionals.
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P2H-7
Results of a pharmacist led medication 
reconciliation process 
 GYIMESI, N.,  TISZAI, Z.,  KELLER, N.,  SÜLE, A.
Department of Pharmacy, Péterfy Hospital and Trauma Centre, 
Budapest, Hungary
BACKGROUND:  Medication discrepancies are 
common. Studies suggest that they occur in up to 
70% of patients at admission or discharge. Medi-
cation reconciliation is a strategy to reduce the oc-
currence of medication discrepancies that may 
lead to adverse drug events. 
AIMS:  A medication reconciliation process was 
introduced in three wards of our hospital in order 
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to improve drug therapy and patient safety. Medi-
cation histories are taken by a clinical pharmacist 
or pharmacy assistant. Patient data, medication 
list according to drug chart and notes of medica-
tion anamnesis are recorded on a form, discrepan-
cies and requests for intervention can be high-
lighted.  In addition, the form includes risk cate-
gorization based on general criteria (eg. polyphar-
macy) and fi elds for drug allergies, side eﬀ ects 
and high alert medications. The data of 114 forms 
from two wards (Septic and General Surgery) 
were collated and analysed in Microsoft Excel.   
RESULTS:   99 patients (87%) were considered as 
”at risk”. The most common risk categories were 
polypharmacy (90 cases) and high alert medica-
tions (72 cases). The average number of medica-
tions taken by a patient was 8. In 72 cases (63%) 
there was at least one discrepancy between the 
drug chart and the medication history. The two 
most common types of discrepancy were patients 
taking medications that were not recorded on 
their charts (36 cases) and missing or inappropri-
ate doses (27 cases), accordingly these were the 
most frequent interventions too. The total number 
of interventions requested was 177. 72 patients 
were monitored  further during their stay and 42 
had a consultation at discharge. 
CONCLUSIONS:  Medication reconcilliation 
plays an important role in reducing potential drug 
related problems. The collation and analysis of 
data highlights areas for improvement. There 
would be benefi ts in further extending the process 
beyond admissions to discharge and other critical 
handover points in the patient care pathway.
P2H-8
Polypharmacy among hospitalized elderly 
patients
 CSATORDAI, M.,  BOR, A.,  SZALAI, G.1, 
 CSONKA, Á.2,  GÁRGYÁN, I .2,  DORÓ, P.1
1University of Szeged, Faculty of Pharmacy, Department of 
Clinical Pharmacy, Szeged, Hungary
2University of Szeged, Faculty of Medicine, Department of 
Traumatology, Szeged, Hungary
BACKGROUND: Polypharmacy (taking 5 or more 
chronic medications concomitantly) is a common 
problem among elderly patients. Concomitant use of 
many drugs may increase the presence of drug-re-
lated problems and decrease the quality of life and 
compliance. Besides this, several medications are po-
tentially inappropriate for elderly patients and these 
medications should be avoided or changed.
AIMS: The aim of the study was to review and 
evaluate the medication of elderly, hospitalized 
patients and to assess the prevalence of polyphar-
macy and potentially inappropriate medications 
(PIM). The collection of data was carried out be-
tween the period of Janurary 2011 and December 
2012, patients 65 years old or above were recruited 
from the Traumatology Department. Data were 
recorded from the patients’ charts and documen-
tation and a retrospective analysis was performed. 
RESULTS:  604 patients met the inclusion crite-
ria (143 male, 461 female; mean age: 81.8±7.52). 
On admission, the mean number of chronic medi-
cation was 7.1±3.8. The prevalence of polypharma-
cy was 74.0% (75.3 % among female patients and 
69.9% among male patients). 26.2% of the patients 
were taking 10 or more medications concomitant-
ly. Regarding ATC codes, the most prevalent ana-
tomical main groups were group C (85.3% of pa-
tients), group N (72.9%) and group A (68.9%). The 
most frequently used active agents were acetylsal-
icylic acid (30.8% of patients), amlodipine (30.5%), 
piracetam (28.6%), alprazolam (27.2%) and panto-
prazole (27.15%). Two of these agents-piracetam 
and alprazolam- are considered as PIM medica-
tions.  Regarding PIM medications, 76.8% of pa-
tients were taking at least one PIM.
CONCLUSIONS: Although polypharmacy is a 
common problem among the elderly and comor-
bidities demand the concomitant use of several 
medications, this group requires special att ention. 
To avoid possible drug related problems, regular 
medication review, simplifi cation of treatment, 
avoiding or changeing PIM medications and pa-
tient education is necessary.
P2H-9
Importance of pharmaceutical care in the 
application of eye drops and determination of 
microbiological contamination
 MERCZEL, S.1,  PÁL, SZ.2,  KOCSIS, B.3,  BOTZ, L.4
Central Pharmacy, Teaching Hospital Mór Kaposi, Kaposvár, Hungary
Institute of Pharmaceutical Technology and Biopharmacy, 
University of Pécs, Hungary
Medical Microbiology and Immunology, University of Pécs, Hungary
Department of Pharmaceutics and Central Clinical Pharmacy, 
University of Pécs, Hungary
BACKGROUND: It is considered to be a huge risk 
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factor of infectious eye diseases when the patient 
uses contaminated eye drops due to inadequate 
adherence.
AIMS: Our aim was to investigate the eﬀ ect of 
magistral preparation conditions of diﬀ erent eye 
drops dispensed in hungarian community phar-
macies, including also the patient adherence and 
its eﬀ ect in the change of microbiological stability 
using preparation and eye drop administration 
models.  
RESULTS:  According to the results of microbio-
logical investigations there was no initial aerob 
contamination detected rigth after the preparation 
of eye drops – applying three diﬀ erent methods. 
However there was a signifi cant risk for the con-
tamination applying increased airfl ow and non-
aseptic conditions. The applied eye drop adminis-
tration model resulted revelation of contaminant 
microbes in the preparation.
CONCLUSIONS: Preparation conditions of ma-
gistral eye drops is well-defi ned and can assure 
the proper microbiological cleanliness. Instruction 
provided for the patient in collaboration with 
ophthalmologists on the application of eye drops 
should be an integral part of pharmaceutical care. 
In conclusion the microbiological stability of eye 
drops is depending on both the preparation meth-
od – including the right choice of the preservative 
agent and the adequate administration.
REFERENCES: 
1. Kauﬀ mann D.H. et al. Br. J. Ophthalmol. 91, 1308-1310 (2007) 
P2H-10
Physical compatibility of vancomycin with 
common continuous administered drugs in the 
intensive care unit
 SZALAI, G.,  KATONA, G.,  MAUTZ, M., 
 JÓJÁRT-LACZKOVICH, O.,  DORÓ, P.
University of Szeged Faculty of Pharmacy Department of 
Clinical Pharmacy, Szeged, Hungary
University of Szeged Faculty of Pharmacy Department of 
Pharmaceutical Technology and Drug Regularoty Aﬀ airs, 
Szeged, Hungary
BACKGROUND:  For the bett er pharmakokinetic/
pharmakodinamic and less toxic eﬀ ect, vancomy-
cin is often used as once daily dosing (2g/24 h) 
regimen as continous infusion in the intensive 
care unit. During the co-administration of intrave-
nous drugs via Y-site, in line incompatibility may 
occur.
AIMS: Our goal was to detect the possible in-
compatibility of vancomycin and other continu-
ously administered drugs. Simulated Y-site ad-
ministration was accomplished by mixing vanco-
mycin and crystalloids, opioid analgesics (mor-
phin, fentanyl, sufentanyl),  cardiovascular drugs 
(urapidil, clonidin, nitroglycerin, amiodaron), 
heparin and regular insulin in a 1:1 (v/v%) ratio in 
polypropylene syringe. The aliquot samples were 
evaluated by visual observation, pH measurment 
and microscope immediately (t0) and 60 (t60) min-
utes after preparation.  
RESULTS:  A total of 13 drug pairs were investi-
gated. Vancomycin was proven physically incom-
patible with heparin and one of the crystalloids 
(white precipitation occured immediately after mix-
ing). The pH ranges of the other 11 samples were 
3.21 – 4.85 after mixing. This pH ranges were accept-
able based on the physical properties of each drugs. 
The pH measured at t60 and the highest change was 
only 0,10. During the microscopic examination we 
found microparticules  at t0 (min.-max.:20-70 um)
and also at t60 (min.-max.:8.7-24.4 um). 
CONCLUSIONS: Eleven of the total 13 drug 
pairs are considered physically compatible there-
fore co-administration through Y-site are consid-
ered safe.
P2H-11
Impact of clinical pharmacy services in a 
multidisciplinary intensive care unit
 KELLY, S.,  KELLER, N.,  SÜLE, A.
Department of Pharmacy, Péterfy Hospital and Trauma Center, 
Budapest, Hungary
BACKGROUND: Providing adequate therapeutic 
management for critical care patients is crucial in 
decreasing the incidence of complications during 
hospitalisation by enhancing medication safety, 
nutritional status and supporting the healing pro-
cess. 
AIMS: To describe the activities of clinical phar-
macists in the Intensive Care Unit (ICU) of the Pé-
terfy Hospital and Trauma Center, including 
pharmacist-led therapeutic monitoring of periop-
erative and septic patients  
RESULTS:  The following clinical pharmacist 
activities were put in practice: providing drug in-
formation for physicians and nurses; clarifi cation 
of drug orders; drug accessibility information; 
pharmacokinetic consultation; detection and re-
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porting of adverse drug reactions; therapeutic 
consultation leading to changes in drug therapy 
and assessment of patient nutritional status and 
general ICU-specifi c parameters (vasopressor 
need, length of stay, length of mechanical ventila-
tion, beginning of mobilization, mortality). These 
activities, as well as a thorough knowledge of pa-
tients’ issues serve to identify pharmacotherapy 
problems and to facilitate interventions that ad-
dress potential errors, often before an incorrect or 
suboptimal therapeutic measure is taken. 
CONCLUSIONS: Dedicated critical care phar-
macists can play a useful and eﬀ ective role in a 
multidisciplinary ICU healthcare team. While 
pharmacist can identify and prevent errors, it re-
mains diﬃ  cult to assess the impact of what has 
otherwise been prevented. This seems to be an in-
herent problem of the ICU sett ing, where ad-
vanced monitoring techniques combined with a 
highly skilled multiprofessional team allow iden-
tifi cation of certain trends before they become 
clinically signifi cant issues. Importantly, pharma-
cists providing comprehensive medication man-
agement do enhance the teams’ ability to recog-
nize and address these issues in time. They also 
provide continuity in individualized care and 
high-level coordination in collaborative practice to 
improve patient safety and therapeutic outcomes. 
P2H-12
Impact of patient education programs among 
adolescents
 GYERMÁN, A.,  BÁCSKAY, I .,  TÓTH, B. E., 
 KOVÁCS, Z.,  SZESZTAI, A.
Department of Pharmaceutical Technologies, Faculty of 
Pharmacy, University of Debrecen, Hungary
BACKGROUND: Today, the side eﬀ ects are re-
sponsible for the 5th common cause of death in 
the USA and EU. This also means 80 billion euros/
year additional cost for health economics. The de-
velopment of side eﬀ ects can be a consequence of 
interactions, but also can happen because of incor-
rect medication. 
AIMS:  At the age of 14, people are allowed to 
buy their own medicines, but it is questionable if 
they understand the informative leafl et. Our aim 
was to evaluate their health status and their level of 
knowledge about the safe use of medications; the 
impact of demand within the framework of the na-
tional educational system of health-education and 
wheter the pharmaceutical care provided by phar-
macists can be possibly in support for this age.   
RESULTS:   Meanwhile, the self classifi ed health 
status of respondents were 4.03/5.00; 24% of them 
take regular medication. 84% of students were 
ever used drugs as a purpose of self-medication, 
21% never goes in a pharmacy, 45% never heard 
about pharmaceutical care. If they have questions 
about their health and medications, most of the re-
spondents turn to their parents. They use websites 
to search information while only 14% found the 
internet trustworthy. Based on our results, we 
prepared a presentation for secondary school stu-
dents about the basic glossary and the correct use 
of medication. The pilot study presentation was 
proved to be successful by feedback: 100% of re-
spondents heard new, useful information, 83% of 
would take part in similar lecture, 61% prefer to 
contact a pharmacist for advice. Updated presen-
tations were hold, they proved successful too.  
CONCLUSIONS:  The proper use of medications 
has a great impact in aspects of pharmacovigi-
lance. Bett er knowledge of health and medication-
related question among young people achieved by 
the increase of confi dence towards pharmacists in 
pharmaceutical care would enhance the next gen-
eration in safer drug use and health-conscious life 
to live. Cooperating with schools can be an eﬀ ec-
tive way to educate our future patients.
This work was supported by EFOP-3.6.1-16-







Added value of diﬀ erent healthcare 
professionals, with special regard to pharmacists 
to COPD therapy experience
 OLAH, M.,  MESZAROS, A.
Semmelweis University, Budapest University Pharmacy and 
Institute of Pharmaceutical Administration
AIMS: This research sets the objective to provide 
an insight how healthcare professionals and phar-
macists can contribute to the well-being of pa-
tients. In order to bett er understand the case, we 
evoked best practice we used in our RCT and the 
results of real life patient follow-up interviews 
ACTA-1703-BBBB.indb   229 9/19/17   6:29 PM
230 Acta Pharmaceutica Hungarica – 7th BBBB Edition – Posters  2017/3-4.
completed after participation in the study. The 
conducted RCT included n=227 patients. 
METHODS: Patients were randomly assigned 
to the educated group and placebo. A major part 
of patients were recruited at pulmonology prima-
ry care centres. In order to provide a unique thera-
py experience and to achieve tailored education, 
patients were given only „draft” information that 
was also subject to change during their personal 
education session. As an exit interview we collect-
ed data from patients on their perceptions of the 
healthcare professional, who helped them partici-
pate in the study and insights on the quality of the 
education they received. 
RESULTS:  Results provide a complex overview 
methodologically how is it worth educating the 
patient to enhance the improvement of the PROs. 
Primary analysis of the data implies that the more 
you sow, the more you reap: patients educated 
within the frame of the pilot in the pharmacy ap-
preciated the quality of care more. Apparently, the 
time invested in their educated multiplied by the 
end: they show bett er results in outcomes; though, 
this can be interpreted as a hint due to the limited 
number of patients educated in the pharmacy. Pa-
tients who took the programme in the pulmonary 
centre provided robust data and were altogether 
slightly less satisfi ed with the education. 
CONCLUSIONS: Patients with chronic condi-
tions defi nitely need more att ention, and educa-
tion is a way to keep them in the loop. In order to 
convey sticky messages, education needs to be tai-
lored and healthcare professionals need to take 
time. Pharmacies seem to be an ideal place for ed-
ucation, though patients are harder to recruit and 
persistence also plummeted more there. 
P2H-14
 Evaluation of drug safety issues related to 
pharmacovigilance of PET radiopharmaceuticals 
in the European Economic Area and eﬃ  ciency 
analysis of the risk-management plan
 
ARATÓ, V. ZS.1, ÉSIK, ZS.1, VALKÓ, K.1, 
RÁDAY, G.2, TÓTH, E. B.3, SZIKRA, D.1 
BERÉNYI, E.1, FARKASINSZKY, G.1
1Division of Nuclear Medicine, Faculty of Medicine, University 
of Debrecen, Hungary
2Raday Drug Ltd, Debrecen, Hungary
3Department of Pharmaceutical Management, Faculty of 
Pharmacy,  University of Debrecen, Hungary
BACKGROUND:  Positron emission tomography 
(PET) is a noninvasive nuclear medicine related imag-
ing procedure. PET imaging provides the opportunity 
for diagnostic purposes, monitoring disease progres-
sion and response to treatment. The most commonly 
used radiopharmaceutical is 18F-Fludeoxyglucose 
(18F-FDG). Radiopharmaceuticals rarely have any 
pharmacodynamic effects or cause adverse reactions. 
However, in accordance with Article 106 of Directive 
2001/83/EC, suffi cient pharmacovigilance system must 
be obtained. 
AIMS: This study has aimed to assess the European 
database of suspected adverse drug reaction reports 
(EDSADR) and EMA public assessment reports, not to 
mention medical literature monitoring (MLM) further-
more to present the necessity of risk-management plan 
(RMP).  
RESULTS:  PET scan occurrence was found as 
172,95 per 105 capita in Hungary and 227,50 per 105 
capita in the European Economic Area (EEA). After 
having examined the EDSADR up to May 2017, 52 in-
dividual cases of 18F-FDG in EudraVigilance were 
found (number of cases/age groups in years: 6 /0-2, 1 
/3-11, 0 /12-17, 19 /18-64, 23 /65-85, 2 /85<, 1 /not 
specifi ed). The 86,5% of the cases occurred in the EEA 
(13,5% in the Non-EEA) and the sex ratio was found as 
7:10 female to male. 19 different reaction groups were 
described. The most common side effects involved skin 
and subcutaneous tissue disorders (23 cases), general 
disorders and administration site conditions (16 cases). 
48 out of the 52 cases were reported by healthcare pro-
fessionals and only 4 reports came from non-healthcare 
professionals. According to the results of the MLM 
(134 Hungarian and 139 global journals) there are neg-
ligible number of fi ndings, but most of them are related 
to dosimetry. 
CONCLUSIONS: Safety profi le of PET radiophar-
maceuticals was proved as satisfactory. For its further 
development, the support of patient reporting is re-
quired. The work of the QPPV essentially needs to be 
aided by a nuclear medicine specialist and clinical ra-
diophysicist in the signal management team. 
This work was supported by EFOP-3.6.1-16-2016-
00022 „Debrecen Venture Catapult” project. 
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S-1
 Innovative and well-tried approaches in 
treatment of the metastatic colorectal cancer
 KLEINER, D.
University Pharmacy Department of Pharmacy Administration, 
Semmelweis University, Budapest, Hungary
Cancer Center, Semmelweis University, Budapest, Hungary
BACKGROUND: In the latest 20 years the median 
overall survival of the metastatic colorectal cancer 
has been doubled. While various factors could in-
fl uence this advancement, the improvements in 
the systemic therapies seem to have mayor role in 
it. The most recent and evidence based knowledge 
and recommendations has been collected by 
ESMO (2016).
RESULTS: Fluoropyrimidine based systemic 
therapies considered fi rst-line treatments. Bolus 
fl uorouracil (5-FU) containing regimens are not 
recommended, because combination of 5-FU with 
calcium folinate seems generally less toxic. Fur-
thermore a cytotoxic doublet with oxaliplatin 
(OX) or irinotecan or a cytotoxic triplet (5-FU, OX, 
irinotecan) may also provide opportunities, with 
regard to the goals and conditions. In the last de-
cade targeted therapies gain signifi cant impor-
tance in the treatment of metastatic colorectal can-
cer, and jet, they indicated in the fi rst-line therapy. 
To avoid side eﬀ ects, especially the cumulative 
toxicity of OX, maintenance therapies have been 
investigated. The second-line treatments are de-
pendent from the fi rst-line treatment. Ramucirum-
ab and afl ibercept are newly approved anti-angio-
genic drugs which are recommended in second-
line treatment too. As third-line therapy, the rec-
ommendations contain a multi-targeted kinase in-
hibitor, regorafenib, but its side-eﬀ ects often lead 
to dose-reduction. A newly approved drug, the 
combination of trifl uridine and tipiracil hydro-
chloride has been also recommended in the guide-
line. The trifl uridine is an antineoplastic thymi-
dine-based nucleoside analogue and seems eﬀ ec-
tive against 5-FU-resistant colorectal cancer cells 
too, while the tipiracil hydrochloride can inhibit 
its fast degradation.
CONCLUSIONS: All in all in the treatment of 
metastatic colorectal cancer targeted therapies 
may gathered ground in the therapies, but well-
tried treatments and pathways could hold new 
possibilities.
REFERENCES:
1. Van Cutsem E. et al. Ann Oncol 27, 1386-422. (2016)
S-2
The new era of thalidomide?
 DÓCZY, V.
Section of Pharmacotherapy and Pharmaceutical Care, 
Hungarian Society for Pharmaceutical Sciences, Budapest, 
Hungary
BACKGROUND: Multiple myeloma is one of the 
most common hematologic malignancy. With the 
introduction of new therapeutic treatment options 
the clinical response of patients with multiple my-
eloma has signifi cantly improved over the past 
two decades. 
AIMS: The presentation gives a comprehensive 
review about the novel therapeutic agents and 
regimens based on the recent developments and 
therapeutic guidelines emphasizing the relevant 
aspects for the clinical pharmacist.   
RESULTS:  Thalidomide is a widely used drug 
at the therapeutic area and it has a well-known 
history regarding its teratogenicity. The safety 
profi les of the antimyeloma agents are varying 
across drug classes and across agents within the 
same class.
CONCLUSIONS: The overview provides up-
dated information about the therapeutic options 
of the multiple myeloma with the aim to help in 
the optimal treatment selection and the manage-
ment of toxicities, which can lead fewer patients 
requiring dose reductions, treatment discontinua-
tion and improved outcomes. 
REFERENCES: 
1. Moreau P et al. Ann Oncol. Suppl 6:vi133-7 (2017)
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S-3
Adverse reactions of PD1 checkpoint inhibitors 
in the therapy of malignant melanoma
 MAKÓ, S.,  SOÓS, GY.
Semmelweis University Dept. of Dermatology, Venereology and 
Dermatooncology
BACKGROUND: Az újabb, immunrendszert sti-
muláló daganatt erápiás gyógyszerek esetében, a 
korábbi kemoterápiáknál ismert súlyos toxikus re-
akciók helyett , egészen másfajta mellékhatásokkal 
szembesülünk. A melanoma malignum terápiájá-
ban a PD1 gátló kezelés 2015 óta érhető el Magyar-
országon, hatóanyagai a nivolumab és a pembro-
lizumab. Ezek a hatóanyagok a T-sejtek aktivitásá-
nak fokozásával segítik az immunrendszer tumor 
ellenes folyamatait. A gyógyszer hatásmechaniz-
musából következik az immunrendszer eredetű 
mellékhatások fellépte, amelyek ritkán súlyos 
mellékhatások is lehetnek. 
AIMS: A klinikán PD1 gátló kezelésben része-
sülő melanomás betegeknél jelentkező adverz re-
akciók elemzése, a kezelés folyamatos követésé-
vel.
RESULTS:  Klinikánkon ezidáig 34 beteg része-
sült nivolumab, és 9 beteg pembrolizumab terápiá-
ban. Betegeinken a következő adverz reakciók lép-
tek fel: pneumonitis, hepatitis, pancreatitis, 
nephritis, hypophysitis, thyreoiditis, dermatitis, 
vitiligo. A mellékhatások egy 3. fokozatú eset kivé-
telével 1-2 fokozat súlyosságúak voltak (NCI-
CTCAE v4 szerint). Az események gyakoriságát te-
kintve megállapíthatjuk, hogy az irodalomban sze-
replő adatokhoz képest a vitiligo, dermatitis, 
thyreoiditis magasabb, a pneumonitis, nephritis és 
hypophysitis alacsonyabb arányban fordult elő kli-
nikánkon. A mellékhatás megjelenése, a bőrtünetek 
és a thyreoiditis kivételével, terápiás konzekvenciá-
val járt, 5 alkalommal a terápia átmeneti felfüg-
gesztésére volt szükség, egy esetben pedig a végle-
ges leállításra. A kialakult adverz reakciók közül a 
dermatitist lokális kortikoszteroidokkal kezelték, a 
hepatitist, pancreatitist és a két pneu monitist per os 
szterioddal. A thyreoditis esetében pajzsmirigyhor-
mon szubsztitúcióra volt szükség, míg a 
hypophysitis esetében per os hydro corti sonra. 
CONCLUSIONS: A megfi gyelt mellékhatások 
enyhébbek a hagyományos kemoterápiák toxikus 
mellékhatásainál (neutropenia, thrombocytope-
nia). Sok esetben szubjektív panaszok nem hívják 
fel a fi gyelmet az esetleges eltérésekre, azaz a be-
tegnek panaszt nem okoz, ezért az egészségügyi 
személyzett ől fokozott  fi gyelmet követel. Az előírt 
kontrollok rendszeres végzése, a páciens szoros 
monitorozása elengedhetetlen. A megjelenő prob-
lémákat számos esetben terápiás szünet kell, hogy 
kövesse. A PD1-gátló terápia a tünetek megszűn-
tével folytatható. 
S-4
Cardiotoxic eﬀ ects of oncology therapies – 
clinical pharmacology aspects 
 CSONTOS, D.,  HIGYISÁN, I .,  TELEKES, A.
Institute Pharmacy and Oncology Department, Bajcsy-
Zsilinszky Hospital and Clinics, Budapest, Hungary
BACKGROUND: European Society of Cardiology 
published a report in 2016 about cardiovascular 
risks of oncology therapies along with methods of 
prevention and treatment. These therapy induced 
cardiac problems may lead to death, therefore it is 
important to pay more att ention to them. A clini-
cal pharmacist’s special knowledge about medi-
cines can help physicians to deliver safe therapy 
their patients. 
AIMS: By using CATO software, treatments with 
cardiac risks were collected retrospectively. The 
cardiac risk was assessed based on ESC’s report.   
RESULTS:  It turned out that the largest quanti-
ty of patients are exposed in case of breast cancer 
based on therapies’ side eﬀ ects. In 2016 we treated 
86 patients with breast cancer, using 25 diﬀ erent 
protocols, all together 111 treatment was deliv-
ered. In 94% of cases medicine with cardiac risk 
was used: trastuzumab (47/111), taxane (46/111), 
anthracycline (49/111).
CONCLUSIONS: Our presentation represents 
methods how clinical pharmacist can improve pa-
tients’ quality of life and longer survival. In our 
practice no serious cardiac adverese eﬀ ects was 
detected in 2016, which is to our hope is because 
of careful cardiac follow-up.
REFERENCES: 
1. Zamorano et al. Eur J Heart Failure 19, 9-42 (2017)
ACTA-1703-BBBB.indb   232 9/19/17   6:29 PM
 2017/3-4. Acta Pharmaceutica Hungarica – 7th BBBB Edition – Satellite Symposium 233
S-5
Potential advantages of nutritional status 
screening and Quality of Life measurements in 
oncology patients 
 TISZAI, Z.,  SÜLE, A.
Péterfy Hospital and Trauma Center, Budapest, Hungary 
BACKGROUND:  Quality of life (QoL) question-
naires are widely used in oncology to assess the 
symptoms and performance of cancer patients. 
Nutritional status is known to aﬀ ect the outcome 
of chemotherapy. Malnutrition and metabolic de-
rangement induced by the disease or the treat-
ment has to be recognized to improve the patients’ 
QoL.
AIMS: To assess the nutritional status of pa-
tients in view of their physical and psychosocial 
condition in the Department of Oncology and He-
matology. The study was conducted using the 
EORTC QLQ-C15-PAL and NRS2002 screening 
tools. Patients receiving chemotherapy were 
screen ed by a clinical pharmacist at the fi rst and 
all subsequent chemotherapy rounds according to 
their appropriate protocols. In this study tenden-
cies between nutritional parameters and QoL val-
ues are evaluated.  
RESULTS:  65 patients were interviewed during 
a year long period between August 2016 and Au-
gust 2017. A deterioration in almost every dimen-
sion of the QoL questionnaire was found. These 
results correspond well with the characteristic 
progression of a malignant disease.  The incidence 
of constipation showed reduction, which can also 
be an artifact of an increased risk of diarrhea due 
to mucositis in the gut or the positive impact of 
enteral nutrition. Regarding psychological factors, 
tenseness did not change during the assessment, 
severity of depression though did increase which 
infl uences the patients’ diet and the complience 
with enteral nutrition. 
CONCLUSIONS: EORTC-C15-PAL is a relevant 
and easy-to-use tool for bedside pharmaceutical 
counseling. NRS2002 is a reliable tool for the 
screening of cancer patients and as a healthcare 
worker the clinical pharmacist implementing the 
assessment can improve the perception of physi-
cal and psychosocial impairments of patients 
struggling with cancer. Data from this assessment 
could oﬀ er a basis for clinical pharmacist inter-
ventions, preferably running in parallel with the 
interview process.
REFERENCES: 
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S-6
Professional and economic evaluation of 
Pharma ceutical Centre of Centralized Cytotoxic 
Drug Preparation
 ÁBRAHÁM, E.,  SCHIRM, SZ.,  BOTZ, L.
University of Pécs, Central Clinical Pharmacy, Pécs, Hungary
BACKGROUND: The Unit of the Centralized Cyto-
toxic Drug Preparation started its work in May 2016 
as  part of the Central Clinical Pharmacy in Pécs. 
AIMS: Our goal was to integrate all the depart-
ments and wards preparing and using chemother-
apeutic infusions at the Univeristy of Pécs.    
RESULTS:  Due to the centralized preparation 
we could reduce the staﬀ  assisting in the prosess. 
The education of  the pharmaceutical technicians, 
who are part of this program is well-controlled by 
the pharmacists. Owing to the integrated infusion 
supply, we can ensure wards a standardized and a 
higher quality assurance in infusion preparation. 
The complete documentation referring to the cyto-
toxic drug therapy is availabe due to  a software 
managed drug preparation of  the  new laborato-
ry. Based on the interface connection between the 
software and the wards, the documentation is al-
ways up-to-date at the laboratory, the wards and 
the pharmacy as well.  The planned therapies and 
therapies received by the patients are automatical-
ly documented.  We have confi rmed a decrease in 
the waste of cytotoxic drugs (about 4% of the 
whole amount of medicine, ATC L01). The oncolo-
gy drug cost adjusted to the number of cases de-
creased by 20% compared to the same timeframe 
previous year. This is a common result from the 
optimized drug utilization  (the use of the over-
fi lled vials) and the drug price change monitoring.
CONCLUSIONS: The appropiate documenta-
tion is important for patient- and medication safe-
ty as well.  As result of the automated documenta-
tion healthcare professionals have less administra-
tive tasks to do. The reduce of expenditures en-
abled the widely use of closed system transfer de-
vice (CSTD)  in the laboratory. 
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S-7
Advantages and disadvantages of biosimilars – 
safety and pharmacoeconomic aspects
 SÜLE, A.
Péterfy Hospital and Trauma Center, Budapest, Hungary
A large number of the best-selling biological me-
dicinal products are, or will soon be, facing com-
petition from similar medicinal products (biosim-
ilars) in the European Union. Biosimilar drugs are 
highly similar to an originator product, deter-
mined by the same comparability concept that has 
been successfully in use for several decades to en-
sure appropriate similarity of biological products 
before and after a change in the manufacturing 
process. In the past 10 years, experience has 
shown that even complex, biotechnologically 
manufactured compounds can be safely produced 
with very close similarity, so that no clinically 
meaningful diﬀ erence in terms of eﬃ  cacy and 
safety is to be expected.
As most biological are used to treat chronic dis-
eases, an intensive discussion is present in the sci-
entifi c community about the interchangeability of 
a biosimilar with its reference product, with the 
main concerns being therapeutic equivalence, tol-
erability and immunogenicity.
In this presentation, the theoretical basis of the 
presumed risks of switching is explored based on 
data already available derived from such practice.
While the evidence in scientifi c literature to de-
termine the appropriate terms for switching oﬀ -
patent biologics and biosimilars is scarce, it seems 
clear that on the basis of current knowledge, it is 
very unlikely and highly diﬃ  cult to substantiate 
that comparable versions of the same active sub-
stance approved in accordance with EU legisla-
tion on a population level, would have diﬀ erent 
safety and/or eﬃ  cacy profi les in individual pa-
tients upon a switch. There is, however, also a 
clear expectation from healthcare professionals 
that a balanced and watchful approach should be 
advocated in this manner as it is the prescribers’ 
responsibility to choose an oﬀ -patent biologic or 
its biosimilar tailored to the individual patient’s 
needs.
In this respect, hospital pharmacists should play 
a key role in the uptake of biosimilars by provid-
ing a ‘hub of information’ to other healthcare pro-
fessionals with regard to real-world use and evi-
dence base of oﬀ -patent biologics and biosimilars. 
Policy makers need to also embrace the profes-
sional opinion of physicians, pharmacists and other 
stakeholders in order to design a procurement and 
reimbursement system that ensures suﬃ  cient fl exi-
bility in enabling the presriber to act in the best in-
terest of the patient, including the availability of 
choice between similar products. Tendering 
schemes should avoid a ‘winner takes it all’ ap-
proach, especially on large, regional/national scales.
In conclusion, this presentation advocates the 
timely uptake of biosimilar products with a bal-
anced approach, supporting fl exible procurement 
and reimbursement mechanisms and emphasizes 
the importance of a multi-stakeholder consensus 
in policy development.
S-8
Parameters associated with nutritional status in 
hospitalized patients: clinical data analysis
 VINCZE, P.,  BÁNSZKI, B.,  ZEMPLÉNYI, A., 
 HORVÁTH, B.,  SOMOGYI-VÉGH, A., 
 LANKÓ, E.,  SCHIRM, SZ.,  BOTZ, L.
Department of Pharmaceutics and Central Clinical Pharmacy, 
University of Pécs, Pécs, Hungary
BACKGROUND: The prevalance of malnutrition in 
hospitalized patients vary between 30-50%. Under-
nourishment may lead to poor wound healing, in-
creased morbidity and mortality, which can lead to 
longer hospital stay and increased health care cost. 
In our previous study  the nutritional status of 121 
inpatients  was screened by the Nutritional Risk 
Screening tool recommended by the European So-
ciety for Clinical Nutrition and Metabolism (ES-
PEN) in the fi rst quarter of 2016. It was found that 
58% of patients were highly and 35% were moder-
ately at risk of malnutrition. Beside questionnaires 
other information sources can be used to assess pa-
rameters that are associated with nutritional status 
in a hospital sett ing. However there are several 
publications regarding the relationship between 
the nutritional status and clinical outcomes, the an-
alyzis of great amount of clinical data with diverse 
structure requires novel approaches. 
AIMS: Our aim is to determine the prevalence 
and patt ern of malnutrition and compare it with 
literature data. Furthermore we would like to ana-
lyze the clinical data with the tools of „Big Data” 
Analytics to explore risk factors associated with 
malnutrition and correlations with clinical out-
comes.   
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RESULTS:  The analysis is in progress.
CONCLUSIONS: The results obtained from the 
„Big Data” anlysis will help to develop clinical de-
cision support tools for comprehensive nutritional 
assessment of high risk patients during admis-
sions and the optimization of nutrition therapy, as 
well to establish cost-eﬀ ectiveness.  
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